Impulse - Meeting Healthcare Pioneers https://www.impulsepodcast.com/ en Mathieu Chaffard Impulse is the podcast where we dive into the most exciting breakthroughs in healthcare of our time. In each episode, we sit down with some of the brightest minds who are using technology to rethink the way we care! https://megaphone.imgix.net/podcasts/ffda70f8-bbd5-11ec-800a-637c380a822d/image/b796dd811f5a1115d084c2d9ef6c9993.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress Impulse - Meeting Healthcare Pioneers https://www.impulsepodcast.com/ no episodic Mathieu Chaffard Impulse is the podcast where we dive into the most exciting breakthroughs in healthcare of our time. In each episode, we sit down with some of the brightest minds who are using technology to rethink the way we care! Impulse is the podcast where we dive into the most exciting breakthroughs in healthcare of our time. In each episode, we sit down with some of the brightest minds who are using technology to rethink the way we care!

]]> Mathieu Chaffard m.chaffard05@gmail.com #57 - Reimagining care for metabolic disorders - Ihsan Almarzooqi - meta[bolic] Which care models will handle the scourge of metabolic disorders? Beyond the societal questions raised by this public health phenomenon, the real concern is whether traditional care models are capable of managing this group of conditions effectively and sustainably. This largely because traditional care models are episodic and put little focus on behaviour change that is dearly needed to reverse the trend. Among those who have realized it and are striving for alternatives, Ihsan Almarzooqi and his team at meta[bolic] stand out. Based in Dubai, they have developed and deployed a unique care model, which they aim to replicate in Europe, starting with the UK. Their approach blends cutting-edge diagnostics, remote monitoring, and a care pathway involving frequent interactions with medical staff—enough to drive long-term behavioural change. And its efficacy has been demonstrated through numerous studies published since its inception. Beyond this hybrid care model, what is striking about Ihsan and the meta[bolic] philosophy is their relentless focus on improving outcomes for patients and incorporating the latest care innovations to raise the bar. Up to the point of reducing their operational margin to extend their knowledge of each patient, as long as it improves the level of care. In this episode, we discuss what makes this care pathway unique, its implementation, the results, and how we can leverage traditional reimbursement schemes while still delivering a continuous and outcome-oriented care experience. An inspiring and thought-provoking conversation on what care models for metabolic disorders can be, despite the constraints posed by most health systems! Timeline: 00:00:00 - What led Ihsan to pioneer new care delivery models 00:06:03 - The extent of the metabolic diseases pandemic 00:10:39 - Why traditional care models fail to address metabolic diseases 00:16:49 - The components that make up the meta[bolic] care model 00:23:37 - How the meta[bolic] care model is funded in the UAE 00:30:57 - Ihsan’s philosophy about evidence generation and how it is lived at meta[bolic] 00:33:28 - Scaling the meta[bolic] model to other geographies beyond the UAE 00:38:45 - How to keep patients engaged throughout their care journey 00:41:55 - Ihsan’s wishes for the democratization of value-based care What we also talked about with Ihsan: Continuous glucose monitors (CGMs) GLP-1 agonists Labcorp p-Tau217 VO2 max test PromarkerD test As mentioned by Ihsan during the episode, you can have a read at Ground Truths by Dr. Eric Topol and his recent book Super Agers, an encyclopedia of the latest medical knowledge around longevity. Ihsan also recommends listening to Dr. Peter Attia’s podcast The Drive, which investigates everything from exercise and nutritional biochemistry to cardiovascular health, cancer, cognitive health, mental and emotional well-being, and beyond. You may also read Ihsan’s publication in NEJM Catalyst Innovations in Care Delivery alongside Hala Zakaria, and Ali Hashemi, on their hybrid care model to manage diabetes in the UAE. You can get in touch with Ihsan via LinkedIn, and follow meta[bolic]’s activities on their website, LinkedIn, Facebook, Instagram, and YouTube. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 05 Jan 2026 07:38:00 -0000 full Mathieu Chaffard Which care models will handle the scourge of metabolic disorders? Beyond the societal questions raised by this public health phenomenon, the real concern is whether traditional care models are capable of managing this group of conditions effectively and sustainably. This largely because traditional care models are episodic and put little focus on behaviour change that is dearly needed to reverse the trend. Among those who have realized it and are striving for alternatives, Ihsan Almarzooqi and his team at meta[bolic] stand out. Based in Dubai, they have developed and deployed a unique care model, which they aim to replicate in Europe, starting with the UK. Their approach blends cutting-edge diagnostics, remote monitoring, and a care pathway involving frequent interactions with medical staff—enough to drive long-term behavioural change. And its efficacy has been demonstrated through numerous studies published since its inception. Beyond this hybrid care model, what is striking about Ihsan and the meta[bolic] philosophy is their relentless focus on improving outcomes for patients and incorporating the latest care innovations to raise the bar. Up to the point of reducing their operational margin to extend their knowledge of each patient, as long as it improves the level of care. In this episode, we discuss what makes this care pathway unique, its implementation, the results, and how we can leverage traditional reimbursement schemes while still delivering a continuous and outcome-oriented care experience. An inspiring and thought-provoking conversation on what care models for metabolic disorders can be, despite the constraints posed by most health systems! Timeline: 00:00:00 - What led Ihsan to pioneer new care delivery models 00:06:03 - The extent of the metabolic diseases pandemic 00:10:39 - Why traditional care models fail to address metabolic diseases 00:16:49 - The components that make up the meta[bolic] care model 00:23:37 - How the meta[bolic] care model is funded in the UAE 00:30:57 - Ihsan’s philosophy about evidence generation and how it is lived at meta[bolic] 00:33:28 - Scaling the meta[bolic] model to other geographies beyond the UAE 00:38:45 - How to keep patients engaged throughout their care journey 00:41:55 - Ihsan’s wishes for the democratization of value-based care What we also talked about with Ihsan: Continuous glucose monitors (CGMs) GLP-1 agonists Labcorp p-Tau217 VO2 max test PromarkerD test As mentioned by Ihsan during the episode, you can have a read at Ground Truths by Dr. Eric Topol and his recent book Super Agers, an encyclopedia of the latest medical knowledge around longevity. Ihsan also recommends listening to Dr. Peter Attia’s podcast The Drive, which investigates everything from exercise and nutritional biochemistry to cardiovascular health, cancer, cognitive health, mental and emotional well-being, and beyond. You may also read Ihsan’s publication in NEJM Catalyst Innovations in Care Delivery alongside Hala Zakaria, and Ali Hashemi, on their hybrid care model to manage diabetes in the UAE. You can get in touch with Ihsan via LinkedIn, and follow meta[bolic]’s activities on their website, LinkedIn, Facebook, Instagram, and YouTube. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Which care models will handle the scourge of metabolic disorders?

Beyond the societal questions raised by this public health phenomenon, the real concern is whether traditional care models are capable of managing this group of conditions effectively and sustainably.

This largely because traditional care models are episodic and put little focus on behaviour change that is dearly needed to reverse the trend.

Among those who have realized it and are striving for alternatives, Ihsan Almarzooqi and his team at meta[bolic] stand out.

Based in Dubai, they have developed and deployed a unique care model, which they aim to replicate in Europe, starting with the UK.

Their approach blends cutting-edge diagnostics, remote monitoring, and a care pathway involving frequent interactions with medical staff—enough to drive long-term behavioural change.

And its efficacy has been demonstrated through numerous studies published since its inception.

Beyond this hybrid care model, what is striking about Ihsan and the meta[bolic] philosophy is their relentless focus on improving outcomes for patients and incorporating the latest care innovations to raise the bar.

Up to the point of reducing their operational margin to extend their knowledge of each patient, as long as it improves the level of care.

In this episode, we discuss what makes this care pathway unique, its implementation, the results, and how we can leverage traditional reimbursement schemes while still delivering a continuous and outcome-oriented care experience.

An inspiring and thought-provoking conversation on what care models for metabolic disorders can be, despite the constraints posed by most health systems!


Timeline:

  • 00:00:00 - What led Ihsan to pioneer new care delivery models
  • 00:06:03 - The extent of the metabolic diseases pandemic
  • 00:10:39 - Why traditional care models fail to address metabolic diseases
  • 00:16:49 - The components that make up the meta[bolic] care model
  • 00:23:37 - How the meta[bolic] care model is funded in the UAE
  • 00:30:57 - Ihsan’s philosophy about evidence generation and how it is lived at meta[bolic]
  • 00:33:28 - Scaling the meta[bolic] model to other geographies beyond the UAE
  • 00:38:45 - How to keep patients engaged throughout their care journey
  • 00:41:55 - Ihsan’s wishes for the democratization of value-based care


What we also talked about with Ihsan:


As mentioned by Ihsan during the episode, you can have a read at Ground Truths by Dr. Eric Topol and his recent book Super Agers, an encyclopedia of the latest medical knowledge around longevity.

Ihsan also recommends listening to Dr. Peter Attia’s podcast The Drive, which investigates everything from exercise and nutritional biochemistry to cardiovascular health, cancer, cognitive health, mental and emotional well-being, and beyond.

You may also read Ihsan’s publication in NEJM Catalyst Innovations in Care Delivery alongside Hala Zakaria, and Ali Hashemi, on their hybrid care model to manage diabetes in the UAE.

You can get in touch with Ihsan via LinkedIn, and follow meta[bolic]’s activities on their website, LinkedIn, Facebook, Instagram, and YouTube.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3258 no [SNIPPET] - Ihsan Almarzooqi on creating a new experience for metabolic health care To discover the whole episode, type "#57 - Reimagining care for metabolic disorders - Ihsan Almarzooqi - meta[bolic]" on your preferred streaming platform. Mon, 05 Jan 2026 07:36:00 -0000 trailer Mathieu Chaffard To discover the whole episode, type "#57 - Reimagining care for metabolic disorders - Ihsan Almarzooqi - meta[bolic]" on your preferred streaming platform. To discover the whole episode, type "#57 - Reimagining care for metabolic disorders - Ihsan Almarzooqi - meta[bolic]" on your preferred streaming platform.


]]> 374 no #56 - Building the one clinical AI assistant - Ali Parsa - Quadrivia What will our interactions with our healthcare system look like in the age of AI? Whether you are a patient, a doctor, or any other stakeholder in that system, the question is worth asking. In a world where healthcare costs continue to skyrocket, it is clear we need a radical solution to reverse the trend. The broader challenge is to restore the balance between demand and supply of care, limited by our capacity to train new doctors. Among those relentlessly working on this task are Ali Parsa and his team at Quadrivia. A true veteran of healthcare entrepreneurship, Ali founded Circle Health Group, now the largest chain of private hospitals in the UK, and Babylon Health, the fallen European digital health unicorn that once pioneered the use of AI for remote medicine, symptom checking, and patient triage. Despite all the highs and lows and whatever may have been said about his journey, Ali remains driven by the same mission: making healthcare more accessible and affordable at scale. Today, his efforts are focused on building Qu, which he aims to establish as the gold standard for clinical AI assistants, serving patients, doctors, and the broader ecosystem of actors in the space. In this episode, Ali reveals the inner workings of this formidable tool, showcasing its ability to automate repetitive tasks that healthcare professionals face daily, and the opportunity it offers patients by being available around the clock to advise, educate, and ensure continuous medical supervision. We also discuss the key role of healthcare professionals in the validation of Qu, how to approach the risks and European regulations to make it widely available, and finally, the time and caution required to confidently integrate AI into patients' lives and routine clinical practice. A fascinating conversation that outlines the future of our interactions with the healthcare world! Timeline: 00:00:00 - Ali’s journey as an entrepreneur building healthcare institutions and digital health solutions 00:11:52 - Why healthcare is not affordable nor accessible in the current system 00:16:17 - The interactions where AI will play a crucial role in healthcare (including a demo of Qu!) 00:25:06 - An approach to validate clinically the behaviour of AI in healthcare 00:29:54 - Ali’s observations on the current struggles around AI regulation in healthcare 00:37:22 - Making AI customisable to accommodate different clinical care practices for similar use cases 00:40:01 - Judging a clinical AI’s performance relative to the real performance of healthcare professionals 00:45:10 - Ali’s ambition and Quadrivia’s plans for the next few years What we also talked about with Ali: Special Purpose Acquisition Company (SPAC) Bakul Patel FDA Lovable Modality Partnership We cited with Ali some of the past episodes of the series: #47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI As mentioned by Ali during the episode, you can have a read at Thinking Machines Lab’s publication “Defeating Nondeterminism in LLM Inference” from September 2025, to dive deep into the nondeterminism problem around the use of LLMs. You can get in touch with Ali via LinkedIn, and follow Quadrivia’s activities on their website and on LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Wed, 10 Dec 2025 08:35:00 -0000 full Mathieu Chaffard What will our interactions with our healthcare system look like in the age of AI? Whether you are a patient, a doctor, or any other stakeholder in that system, the question is worth asking. In a world where healthcare costs continue to skyrocket, it is clear we need a radical solution to reverse the trend. The broader challenge is to restore the balance between demand and supply of care, limited by our capacity to train new doctors. Among those relentlessly working on this task are Ali Parsa and his team at Quadrivia. A true veteran of healthcare entrepreneurship, Ali founded Circle Health Group, now the largest chain of private hospitals in the UK, and Babylon Health, the fallen European digital health unicorn that once pioneered the use of AI for remote medicine, symptom checking, and patient triage. Despite all the highs and lows and whatever may have been said about his journey, Ali remains driven by the same mission: making healthcare more accessible and affordable at scale. Today, his efforts are focused on building Qu, which he aims to establish as the gold standard for clinical AI assistants, serving patients, doctors, and the broader ecosystem of actors in the space. In this episode, Ali reveals the inner workings of this formidable tool, showcasing its ability to automate repetitive tasks that healthcare professionals face daily, and the opportunity it offers patients by being available around the clock to advise, educate, and ensure continuous medical supervision. We also discuss the key role of healthcare professionals in the validation of Qu, how to approach the risks and European regulations to make it widely available, and finally, the time and caution required to confidently integrate AI into patients' lives and routine clinical practice. A fascinating conversation that outlines the future of our interactions with the healthcare world! Timeline: 00:00:00 - Ali’s journey as an entrepreneur building healthcare institutions and digital health solutions 00:11:52 - Why healthcare is not affordable nor accessible in the current system 00:16:17 - The interactions where AI will play a crucial role in healthcare (including a demo of Qu!) 00:25:06 - An approach to validate clinically the behaviour of AI in healthcare 00:29:54 - Ali’s observations on the current struggles around AI regulation in healthcare 00:37:22 - Making AI customisable to accommodate different clinical care practices for similar use cases 00:40:01 - Judging a clinical AI’s performance relative to the real performance of healthcare professionals 00:45:10 - Ali’s ambition and Quadrivia’s plans for the next few years What we also talked about with Ali: Special Purpose Acquisition Company (SPAC) Bakul Patel FDA Lovable Modality Partnership We cited with Ali some of the past episodes of the series: #47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI As mentioned by Ali during the episode, you can have a read at Thinking Machines Lab’s publication “Defeating Nondeterminism in LLM Inference” from September 2025, to dive deep into the nondeterminism problem around the use of LLMs. You can get in touch with Ali via LinkedIn, and follow Quadrivia’s activities on their website and on LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! What will our interactions with our healthcare system look like in the age of AI?

Whether you are a patient, a doctor, or any other stakeholder in that system, the question is worth asking.

In a world where healthcare costs continue to skyrocket, it is clear we need a radical solution to reverse the trend.

The broader challenge is to restore the balance between demand and supply of care, limited by our capacity to train new doctors.

Among those relentlessly working on this task are Ali Parsa and his team at Quadrivia.

A true veteran of healthcare entrepreneurship, Ali founded Circle Health Group, now the largest chain of private hospitals in the UK, and Babylon Health, the fallen European digital health unicorn that once pioneered the use of AI for remote medicine, symptom checking, and patient triage.

Despite all the highs and lows and whatever may have been said about his journey, Ali remains driven by the same mission: making healthcare more accessible and affordable at scale.

Today, his efforts are focused on building Qu, which he aims to establish as the gold standard for clinical AI assistants, serving patients, doctors, and the broader ecosystem of actors in the space.

In this episode, Ali reveals the inner workings of this formidable tool, showcasing its ability to automate repetitive tasks that healthcare professionals face daily, and the opportunity it offers patients by being available around the clock to advise, educate, and ensure continuous medical supervision.

We also discuss the key role of healthcare professionals in the validation of Qu, how to approach the risks and European regulations to make it widely available, and finally, the time and caution required to confidently integrate AI into patients' lives and routine clinical practice.

A fascinating conversation that outlines the future of our interactions with the healthcare world!


Timeline:

  • 00:00:00 - Ali’s journey as an entrepreneur building healthcare institutions and digital health solutions
  • 00:11:52 - Why healthcare is not affordable nor accessible in the current system
  • 00:16:17 - The interactions where AI will play a crucial role in healthcare (including a demo of Qu!)
  • 00:25:06 - An approach to validate clinically the behaviour of AI in healthcare
  • 00:29:54 - Ali’s observations on the current struggles around AI regulation in healthcare
  • 00:37:22 - Making AI customisable to accommodate different clinical care practices for similar use cases
  • 00:40:01 - Judging a clinical AI’s performance relative to the real performance of healthcare professionals
  • 00:45:10 - Ali’s ambition and Quadrivia’s plans for the next few years


What we also talked about with Ali:


We cited with Ali some of the past episodes of the series:


As mentioned by Ali during the episode, you can have a read at Thinking Machines Lab’s publication “Defeating Nondeterminism in LLM Inference” from September 2025, to dive deep into the nondeterminism problem around the use of LLMs.

You can get in touch with Ali via LinkedIn, and follow Quadrivia’s activities on their website and on LinkedIn.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3282 no [SNIPPET] - Ali Parsa on ways to validate AI models in clinical practice To discover the whole episode, type "#56 - Building the one clinical AI assistant - Ali Parsa - Quadrivia" on your preferred streaming platform. Tue, 09 Dec 2025 08:35:00 -0000 trailer Mathieu Chaffard To discover the whole episode, type "#56 - Building the one clinical AI assistant - Ali Parsa - Quadrivia" on your preferred streaming platform. To discover the whole episode, type "#56 - Building the one clinical AI assistant - Ali Parsa - Quadrivia" on your preferred streaming platform.


]]> 416 no #55 - Reinventing organ transportation - Lisa Anderson - Paragonix Technologies Do you know how organs are traditionally transported for transplantation purposes? In a cooler filled with ice. When I learned that this approach was the most widespread method, I admit I was quite shocked... We talk here about "living" organs whose preservation is crucial for the success of their transplant! And as you can imagine, these transplants are often vital. The good news is: some people have racked their brains and rolled up their sleeves to change all that! And one of them is none other than Lisa Anderson, Co-Founder and President of Paragonix Technologies. With her team, she has literally redefined how organs could be transported, wiping the slate clean of an archaic, despite standard method. Last year, their technology was named one of TIME’s 200 Best Inventions in the Medical Care category. A technology that allows organs to be preserved and monitored under ideal conditions of temperature, pressure, and perfusion. Since its creation in 2010, the company has enabled the transport of over 10,000 hearts, lungs, kidneys, livers, and pancreases combined to date. A paradigm shift, which not only allows for better preservation of these tissues during transport but is also accompanied by a surprising improvement in transplant outcomes, and helps democratise access to them. We talk about all of this with Lisa, from the complexity of developing such a system to the change management required to lead to its acceptance in the medical field. And everything that this changes for the patients who benefit from it every day. A conversation that dusts off a long-established medical practice and lifts the veil on a unique MedTech success story! Timeline: 00:00:00 - How Lisa got into the transplantation and organ transportation space 00:05:54 - The criticality of organ preservation before a graft 00:08:27 - The parameters to control when transporting organs 00:11:38 - The benefits of improved organ preservation on graft success 00:19:01 - Paragonix Technologies’ clients and commercial models 00:21:20 - Sustainability considerations in the organ transportation business 00:25:29 - Paragonix Technologies’ plans for geographic expansion 00:28:00 - The journey from A to Z of an organ between its donor and recipient 00:30:56 - Changing practices and mindsets around organ transportation 00:33:20 - The engineering challenges around the creation of Paragonix Technologies’ first products 00:40:07 - Matching better the demand and supply of organ transplants What we also talked about with Lisa: Getinge As mentioned by Lisa during the episode, you can have a read at Paragonix Technologies’ latest publications here and find out more about their products and technology on their website. You can get in touch with Lisa via LinkedIn, and follow Paragonix Technologies’ activities on LinkedIn, X, Facebook, and YouTube. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 30 Nov 2025 21:04:00 -0000 full Mathieu Chaffard Do you know how organs are traditionally transported for transplantation purposes? In a cooler filled with ice. When I learned that this approach was the most widespread method, I admit I was quite shocked... We talk here about "living" organs whose preservation is crucial for the success of their transplant! And as you can imagine, these transplants are often vital. The good news is: some people have racked their brains and rolled up their sleeves to change all that! And one of them is none other than Lisa Anderson, Co-Founder and President of Paragonix Technologies. With her team, she has literally redefined how organs could be transported, wiping the slate clean of an archaic, despite standard method. Last year, their technology was named one of TIME’s 200 Best Inventions in the Medical Care category. A technology that allows organs to be preserved and monitored under ideal conditions of temperature, pressure, and perfusion. Since its creation in 2010, the company has enabled the transport of over 10,000 hearts, lungs, kidneys, livers, and pancreases combined to date. A paradigm shift, which not only allows for better preservation of these tissues during transport but is also accompanied by a surprising improvement in transplant outcomes, and helps democratise access to them. We talk about all of this with Lisa, from the complexity of developing such a system to the change management required to lead to its acceptance in the medical field. And everything that this changes for the patients who benefit from it every day. A conversation that dusts off a long-established medical practice and lifts the veil on a unique MedTech success story! Timeline: 00:00:00 - How Lisa got into the transplantation and organ transportation space 00:05:54 - The criticality of organ preservation before a graft 00:08:27 - The parameters to control when transporting organs 00:11:38 - The benefits of improved organ preservation on graft success 00:19:01 - Paragonix Technologies’ clients and commercial models 00:21:20 - Sustainability considerations in the organ transportation business 00:25:29 - Paragonix Technologies’ plans for geographic expansion 00:28:00 - The journey from A to Z of an organ between its donor and recipient 00:30:56 - Changing practices and mindsets around organ transportation 00:33:20 - The engineering challenges around the creation of Paragonix Technologies’ first products 00:40:07 - Matching better the demand and supply of organ transplants What we also talked about with Lisa: Getinge As mentioned by Lisa during the episode, you can have a read at Paragonix Technologies’ latest publications here and find out more about their products and technology on their website. You can get in touch with Lisa via LinkedIn, and follow Paragonix Technologies’ activities on LinkedIn, X, Facebook, and YouTube. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Do you know how organs are traditionally transported for transplantation purposes?

In a cooler filled with ice.

When I learned that this approach was the most widespread method, I admit I was quite shocked...

We talk here about "living" organs whose preservation is crucial for the success of their transplant!

And as you can imagine, these transplants are often vital.

The good news is: some people have racked their brains and rolled up their sleeves to change all that!

And one of them is none other than Lisa Anderson, Co-Founder and President of Paragonix Technologies.

With her team, she has literally redefined how organs could be transported, wiping the slate clean of an archaic, despite standard method.

Last year, their technology was named one of TIME’s 200 Best Inventions in the Medical Care category.

A technology that allows organs to be preserved and monitored under ideal conditions of temperature, pressure, and perfusion.

Since its creation in 2010, the company has enabled the transport of over 10,000 hearts, lungs, kidneys, livers, and pancreases combined to date.

A paradigm shift, which not only allows for better preservation of these tissues during transport but is also accompanied by a surprising improvement in transplant outcomes, and helps democratise access to them.

We talk about all of this with Lisa, from the complexity of developing such a system to the change management required to lead to its acceptance in the medical field.

And everything that this changes for the patients who benefit from it every day.

A conversation that dusts off a long-established medical practice and lifts the veil on a unique MedTech success story!


Timeline:

  • 00:00:00 - How Lisa got into the transplantation and organ transportation space
  • 00:05:54 - The criticality of organ preservation before a graft
  • 00:08:27 - The parameters to control when transporting organs
  • 00:11:38 - The benefits of improved organ preservation on graft success
  • 00:19:01 - Paragonix Technologies’ clients and commercial models
  • 00:21:20 - Sustainability considerations in the organ transportation business
  • 00:25:29 - Paragonix Technologies’ plans for geographic expansion
  • 00:28:00 - The journey from A to Z of an organ between its donor and recipient
  • 00:30:56 - Changing practices and mindsets around organ transportation
  • 00:33:20 - The engineering challenges around the creation of Paragonix Technologies’ first products
  • 00:40:07 - Matching better the demand and supply of organ transplants


What we also talked about with Lisa:


As mentioned by Lisa during the episode, you can have a read at Paragonix Technologies’ latest publications here and find out more about their products and technology on their website.

You can get in touch with Lisa via LinkedIn, and follow Paragonix Technologies’ activities on LinkedIn, X, Facebook, and YouTube.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2878 no [SNIPPET] - Lisa Anderson on the critical parameters for organ preservation To discover the whole episode, type "#55 - Reinventing organ transportation - Lisa Anderson - Paragonix Technologies" on your preferred streaming platform. Sun, 30 Nov 2025 21:01:00 -0000 trailer Mathieu Chaffard To discover the whole episode, type "#55 - Reinventing organ transportation - Lisa Anderson - Paragonix Technologies" on your preferred streaming platform. To discover the whole episode, type "#55 - Reinventing organ transportation - Lisa Anderson - Paragonix Technologies" on your preferred streaming platform.


]]> 270 no #54 - Making the smartphone a psychiatrist - Hannes Klöpper - HelloBetter While studies have yet to prove a direct causal link, the correlation between smartphone use and declining mental health is well-established, a trend especially concerning among young people. But what if the same technology contributing to the problem could also be the solution? It turns out the therapeutic potential of our smartphones for mental health is no longer up for debate, and one company at the forefront of this revolution is HelloBetter. In this episode, we dive into the fascinating world of digital cognitive behavioural therapy with Hannes Klöpper, its Co-Founder and CEO. Hannes breaks down how his team developed one of the world's most extensive portfolios of digital mental health therapies, covering conditions from depression and burnout to panic attacks and vaginismus. These treatments demonstrate how digital-first solutions can be remarkably effective, prescribable by healthcare professionals, and accessible anytime, anywhere. We also explore the game-changing potential of AI and Large Language Models (LLMs) in mental health, and how they are opening new frontiers for preventing and detecting mental health symptoms early! Timeline: 00:00:00 - What drew Hannes to the cause of HelloBetter 00:05:55 - The power of delivering cognitive behavioural therapy through a smartphone 00:11:50 - How HelloBetter supports patients as an intervention for mental health distress 00:16:20 - The mental health conditions for which HelloBetter provides digital therapeutic programs 00:20:24 - How the therapeutic performance of HelloBetter’s programs is evaluated 00:25:39 - The duality of smartphones as vectors of mental illnesses and vehicles for their treatment. 00:28:54 - What AI and LLMs change for mental health care 00:39:15 - How Hannes keeps his own mental health in check What we also talked about with Hannes: Vaginismus Panic attacks ChatGPT Technical University of Munich Stanford University As mentioned by Hannes during the episode, you can have a read at Exits & Outcomes, Second Opinion, and Healthtech Off The Record, three newsletters that provide in-depth insights and news about the healthtech business. You can get in touch with Hannes via LinkedIn, and follow HelloBetter’s activities on their website, LinkedIn, X, Instagram, and Facebook. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 24 Nov 2025 06:19:00 -0000 full Mathieu Chaffard While studies have yet to prove a direct causal link, the correlation between smartphone use and declining mental health is well-established, a trend especially concerning among young people. But what if the same technology contributing to the problem could also be the solution? It turns out the therapeutic potential of our smartphones for mental health is no longer up for debate, and one company at the forefront of this revolution is HelloBetter. In this episode, we dive into the fascinating world of digital cognitive behavioural therapy with Hannes Klöpper, its Co-Founder and CEO. Hannes breaks down how his team developed one of the world's most extensive portfolios of digital mental health therapies, covering conditions from depression and burnout to panic attacks and vaginismus. These treatments demonstrate how digital-first solutions can be remarkably effective, prescribable by healthcare professionals, and accessible anytime, anywhere. We also explore the game-changing potential of AI and Large Language Models (LLMs) in mental health, and how they are opening new frontiers for preventing and detecting mental health symptoms early! Timeline: 00:00:00 - What drew Hannes to the cause of HelloBetter 00:05:55 - The power of delivering cognitive behavioural therapy through a smartphone 00:11:50 - How HelloBetter supports patients as an intervention for mental health distress 00:16:20 - The mental health conditions for which HelloBetter provides digital therapeutic programs 00:20:24 - How the therapeutic performance of HelloBetter’s programs is evaluated 00:25:39 - The duality of smartphones as vectors of mental illnesses and vehicles for their treatment. 00:28:54 - What AI and LLMs change for mental health care 00:39:15 - How Hannes keeps his own mental health in check What we also talked about with Hannes: Vaginismus Panic attacks ChatGPT Technical University of Munich Stanford University As mentioned by Hannes during the episode, you can have a read at Exits & Outcomes, Second Opinion, and Healthtech Off The Record, three newsletters that provide in-depth insights and news about the healthtech business. You can get in touch with Hannes via LinkedIn, and follow HelloBetter’s activities on their website, LinkedIn, X, Instagram, and Facebook. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! While studies have yet to prove a direct causal link, the correlation between smartphone use and declining mental health is well-established, a trend especially concerning among young people.

But what if the same technology contributing to the problem could also be the solution?

It turns out the therapeutic potential of our smartphones for mental health is no longer up for debate, and one company at the forefront of this revolution is HelloBetter.

In this episode, we dive into the fascinating world of digital cognitive behavioural therapy with Hannes Klöpper, its Co-Founder and CEO.

Hannes breaks down how his team developed one of the world's most extensive portfolios of digital mental health therapies, covering conditions from depression and burnout to panic attacks and vaginismus.

These treatments demonstrate how digital-first solutions can be remarkably effective, prescribable by healthcare professionals, and accessible anytime, anywhere.

We also explore the game-changing potential of AI and Large Language Models (LLMs) in mental health, and how they are opening new frontiers for preventing and detecting mental health symptoms early!


Timeline:

00:00:00 - What drew Hannes to the cause of HelloBetter

00:05:55 - The power of delivering cognitive behavioural therapy through a smartphone

00:11:50 - How HelloBetter supports patients as an intervention for mental health distress

00:16:20 - The mental health conditions for which HelloBetter provides digital therapeutic programs

00:20:24 - How the therapeutic performance of HelloBetter’s programs is evaluated

00:25:39 - The duality of smartphones as vectors of mental illnesses and vehicles for their treatment.

00:28:54 - What AI and LLMs change for mental health care

00:39:15 - How Hannes keeps his own mental health in check


What we also talked about with Hannes:


As mentioned by Hannes during the episode, you can have a read at Exits & Outcomes, Second Opinion, and Healthtech Off The Record, three newsletters that provide in-depth insights and news about the healthtech business.

You can get in touch with Hannes via LinkedIn, and follow HelloBetter’s activities on their website, LinkedIn, X, Instagram, and Facebook.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2932 no [SNIPPET] - Hannes Klöpper on the limitations of traditional LLMs for mental health support To discover the whole episode, type "#54 - Making the smartphone a psychiatrist - Hannes Klöpper - HelloBetter" on your preferred streaming platform. Mon, 24 Nov 2025 06:16:00 -0000 trailer Mathieu Chaffard To discover the whole episode, type "#54 - Making the smartphone a psychiatrist - Hannes Klöpper - HelloBetter" on your preferred streaming platform. To discover the whole episode, type "#54 - Making the smartphone a psychiatrist - Hannes Klöpper - HelloBetter" on your preferred streaming platform.


]]> 159 #53 - Engineering living tissue therapeutics - Simon Mackenzie - Cellbricks Therapeutics Is there a future where we will manufacture entire organs? If that's the case, it’s not tomorrow. Yet, the era of regenerative medicine and tissue engineering is very much real and happening now! In some fields, like in dentistry, we are already 3D printing implants that are placed in patients' mouths. In others, like in orthopedic or plastic surgery, cells are harvested from patients to be modified and placed back into their bodies. But what we can't do yet is create complex, functional tissue constructs that can actively remodel and integrate with the human body to restore physiological function. This is the challenge that Simon Mackenzie and his team at Cellbricks Therapeutics are striving to overcome. The technology they have developed is fascinating, sitting at the crossroads of biomaterials, cellular engineering, and 3D printing. A discipline that aims to create the first "tissue therapeutics." The prospects it opens up are incredible: building grafts to heal complex wounds, functional implants for the liver, pancreatic islets for insulin production, and much more! In this episode, we explore the inner workings of this fascinating field and the road ahead before the first tissue therapeutics are used routinely in the clinic, from a technical and regulatory perspective. A thought-provoking conversation offering a glimpse into what a truly "regenerative" medicine could look like in the future! Timeline: 00:00:00 - Simon’s background as a Biochemist and seasoned executive in the life sciences industry 00:08:28 - Defining bioprinting, biofabrication, and tissue therapeutics 00:12:56 - Cellbricks’ mission to recover tissue loss thanks to engineered tissue therapeutics 00:20:52 - Current evidence on the therapeutic potential of biofabricated tissues 00:24:55 - Cellbricks’ biofabrication platform to engineer living tissues 00:30:33 - The challenges around the transport of biofabricated tissues 00:35:36 - The path toward broad use of biofabricated tissues in medicine What we also talked about with Simon: Erik Gatenholm Cellink BICO Aspect Biosystems Daniela Marino Cutiss Organoids L’Oréal Lisa Anderson Paragonix Technologies As suggested by Simon during the episode, you can learn more about biofabrication and tissue engineering on the Advanced Regenerative Manufacturing Institute website. You can get in touch with Simon via LinkedIn, and follow Cellbricks Therapeutics’ activities on their website, and LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 17 Nov 2025 20:50:00 -0000 full Mathieu Chaffard Is there a future where we will manufacture entire organs? If that's the case, it’s not tomorrow. Yet, the era of regenerative medicine and tissue engineering is very much real and happening now! In some fields, like in dentistry, we are already 3D printing implants that are placed in patients' mouths. In others, like in orthopedic or plastic surgery, cells are harvested from patients to be modified and placed back into their bodies. But what we can't do yet is create complex, functional tissue constructs that can actively remodel and integrate with the human body to restore physiological function. This is the challenge that Simon Mackenzie and his team at Cellbricks Therapeutics are striving to overcome. The technology they have developed is fascinating, sitting at the crossroads of biomaterials, cellular engineering, and 3D printing. A discipline that aims to create the first "tissue therapeutics." The prospects it opens up are incredible: building grafts to heal complex wounds, functional implants for the liver, pancreatic islets for insulin production, and much more! In this episode, we explore the inner workings of this fascinating field and the road ahead before the first tissue therapeutics are used routinely in the clinic, from a technical and regulatory perspective. A thought-provoking conversation offering a glimpse into what a truly "regenerative" medicine could look like in the future! Timeline: 00:00:00 - Simon’s background as a Biochemist and seasoned executive in the life sciences industry 00:08:28 - Defining bioprinting, biofabrication, and tissue therapeutics 00:12:56 - Cellbricks’ mission to recover tissue loss thanks to engineered tissue therapeutics 00:20:52 - Current evidence on the therapeutic potential of biofabricated tissues 00:24:55 - Cellbricks’ biofabrication platform to engineer living tissues 00:30:33 - The challenges around the transport of biofabricated tissues 00:35:36 - The path toward broad use of biofabricated tissues in medicine What we also talked about with Simon: Erik Gatenholm Cellink BICO Aspect Biosystems Daniela Marino Cutiss Organoids L’Oréal Lisa Anderson Paragonix Technologies As suggested by Simon during the episode, you can learn more about biofabrication and tissue engineering on the Advanced Regenerative Manufacturing Institute website. You can get in touch with Simon via LinkedIn, and follow Cellbricks Therapeutics’ activities on their website, and LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Is there a future where we will manufacture entire organs?

If that's the case, it’s not tomorrow.

Yet, the era of regenerative medicine and tissue engineering is very much real and happening now!

In some fields, like in dentistry, we are already 3D printing implants that are placed in patients' mouths.

In others, like in orthopedic or plastic surgery, cells are harvested from patients to be modified and placed back into their bodies.

But what we can't do yet is create complex, functional tissue constructs that can actively remodel and integrate with the human body to restore physiological function.

This is the challenge that Simon Mackenzie and his team at Cellbricks Therapeutics are striving to overcome.

The technology they have developed is fascinating, sitting at the crossroads of biomaterials, cellular engineering, and 3D printing.

A discipline that aims to create the first "tissue therapeutics."

The prospects it opens up are incredible: building grafts to heal complex wounds, functional implants for the liver, pancreatic islets for insulin production, and much more!

In this episode, we explore the inner workings of this fascinating field and the road ahead before the first tissue therapeutics are used routinely in the clinic, from a technical and regulatory perspective.

A thought-provoking conversation offering a glimpse into what a truly "regenerative" medicine could look like in the future!


Timeline:

  • 00:00:00 - Simon’s background as a Biochemist and seasoned executive in the life sciences industry
  • 00:08:28 - Defining bioprinting, biofabrication, and tissue therapeutics
  • 00:12:56 - Cellbricks’ mission to recover tissue loss thanks to engineered tissue therapeutics
  • 00:20:52 - Current evidence on the therapeutic potential of biofabricated tissues
  • 00:24:55 - Cellbricks’ biofabrication platform to engineer living tissues
  • 00:30:33 - The challenges around the transport of biofabricated tissues
  • 00:35:36 - The path toward broad use of biofabricated tissues in medicine


What we also talked about with Simon:


As suggested by Simon during the episode, you can learn more about biofabrication and tissue engineering on the Advanced Regenerative Manufacturing Institute website.

You can get in touch with Simon via LinkedIn, and follow Cellbricks Therapeutics’ activities on their website, and LinkedIn.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3096 no [SNIPPET] - Simon Mackenzie on the definition of bioprinting To discover the whole episode, type "#53 - Engineering living tissue therapeutics - Simon Mackenzie - Cellbricks Therapeutics" on your preferred streaming platform. Mon, 17 Nov 2025 20:46:00 -0000 full Mathieu Chaffard To discover the whole episode, type "#53 - Engineering living tissue therapeutics - Simon Mackenzie - Cellbricks Therapeutics" on your preferred streaming platform. To discover the whole episode, type "#53 - Engineering living tissue therapeutics - Simon Mackenzie - Cellbricks Therapeutics" on your preferred streaming platform.


]]> 323 no #52 - Sensing hydration through the skin - Mark Kendall - WearOptimo Is there a simple way to know your hydration level? Not really. It's a surprising reality, considering our bodies are composed of roughly 60% water. When you consider that half of all people drink less than recommended and that chronic dehydration leads to an increased risk of chronic diseases and premature mortality, it becomes clear that monitoring this parameter daily is a public health imperative. The good news is that Mark Kendall and his team at WearOptimo have developed a technology that could be a game-changer. It's a wearable sensor, similar to a continuous glucose monitoring (CGM) patch, capable of continuously and non-invasively measuring our body's water content at any given moment—a technological feat that relies on one of our largest water reservoirs: our skin. In this episode, we unpack how Mark and his team developed this sensor and explore the science behind how it works. We discuss what this could change for our understanding of human physiology, not only in extreme situations for elite athletes but, more importantly, in our everyday lives. Join us for an episode on the fundamental role of water in the body, the skin's critical role in its regulation, and the window of opportunity this organ opens for sensing other essential molecules right from its surface! Timeline: 00:00:00 - Mark’s journey as a biomedical engineer creating technologies for drug delivery and sensing through the skin 00:05:10 - The dehydration pandemic and the opportunity around hydration sensing 00:12:34 - Building a skin patch to monitor hydration levels with clinical-grade precision and no needle 00:22:47 - Relevant use cases for the WearOptimo sensor and complementarity with other wearables 00:25:40 - Going toward one wearable platform to measure multiple biomarkers at once 00:27:20 - The next steps for WearOptimo and scaling up its commercialisation efforts 00:29:55 - Working alongside ex-Formula 1 driver Mark Webber to understand hydration in elite athletes 00:34:10 - Mark’s tips and tricks to stay hydrated What we also talked about with Mark: Gates Foundation Nanopatch Continuous Glucose Monitoring Whole-body impedance Formula 1 Mark Webber Oscar Piastri Prof. Robert Langer Moderna We mentioned with Mark some of the past episodes of the series: #39 - Crafting the best connected health experience - Matthieu Menanteau - Withings #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio As suggested by Mark during the episode, you can learn more about the long-term health outcomes associated with hydration status by reading the paper from Natalia I. Dmitrieva et al. published in Nature Reviews Nephrology in 2024. You can also watch Mark’s TED Talk about the Nanopatch, the needle-free immunisation technology that he pioneered, on YouTube. You can get in touch with Mark via LinkedIn, and follow WearOptimo’s activities on their website, LinkedIn, and X. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 10 Nov 2025 20:36:00 -0000 full Mathieu Chaffard Is there a simple way to know your hydration level? Not really. It's a surprising reality, considering our bodies are composed of roughly 60% water. When you consider that half of all people drink less than recommended and that chronic dehydration leads to an increased risk of chronic diseases and premature mortality, it becomes clear that monitoring this parameter daily is a public health imperative. The good news is that Mark Kendall and his team at WearOptimo have developed a technology that could be a game-changer. It's a wearable sensor, similar to a continuous glucose monitoring (CGM) patch, capable of continuously and non-invasively measuring our body's water content at any given moment—a technological feat that relies on one of our largest water reservoirs: our skin. In this episode, we unpack how Mark and his team developed this sensor and explore the science behind how it works. We discuss what this could change for our understanding of human physiology, not only in extreme situations for elite athletes but, more importantly, in our everyday lives. Join us for an episode on the fundamental role of water in the body, the skin's critical role in its regulation, and the window of opportunity this organ opens for sensing other essential molecules right from its surface! Timeline: 00:00:00 - Mark’s journey as a biomedical engineer creating technologies for drug delivery and sensing through the skin 00:05:10 - The dehydration pandemic and the opportunity around hydration sensing 00:12:34 - Building a skin patch to monitor hydration levels with clinical-grade precision and no needle 00:22:47 - Relevant use cases for the WearOptimo sensor and complementarity with other wearables 00:25:40 - Going toward one wearable platform to measure multiple biomarkers at once 00:27:20 - The next steps for WearOptimo and scaling up its commercialisation efforts 00:29:55 - Working alongside ex-Formula 1 driver Mark Webber to understand hydration in elite athletes 00:34:10 - Mark’s tips and tricks to stay hydrated What we also talked about with Mark: Gates Foundation Nanopatch Continuous Glucose Monitoring Whole-body impedance Formula 1 Mark Webber Oscar Piastri Prof. Robert Langer Moderna We mentioned with Mark some of the past episodes of the series: #39 - Crafting the best connected health experience - Matthieu Menanteau - Withings #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio As suggested by Mark during the episode, you can learn more about the long-term health outcomes associated with hydration status by reading the paper from Natalia I. Dmitrieva et al. published in Nature Reviews Nephrology in 2024. You can also watch Mark’s TED Talk about the Nanopatch, the needle-free immunisation technology that he pioneered, on YouTube. You can get in touch with Mark via LinkedIn, and follow WearOptimo’s activities on their website, LinkedIn, and X. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Is there a simple way to know your hydration level?

Not really.

It's a surprising reality, considering our bodies are composed of roughly 60% water.

When you consider that half of all people drink less than recommended and that chronic dehydration leads to an increased risk of chronic diseases and premature mortality, it becomes clear that monitoring this parameter daily is a public health imperative.

The good news is that Mark Kendall and his team at WearOptimo have developed a technology that could be a game-changer.

It's a wearable sensor, similar to a continuous glucose monitoring (CGM) patch, capable of continuously and non-invasively measuring our body's water content at any given moment—a technological feat that relies on one of our largest water reservoirs: our skin.

In this episode, we unpack how Mark and his team developed this sensor and explore the science behind how it works.

We discuss what this could change for our understanding of human physiology, not only in extreme situations for elite athletes but, more importantly, in our everyday lives.

Join us for an episode on the fundamental role of water in the body, the skin's critical role in its regulation, and the window of opportunity this organ opens for sensing other essential molecules right from its surface!


Timeline:

  • 00:00:00 - Mark’s journey as a biomedical engineer creating technologies for drug delivery and sensing through the skin
  • 00:05:10 - The dehydration pandemic and the opportunity around hydration sensing
  • 00:12:34 - Building a skin patch to monitor hydration levels with clinical-grade precision and no needle
  • 00:22:47 - Relevant use cases for the WearOptimo sensor and complementarity with other wearables
  • 00:25:40 - Going toward one wearable platform to measure multiple biomarkers at once
  • 00:27:20 - The next steps for WearOptimo and scaling up its commercialisation efforts
  • 00:29:55 - Working alongside ex-Formula 1 driver Mark Webber to understand hydration in elite athletes
  • 00:34:10 - Mark’s tips and tricks to stay hydrated


What we also talked about with Mark:


We mentioned with Mark some of the past episodes of the series:


As suggested by Mark during the episode, you can learn more about the long-term health outcomes associated with hydration status by reading the paper from Natalia I. Dmitrieva et al. published in Nature Reviews Nephrology in 2024.

You can also watch Mark’s TED Talk about the Nanopatch, the needle-free immunisation technology that he pioneered, on YouTube.

You can get in touch with Mark via LinkedIn, and follow WearOptimo’s activities on their website, LinkedIn, and X.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2759 no [SNIPPET] - Mark Kendall on the current dehydration pandemic To discover the whole episode, type "#52 - Sensing hydration through the skin - Mark Kendall - WearOptimo" on your preferred streaming platform. Mon, 10 Nov 2025 20:33:00 -0000 full Mathieu Chaffard To discover the whole episode, type "#52 - Sensing hydration through the skin - Mark Kendall - WearOptimo" on your preferred streaming platform. To discover the whole episode, type "#52 - Sensing hydration through the skin - Mark Kendall - WearOptimo" on your preferred streaming platform.


]]> 220 no #51 - Bridging Web3 and healthcare - Anca Petre - Tech Anatomy Three years after the 2022 "crypto winter" severely damaged public confidence in these technologies (even among healthcare leaders), the term Web3 is conspicuously absent from the current healthtech space. So, what happened? And where do we really stand with the adoption of these technologies within our healthcare systems? Anca Petre is perfectly positioned to give us answers. A trained pharmacist, she has been exploring Web3 and its healthcare applications for over eight years, speaking on the international stage to educate and share key insights on using these technologies to improve health outcomes. Her assessment is stark: while the core value proposition of Web3 in health remains intact—offering breakthroughs in traceability, security, and patient control over data—its adoption by key players is still marginal. In this episode, Anca shares her analysis of the current landscape, her belief in the untapped potential of these technologies, and a preview of what tomorrow's medical research could look like, powered by decentralised science. Tune in for a conversation with a true health geek, one with her feet firmly planted in the realities of today's systems! Timeline: 00:00:00 - Anca’s journey at the interface of healthcare, Web3, and content creation 00:04:14 - Today’s value proposition and use cases for Web3 in healthcare 00:07:02 - Why we hear less about Web3 in healthcare these days 00:13:51 - Making the Web3 user experience flawless in healthcare 00:16:50 - Where Web3 did not live up to its promises in healthcare 00:18:32 - The interplays of Web3 and AI in healthcare 00:24:39 - Healthcare innovation and its dependencies on systemic changes 00:33:49 - Paving a new way for medical research with decentralised science What we also talked about with Anca: Jim Nasr MedShake Studio ChatGPT Metaverse NFTs Decentralised Autonomous Organisation (DAO) DeSci Nordics We cited with Anca some of the past episodes of the series: #10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation As suggested by Anca during the episode, you can learn more about Web3 and its applications in healthcare through the podcast Tech Anatomy that she is hosting and producing. For further information on the topic, she recommends consulting IEEE.org, following Allie K. Miller’s work, and looking at Molecule.xyz in case you want to dive deeper into decentralised science. You can follow Anca’s activities on LinkedIn, X, and YouTube, and discover the other podcasts she is producing for healthcare clients with MedShake Studio! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 02 Nov 2025 21:18:00 -0000 full Mathieu Chaffard Three years after the 2022 "crypto winter" severely damaged public confidence in these technologies (even among healthcare leaders), the term Web3 is conspicuously absent from the current healthtech space. So, what happened? And where do we really stand with the adoption of these technologies within our healthcare systems? Anca Petre is perfectly positioned to give us answers. A trained pharmacist, she has been exploring Web3 and its healthcare applications for over eight years, speaking on the international stage to educate and share key insights on using these technologies to improve health outcomes. Her assessment is stark: while the core value proposition of Web3 in health remains intact—offering breakthroughs in traceability, security, and patient control over data—its adoption by key players is still marginal. In this episode, Anca shares her analysis of the current landscape, her belief in the untapped potential of these technologies, and a preview of what tomorrow's medical research could look like, powered by decentralised science. Tune in for a conversation with a true health geek, one with her feet firmly planted in the realities of today's systems! Timeline: 00:00:00 - Anca’s journey at the interface of healthcare, Web3, and content creation 00:04:14 - Today’s value proposition and use cases for Web3 in healthcare 00:07:02 - Why we hear less about Web3 in healthcare these days 00:13:51 - Making the Web3 user experience flawless in healthcare 00:16:50 - Where Web3 did not live up to its promises in healthcare 00:18:32 - The interplays of Web3 and AI in healthcare 00:24:39 - Healthcare innovation and its dependencies on systemic changes 00:33:49 - Paving a new way for medical research with decentralised science What we also talked about with Anca: Jim Nasr MedShake Studio ChatGPT Metaverse NFTs Decentralised Autonomous Organisation (DAO) DeSci Nordics We cited with Anca some of the past episodes of the series: #10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation As suggested by Anca during the episode, you can learn more about Web3 and its applications in healthcare through the podcast Tech Anatomy that she is hosting and producing. For further information on the topic, she recommends consulting IEEE.org, following Allie K. Miller’s work, and looking at Molecule.xyz in case you want to dive deeper into decentralised science. You can follow Anca’s activities on LinkedIn, X, and YouTube, and discover the other podcasts she is producing for healthcare clients with MedShake Studio! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Three years after the 2022 "crypto winter" severely damaged public confidence in these technologies (even among healthcare leaders), the term Web3 is conspicuously absent from the current healthtech space.

So, what happened?

And where do we really stand with the adoption of these technologies within our healthcare systems?

Anca Petre is perfectly positioned to give us answers.

A trained pharmacist, she has been exploring Web3 and its healthcare applications for over eight years, speaking on the international stage to educate and share key insights on using these technologies to improve health outcomes.

Her assessment is stark: while the core value proposition of Web3 in health remains intact—offering breakthroughs in traceability, security, and patient control over data—its adoption by key players is still marginal.

In this episode, Anca shares her analysis of the current landscape, her belief in the untapped potential of these technologies, and a preview of what tomorrow's medical research could look like, powered by decentralised science.

Tune in for a conversation with a true health geek, one with her feet firmly planted in the realities of today's systems!


Timeline:

  • 00:00:00 - Anca’s journey at the interface of healthcare, Web3, and content creation
  • 00:04:14 - Today’s value proposition and use cases for Web3 in healthcare
  • 00:07:02 - Why we hear less about Web3 in healthcare these days
  • 00:13:51 - Making the Web3 user experience flawless in healthcare
  • 00:16:50 - Where Web3 did not live up to its promises in healthcare
  • 00:18:32 - The interplays of Web3 and AI in healthcare
  • 00:24:39 - Healthcare innovation and its dependencies on systemic changes
  • 00:33:49 - Paving a new way for medical research with decentralised science


What we also talked about with Anca:


We cited with Anca some of the past episodes of the series:


As suggested by Anca during the episode, you can learn more about Web3 and its applications in healthcare through the podcast Tech Anatomy that she is hosting and producing.

For further information on the topic, she recommends consulting IEEE.org, following Allie K. Miller’s work, and looking at Molecule.xyz in case you want to dive deeper into decentralised science.

You can follow Anca’s activities on LinkedIn, X, and YouTube, and discover the other podcasts she is producing for healthcare clients with MedShake Studio!

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3165 no [SNIPPET] - Anca Petre on the power of decentralised science To discover the whole episode, type "#51 - Bridging web3 and healthcare - Anca Petre - Tech Anatomy" on your preferred streaming platform. Sun, 02 Nov 2025 17:27:00 -0000 full Mathieu Chaffard To discover the whole episode, type "#51 - Bridging web3 and healthcare - Anca Petre - Tech Anatomy" on your preferred streaming platform. To discover the whole episode, type "#51 - Bridging web3 and healthcare - Anca Petre - Tech Anatomy" on your preferred streaming platform.


]]> 316 no #50 - Scaling drug discovery with quantum physics and AI - Maximilien Levesque - Aqemia What's the link between quantum physics, AI, and drug discovery? Maximilien Levesque might be the perfect person to answer. A former theoretical physicist, he realised his research could transform drug development by fundamentally understanding how molecules interact at the atomic level. In 2019, he co-founded Aqemia with Emmanuelle Martiano Rolland to turn that vision into reality. Their mission is bold: to design new molecules, atom by atom, capable of binding "undruggable" therapeutic targets. Unlike AI models that base themselves on existing compounds, Aqemia's generative engine creates novel structures, opening up a new universe of possibilities. In this episode, Maximilien pulls back the curtain on one of TechBio's most promising startups. With passion and clarity, he breaks down their approach to drug design, explaining how these "digitally-native" compounds go from the numeric world to real-world testing. A conversation to understand the ins and outs of an ongoing revolution in the pharmaceutical industry! Timeline: 00:00:00 - Maximilien’s background as a researcher in mathematics and quantum physics 00:03:46 - What drew Maximilien to drug discovery 00:05:43 - The link between quantum physics and drug discovery 00:10:27 - Aqemia’s technology to design new molecules atom-by-atom 00:18:36 - Aqemia’s pipeline and ongoing preclinical programs 00:20:27 - The difference between AI-based drug discovery and physics-based drug discovery 00:27:55 - Striking a balance between internal development programs and external collaborations 00:32:35 - Aqemia’s approach to talent recruitment at the interface of biology, mathematics, and computer science 00:34:23 - Maximilien’s wish to enter clinical trials in 2026 What we also talked about with Maximilien: HIMSS Europe École Normale Supérieur (ENS) Centre National de la Recherche Scientifique (CNRS) Commissariat à l’Énergie Atomique et aux Énergies Alternatives (CEA) Ornstein-Zernike equation American Institute of Physics Sanofi Institut Gustave Roussy We cited with Maximilien some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin #33 - Building the next TechBio venture - Mati Gill - AION Labs #13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas You can learn more about Maximilien’s publications here and prompt ChatGPT, as he suggested, to find out more about quantum physics, AI, and their applications in the field of drug discovery! You can reach out to Maximilien via LinkedIn and follow Aqemia’s activities on their website and LinkedIn page! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 26 Oct 2025 21:41:00 -0000 full Mathieu Chaffard What's the link between quantum physics, AI, and drug discovery? Maximilien Levesque might be the perfect person to answer. A former theoretical physicist, he realised his research could transform drug development by fundamentally understanding how molecules interact at the atomic level. In 2019, he co-founded Aqemia with Emmanuelle Martiano Rolland to turn that vision into reality. Their mission is bold: to design new molecules, atom by atom, capable of binding "undruggable" therapeutic targets. Unlike AI models that base themselves on existing compounds, Aqemia's generative engine creates novel structures, opening up a new universe of possibilities. In this episode, Maximilien pulls back the curtain on one of TechBio's most promising startups. With passion and clarity, he breaks down their approach to drug design, explaining how these "digitally-native" compounds go from the numeric world to real-world testing. A conversation to understand the ins and outs of an ongoing revolution in the pharmaceutical industry! Timeline: 00:00:00 - Maximilien’s background as a researcher in mathematics and quantum physics 00:03:46 - What drew Maximilien to drug discovery 00:05:43 - The link between quantum physics and drug discovery 00:10:27 - Aqemia’s technology to design new molecules atom-by-atom 00:18:36 - Aqemia’s pipeline and ongoing preclinical programs 00:20:27 - The difference between AI-based drug discovery and physics-based drug discovery 00:27:55 - Striking a balance between internal development programs and external collaborations 00:32:35 - Aqemia’s approach to talent recruitment at the interface of biology, mathematics, and computer science 00:34:23 - Maximilien’s wish to enter clinical trials in 2026 What we also talked about with Maximilien: HIMSS Europe École Normale Supérieur (ENS) Centre National de la Recherche Scientifique (CNRS) Commissariat à l’Énergie Atomique et aux Énergies Alternatives (CEA) Ornstein-Zernike equation American Institute of Physics Sanofi Institut Gustave Roussy We cited with Maximilien some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin #33 - Building the next TechBio venture - Mati Gill - AION Labs #13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas You can learn more about Maximilien’s publications here and prompt ChatGPT, as he suggested, to find out more about quantum physics, AI, and their applications in the field of drug discovery! You can reach out to Maximilien via LinkedIn and follow Aqemia’s activities on their website and LinkedIn page! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! What's the link between quantum physics, AI, and drug discovery?

Maximilien Levesque might be the perfect person to answer.

A former theoretical physicist, he realised his research could transform drug development by fundamentally understanding how molecules interact at the atomic level.

In 2019, he co-founded Aqemia with Emmanuelle Martiano Rolland to turn that vision into reality.

Their mission is bold: to design new molecules, atom by atom, capable of binding "undruggable" therapeutic targets.

Unlike AI models that base themselves on existing compounds, Aqemia's generative engine creates novel structures, opening up a new universe of possibilities.

In this episode, Maximilien pulls back the curtain on one of TechBio's most promising startups.

With passion and clarity, he breaks down their approach to drug design, explaining how these "digitally-native" compounds go from the numeric world to real-world testing.

A conversation to understand the ins and outs of an ongoing revolution in the pharmaceutical industry!


Timeline:

  • 00:00:00 - Maximilien’s background as a researcher in mathematics and quantum physics
  • 00:03:46 - What drew Maximilien to drug discovery
  • 00:05:43 - The link between quantum physics and drug discovery
  • 00:10:27 - Aqemia’s technology to design new molecules atom-by-atom
  • 00:18:36 - Aqemia’s pipeline and ongoing preclinical programs
  • 00:20:27 - The difference between AI-based drug discovery and physics-based drug discovery
  • 00:27:55 - Striking a balance between internal development programs and external collaborations
  • 00:32:35 - Aqemia’s approach to talent recruitment at the interface of biology, mathematics, and computer science
  • 00:34:23 - Maximilien’s wish to enter clinical trials in 2026


What we also talked about with Maximilien:


We cited with Maximilien some of the past episodes of the series:


You can learn more about Maximilien’s publications here and prompt ChatGPT, as he suggested, to find out more about quantum physics, AI, and their applications in the field of drug discovery!

You can reach out to Maximilien via LinkedIn and follow Aqemia’s activities on their website and LinkedIn page!

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2779 no [SNIPPET] - Maximilien Levesque on the power of quantum physics and AI for drug discovery To discover the whole episode, type "#50 - Scaling drug discovery with quantum physics and AI - Maximilien Levesque - Aqemia" on your preferred streaming platform. Sun, 26 Oct 2025 21:34:00 -0000 full Mathieu Chaffard To discover the whole episode, type "#50 - Scaling drug discovery with quantum physics and AI - Maximilien Levesque - Aqemia" on your preferred streaming platform. To discover the whole episode, type "#50 - Scaling drug discovery with quantum physics and AI - Maximilien Levesque - Aqemia" on your preferred streaming platform.


]]> 186 no #49 - Reverse-engineering cancer survival - Nicolas Wolikow - Cure51 Can we learn from extreme cancer survivors to develop new treatments? This is the bet that Nicolas Wolikow and his team at Cure51 are making. Backed by the world's top cancer centers and specialists, they work around the clock to build the largest-ever health dataset of patients who defied the odds—people diagnosed with stage 4 cancer who were given a few months to live, yet survived more than five years. The goal is to understand what makes their biology unique and what characterises their incredible response to the treatments they received. A unique approach to identify new therapeutic targets and enrich our arsenal against a disease whose incidence continues to grow day by day. In this episode, Nicolas lifts the veil on the rigorous method they follow to achieve this feat, from the collection of clinical and multi-omics data to the identification of these targets and their validation in clinical trials. A method to reverse-engineer cancer survival, founded on the latest progress in computational biology, and whose success depends on the close collaboration between patients, hospitals, and industrial partners! Timeline: 00:00:00 - Nicolas’ background as an entrepreneur at the interface of healthcare, technology, and digital innovation 00:06:45 - Understanding the mechanisms behind cancer thanks to exceptional survivors 00:10:24 - Stories of patients in full remission after a stage 4 cancer diagnosis 00:12:21 - Building the platform to host the largest dataset of cancer survivors ever made 00:14:36 - Making sense of the survivors’ data to identify underlying biological mechanisms 00:19:28 - Early findings and novel therapeutic targets investigated so far 00:28:18 - The economic model behind Cure51 00:30:45 - Convincing hospitals and health systems to join Cure51’s mission What we also talked about with Nicolas: HLTH Europe Cancer stages Chemotherapy Rosalind Franklin Variant.bio We cited with Nicolas some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin As Nicolas mentioned during the episode, you can learn more about Cure51’s activities on their website, and follow their latest news on LinkedIn, Instagram, and Facebook. You can reach out to Nicolas via LinkedIn and find more details about the ROSALIND study in this abstract. To hear Camille Moses’ incredible story as a cancer survivor, we invite you to listen to her testimonial on the Project Purple podcast. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 19 Oct 2025 21:33:00 -0000 full Mathieu Chaffard Can we learn from extreme cancer survivors to develop new treatments? This is the bet that Nicolas Wolikow and his team at Cure51 are making. Backed by the world's top cancer centers and specialists, they work around the clock to build the largest-ever health dataset of patients who defied the odds—people diagnosed with stage 4 cancer who were given a few months to live, yet survived more than five years. The goal is to understand what makes their biology unique and what characterises their incredible response to the treatments they received. A unique approach to identify new therapeutic targets and enrich our arsenal against a disease whose incidence continues to grow day by day. In this episode, Nicolas lifts the veil on the rigorous method they follow to achieve this feat, from the collection of clinical and multi-omics data to the identification of these targets and their validation in clinical trials. A method to reverse-engineer cancer survival, founded on the latest progress in computational biology, and whose success depends on the close collaboration between patients, hospitals, and industrial partners! Timeline: 00:00:00 - Nicolas’ background as an entrepreneur at the interface of healthcare, technology, and digital innovation 00:06:45 - Understanding the mechanisms behind cancer thanks to exceptional survivors 00:10:24 - Stories of patients in full remission after a stage 4 cancer diagnosis 00:12:21 - Building the platform to host the largest dataset of cancer survivors ever made 00:14:36 - Making sense of the survivors’ data to identify underlying biological mechanisms 00:19:28 - Early findings and novel therapeutic targets investigated so far 00:28:18 - The economic model behind Cure51 00:30:45 - Convincing hospitals and health systems to join Cure51’s mission What we also talked about with Nicolas: HLTH Europe Cancer stages Chemotherapy Rosalind Franklin Variant.bio We cited with Nicolas some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin As Nicolas mentioned during the episode, you can learn more about Cure51’s activities on their website, and follow their latest news on LinkedIn, Instagram, and Facebook. You can reach out to Nicolas via LinkedIn and find more details about the ROSALIND study in this abstract. To hear Camille Moses’ incredible story as a cancer survivor, we invite you to listen to her testimonial on the Project Purple podcast. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Can we learn from extreme cancer survivors to develop new treatments?

This is the bet that Nicolas Wolikow and his team at Cure51 are making.

Backed by the world's top cancer centers and specialists, they work around the clock to build the largest-ever health dataset of patients who defied the odds—people diagnosed with stage 4 cancer who were given a few months to live, yet survived more than five years.

The goal is to understand what makes their biology unique and what characterises their incredible response to the treatments they received.

A unique approach to identify new therapeutic targets and enrich our arsenal against a disease whose incidence continues to grow day by day.

In this episode, Nicolas lifts the veil on the rigorous method they follow to achieve this feat, from the collection of clinical and multi-omics data to the identification of these targets and their validation in clinical trials.

A method to reverse-engineer cancer survival, founded on the latest progress in computational biology, and whose success depends on the close collaboration between patients, hospitals, and industrial partners!


Timeline:

  • 00:00:00 - Nicolas’ background as an entrepreneur at the interface of healthcare, technology, and digital innovation
  • 00:06:45 - Understanding the mechanisms behind cancer thanks to exceptional survivors
  • 00:10:24 - Stories of patients in full remission after a stage 4 cancer diagnosis
  • 00:12:21 - Building the platform to host the largest dataset of cancer survivors ever made
  • 00:14:36 - Making sense of the survivors’ data to identify underlying biological mechanisms
  • 00:19:28 - Early findings and novel therapeutic targets investigated so far
  • 00:28:18 - The economic model behind Cure51
  • 00:30:45 - Convincing hospitals and health systems to join Cure51’s mission


What we also talked about with Nicolas:


We cited with Nicolas some of the past episodes of the series:


As Nicolas mentioned during the episode, you can learn more about Cure51’s activities on their website, and follow their latest news on LinkedIn, Instagram, and Facebook.

You can reach out to Nicolas via LinkedIn and find more details about the ROSALIND study in this abstract.

To hear Camille Moses’ incredible story as a cancer survivor, we invite you to listen to her testimonial on the Project Purple podcast.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2626 no [SNIPPET] - Nicolas Wolikow on understanding the mechanisms behind cancer To discover the whole episode, type "#49 - Reverse-engineering cancer survival - Nicolas Wolikow - Cure51" on your preferred streaming platform. Sun, 19 Oct 2025 21:31:00 -0000 full Mathieu Chaffard To discover the whole episode, type "#49 - Reverse-engineering cancer survival - Nicolas Wolikow - Cure51" on your preferred streaming platform. To discover the whole episode, type "#49 - Reverse-engineering cancer survival - Nicolas Wolikow - Cure51" on your preferred streaming platform.


]]> 232 no #48 - Driving precision medicine with real-world data - Blythe Adamson - Flatiron Health Disclaimer: Blythe and I both work for Roche; nevertheless, all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. What's really behind the term "real-world data" in clinical science? And what can it actually be used for? I asked Blythe Adamson of Flatiron Health to find out the answer. It turns out real-world data is all the medical data collected in the “real world”, meaning outside of any clinical trial. In other words, it's the vast majority of medical data that exists. This includes everything from the results of blood tests, scans, and vaccinations to doctors' handwritten notes. While the idea of using it to develop new treatments seems obvious, the reality is far from simple. Because access to this data is disparate and varies from one country to another. Because the diversity of their modality renders their interpretation complex. And because until recently, we did not have the computational tools to make it work. But now, in the age of AI and mass digitalisation of healthcare, all of this is changing at lightning speed. Drawing on her expertise at the intersection of epidemiology, data science, and health policy, Blythe walks us through the immense challenges and opportunities of real-world data, and how they are poised to revolutionise the development of tomorrow's therapies. An episode to understand precision medicine and the central role of real-world evidence! Timeline: 00:00:00 - Blythe’s background at the interface of epidemiology, data science, and health policy 00:09:33 - The power of real-world data in medicine and drug development 00:17:11 - The barriers to accessing and leveraging real-world data at scale 00:20:26 - Two examples where AI can help make sense of real-world data 00:25:46 - Traditionally overlooked real-world data modalities in medicine 00:27:52 - Breaking down language barriers across real-world datasets 00:35:10 - Some predictions on the next AI-driven breakthroughs in oncology What we also talked about with Blythe: Operation Warp Speed Resilience Patient-Reported Outcome Measures (PROMs) Trusted Research Environments De-identification American Society of Clinical Oncology (ASCO) Circulating tumor DNA (ctDNA) American Heart Association European Society of Cardiology We cited with Blythe some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin As Blythe mentioned during the episode, you can visit her blog at blytheadamson.com for more information about her work. The book recommended by Blythe is Spillover: Animal Infections and the Next Human Pandemic by David Quammen. You can get in touch with Blythe via LinkedIn, and follow the activities of Flatiron Health on LinkedIn, X, and Instagram. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 21 Sep 2025 19:51:00 -0000 full Mathieu Chaffard Disclaimer: Blythe and I both work for Roche; nevertheless, all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. What's really behind the term "real-world data" in clinical science? And what can it actually be used for? I asked Blythe Adamson of Flatiron Health to find out the answer. It turns out real-world data is all the medical data collected in the “real world”, meaning outside of any clinical trial. In other words, it's the vast majority of medical data that exists. This includes everything from the results of blood tests, scans, and vaccinations to doctors' handwritten notes. While the idea of using it to develop new treatments seems obvious, the reality is far from simple. Because access to this data is disparate and varies from one country to another. Because the diversity of their modality renders their interpretation complex. And because until recently, we did not have the computational tools to make it work. But now, in the age of AI and mass digitalisation of healthcare, all of this is changing at lightning speed. Drawing on her expertise at the intersection of epidemiology, data science, and health policy, Blythe walks us through the immense challenges and opportunities of real-world data, and how they are poised to revolutionise the development of tomorrow's therapies. An episode to understand precision medicine and the central role of real-world evidence! Timeline: 00:00:00 - Blythe’s background at the interface of epidemiology, data science, and health policy 00:09:33 - The power of real-world data in medicine and drug development 00:17:11 - The barriers to accessing and leveraging real-world data at scale 00:20:26 - Two examples where AI can help make sense of real-world data 00:25:46 - Traditionally overlooked real-world data modalities in medicine 00:27:52 - Breaking down language barriers across real-world datasets 00:35:10 - Some predictions on the next AI-driven breakthroughs in oncology What we also talked about with Blythe: Operation Warp Speed Resilience Patient-Reported Outcome Measures (PROMs) Trusted Research Environments De-identification American Society of Clinical Oncology (ASCO) Circulating tumor DNA (ctDNA) American Heart Association European Society of Cardiology We cited with Blythe some of the past episodes of the series: #40 - Cracking biology through AI - JP Vert - Owkin As Blythe mentioned during the episode, you can visit her blog at blytheadamson.com for more information about her work. The book recommended by Blythe is Spillover: Animal Infections and the Next Human Pandemic by David Quammen. You can get in touch with Blythe via LinkedIn, and follow the activities of Flatiron Health on LinkedIn, X, and Instagram. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Disclaimer: Blythe and I both work for Roche; nevertheless, all opinions expressed in this episode are our own and do not necessarily represent the position of our employer.


What's really behind the term "real-world data" in clinical science?

And what can it actually be used for?

I asked Blythe Adamson of Flatiron Health to find out the answer.

It turns out real-world data is all the medical data collected in the “real world”, meaning outside of any clinical trial.

In other words, it's the vast majority of medical data that exists.

This includes everything from the results of blood tests, scans, and vaccinations to doctors' handwritten notes.

While the idea of using it to develop new treatments seems obvious, the reality is far from simple.

Because access to this data is disparate and varies from one country to another.

Because the diversity of their modality renders their interpretation complex.

And because until recently, we did not have the computational tools to make it work.

But now, in the age of AI and mass digitalisation of healthcare, all of this is changing at lightning speed.

Drawing on her expertise at the intersection of epidemiology, data science, and health policy, Blythe walks us through the immense challenges and opportunities of real-world data, and how they are poised to revolutionise the development of tomorrow's therapies.

An episode to understand precision medicine and the central role of real-world evidence!


Timeline:

  • 00:00:00 - Blythe’s background at the interface of epidemiology, data science, and health policy
  • 00:09:33 - The power of real-world data in medicine and drug development
  • 00:17:11 - The barriers to accessing and leveraging real-world data at scale
  • 00:20:26 - Two examples where AI can help make sense of real-world data
  • 00:25:46 - Traditionally overlooked real-world data modalities in medicine
  • 00:27:52 - Breaking down language barriers across real-world datasets
  • 00:35:10 - Some predictions on the next AI-driven breakthroughs in oncology


What we also talked about with Blythe:


We cited with Blythe some of the past episodes of the series:


As Blythe mentioned during the episode, you can visit her blog at blytheadamson.com for more information about her work.

The book recommended by Blythe is Spillover: Animal Infections and the Next Human Pandemic by David Quammen.

You can get in touch with Blythe via LinkedIn, and follow the activities of Flatiron Health on LinkedIn, X, and Instagram.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2562 no [SNIPPET] - Blythe Adamson on the power of real-world data for precision medicine To discover the whole episode, type "#48 - Driving precision medicine with real-world data - Blythe Adamson - Flatiron Health" on your preferred streaming platform. Sun, 21 Sep 2025 19:45:00 -0000 full Mathieu Chaffard To discover the whole episode, type "#48 - Driving precision medicine with real-world data - Blythe Adamson - Flatiron Health" on your preferred streaming platform. To discover the whole episode, type "#48 - Driving precision medicine with real-world data - Blythe Adamson - Flatiron Health" on your preferred streaming platform.


]]> 215 no #47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI How can we solve the puzzle of regulating AI in healthcare? This is the question that Dr. Ricardo Baptista Leite and his team at HealthAI - The Global Agency for Responsible AI in Health ask themselves every day. Their goal? To help international organizations, governments, and local stakeholders strike a balance between regulation and access to the latest innovation in the field. A thorny equation, considering the speed of progress in AI and the time it takes to establish a regulatory framework that, by definition, applies in the long term. With passion and enthusiasm, Ricardo shares the approach they are taking to achieve their mission: by fostering a global community to share best practices and adverse events, by building tailored in-country mechanisms aligned with international guidelines, and by curating the most comprehensive directory of registered AI solutions, which countries and innovators can consider. One thing seems certain: we must evaluate these new technologies from a risk-benefit perspective, drawing on the well-known methods of post-market monitoring that have been applied to pharmaceutical products for decades. A way to remain critical of their use, grant patients and healthcare professionals access to them, and to drive this transformative shift with confidence and security. Timeline: 00:00:00 - Ricardo’s background at the interface of medicine, research, and health policy 00:04:55 - Why we are at a turning point in healthcare 00:08:33 - HealthAI’s role in translating international guidelines for AI use in healthcare to local realities 00:13:08 - Bridging long-term regulation and rapid technological progress 00:21:55 - Curating the right AI solutions in healthcare 00:25:55 - Building trust and adoption among clinicians and patients 00:32:26 - The parallel between elevators and AI in healthcare 00:37:30 - The potential of AI for predictive population health management What we also talked about with Ricardo: HIMSS Europe Software as a Medical Device (SaMD) Stéphanie Allassonniere Agentic AI Ambient AI Elisha Otis As Ricardo mentioned during the episode, you can learn more about HealthAI here and follow their activities on LinkedIn, X, Instagram, and YouTube. The books recommended in the episode include AI Snake Oil: What Artificial Intelligence Can Do, What It Can’t, and How to Tell the Difference by Arvind Narayanan and Sayash Kapoor, Outlive: The Science and Art of Longevity by Peter Attia, and Power and Progress: Our Thousand-Year Struggle Over Technology and Prosperity by Daron Acemoglu and Simon Johnson. We both strongly recommend the newsletter Ground Truths by Dr. Eric Topol, a reference for staying up to date on the latest advances in medicine. You can get in touch with Ricardo via LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 14 Sep 2025 20:27:00 -0000 full Mathieu Chaffard How can we solve the puzzle of regulating AI in healthcare? This is the question that Dr. Ricardo Baptista Leite and his team at HealthAI - The Global Agency for Responsible AI in Health ask themselves every day. Their goal? To help international organizations, governments, and local stakeholders strike a balance between regulation and access to the latest innovation in the field. A thorny equation, considering the speed of progress in AI and the time it takes to establish a regulatory framework that, by definition, applies in the long term. With passion and enthusiasm, Ricardo shares the approach they are taking to achieve their mission: by fostering a global community to share best practices and adverse events, by building tailored in-country mechanisms aligned with international guidelines, and by curating the most comprehensive directory of registered AI solutions, which countries and innovators can consider. One thing seems certain: we must evaluate these new technologies from a risk-benefit perspective, drawing on the well-known methods of post-market monitoring that have been applied to pharmaceutical products for decades. A way to remain critical of their use, grant patients and healthcare professionals access to them, and to drive this transformative shift with confidence and security. Timeline: 00:00:00 - Ricardo’s background at the interface of medicine, research, and health policy 00:04:55 - Why we are at a turning point in healthcare 00:08:33 - HealthAI’s role in translating international guidelines for AI use in healthcare to local realities 00:13:08 - Bridging long-term regulation and rapid technological progress 00:21:55 - Curating the right AI solutions in healthcare 00:25:55 - Building trust and adoption among clinicians and patients 00:32:26 - The parallel between elevators and AI in healthcare 00:37:30 - The potential of AI for predictive population health management What we also talked about with Ricardo: HIMSS Europe Software as a Medical Device (SaMD) Stéphanie Allassonniere Agentic AI Ambient AI Elisha Otis As Ricardo mentioned during the episode, you can learn more about HealthAI here and follow their activities on LinkedIn, X, Instagram, and YouTube. The books recommended in the episode include AI Snake Oil: What Artificial Intelligence Can Do, What It Can’t, and How to Tell the Difference by Arvind Narayanan and Sayash Kapoor, Outlive: The Science and Art of Longevity by Peter Attia, and Power and Progress: Our Thousand-Year Struggle Over Technology and Prosperity by Daron Acemoglu and Simon Johnson. We both strongly recommend the newsletter Ground Truths by Dr. Eric Topol, a reference for staying up to date on the latest advances in medicine. You can get in touch with Ricardo via LinkedIn. ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! How can we solve the puzzle of regulating AI in healthcare?

This is the question that Dr. Ricardo Baptista Leite and his team at HealthAI - The Global Agency for Responsible AI in Health ask themselves every day.

Their goal?

To help international organizations, governments, and local stakeholders strike a balance between regulation and access to the latest innovation in the field.

A thorny equation, considering the speed of progress in AI and the time it takes to establish a regulatory framework that, by definition, applies in the long term.

With passion and enthusiasm, Ricardo shares the approach they are taking to achieve their mission: by fostering a global community to share best practices and adverse events, by building tailored in-country mechanisms aligned with international guidelines, and by curating the most comprehensive directory of registered AI solutions, which countries and innovators can consider.

One thing seems certain: we must evaluate these new technologies from a risk-benefit perspective, drawing on the well-known methods of post-market monitoring that have been applied to pharmaceutical products for decades.

A way to remain critical of their use, grant patients and healthcare professionals access to them, and to drive this transformative shift with confidence and security.


Timeline:

00:00:00 - Ricardo’s background at the interface of medicine, research, and health policy

00:04:55 - Why we are at a turning point in healthcare

00:08:33 - HealthAI’s role in translating international guidelines for AI use in healthcare to local realities

00:13:08 - Bridging long-term regulation and rapid technological progress

00:21:55 - Curating the right AI solutions in healthcare

00:25:55 - Building trust and adoption among clinicians and patients

00:32:26 - The parallel between elevators and AI in healthcare

00:37:30 - The potential of AI for predictive population health management


What we also talked about with Ricardo:


As Ricardo mentioned during the episode, you can learn more about HealthAI here and follow their activities on LinkedIn, X, Instagram, and YouTube.


The books recommended in the episode include AI Snake Oil: What Artificial Intelligence Can Do, What It Can’t, and How to Tell the Difference by Arvind Narayanan and Sayash Kapoor, Outlive: The Science and Art of Longevity by Peter Attia, and Power and Progress: Our Thousand-Year Struggle Over Technology and Prosperity by Daron Acemoglu and Simon Johnson.

We both strongly recommend the newsletter Ground Truths by Dr. Eric Topol, a reference for staying up to date on the latest advances in medicine.

You can get in touch with Ricardo via LinkedIn.

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3123 no [SNIPPET] - Dr. Ricardo Baptista Leite on blind spots in health systems To discover the whole episode, type "#47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI" on your preferred streaming platform. Sun, 14 Sep 2025 20:23:00 -0000 full Mathieu Chaffard To discover the whole episode, type "#47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI" on your preferred streaming platform. To discover the whole episode, type "#47 - Pushing responsible AI in health - Dr. Ricardo Baptista Leite - HealthAI" on your preferred streaming platform.


]]> 218 no #46 - Rethinking the stethoscope and its use - Diana van Stijn - Lapsi Health When we think of the term "medicine," one of the symbols that comes to mind is the stethoscope. Its use in almost every physical examination by healthcare providers makes it one of the most iconic and widely recognized medical devices. Despite the emergence of digital technologies and the first electronic stethoscopes, their operating principle and design still rely heavily on the patent filed by Dr. David Littmann in the 1960s. But in the era of miniaturization and artificial intelligence, there is a reason to believe that the stethoscope is ripe for a true transformation. Among those who share this opinion are Lapsi Health and the team of Diana van Stijn. Inspired by her experience as a pediatrician and the central role of body sounds in her profession, Diana envisions a new kind of stethoscope—without tubing, fitting in the palm of a hand, and leveraging the latest technological advancements to better equip physicians. This vision gave birth to Keikku, a next-generation digital stethoscope. Beyond rethinking the format and use of the stethoscope for doctors, Diana and her colleagues imagine a future where patients can use it themselves, paving the way for continuous auscultation. In this episode, we explore how Diana and her team are turning this vision into reality, and what it could mean for the prevention, detection, and monitoring of diseases, extending far beyond pediatrics. With humor and enthusiasm, Diana also shares a few secrets about her approach to balancing clinical practice, motherhood, and entrepreneurship in healthcare! Timeline: 00:00:00 - Diana’s background as a Pediatrician, startup Co-Founder, and former National Team Swimmer 00:11:10 - The role of body sounds in medicine 00:15:08 - Early ideas on disrupting traditional stethoscopes 00:22:21 - Building Keikku, a portable, intuitive, and radically modern stethoscope 00:26:43 - Incorporating AI in the interpretation of body sounds 00:30:50 - Moving toward continuous auscultation and getting Keikku into the hands of patients What we also talked about with Diana: Shavini Fernando MedTech World Cirque du Soleil Jhonatan Bringas Dimitriades Magnetic Resonance Imaging Computed Tomography As Diana mentioned during the episode, you can learn more about Keikku here and the other devices in Lapsi Health’s pipeline via their official website. To dive further into some of the topics mentioned in the episode, Diana recommends reading Intelligence-Based Medicine: Artificial Intelligence and Human Cognition in Clinical Medicine and Healthcare by Anthony C. Chang and the article published on JMIR Publications that she co-authored, Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in Pediatrics by Bhargava H. et al. You can follow Lapsi Health’s activities on LinkedIn, and get in touch with Diana via LinkedIn too! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 07 Sep 2025 19:25:00 -0000 full Mathieu Chaffard When we think of the term "medicine," one of the symbols that comes to mind is the stethoscope. Its use in almost every physical examination by healthcare providers makes it one of the most iconic and widely recognized medical devices. Despite the emergence of digital technologies and the first electronic stethoscopes, their operating principle and design still rely heavily on the patent filed by Dr. David Littmann in the 1960s. But in the era of miniaturization and artificial intelligence, there is a reason to believe that the stethoscope is ripe for a true transformation. Among those who share this opinion are Lapsi Health and the team of Diana van Stijn. Inspired by her experience as a pediatrician and the central role of body sounds in her profession, Diana envisions a new kind of stethoscope—without tubing, fitting in the palm of a hand, and leveraging the latest technological advancements to better equip physicians. This vision gave birth to Keikku, a next-generation digital stethoscope. Beyond rethinking the format and use of the stethoscope for doctors, Diana and her colleagues imagine a future where patients can use it themselves, paving the way for continuous auscultation. In this episode, we explore how Diana and her team are turning this vision into reality, and what it could mean for the prevention, detection, and monitoring of diseases, extending far beyond pediatrics. With humor and enthusiasm, Diana also shares a few secrets about her approach to balancing clinical practice, motherhood, and entrepreneurship in healthcare! Timeline: 00:00:00 - Diana’s background as a Pediatrician, startup Co-Founder, and former National Team Swimmer 00:11:10 - The role of body sounds in medicine 00:15:08 - Early ideas on disrupting traditional stethoscopes 00:22:21 - Building Keikku, a portable, intuitive, and radically modern stethoscope 00:26:43 - Incorporating AI in the interpretation of body sounds 00:30:50 - Moving toward continuous auscultation and getting Keikku into the hands of patients What we also talked about with Diana: Shavini Fernando MedTech World Cirque du Soleil Jhonatan Bringas Dimitriades Magnetic Resonance Imaging Computed Tomography As Diana mentioned during the episode, you can learn more about Keikku here and the other devices in Lapsi Health’s pipeline via their official website. To dive further into some of the topics mentioned in the episode, Diana recommends reading Intelligence-Based Medicine: Artificial Intelligence and Human Cognition in Clinical Medicine and Healthcare by Anthony C. Chang and the article published on JMIR Publications that she co-authored, Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in Pediatrics by Bhargava H. et al. You can follow Lapsi Health’s activities on LinkedIn, and get in touch with Diana via LinkedIn too! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! When we think of the term "medicine," one of the symbols that comes to mind is the stethoscope.

Its use in almost every physical examination by healthcare providers makes it one of the most iconic and widely recognized medical devices.

Despite the emergence of digital technologies and the first electronic stethoscopes, their operating principle and design still rely heavily on the patent filed by Dr. David Littmann in the 1960s.

But in the era of miniaturization and artificial intelligence, there is a reason to believe that the stethoscope is ripe for a true transformation.

Among those who share this opinion are Lapsi Health and the team of Diana van Stijn.

Inspired by her experience as a pediatrician and the central role of body sounds in her profession, Diana envisions a new kind of stethoscope—without tubing, fitting in the palm of a hand, and leveraging the latest technological advancements to better equip physicians.

This vision gave birth to Keikku, a next-generation digital stethoscope.

Beyond rethinking the format and use of the stethoscope for doctors, Diana and her colleagues imagine a future where patients can use it themselves, paving the way for continuous auscultation.

In this episode, we explore how Diana and her team are turning this vision into reality, and what it could mean for the prevention, detection, and monitoring of diseases, extending far beyond pediatrics.

With humor and enthusiasm, Diana also shares a few secrets about her approach to balancing clinical practice, motherhood, and entrepreneurship in healthcare!


Timeline:

00:00:00 - Diana’s background as a Pediatrician, startup Co-Founder, and former National Team Swimmer

00:11:10 - The role of body sounds in medicine

00:15:08 - Early ideas on disrupting traditional stethoscopes

00:22:21 - Building Keikku, a portable, intuitive, and radically modern stethoscope

00:26:43 - Incorporating AI in the interpretation of body sounds

00:30:50 - Moving toward continuous auscultation and getting Keikku into the hands of patients


What we also talked about with Diana:


As Diana mentioned during the episode, you can learn more about Keikku here and the other devices in Lapsi Health’s pipeline via their official website.

To dive further into some of the topics mentioned in the episode, Diana recommends reading Intelligence-Based Medicine: Artificial Intelligence and Human Cognition in Clinical Medicine and Healthcare by Anthony C. Chang and the article published on JMIR Publications that she co-authored, Promises, Pitfalls, and Clinical Applications of Artificial Intelligence in Pediatrics by Bhargava H. et al.

You can follow Lapsi Health’s activities on LinkedIn, and get in touch with Diana via LinkedIn too!

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2805 no [SNIPPET] - Diana van Stijn on the magic of body sounds To discover the whole episode type "#46 - Rethinking the stethoscope and its use - Diana van Stijn - Lapsi Health" on your preferred streaming platform. Sun, 07 Sep 2025 19:21:00 -0000 full Mathieu Chaffard To discover the whole episode type "#46 - Rethinking the stethoscope and its use - Diana van Stijn - Lapsi Health" on your preferred streaming platform. To discover the whole episode type "#46 - Rethinking the stethoscope and its use - Diana van Stijn - Lapsi Health" on your preferred streaming platform.

]]> 226 no #45 - Measuring oxygen with a smart earring - Shavini Fernando - OxiWear Do you have to come close to death to invent a groundbreaking medical device? That’s certainly not something we would wish upon every medtech entrepreneur. But it is the story of Shavini Fernando and the connected earring OxiWear that she developed. Shavini lives with Eisenmenger syndrome, a condition where the two ventricles of her heart communicate. This condition dramatically increases the pressure in her pulmonary vasculature and severely limits the oxygen carried in her blood. It’s a critical situation that has already caused her four cardiac arrests and three strokes, all of which she has survived. Constantly reliant on supplemental oxygen to live, she dreamed of a way to measure her oxygen levels in real time while staying active. This would allow her to anticipate sudden variations in the future and the life-threatening risks they bring. And she made that dream come true by creating the first connected earring, FDA-certified, capable of measuring blood oxygen saturation in real time. All in a discreet format, lighter than an AirPod, and designed for use during everyday activities, including sports. In many ways, this innovation has transformed her own life, as well as those of hundreds of patients who have benefited from it so far. In this episode, we revisit her story as a patient and survivor. Shavini opens up about the immense challenges of living with Eisenmenger syndrome and developing OxiWear, sharing her vision for this technology and the potential it holds for the future of cardiorespiratory monitoring. A touching and sincere conversation with a truly exceptional figure in the healthtech ecosystem! Timeline: 00:00:00 - Shavini’s story as a pulmonary hypertension patient surviving four cardiac arrests and three strokes 00:19:13 - Building the first smart earring to continuously measure oxygen levels while staying active 00:25:20 - The design behind OxiWear and the challenges to bring it to life 00:31:24 - The blessing of COVID to access funding and educate the general public about cardiorespiratory health 00:36:57 - Making OxiWear the ultimate cardiorespiratory device for remote patient monitoring 00:39:47 - The business model behind OxiWear from a medical and consumer perspective 00:43:10 - Overcoming the torture of creating a medical device from scratch What we also talked about with Shavini: MedTech World Georgetown University Johns Hopkins University Leonsis Family Entrepreneurship Prize “Bark Tank” created by Ted Leonsis MassMEDIC Renal cholesteatoma Sickle cell anemia Photoplethysmography As we mentioned during the episode, you can watch here the recording of the panel I hosted alongside Shavini at MedTech World in 2024. As Shavini shared in the episode, you can learn more about OxiWear at Oxiwear.com and [Oxiwear.fitness](http://Oxiwear.fitnesshttps://www.oxiwear.fitness/). Although we did not explicitly talk about it, I also recommend you watch Shavini’s TEDx Talk recorded in 2019. You can follow OxiWear’s activities on LinkedIn, Facebook, X, TikTok, and get in touch with Shavini via LinkedIn too! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 31 Aug 2025 15:43:00 -0000 full Mathieu Chaffard Do you have to come close to death to invent a groundbreaking medical device? That’s certainly not something we would wish upon every medtech entrepreneur. But it is the story of Shavini Fernando and the connected earring OxiWear that she developed. Shavini lives with Eisenmenger syndrome, a condition where the two ventricles of her heart communicate. This condition dramatically increases the pressure in her pulmonary vasculature and severely limits the oxygen carried in her blood. It’s a critical situation that has already caused her four cardiac arrests and three strokes, all of which she has survived. Constantly reliant on supplemental oxygen to live, she dreamed of a way to measure her oxygen levels in real time while staying active. This would allow her to anticipate sudden variations in the future and the life-threatening risks they bring. And she made that dream come true by creating the first connected earring, FDA-certified, capable of measuring blood oxygen saturation in real time. All in a discreet format, lighter than an AirPod, and designed for use during everyday activities, including sports. In many ways, this innovation has transformed her own life, as well as those of hundreds of patients who have benefited from it so far. In this episode, we revisit her story as a patient and survivor. Shavini opens up about the immense challenges of living with Eisenmenger syndrome and developing OxiWear, sharing her vision for this technology and the potential it holds for the future of cardiorespiratory monitoring. A touching and sincere conversation with a truly exceptional figure in the healthtech ecosystem! Timeline: 00:00:00 - Shavini’s story as a pulmonary hypertension patient surviving four cardiac arrests and three strokes 00:19:13 - Building the first smart earring to continuously measure oxygen levels while staying active 00:25:20 - The design behind OxiWear and the challenges to bring it to life 00:31:24 - The blessing of COVID to access funding and educate the general public about cardiorespiratory health 00:36:57 - Making OxiWear the ultimate cardiorespiratory device for remote patient monitoring 00:39:47 - The business model behind OxiWear from a medical and consumer perspective 00:43:10 - Overcoming the torture of creating a medical device from scratch What we also talked about with Shavini: MedTech World Georgetown University Johns Hopkins University Leonsis Family Entrepreneurship Prize “Bark Tank” created by Ted Leonsis MassMEDIC Renal cholesteatoma Sickle cell anemia Photoplethysmography As we mentioned during the episode, you can watch here the recording of the panel I hosted alongside Shavini at MedTech World in 2024. As Shavini shared in the episode, you can learn more about OxiWear at Oxiwear.com and [Oxiwear.fitness](http://Oxiwear.fitnesshttps://www.oxiwear.fitness/). Although we did not explicitly talk about it, I also recommend you watch Shavini’s TEDx Talk recorded in 2019. You can follow OxiWear’s activities on LinkedIn, Facebook, X, TikTok, and get in touch with Shavini via LinkedIn too! ✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! ⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast! 👍 Lastly, don’t forget to follow our activities on LinkedIn and our website! Do you have to come close to death to invent a groundbreaking medical device?

That’s certainly not something we would wish upon every medtech entrepreneur.

But it is the story of Shavini Fernando and the connected earring OxiWear that she developed.

Shavini lives with Eisenmenger syndrome, a condition where the two ventricles of her heart communicate.

This condition dramatically increases the pressure in her pulmonary vasculature and severely limits the oxygen carried in her blood.

It’s a critical situation that has already caused her four cardiac arrests and three strokes, all of which she has survived.

Constantly reliant on supplemental oxygen to live, she dreamed of a way to measure her oxygen levels in real time while staying active.

This would allow her to anticipate sudden variations in the future and the life-threatening risks they bring.

And she made that dream come true by creating the first connected earring, FDA-certified, capable of measuring blood oxygen saturation in real time.

All in a discreet format, lighter than an AirPod, and designed for use during everyday activities, including sports.

In many ways, this innovation has transformed her own life, as well as those of hundreds of patients who have benefited from it so far.

In this episode, we revisit her story as a patient and survivor.

Shavini opens up about the immense challenges of living with Eisenmenger syndrome and developing OxiWear, sharing her vision for this technology and the potential it holds for the future of cardiorespiratory monitoring.

A touching and sincere conversation with a truly exceptional figure in the healthtech ecosystem!


Timeline:

00:00:00 - Shavini’s story as a pulmonary hypertension patient surviving four cardiac arrests and three strokes

00:19:13 - Building the first smart earring to continuously measure oxygen levels while staying active

00:25:20 - The design behind OxiWear and the challenges to bring it to life

00:31:24 - The blessing of COVID to access funding and educate the general public about cardiorespiratory health

00:36:57 - Making OxiWear the ultimate cardiorespiratory device for remote patient monitoring

00:39:47 - The business model behind OxiWear from a medical and consumer perspective

00:43:10 - Overcoming the torture of creating a medical device from scratch


What we also talked about with Shavini:


As we mentioned during the episode, you can watch here the recording of the panel I hosted alongside Shavini at MedTech World in 2024.

As Shavini shared in the episode, you can learn more about OxiWear at Oxiwear.com and [Oxiwear.fitness](http://Oxiwear.fitnesshttps://www.oxiwear.fitness/).

Although we did not explicitly talk about it, I also recommend you watch Shavini’s TEDx Talk recorded in 2019.

You can follow OxiWear’s activities on LinkedIn, Facebook, X, TikTok, and get in touch with Shavini via LinkedIn too!

✉️ If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

⭐️ And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

🙏 You can also support my work by doing a PayPal donation @ImpulsePodcast!

👍 Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3158 no [SNIPPET] - Shavini Fernando on designing smart wearables right To discover the whole episode type "#45 - Measuring oxygen with a smart earring - Shavini Fernando - OxiWear" on your preferred streaming platform. Sun, 31 Aug 2025 15:31:00 -0000 full Mathieu Chaffard To discover the whole episode type "#45 - Measuring oxygen with a smart earring - Shavini Fernando - OxiWear" on your preferred streaming platform. To discover the whole episode type "#45 - Measuring oxygen with a smart earring - Shavini Fernando - OxiWear" on your preferred streaming platform.

]]> 237 no #44 - Predicting cancer treatment response - Andre Esteva - Artera One of the greatest fantasies in medicine is to one day be able to offer any patient a therapy perfectly adapted to their profile and needs. A "personalized" medicine. The term was introduced to the public in 1999 through an article in The Wall Street Journal titled "New Era of Personalized Medicine: Targeting Drugs for Each Unique Genetic Profile." The enthusiasm for these next-generation therapies was fueled by advances in DNA sequencing, which hinted at future discoveries in genomics and rapid progress in medicine. Twenty-five years later, it is clear that personalized medicine has become a reality (e.g., for the treatment of cancer or rare diseases), and technological progress continues to bring us closer to this ideal. But while developing new personalized therapies is one approach, identifying the most effective current therapies for each patient is another, equally powerful one. And thanks to the multimodal analysis capabilities enabled by AI, this field is rapidly expanding. Andre Esteva is one of the pioneers in this area, having significantly advanced medical research in this direction before venturing into entrepreneurship to make this technology available broadly. In less than three years, his company Artera has already achieved many things that most healthtech startups take much longer to reach: The launch of the first AI-based predictive test to evaluate treatment response to hormonal therapy in prostate cancer. The inclusion of the test in the National Comprehensive Cancer Network (NCCN) guidelines nationwide. The obtention of federal reimbursement for the test. In this episode, Andre shares his vision of predictive medicine in the AI era, the potential of this technology for complex diseases such as cancer, and the keys to their success and recognition on the international medical scene! Timeline: 00:00:00 - Andre’s background as a researcher and entrepreneur in medical AI 00:06:01 - The origins of Artera and the vision of personalizing therapy for cancer patients 00:09:29 - Why AI is so relevant for predictive and prognostic medical applications 00:11:51 - How the ArteraAI Prostate Cancer test works 00:19:57 - Getting the test included in national guidelines within a year 00:24:16 - Developing further therapy prediction tests for cancer and beyond 00:26:03 - Lessons learned from securing national reimbursement within two years 00:29:22 - Andre’s view on current and future applications of AI in medicine What we also talked about with Andre: Salesforce H&E stain Prostate-specific antigen Chemotherapy Computer vision Large Language Models (LLMs) AI agents AlphaFold NeurIPS Computer Vision and Pattern Recognition Conference Marc Benioff We cited with Andre some of the past episodes of the series: #43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos #41 - Making sense of the gut microbiome - Leo Grady - Jona #40 - Cracking biology through AI - Jean-Philippe Vert - Owkin #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo As Andre mentioned during the episode, you can read their landmark paper published in npj Digital Medicine in 2021 to dive deeper into the technology they have developed. For further information about Artera’s publications and all the scientific work they do, take a look at the News & Insights section of their website. You can follow Artera’s activities on LinkedIn and X, and get in touch with Andre via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 16 Dec 2024 14:22:00 -0000 full Mathieu Chaffard One of the greatest fantasies in medicine is to one day be able to offer any patient a therapy perfectly adapted to their profile and needs. A "personalized" medicine. The term was introduced to the public in 1999 through an article in The Wall Street Journal titled "New Era of Personalized Medicine: Targeting Drugs for Each Unique Genetic Profile." The enthusiasm for these next-generation therapies was fueled by advances in DNA sequencing, which hinted at future discoveries in genomics and rapid progress in medicine. Twenty-five years later, it is clear that personalized medicine has become a reality (e.g., for the treatment of cancer or rare diseases), and technological progress continues to bring us closer to this ideal. But while developing new personalized therapies is one approach, identifying the most effective current therapies for each patient is another, equally powerful one. And thanks to the multimodal analysis capabilities enabled by AI, this field is rapidly expanding. Andre Esteva is one of the pioneers in this area, having significantly advanced medical research in this direction before venturing into entrepreneurship to make this technology available broadly. In less than three years, his company Artera has already achieved many things that most healthtech startups take much longer to reach: The launch of the first AI-based predictive test to evaluate treatment response to hormonal therapy in prostate cancer. The inclusion of the test in the National Comprehensive Cancer Network (NCCN) guidelines nationwide. The obtention of federal reimbursement for the test. In this episode, Andre shares his vision of predictive medicine in the AI era, the potential of this technology for complex diseases such as cancer, and the keys to their success and recognition on the international medical scene! Timeline: 00:00:00 - Andre’s background as a researcher and entrepreneur in medical AI 00:06:01 - The origins of Artera and the vision of personalizing therapy for cancer patients 00:09:29 - Why AI is so relevant for predictive and prognostic medical applications 00:11:51 - How the ArteraAI Prostate Cancer test works 00:19:57 - Getting the test included in national guidelines within a year 00:24:16 - Developing further therapy prediction tests for cancer and beyond 00:26:03 - Lessons learned from securing national reimbursement within two years 00:29:22 - Andre’s view on current and future applications of AI in medicine What we also talked about with Andre: Salesforce H&E stain Prostate-specific antigen Chemotherapy Computer vision Large Language Models (LLMs) AI agents AlphaFold NeurIPS Computer Vision and Pattern Recognition Conference Marc Benioff We cited with Andre some of the past episodes of the series: #43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos #41 - Making sense of the gut microbiome - Leo Grady - Jona #40 - Cracking biology through AI - Jean-Philippe Vert - Owkin #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo As Andre mentioned during the episode, you can read their landmark paper published in npj Digital Medicine in 2021 to dive deeper into the technology they have developed. For further information about Artera’s publications and all the scientific work they do, take a look at the News & Insights section of their website. You can follow Artera’s activities on LinkedIn and X, and get in touch with Andre via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! One of the greatest fantasies in medicine is to one day be able to offer any patient a therapy perfectly adapted to their profile and needs.

A "personalized" medicine.

The term was introduced to the public in 1999 through an article in The Wall Street Journal titled "New Era of Personalized Medicine: Targeting Drugs for Each Unique Genetic Profile."

The enthusiasm for these next-generation therapies was fueled by advances in DNA sequencing, which hinted at future discoveries in genomics and rapid progress in medicine.

Twenty-five years later, it is clear that personalized medicine has become a reality (e.g., for the treatment of cancer or rare diseases), and technological progress continues to bring us closer to this ideal.

But while developing new personalized therapies is one approach, identifying the most effective current therapies for each patient is another, equally powerful one.

And thanks to the multimodal analysis capabilities enabled by AI, this field is rapidly expanding.

Andre Esteva is one of the pioneers in this area, having significantly advanced medical research in this direction before venturing into entrepreneurship to make this technology available broadly.

In less than three years, his company Artera has already achieved many things that most healthtech startups take much longer to reach:

  • The launch of the first AI-based predictive test to evaluate treatment response to hormonal therapy in prostate cancer.
  • The inclusion of the test in the National Comprehensive Cancer Network (NCCN) guidelines nationwide.
  • The obtention of federal reimbursement for the test.

In this episode, Andre shares his vision of predictive medicine in the AI era, the potential of this technology for complex diseases such as cancer, and the keys to their success and recognition on the international medical scene!


Timeline:

00:00:00 - Andre’s background as a researcher and entrepreneur in medical AI

00:06:01 - The origins of Artera and the vision of personalizing therapy for cancer patients

00:09:29 - Why AI is so relevant for predictive and prognostic medical applications

00:11:51 - How the ArteraAI Prostate Cancer test works

00:19:57 - Getting the test included in national guidelines within a year

00:24:16 - Developing further therapy prediction tests for cancer and beyond

00:26:03 - Lessons learned from securing national reimbursement within two years

00:29:22 - Andre’s view on current and future applications of AI in medicine


What we also talked about with Andre:

We cited with Andre some of the past episodes of the series:

As Andre mentioned during the episode, you can read their landmark paper published in npj Digital Medicine in 2021 to dive deeper into the technology they have developed.

For further information about Artera’s publications and all the scientific work they do, take a look at the News & Insights section of their website.

You can follow Artera’s activities on LinkedIn and X, and get in touch with Andre via LinkedIn!

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2575 no [SNIPPET] - Andre Esteva on the relevance of AI for clinical decision-making To discover the whole episode type "#44 - Predicting cancer treatment response - Andre Esteva - Artera" on your preferred streaming platform. Mon, 16 Dec 2024 14:18:11 -0000 full Mathieu Chaffard To discover the whole episode type "#44 - Predicting cancer treatment response - Andre Esteva - Artera" on your preferred streaming platform. To discover the whole episode type "#44 - Predicting cancer treatment response - Andre Esteva - Artera" on your preferred streaming platform.

]]> 153 no #43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos According to the WHO, unsafe medication practices and medication errors are a leading cause of avoidable harm in health systems across the globe. In the European Union alone, this translates to nearly 200,000 deaths annually. The magnitude of this problem has led to global initiatives such as "Medication Without Harm," launched in 2017, aiming to reduce medical errors by 50% over five years. Although there is a need for more data on the results of this initiative, we are far from having reached the goal. The key lies in our ability to access medical information, specifically related to prescriptions. Direct access to reliable information, accounting for individual patient characteristics, and able to fit with the tools used by healthcare professionals. A next-generation medical database, incorporating all known information about medications in structured and interoperable bricks capable of supporting caregivers in safer and more effective prescribing practices. It turns out this database exists and has been developed by Pharmacist Emmanuel Bilbault and his team at Posos! Approved less than a year ago by French health authorities, it offers a new perspective on how to approach medical prescriptions in the era of AI and digital health. A way to give back time to every healthcare professional and ensure an unprecedented level of care quality for patients. We talked with Emmanuel about the creation of this new tool - used today by more than 85,000 healthcare professionals in Europe - and what it changes in our fight against medical errors. Timeline: 00:00:00 - What pushed Emmanuel to quit the Pharma industry and found Posos 00:11:11 - The first multilingual, structured, and encoded drug database to streamline medical prescribing 00:16:31 - How Posos is leveraging AI to supercharge its platform 00:22:54 - Keeping the drug database up to date across geographies 00:24:37 - The impact Posos has on healthcare professionals, patients, and health systems 00:29:59 - Toward providing patient access to Posos’ drug database 00:32:40 - Lessons learned from scaling Posos in France and abroad 00:40:47 - Emmanuel’s view on the current healthcare transformation What we also talked about with Emmanuel: Teva Pharmaceuticals IBM’s Watson Health Electronic Health Records SNOMED CT ICD-10-CM ATC MedDRA Named Entity Recognition Optical Character Recognition Word Embedding Machine Learning Pharmagest Ambient AI Nabla We cited with Emmanuel some of the past episodes of the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens As mentioned by Emmanuel during the episode, we recommend taking a look at this page to learn more about the SNOMED CT clinical terminology, as the most comprehensive, multilingual clinical healthcare terminology in the world. You can follow Posos’ activities on LinkedIn, Instagram, and X, and get in touch with Emmanuel via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 08 Dec 2024 20:12:00 -0000 full Mathieu Chaffard According to the WHO, unsafe medication practices and medication errors are a leading cause of avoidable harm in health systems across the globe. In the European Union alone, this translates to nearly 200,000 deaths annually. The magnitude of this problem has led to global initiatives such as "Medication Without Harm," launched in 2017, aiming to reduce medical errors by 50% over five years. Although there is a need for more data on the results of this initiative, we are far from having reached the goal. The key lies in our ability to access medical information, specifically related to prescriptions. Direct access to reliable information, accounting for individual patient characteristics, and able to fit with the tools used by healthcare professionals. A next-generation medical database, incorporating all known information about medications in structured and interoperable bricks capable of supporting caregivers in safer and more effective prescribing practices. It turns out this database exists and has been developed by Pharmacist Emmanuel Bilbault and his team at Posos! Approved less than a year ago by French health authorities, it offers a new perspective on how to approach medical prescriptions in the era of AI and digital health. A way to give back time to every healthcare professional and ensure an unprecedented level of care quality for patients. We talked with Emmanuel about the creation of this new tool - used today by more than 85,000 healthcare professionals in Europe - and what it changes in our fight against medical errors. Timeline: 00:00:00 - What pushed Emmanuel to quit the Pharma industry and found Posos 00:11:11 - The first multilingual, structured, and encoded drug database to streamline medical prescribing 00:16:31 - How Posos is leveraging AI to supercharge its platform 00:22:54 - Keeping the drug database up to date across geographies 00:24:37 - The impact Posos has on healthcare professionals, patients, and health systems 00:29:59 - Toward providing patient access to Posos’ drug database 00:32:40 - Lessons learned from scaling Posos in France and abroad 00:40:47 - Emmanuel’s view on the current healthcare transformation What we also talked about with Emmanuel: Teva Pharmaceuticals IBM’s Watson Health Electronic Health Records SNOMED CT ICD-10-CM ATC MedDRA Named Entity Recognition Optical Character Recognition Word Embedding Machine Learning Pharmagest Ambient AI Nabla We cited with Emmanuel some of the past episodes of the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens As mentioned by Emmanuel during the episode, we recommend taking a look at this page to learn more about the SNOMED CT clinical terminology, as the most comprehensive, multilingual clinical healthcare terminology in the world. You can follow Posos’ activities on LinkedIn, Instagram, and X, and get in touch with Emmanuel via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! According to the WHO, unsafe medication practices and medication errors are a leading cause of avoidable harm in health systems across the globe.

In the European Union alone, this translates to nearly 200,000 deaths annually.

The magnitude of this problem has led to global initiatives such as "Medication Without Harm," launched in 2017, aiming to reduce medical errors by 50% over five years.

Although there is a need for more data on the results of this initiative, we are far from having reached the goal.

The key lies in our ability to access medical information, specifically related to prescriptions.

Direct access to reliable information, accounting for individual patient characteristics, and able to fit with the tools used by healthcare professionals.

A next-generation medical database, incorporating all known information about medications in structured and interoperable bricks capable of supporting caregivers in safer and more effective prescribing practices.

It turns out this database exists and has been developed by Pharmacist Emmanuel Bilbault and his team at Posos!

Approved less than a year ago by French health authorities, it offers a new perspective on how to approach medical prescriptions in the era of AI and digital health.

A way to give back time to every healthcare professional and ensure an unprecedented level of care quality for patients.

We talked with Emmanuel about the creation of this new tool - used today by more than 85,000 healthcare professionals in Europe - and what it changes in our fight against medical errors.


Timeline:

00:00:00 - What pushed Emmanuel to quit the Pharma industry and found Posos

00:11:11 - The first multilingual, structured, and encoded drug database to streamline medical prescribing

00:16:31 - How Posos is leveraging AI to supercharge its platform

00:22:54 - Keeping the drug database up to date across geographies

00:24:37 - The impact Posos has on healthcare professionals, patients, and health systems

00:29:59 - Toward providing patient access to Posos’ drug database

00:32:40 - Lessons learned from scaling Posos in France and abroad

00:40:47 - Emmanuel’s view on the current healthcare transformation


What we also talked about with Emmanuel:


We cited with Emmanuel some of the past episodes of the series:


As mentioned by Emmanuel during the episode, we recommend taking a look at this page to learn more about the SNOMED CT clinical terminology, as the most comprehensive, multilingual clinical healthcare terminology in the world.

You can follow Posos’ activities on LinkedIn, Instagram, and X, and get in touch with Emmanuel via LinkedIn!

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3065 no [SNIPPET] - Emmanuel Bilbault on the complexity of modern medication prescribing To discover the whole episode type "#43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos" on your preferred streaming platform. Sun, 08 Dec 2024 20:10:55 -0000 full Mathieu Chaffard To discover the whole episode type "#43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos" on your preferred streaming platform. To discover the whole episode type "#43 - Rethinking medical prescriptions to save lives - Emmanuel Bilbault - Posos" on your preferred streaming platform.

]]> 333 no #42 - Extending reality to transform surgery - George Papagiannakis - ORamaVR What will the future of surgery look like? According to Dr. George Papagiannakis, we must count on virtual simulation. After all, simulators are an integral part of professional training in highly demanding fields like aviation or F1. So why not medicine? The approach might seem futuristic, but George and his team at ORamaVR share a vision that makes a lot of sense. Integrating extended reality in surgery means increasing the volume of hours spent operating. It means preparing each surgery on a virtual patient with properties close to the real case. It means simulating complications and unforeseen situations safely. And it means reducing the risk of errors in the real world. Following his motto "never first time with the real patient", George immerses us in the universe of extended reality and reveals its potential for medicine and surgery. What is extended reality? What makes a good virtual medical simulation? And what is the impact of this technology today and in the future? Many questions that George addresses with passion and enthusiasm, in a conversation reminiscent of Ready Player One! Timeline: 00:00:00 - Addressing the millions of fatal medical errors worldwide 00:05:20 - Defining extended reality and underlying technologies 00:07:31 - Medical applications of extended reality 00:10:52 - The impact of extended reality on medical training and practice 00:16:25 - What makes a virtual medical environment feel real 00:23:32 - How to recreate the feel of touch and dexterity virtually 00:29:28 - Enabling all healthcare professionals to create virtual environments with AI What we also talked about with George: Prof. Shafi Ahmed Apple Vision Pro Magic Leap Microsoft HoloLens NHS The Anatomy Lesson of Dr. Nicolaes Tulp by Rembrandt IKEA Global illumination Dall-E ChatGPT NotebookLM Frost & Sullivan Meta We cited with George some of the past episodes of the series: #9 - Creating the Gran Turismo of surgery - Raimundo Sierra - Virtamed #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health #32 - Accelerating radiology with AI - Amine Korchi - Radiologist #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy As mentioned by George during the episode, we recommend taking a look at some of the simulations available on the official YouTube channel of ORamaVR, it will bring to life many aspects that we discuss in the episode! You can follow ORamaVR’s activities on LinkedIn, Instagram, and get in touch with George via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 02 Dec 2024 09:11:00 -0000 full Mathieu Chaffard What will the future of surgery look like? According to Dr. George Papagiannakis, we must count on virtual simulation. After all, simulators are an integral part of professional training in highly demanding fields like aviation or F1. So why not medicine? The approach might seem futuristic, but George and his team at ORamaVR share a vision that makes a lot of sense. Integrating extended reality in surgery means increasing the volume of hours spent operating. It means preparing each surgery on a virtual patient with properties close to the real case. It means simulating complications and unforeseen situations safely. And it means reducing the risk of errors in the real world. Following his motto "never first time with the real patient", George immerses us in the universe of extended reality and reveals its potential for medicine and surgery. What is extended reality? What makes a good virtual medical simulation? And what is the impact of this technology today and in the future? Many questions that George addresses with passion and enthusiasm, in a conversation reminiscent of Ready Player One! Timeline: 00:00:00 - Addressing the millions of fatal medical errors worldwide 00:05:20 - Defining extended reality and underlying technologies 00:07:31 - Medical applications of extended reality 00:10:52 - The impact of extended reality on medical training and practice 00:16:25 - What makes a virtual medical environment feel real 00:23:32 - How to recreate the feel of touch and dexterity virtually 00:29:28 - Enabling all healthcare professionals to create virtual environments with AI What we also talked about with George: Prof. Shafi Ahmed Apple Vision Pro Magic Leap Microsoft HoloLens NHS The Anatomy Lesson of Dr. Nicolaes Tulp by Rembrandt IKEA Global illumination Dall-E ChatGPT NotebookLM Frost & Sullivan Meta We cited with George some of the past episodes of the series: #9 - Creating the Gran Turismo of surgery - Raimundo Sierra - Virtamed #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health #32 - Accelerating radiology with AI - Amine Korchi - Radiologist #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy As mentioned by George during the episode, we recommend taking a look at some of the simulations available on the official YouTube channel of ORamaVR, it will bring to life many aspects that we discuss in the episode! You can follow ORamaVR’s activities on LinkedIn, Instagram, and get in touch with George via LinkedIn! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! What will the future of surgery look like?

According to Dr. George Papagiannakis, we must count on virtual simulation.

After all, simulators are an integral part of professional training in highly demanding fields like aviation or F1. So why not medicine?

The approach might seem futuristic, but George and his team at ORamaVR share a vision that makes a lot of sense.

Integrating extended reality in surgery means increasing the volume of hours spent operating.

It means preparing each surgery on a virtual patient with properties close to the real case.

It means simulating complications and unforeseen situations safely.

And it means reducing the risk of errors in the real world.

Following his motto "never first time with the real patient", George immerses us in the universe of extended reality and reveals its potential for medicine and surgery.

What is extended reality?

What makes a good virtual medical simulation?

And what is the impact of this technology today and in the future?

Many questions that George addresses with passion and enthusiasm, in a conversation reminiscent of Ready Player One!


Timeline:

00:00:00 - Addressing the millions of fatal medical errors worldwide

00:05:20 - Defining extended reality and underlying technologies

00:07:31 - Medical applications of extended reality

00:10:52 - The impact of extended reality on medical training and practice

00:16:25 - What makes a virtual medical environment feel real

00:23:32 - How to recreate the feel of touch and dexterity virtually

00:29:28 - Enabling all healthcare professionals to create virtual environments with AI


What we also talked about with George:


We cited with George some of the past episodes of the series:


As mentioned by George during the episode, we recommend taking a look at some of the simulations available on the official YouTube channel of ORamaVR, it will bring to life many aspects that we discuss in the episode!

You can follow ORamaVR’s activities on LinkedIn, Instagram, and get in touch with George via LinkedIn!

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2510 no [SNIPPET] - George Papagiannakis on reaching proficiency in medicine with virtual reality To discover the whole episode type "#42 - Extending reality to transform surgery - George Papagiannakis - ORamaVR" on your preferred streaming platform. Mon, 02 Dec 2024 08:44:30 -0000 full Mathieu Chaffard To discover the whole episode type "#42 - Extending reality to transform surgery - George Papagiannakis - ORamaVR" on your preferred streaming platform. To discover the whole episode type "#42 - Extending reality to transform surgery - George Papagiannakis - ORamaVR" on your preferred streaming platform.

]]> 180 no #41 - Making sense of the gut microbiome - Leo Grady - Jona Our gut contains a world of microorganisms that impact many aspects of our health, well beyond the gastrointestinal system. In fact, more than 30 trillion bacteria, archaea, fungi, and viruses live in the digestive tract of every human, a number that is higher than the number of human cells that make up our body! Each microbiome is unique to an individual, and its genetic heritage represents approximately 100 times that of the human genome. This field is fascinating and science is advancing rapidly, as evidenced by the 2,000 publications generated monthly on the subject. A better understanding of this remarkable ecosystem might bring critical answers to address numerous pathologies and health disorders. This is the mission of Leo Grady and his team at Jona, whose technology enables microbiome analysis based on an at-home test, combined with artificial intelligence to reveal what the current literature says about each person's microbiome. Unveiling the propensity for certain disease risks, along with individual nutritional preferences, Jona can model the body's reaction according to potential changes in the microbiome, and provide valuable insights on behaviors and nutrition that can ultimately improve one’s health. A dive into the heart of the microbiome and its secrets, which today's technology is about to unlock! Timeline: 00:00:00 - Leo’s journey from his PhD in computer vision to AI applications in medicine 00:06:47 - The idea behind Jona and understanding the microbiome better 00:10:33 - What we do know and ignore about the microbiome 00:13:05 - The Jona test kit and what it can interpret from one’s microbiome picture 00:20:17 - The volume and complexity of studies around the microbiome 00:22:11 - The impact of Jona and Leo’s son's story 00:25:38 - Who is Jona for 00:29:00 - Leo’s vision for the future of Jona and AI in healthcare What we also talked about with Leo: Neural networks Siemens HeartFlow Paige AI Memorial Sloan Kettering Crohn’s disease Thomas Clozel We cited with Leo some of the past episodes of the series: #32 - Accelerating radiology with AI - Amine Korchi - Radiologist #35 - Making surgery smarter and safer - Björn Von Siemens - Caresyntax #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo #40 - Cracking biology through AI - Jean-Philippe Vert - Owkin As mentioned by Leo during the episode, we recommend looking at the Jona Journal which sheds light on the latest findings on the microbiome fueled by their research platform, and understanding the current literature. Leo also recommends listening to The Mind-Gut Conversation Podcast by Emeran Meyer to find out more, and We Contain Multitudes by Sarah Henstra as a complementary read. You can follow Jona’s activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Leo via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Tue, 26 Nov 2024 09:25:00 -0000 full Mathieu Chaffard Our gut contains a world of microorganisms that impact many aspects of our health, well beyond the gastrointestinal system. In fact, more than 30 trillion bacteria, archaea, fungi, and viruses live in the digestive tract of every human, a number that is higher than the number of human cells that make up our body! Each microbiome is unique to an individual, and its genetic heritage represents approximately 100 times that of the human genome. This field is fascinating and science is advancing rapidly, as evidenced by the 2,000 publications generated monthly on the subject. A better understanding of this remarkable ecosystem might bring critical answers to address numerous pathologies and health disorders. This is the mission of Leo Grady and his team at Jona, whose technology enables microbiome analysis based on an at-home test, combined with artificial intelligence to reveal what the current literature says about each person's microbiome. Unveiling the propensity for certain disease risks, along with individual nutritional preferences, Jona can model the body's reaction according to potential changes in the microbiome, and provide valuable insights on behaviors and nutrition that can ultimately improve one’s health. A dive into the heart of the microbiome and its secrets, which today's technology is about to unlock! Timeline: 00:00:00 - Leo’s journey from his PhD in computer vision to AI applications in medicine 00:06:47 - The idea behind Jona and understanding the microbiome better 00:10:33 - What we do know and ignore about the microbiome 00:13:05 - The Jona test kit and what it can interpret from one’s microbiome picture 00:20:17 - The volume and complexity of studies around the microbiome 00:22:11 - The impact of Jona and Leo’s son's story 00:25:38 - Who is Jona for 00:29:00 - Leo’s vision for the future of Jona and AI in healthcare What we also talked about with Leo: Neural networks Siemens HeartFlow Paige AI Memorial Sloan Kettering Crohn’s disease Thomas Clozel We cited with Leo some of the past episodes of the series: #32 - Accelerating radiology with AI - Amine Korchi - Radiologist #35 - Making surgery smarter and safer - Björn Von Siemens - Caresyntax #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo #40 - Cracking biology through AI - Jean-Philippe Vert - Owkin As mentioned by Leo during the episode, we recommend looking at the Jona Journal which sheds light on the latest findings on the microbiome fueled by their research platform, and understanding the current literature. Leo also recommends listening to The Mind-Gut Conversation Podcast by Emeran Meyer to find out more, and We Contain Multitudes by Sarah Henstra as a complementary read. You can follow Jona’s activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Leo via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Our gut contains a world of microorganisms that impact many aspects of our health, well beyond the gastrointestinal system.

In fact, more than 30 trillion bacteria, archaea, fungi, and viruses live in the digestive tract of every human, a number that is higher than the number of human cells that make up our body!

Each microbiome is unique to an individual, and its genetic heritage represents approximately 100 times that of the human genome.

This field is fascinating and science is advancing rapidly, as evidenced by the 2,000 publications generated monthly on the subject.

A better understanding of this remarkable ecosystem might bring critical answers to address numerous pathologies and health disorders.

This is the mission of Leo Grady and his team at Jona, whose technology enables microbiome analysis based on an at-home test, combined with artificial intelligence to reveal what the current literature says about each person's microbiome.

Unveiling the propensity for certain disease risks, along with individual nutritional preferences, Jona can model the body's reaction according to potential changes in the microbiome, and provide valuable insights on behaviors and nutrition that can ultimately improve one’s health.

A dive into the heart of the microbiome and its secrets, which today's technology is about to unlock!


Timeline:

00:00:00 - Leo’s journey from his PhD in computer vision to AI applications in medicine

00:06:47 - The idea behind Jona and understanding the microbiome better

00:10:33 - What we do know and ignore about the microbiome

00:13:05 - The Jona test kit and what it can interpret from one’s microbiome picture

00:20:17 - The volume and complexity of studies around the microbiome

00:22:11 - The impact of Jona and Leo’s son's story

00:25:38 - Who is Jona for

00:29:00 - Leo’s vision for the future of Jona and AI in healthcare


What we also talked about with Leo:


We cited with Leo some of the past episodes of the series:


As mentioned by Leo during the episode, we recommend looking at the Jona Journal which sheds light on the latest findings on the microbiome fueled by their research platform, and understanding the current literature.

Leo also recommends listening to The Mind-Gut Conversation Podcast by Emeran Meyer to find out more, and We Contain Multitudes by Sarah Henstra as a complementary read.

You can follow Jona’s activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Leo via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2839 no [SNIPPET] - Leo Grady on why understanding the microbiome is an AI problem To discover the whole episode type "#41 - Making sense of the gut microbiome - Leo Grady - Jona" on your preferred streaming platform. Tue, 26 Nov 2024 09:23:00 -0000 full Mathieu Chaffard To discover the whole episode type "#41 - Making sense of the gut microbiome - Leo Grady - Jona" on your preferred streaming platform. To discover the whole episode type "#41 - Making sense of the gut microbiome - Leo Grady - Jona" on your preferred streaming platform.

]]> 303 no #40 - Cracking biology through AI - Jean-Philippe Vert - Owkin All experts agree: if there's one sector that AI will transform, it's healthcare. Whether it's understanding pathologies, developing personalized treatments, the doctor-patient relationship, diagnostic methods, or creating tools to facilitate the work of healthcare professionals, everything is affected by the ongoing transformation! This revolution raises many expectations and questions about the real impact these new technologies will have on tomorrow's medicine. One of the leading figures in this movement on the international scene is none other than the French-American company Owkin, which aims to be "the first end-to-end AI biotech company," whose R&D activities are overseen by Jean-Philippe Vert, himself a true pioneer in the field of machine learning and computational biology. The first “AI-first” biotech company of its kind, bringing a breath of fresh air to an industry known for being extremely costly and time-consuming. So how does AI accelerate the development of new therapies? What is its role in identifying new molecules and targets? How can it be used to create new diagnostic tools? Can we leverage patient data without compromising their safety and privacy? And what can we expect from future models and their impact on our understanding of biology? These are all fascinating questions that Jean-Philippe breaks down with pedagogy and realism, shedding light on one of the most exciting fields of medicine in this era! Timeline: 00:00:00 - Jean-Philippe’s background at the interface of mathematics, computer science, and life sciences 00:07:10 - Owkin’s mission to become the first end-to-end AI biotech firm 00:09:48 - Leveraging AI for drug discovery and new treatment modalities 00:14:35 - Selecting target indications and therapeutic areas 00:17:13 - Changing the way we run clinical trials through AI 00:22:03 - Unlocking patient data across hospitals while preserving safety and privacy 00:25:40 - Developing AI-based diagnostics and driving clinical adoption 00:34:50 - Towards the first AI foundation model to understand biology What we also talked about with Jean-Philippe Google DeepMind Large Language Models (LLMs) Digital twins External control arms Federated learning Digital pathology MSIntuit CRC Bioptimus Neural networks As mentioned by Jean-Philippe during the episode, we recommend taking a look at Owkin and Bioptimus websites as well as their respective Publications & News section to learn more about their technology and stay posted on their latest activities. If you are a data scientist or machine learning enthusiast, you can tackle one of the many biology-related challenges proposed by Kaggle on their platform. To learn more about Owkin’s portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Pipeline section. You can follow Owkin’s activities on LinkedIn, X, and YouTube, and Bioptimus on LinkedIn and X. To get in touch with Jean-Philippe, contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 18 Nov 2024 10:37:00 -0000 full Mathieu Chaffard All experts agree: if there's one sector that AI will transform, it's healthcare. Whether it's understanding pathologies, developing personalized treatments, the doctor-patient relationship, diagnostic methods, or creating tools to facilitate the work of healthcare professionals, everything is affected by the ongoing transformation! This revolution raises many expectations and questions about the real impact these new technologies will have on tomorrow's medicine. One of the leading figures in this movement on the international scene is none other than the French-American company Owkin, which aims to be "the first end-to-end AI biotech company," whose R&D activities are overseen by Jean-Philippe Vert, himself a true pioneer in the field of machine learning and computational biology. The first “AI-first” biotech company of its kind, bringing a breath of fresh air to an industry known for being extremely costly and time-consuming. So how does AI accelerate the development of new therapies? What is its role in identifying new molecules and targets? How can it be used to create new diagnostic tools? Can we leverage patient data without compromising their safety and privacy? And what can we expect from future models and their impact on our understanding of biology? These are all fascinating questions that Jean-Philippe breaks down with pedagogy and realism, shedding light on one of the most exciting fields of medicine in this era! Timeline: 00:00:00 - Jean-Philippe’s background at the interface of mathematics, computer science, and life sciences 00:07:10 - Owkin’s mission to become the first end-to-end AI biotech firm 00:09:48 - Leveraging AI for drug discovery and new treatment modalities 00:14:35 - Selecting target indications and therapeutic areas 00:17:13 - Changing the way we run clinical trials through AI 00:22:03 - Unlocking patient data across hospitals while preserving safety and privacy 00:25:40 - Developing AI-based diagnostics and driving clinical adoption 00:34:50 - Towards the first AI foundation model to understand biology What we also talked about with Jean-Philippe Google DeepMind Large Language Models (LLMs) Digital twins External control arms Federated learning Digital pathology MSIntuit CRC Bioptimus Neural networks As mentioned by Jean-Philippe during the episode, we recommend taking a look at Owkin and Bioptimus websites as well as their respective Publications & News section to learn more about their technology and stay posted on their latest activities. If you are a data scientist or machine learning enthusiast, you can tackle one of the many biology-related challenges proposed by Kaggle on their platform. To learn more about Owkin’s portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Pipeline section. You can follow Owkin’s activities on LinkedIn, X, and YouTube, and Bioptimus on LinkedIn and X. To get in touch with Jean-Philippe, contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! All experts agree: if there's one sector that AI will transform, it's healthcare.

Whether it's understanding pathologies, developing personalized treatments, the doctor-patient relationship, diagnostic methods, or creating tools to facilitate the work of healthcare professionals, everything is affected by the ongoing transformation!

This revolution raises many expectations and questions about the real impact these new technologies will have on tomorrow's medicine.

One of the leading figures in this movement on the international scene is none other than the French-American company Owkin, which aims to be "the first end-to-end AI biotech company," whose R&D activities are overseen by Jean-Philippe Vert, himself a true pioneer in the field of machine learning and computational biology.

The first “AI-first” biotech company of its kind, bringing a breath of fresh air to an industry known for being extremely costly and time-consuming.

So how does AI accelerate the development of new therapies?

What is its role in identifying new molecules and targets?

How can it be used to create new diagnostic tools?

Can we leverage patient data without compromising their safety and privacy?

And what can we expect from future models and their impact on our understanding of biology?

These are all fascinating questions that Jean-Philippe breaks down with pedagogy and realism, shedding light on one of the most exciting fields of medicine in this era!


Timeline:

00:00:00 - Jean-Philippe’s background at the interface of mathematics, computer science, and life sciences

00:07:10 - Owkin’s mission to become the first end-to-end AI biotech firm

00:09:48 - Leveraging AI for drug discovery and new treatment modalities

00:14:35 - Selecting target indications and therapeutic areas

00:17:13 - Changing the way we run clinical trials through AI

00:22:03 - Unlocking patient data across hospitals while preserving safety and privacy

00:25:40 - Developing AI-based diagnostics and driving clinical adoption

00:34:50 - Towards the first AI foundation model to understand biology


What we also talked about with Jean-Philippe


As mentioned by Jean-Philippe during the episode, we recommend taking a look at Owkin and Bioptimus websites as well as their respective Publications & News section to learn more about their technology and stay posted on their latest activities.

If you are a data scientist or machine learning enthusiast, you can tackle one of the many biology-related challenges proposed by Kaggle on their platform.

To learn more about Owkin’s portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Pipeline section.

You can follow Owkin’s activities on LinkedIn, X, and YouTube, and Bioptimus on LinkedIn and X.

To get in touch with Jean-Philippe, contact him over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3104 no [SNIPPET] - Jean-Philippe Vert on what AI changes for healthcare To discover the whole episode type "#40 - Cracking biology through AI - Jean-Philippe Vert - Owkin" on your preferred streaming platform. Mon, 18 Nov 2024 10:18:00 -0000 full Mathieu Chaffard To discover the whole episode type "#40 - Cracking biology through AI - Jean-Philippe Vert - Owkin" on your preferred streaming platform. To discover the whole episode type "#40 - Cracking biology through AI - Jean-Philippe Vert - Owkin" on your preferred streaming platform.

]]> 335 no #39 - Crafting the best connected health experience - Matthieu Menanteau - Withings Among pioneering companies in connected health devices, few have been as forward-thinking as Withings, a flagship of French technology. Their first connected scales date back to 2009 (when smartphones were still emerging!) and remain the industry standard today. For that time, it was a subtle blend combining sleek design, intuitive user experience, and medical precision. A formula that Withings has successfully applied and developed in many other areas, from smartwatches to sleep sensors, thermometers, blood pressure monitors, or even a urinalysis device for your toilet! Their portfolio covers a wide range of medical parameters and helps hundreds of thousands of individuals manage their health daily. Matthieu Menanteau is one of the minds behind Withings' creations over the past 8 years. In this highly insightful episode, he shares Withings' philosophy and approach to creating the ultimate connected health experience, one that allows everyone to better understand themselves and take control of their health journey. We discuss: Withings' philosophy to innovate successfully in today's connected health sector Three development pillars that form the essence of Withings products The ongoing integration of consumer health with health systems and telemedicine The power of continuous medical data in the age of AI and big data A conversation that brings new perspectives on the future of connected health, and how technology can integrate into our daily lives to guide us toward healthier behaviors! Timeline: 00:00:00 - Withings’ origins and vision for connected health 00:07:18 - Providing the ultimate health companion 00:10:03 - Biomarkers and indications covered by Withings 00:13:11 - A home urinalysis laboratory 00:17:44 - Bringing the medical check-up at home 00:21:11 - A dual approach to driving innovation in connected health 00:26:20 - Towards an overwhelming mass of connected health devices? 00:31:47 - Withings’ three pillars of product development 00:38:05 - The role of AI in creating the ultimate connected health experience What we also talked about with Matthieu: Type 2 diabetes Lean mass Visceral fat Hydration pH Vitamin C Ketones Oxygen saturation Cuffless blood pressure measurement Apple CE mark FDA Edge computing Doctolib Alan CES We cited with Matthieu some of the past episodes of the series: #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden As mentioned by Matthieu during the episode, we recommend taking a look at the Research section of the Withings website, to learn more about current and future publications surrounding their products. To learn more about their portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Products section. You can follow Withings’ activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Matthieu via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 10 Nov 2024 20:30:00 -0000 full Mathieu Chaffard Among pioneering companies in connected health devices, few have been as forward-thinking as Withings, a flagship of French technology. Their first connected scales date back to 2009 (when smartphones were still emerging!) and remain the industry standard today. For that time, it was a subtle blend combining sleek design, intuitive user experience, and medical precision. A formula that Withings has successfully applied and developed in many other areas, from smartwatches to sleep sensors, thermometers, blood pressure monitors, or even a urinalysis device for your toilet! Their portfolio covers a wide range of medical parameters and helps hundreds of thousands of individuals manage their health daily. Matthieu Menanteau is one of the minds behind Withings' creations over the past 8 years. In this highly insightful episode, he shares Withings' philosophy and approach to creating the ultimate connected health experience, one that allows everyone to better understand themselves and take control of their health journey. We discuss: Withings' philosophy to innovate successfully in today's connected health sector Three development pillars that form the essence of Withings products The ongoing integration of consumer health with health systems and telemedicine The power of continuous medical data in the age of AI and big data A conversation that brings new perspectives on the future of connected health, and how technology can integrate into our daily lives to guide us toward healthier behaviors! Timeline: 00:00:00 - Withings’ origins and vision for connected health 00:07:18 - Providing the ultimate health companion 00:10:03 - Biomarkers and indications covered by Withings 00:13:11 - A home urinalysis laboratory 00:17:44 - Bringing the medical check-up at home 00:21:11 - A dual approach to driving innovation in connected health 00:26:20 - Towards an overwhelming mass of connected health devices? 00:31:47 - Withings’ three pillars of product development 00:38:05 - The role of AI in creating the ultimate connected health experience What we also talked about with Matthieu: Type 2 diabetes Lean mass Visceral fat Hydration pH Vitamin C Ketones Oxygen saturation Cuffless blood pressure measurement Apple CE mark FDA Edge computing Doctolib Alan CES We cited with Matthieu some of the past episodes of the series: #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden As mentioned by Matthieu during the episode, we recommend taking a look at the Research section of the Withings website, to learn more about current and future publications surrounding their products. To learn more about their portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Products section. You can follow Withings’ activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Matthieu via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Among pioneering companies in connected health devices, few have been as forward-thinking as Withings, a flagship of French technology.

Their first connected scales date back to 2009 (when smartphones were still emerging!) and remain the industry standard today.

For that time, it was a subtle blend combining sleek design, intuitive user experience, and medical precision.

A formula that Withings has successfully applied and developed in many other areas, from smartwatches to sleep sensors, thermometers, blood pressure monitors, or even a urinalysis device for your toilet!

Their portfolio covers a wide range of medical parameters and helps hundreds of thousands of individuals manage their health daily.

Matthieu Menanteau is one of the minds behind Withings' creations over the past 8 years.

In this highly insightful episode, he shares Withings' philosophy and approach to creating the ultimate connected health experience, one that allows everyone to better understand themselves and take control of their health journey.

We discuss:

  • Withings' philosophy to innovate successfully in today's connected health sector
  • Three development pillars that form the essence of Withings products
  • The ongoing integration of consumer health with health systems and telemedicine
  • The power of continuous medical data in the age of AI and big data


A conversation that brings new perspectives on the future of connected health, and how technology can integrate into our daily lives to guide us toward healthier behaviors!


Timeline:

00:00:00 - Withings’ origins and vision for connected health

00:07:18 - Providing the ultimate health companion

00:10:03 - Biomarkers and indications covered by Withings

00:13:11 - A home urinalysis laboratory

00:17:44 - Bringing the medical check-up at home

00:21:11 - A dual approach to driving innovation in connected health

00:26:20 - Towards an overwhelming mass of connected health devices?

00:31:47 - Withings’ three pillars of product development

00:38:05 - The role of AI in creating the ultimate connected health experience


What we also talked about with Matthieu:


We cited with Matthieu some of the past episodes of the series:


As mentioned by Matthieu during the episode, we recommend taking a look at the Research section of the Withings website, to learn more about current and future publications surrounding their products.

To learn more about their portfolio and the diversity of biomarkers and health conditions they cover, take a look at their Products section.

You can follow Withings’ activities on LinkedIn, X, Instagram, and YouTube, and get in touch with Matthieu via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3150 no [SNIPPET] - Matthieu Menanteau on the three pillars of a Withings product To discover the whole episode type "#39 - Crafting the best connected health experience - Matthieu Menanteau - Withings" on your preferred streaming platform Sun, 10 Nov 2024 20:28:00 -0000 full Mathieu Chaffard To discover the whole episode type "#39 - Crafting the best connected health experience - Matthieu Menanteau - Withings" on your preferred streaming platform To discover the whole episode type "#39 - Crafting the best connected health experience - Matthieu Menanteau - Withings" on your preferred streaming platform

]]> 342 no #38 - Rethinking medical biology with AI - Alexandre Guenoun - Kiro Medical biology and laboratories play an essential role in any health system. No wonder 70 to 80% of all medical decisions are based on laboratory test results. But even within the most advanced healthcare systems, the communication and analysis of lab data remain archaic. Processing times can be lengthy, even after the analysis is completed. Results are expressed as "out of range" or "in range", without complementary or actionable information. An experience still far from current technological standards, and a gap that Alexandre Guenoun and his team at Kiro intend to solve by redefining our experience of medical biology! Through faster and more personalized results for patients. With a suite of integrated clinical decision support tools for healthcare professionals. And a longitudinal database to accelerate biomedical research. A key service of any health system, at a turning point in France and beyond. We talk with Alexandre about: The importance of engaging each individual in their health journey The shift from disease-centered medicine to service-centered The Kiro experience for patients and healthcare professionals The role of technology in matching healthcare demand and supply The criticality of change management in healthcare innovation A key episode to understand the future of medical biology! Timeline: 00:00:00 - What drew Alexandre to healthcare and entrepreneurship 00:08:41 - How technology can make clinical biology smarter and more personalized 00:11:24 - The Kiro experience for patients and healthcare professionals 00:24:56 - Interpreting medical biology data with AI 00:28:16 - Matching demand and supply in health systems 00:31:01 - Scaling Kiro in Europe and beyond 00:34:01 - Leading change management with healthcare professionals What we also talked about with Alexandre: ZEBRA MEDICAL ESSEC Business School UC Berkeley Agoranov GPT-4o Sacha Loiseau This episode is brought to you in collaboration with Health.Tech, the heartbeat of healthtech! As mentioned by Alexandre during the episode, you can have a look at Kiro’s Product page to understand better their technology and stay posted on their latest progress. Alexandre also recommends reading The Hard Thing About Hard Things: Building a Business When There Are No Easy Answers by Ben Horowitz. You can follow Kiro's activities on LinkedIn and get in touch with Alexandre via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 04 Nov 2024 09:57:00 -0000 full Mathieu Chaffard Medical biology and laboratories play an essential role in any health system. No wonder 70 to 80% of all medical decisions are based on laboratory test results. But even within the most advanced healthcare systems, the communication and analysis of lab data remain archaic. Processing times can be lengthy, even after the analysis is completed. Results are expressed as "out of range" or "in range", without complementary or actionable information. An experience still far from current technological standards, and a gap that Alexandre Guenoun and his team at Kiro intend to solve by redefining our experience of medical biology! Through faster and more personalized results for patients. With a suite of integrated clinical decision support tools for healthcare professionals. And a longitudinal database to accelerate biomedical research. A key service of any health system, at a turning point in France and beyond. We talk with Alexandre about: The importance of engaging each individual in their health journey The shift from disease-centered medicine to service-centered The Kiro experience for patients and healthcare professionals The role of technology in matching healthcare demand and supply The criticality of change management in healthcare innovation A key episode to understand the future of medical biology! Timeline: 00:00:00 - What drew Alexandre to healthcare and entrepreneurship 00:08:41 - How technology can make clinical biology smarter and more personalized 00:11:24 - The Kiro experience for patients and healthcare professionals 00:24:56 - Interpreting medical biology data with AI 00:28:16 - Matching demand and supply in health systems 00:31:01 - Scaling Kiro in Europe and beyond 00:34:01 - Leading change management with healthcare professionals What we also talked about with Alexandre: ZEBRA MEDICAL ESSEC Business School UC Berkeley Agoranov GPT-4o Sacha Loiseau This episode is brought to you in collaboration with Health.Tech, the heartbeat of healthtech! As mentioned by Alexandre during the episode, you can have a look at Kiro’s Product page to understand better their technology and stay posted on their latest progress. Alexandre also recommends reading The Hard Thing About Hard Things: Building a Business When There Are No Easy Answers by Ben Horowitz. You can follow Kiro's activities on LinkedIn and get in touch with Alexandre via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Medical biology and laboratories play an essential role in any health system.

No wonder 70 to 80% of all medical decisions are based on laboratory test results.

But even within the most advanced healthcare systems, the communication and analysis of lab data remain archaic.

Processing times can be lengthy, even after the analysis is completed.

Results are expressed as "out of range" or "in range", without complementary or actionable information.

An experience still far from current technological standards, and a gap that Alexandre Guenoun and his team at Kiro intend to solve by redefining our experience of medical biology!

Through faster and more personalized results for patients.

With a suite of integrated clinical decision support tools for healthcare professionals.

And a longitudinal database to accelerate biomedical research.

A key service of any health system, at a turning point in France and beyond.

We talk with Alexandre about:

  • The importance of engaging each individual in their health journey
  • The shift from disease-centered medicine to service-centered
  • The Kiro experience for patients and healthcare professionals
  • The role of technology in matching healthcare demand and supply
  • The criticality of change management in healthcare innovation


A key episode to understand the future of medical biology!


Timeline:

00:00:00 - What drew Alexandre to healthcare and entrepreneurship

00:08:41 - How technology can make clinical biology smarter and more personalized

00:11:24 - The Kiro experience for patients and healthcare professionals

00:24:56 - Interpreting medical biology data with AI

00:28:16 - Matching demand and supply in health systems

00:31:01 - Scaling Kiro in Europe and beyond

00:34:01 - Leading change management with healthcare professionals


What we also talked about with Alexandre:


This episode is brought to you in collaboration with Health.Tech, the heartbeat of healthtech!

As mentioned by Alexandre during the episode, you can have a look at Kiro’s Product page to understand better their technology and stay posted on their latest progress. Alexandre also recommends reading The Hard Thing About Hard Things: Building a Business When There Are No Easy Answers by Ben Horowitz.

You can follow Kiro's activities on LinkedIn and get in touch with Alexandre via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2960 no [SNIPPET] - Alexandre Guenoun on rethinking the clinical biology experience To discover the whole episode type "#38 - Rethinking medical biology with AI - Alexandre Guenoun - Kiro" on your preferred streaming platform. Mon, 04 Nov 2024 09:53:00 -0000 full Mathieu Chaffard To discover the whole episode type "#38 - Rethinking medical biology with AI - Alexandre Guenoun - Kiro" on your preferred streaming platform. To discover the whole episode type "#38 - Rethinking medical biology with AI - Alexandre Guenoun - Kiro" on your preferred streaming platform.

]]> 260 no #37 - Hacking the dopamine system for good - Tryggvi Thorgeirsson - Sidekick Health Can the attention economy be harnessed to serve health? Paradoxical as it may seem, this is the thesis of Tryggvi Thorgeirsson and his team at Sidekick Health. As a medical doctor trained in Iceland in the 2000s, Tryggvi experienced rural medicine firsthand and what working as a general practitioner in a remote setting means. And he quickly found himself confronted with the limitations posed by the healthcare system at the time: Prescribing medications at the expense of other therapies where patients are guided toward healthier behaviors. The silos and impossibility of establishing a care plan that simultaneously takes into account multiple conditions. A purely reactive approach based on a brick-and-mortar model running out of steam. The emergence of smartphones and their potential as health companions became obvious to him. Based on this intuition, he co-founded Sidekick Health alongside his fellow physician and colleague Saemundur Oddsson. The company is now one of the leaders in digital therapeutics, offering a vast portfolio of therapies accessible from each patient's pocket, prescribed by thousands of doctors in Europe and the US. We talk with Tryggvi about the principles behind how these digital therapies work, how attention levers can be used to support long-term behavior change, and the growing impact these solutions have on individuals and healthcare systems. In the era of social media and the mental plague they represent, this episode brings a refreshing perspective on how dopamine can be used to put the health of individuals back in their own hands. Timeline: 00:00:00 - Tryggvi’s background as a medical doctor and electrical engineer 00:04:05 - What felt missing in Tryggvi’s rural medical practice 00:07:14 - Seeing early the potential of smartphones for healthcare 00:11:08 - Tryggvi’s definition of digital therapeutics 00:13:44 - The impact of digital therapeutics on clinical outcomes and cost of care 00:16:44 - Driving behavioral change and medical education through timely bite-sized pieces and gamification 00:18:40 - Sidekick Health’s approach to designing tailored and impactful digital health programs across multiple conditions 00:27:46 - Putting AI at the center of digital health programs and their usage 00:30:13 - Tryggvi’s vision for the future of healthcare What we also talked about with Tryggvi: PINK! Prof. Pia Wülfing Pear Therapeutics Daniel Kahneman Harvard T.H. Chan School of Public Health We cited with Tryggvi some of the past episodes of the series: #7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze #17 - Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health #30 - Building the Shopify of digital health - Dan Vahdat - Huma As mentioned by Tryggvi during the episode, we recommend reading Exits & Outcomes by Brian Dolan as well as Second Opinion by Christina Farr, two newsletters that will keep you posted on the latest in digital health. To dive further into the programs and use cases around Sidekick Health’s technology, take a look at their website. You can follow Sidekick Health’s activities on LinkedIn and X, and get in touch with Tryggvi via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Wed, 30 Oct 2024 07:04:00 -0000 full Mathieu Chaffard Can the attention economy be harnessed to serve health? Paradoxical as it may seem, this is the thesis of Tryggvi Thorgeirsson and his team at Sidekick Health. As a medical doctor trained in Iceland in the 2000s, Tryggvi experienced rural medicine firsthand and what working as a general practitioner in a remote setting means. And he quickly found himself confronted with the limitations posed by the healthcare system at the time: Prescribing medications at the expense of other therapies where patients are guided toward healthier behaviors. The silos and impossibility of establishing a care plan that simultaneously takes into account multiple conditions. A purely reactive approach based on a brick-and-mortar model running out of steam. The emergence of smartphones and their potential as health companions became obvious to him. Based on this intuition, he co-founded Sidekick Health alongside his fellow physician and colleague Saemundur Oddsson. The company is now one of the leaders in digital therapeutics, offering a vast portfolio of therapies accessible from each patient's pocket, prescribed by thousands of doctors in Europe and the US. We talk with Tryggvi about the principles behind how these digital therapies work, how attention levers can be used to support long-term behavior change, and the growing impact these solutions have on individuals and healthcare systems. In the era of social media and the mental plague they represent, this episode brings a refreshing perspective on how dopamine can be used to put the health of individuals back in their own hands. Timeline: 00:00:00 - Tryggvi’s background as a medical doctor and electrical engineer 00:04:05 - What felt missing in Tryggvi’s rural medical practice 00:07:14 - Seeing early the potential of smartphones for healthcare 00:11:08 - Tryggvi’s definition of digital therapeutics 00:13:44 - The impact of digital therapeutics on clinical outcomes and cost of care 00:16:44 - Driving behavioral change and medical education through timely bite-sized pieces and gamification 00:18:40 - Sidekick Health’s approach to designing tailored and impactful digital health programs across multiple conditions 00:27:46 - Putting AI at the center of digital health programs and their usage 00:30:13 - Tryggvi’s vision for the future of healthcare What we also talked about with Tryggvi: PINK! Prof. Pia Wülfing Pear Therapeutics Daniel Kahneman Harvard T.H. Chan School of Public Health We cited with Tryggvi some of the past episodes of the series: #7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze #17 - Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health #30 - Building the Shopify of digital health - Dan Vahdat - Huma As mentioned by Tryggvi during the episode, we recommend reading Exits & Outcomes by Brian Dolan as well as Second Opinion by Christina Farr, two newsletters that will keep you posted on the latest in digital health. To dive further into the programs and use cases around Sidekick Health’s technology, take a look at their website. You can follow Sidekick Health’s activities on LinkedIn and X, and get in touch with Tryggvi via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Can the attention economy be harnessed to serve health?

Paradoxical as it may seem, this is the thesis of Tryggvi Thorgeirsson and his team at Sidekick Health.

As a medical doctor trained in Iceland in the 2000s, Tryggvi experienced rural medicine firsthand and what working as a general practitioner in a remote setting means.

And he quickly found himself confronted with the limitations posed by the healthcare system at the time:

  • Prescribing medications at the expense of other therapies where patients are guided toward healthier behaviors.
  • The silos and impossibility of establishing a care plan that simultaneously takes into account multiple conditions.
  • A purely reactive approach based on a brick-and-mortar model running out of steam.


The emergence of smartphones and their potential as health companions became obvious to him.

Based on this intuition, he co-founded Sidekick Health alongside his fellow physician and colleague Saemundur Oddsson.

The company is now one of the leaders in digital therapeutics, offering a vast portfolio of therapies accessible from each patient's pocket, prescribed by thousands of doctors in Europe and the US.

We talk with Tryggvi about the principles behind how these digital therapies work, how attention levers can be used to support long-term behavior change, and the growing impact these solutions have on individuals and healthcare systems.

In the era of social media and the mental plague they represent, this episode brings a refreshing perspective on how dopamine can be used to put the health of individuals back in their own hands.


Timeline:

00:00:00 - Tryggvi’s background as a medical doctor and electrical engineer

00:04:05 - What felt missing in Tryggvi’s rural medical practice

00:07:14 - Seeing early the potential of smartphones for healthcare

00:11:08 - Tryggvi’s definition of digital therapeutics

00:13:44 - The impact of digital therapeutics on clinical outcomes and cost of care

00:16:44 - Driving behavioral change and medical education through timely bite-sized pieces and gamification

00:18:40 - Sidekick Health’s approach to designing tailored and impactful digital health programs across multiple conditions

00:27:46 - Putting AI at the center of digital health programs and their usage

00:30:13 - Tryggvi’s vision for the future of healthcare


What we also talked about with Tryggvi:


We cited with Tryggvi some of the past episodes of the series:


As mentioned by Tryggvi during the episode, we recommend reading Exits & Outcomes by Brian Dolan as well as Second Opinion by Christina Farr, two newsletters that will keep you posted on the latest in digital health.

To dive further into the programs and use cases around Sidekick Health’s technology, take a look at their website.

You can follow Sidekick Health’s activities on LinkedIn and X, and get in touch with Tryggvi via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2660 no [SNIPPET] - Tryggvi Thorgeirsson on human decision-making and how it can drive healthy behaviors To discover the whole episode type "#37 - Hacking the dopamine system for good - Tryggvi Thorgeirsson - Sidekick Health" on your preferred streaming platform. Wed, 30 Oct 2024 06:56:00 -0000 full Mathieu Chaffard To discover the whole episode type "#37 - Hacking the dopamine system for good - Tryggvi Thorgeirsson - Sidekick Health" on your preferred streaming platform. To discover the whole episode type "#37 - Hacking the dopamine system for good - Tryggvi Thorgeirsson - Sidekick Health" on your preferred streaming platform.

]]> 216 no #36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo Making healthcare preventive and better able to catch serious conditions earlier is a recurring topic for governments, health systems, and ultimately patients. As healthcare resources become scarce while chronic conditions and their burden on society grow larger, a preventive and more proactive approach to healthcare is undoubtedly part of the solution. There are many ways to go about it, with one emerging trend over the past few years focusing on holistic check-ups, providing a large set of scans, biological assays, and complimentary exams all at once on the same day, helping to give a broad snapshot of one’s health status. One approach that has triggered debate within the medical community focuses on full-body MRI scans delivered to individuals who can afford it, as the ultimate disease prevention tool. A detailed view of the inside of one’s body, based on one of the most widely used medical imaging methods. Some criticize the lack of evidence around the true benefits these scans bring to patients and health systems, pointing to the high price charged for them. Others testify to the diagnostic help these scans offer, lifting the veil on previously unexplained patient cases, and highlighting the possibility of taking action long before certain symptoms are expressed. One way or another, these reactions reflect an approach to medical screening that challenges traditional practices and raises questions. In this episode with the Founder and CEO of Prenuvo, Andrew Lacy addresses the main questions raised by this practice, offering new perspectives on how to apprehend these scans as a medical analysis tool, how they can complement existing care practices, and the complexity linked to the evaluation of the impact that these scans can have on health systems. An eye-opening conversation on what might constitute a part of future preventive healthcare! Timeline: 00:00:00 - Andrew’s background as a serial tech entrepreneur and his move into healthcare 00:04:15 - The idea behind Prenuvo and full-body scans as an early medical screening method 00:06:49 - What the Prenuvo experience looks like compared to a typical medical check-up 00:10:11 - The Prenuvo scanner and what it can see inside the body 00:14:41 - Can Prenuvo scans diagnose certain conditions? 00:18:44 - For whom are these scans for? 00:21:35 - Building the case for full-body MRI scans benefits toward health systems 00:25:39 - Making full-body MRI scans more affordable 00:27:30 - How Prenuvo leverages AI throughout its operations 00:30:21 - Empowering patients to drive long-term behavioral change 00:34:43 - Prenuvo’s plans for geographic expansion and growth What we also talked about with Andrew: Dr. Raj Attariwala This episode was made possible with the support of HLTH Europe! As mentioned by Andrew during the episode, we recommend taking a look at the Research section of Prenuvo’s website, to be informed about the latest in multi-parametric MRI studies and its applications across multiple disease areas. You can also find out more on PubMed for further studies on these topics. To dive further into the technology behind Prenuvo’s scans, head out to The Scan section of their website. You can follow Prenuvo’s activities on LinkedIn, Instagram, and X, and get in touch with Andrew via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Thu, 24 Oct 2024 07:16:00 -0000 full Mathieu Chaffard Making healthcare preventive and better able to catch serious conditions earlier is a recurring topic for governments, health systems, and ultimately patients. As healthcare resources become scarce while chronic conditions and their burden on society grow larger, a preventive and more proactive approach to healthcare is undoubtedly part of the solution. There are many ways to go about it, with one emerging trend over the past few years focusing on holistic check-ups, providing a large set of scans, biological assays, and complimentary exams all at once on the same day, helping to give a broad snapshot of one’s health status. One approach that has triggered debate within the medical community focuses on full-body MRI scans delivered to individuals who can afford it, as the ultimate disease prevention tool. A detailed view of the inside of one’s body, based on one of the most widely used medical imaging methods. Some criticize the lack of evidence around the true benefits these scans bring to patients and health systems, pointing to the high price charged for them. Others testify to the diagnostic help these scans offer, lifting the veil on previously unexplained patient cases, and highlighting the possibility of taking action long before certain symptoms are expressed. One way or another, these reactions reflect an approach to medical screening that challenges traditional practices and raises questions. In this episode with the Founder and CEO of Prenuvo, Andrew Lacy addresses the main questions raised by this practice, offering new perspectives on how to apprehend these scans as a medical analysis tool, how they can complement existing care practices, and the complexity linked to the evaluation of the impact that these scans can have on health systems. An eye-opening conversation on what might constitute a part of future preventive healthcare! Timeline: 00:00:00 - Andrew’s background as a serial tech entrepreneur and his move into healthcare 00:04:15 - The idea behind Prenuvo and full-body scans as an early medical screening method 00:06:49 - What the Prenuvo experience looks like compared to a typical medical check-up 00:10:11 - The Prenuvo scanner and what it can see inside the body 00:14:41 - Can Prenuvo scans diagnose certain conditions? 00:18:44 - For whom are these scans for? 00:21:35 - Building the case for full-body MRI scans benefits toward health systems 00:25:39 - Making full-body MRI scans more affordable 00:27:30 - How Prenuvo leverages AI throughout its operations 00:30:21 - Empowering patients to drive long-term behavioral change 00:34:43 - Prenuvo’s plans for geographic expansion and growth What we also talked about with Andrew: Dr. Raj Attariwala This episode was made possible with the support of HLTH Europe! As mentioned by Andrew during the episode, we recommend taking a look at the Research section of Prenuvo’s website, to be informed about the latest in multi-parametric MRI studies and its applications across multiple disease areas. You can also find out more on PubMed for further studies on these topics. To dive further into the technology behind Prenuvo’s scans, head out to The Scan section of their website. You can follow Prenuvo’s activities on LinkedIn, Instagram, and X, and get in touch with Andrew via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Making healthcare preventive and better able to catch serious conditions earlier is a recurring topic for governments, health systems, and ultimately patients.

As healthcare resources become scarce while chronic conditions and their burden on society grow larger, a preventive and more proactive approach to healthcare is undoubtedly part of the solution.

There are many ways to go about it, with one emerging trend over the past few years focusing on holistic check-ups, providing a large set of scans, biological assays, and complimentary exams all at once on the same day, helping to give a broad snapshot of one’s health status.

One approach that has triggered debate within the medical community focuses on full-body MRI scans delivered to individuals who can afford it, as the ultimate disease prevention tool.

A detailed view of the inside of one’s body, based on one of the most widely used medical imaging methods.

Some criticize the lack of evidence around the true benefits these scans bring to patients and health systems, pointing to the high price charged for them.

Others testify to the diagnostic help these scans offer, lifting the veil on previously unexplained patient cases, and highlighting the possibility of taking action long before certain symptoms are expressed.

One way or another, these reactions reflect an approach to medical screening that challenges traditional practices and raises questions.

In this episode with the Founder and CEO of Prenuvo, Andrew Lacy addresses the main questions raised by this practice, offering new perspectives on how to apprehend these scans as a medical analysis tool, how they can complement existing care practices, and the complexity linked to the evaluation of the impact that these scans can have on health systems.

An eye-opening conversation on what might constitute a part of future preventive healthcare!


Timeline:

00:00:00 - Andrew’s background as a serial tech entrepreneur and his move into healthcare

00:04:15 - The idea behind Prenuvo and full-body scans as an early medical screening method

00:06:49 - What the Prenuvo experience looks like compared to a typical medical check-up

00:10:11 - The Prenuvo scanner and what it can see inside the body

00:14:41 - Can Prenuvo scans diagnose certain conditions?

00:18:44 - For whom are these scans for?

00:21:35 - Building the case for full-body MRI scans benefits toward health systems

00:25:39 - Making full-body MRI scans more affordable

00:27:30 - How Prenuvo leverages AI throughout its operations

00:30:21 - Empowering patients to drive long-term behavioral change

00:34:43 - Prenuvo’s plans for geographic expansion and growth


What we also talked about with Andrew:


This episode was made possible with the support of HLTH Europe!

As mentioned by Andrew during the episode, we recommend taking a look at the Research section of Prenuvo’s website, to be informed about the latest in multi-parametric MRI studies and its applications across multiple disease areas. You can also find out more on PubMed for further studies on these topics.

To dive further into the technology behind Prenuvo’s scans, head out to The Scan section of their website.

You can follow Prenuvo’s activities on LinkedIn, Instagram, and X, and get in touch with Andrew via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2865 [SNIPPET] - Andrew Lacy on the complexity of measuring the benefits of full-body MRI scans for health systems To discover the whole episode type "#36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo" on your preferred streaming platform. Thu, 24 Oct 2024 07:13:00 -0000 full Mathieu Chaffard To discover the whole episode type "#36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo" on your preferred streaming platform. To discover the whole episode type "#36 - Turning healthcare preventive with full-body MRI scans - Andrew Lacy - Prenuvo" on your preferred streaming platform.

]]> 262 #35 - Making surgery smarter and safer - Björn Von Siemens - Caresyntax Modernizing surgery by making it smarter, safer, and more predictive. This is the mission of Björn Von Siemens and his team at Caresyntax. By developing a platform that integrates into hospitals’ infrastructures and leveraging their data flows throughout the planning, execution, and follow-up of surgeries, the company has established itself as a leader in connected surgery. Their impact on health systems worldwide is massive and continues to grow at pace: +3000 equipped operating rooms +30,000 surgical teams served +3 million surgeries assisted each year In a world where healthcare resources are growing scarce and where access to surgery is highly unequal, Caresyntax aims to be one of those enabling a profound change in medicine at scale, for the benefit of patients, healthcare professionals, and hospitals. By helping them optimize the use of operating rooms, staffing, and costs. By providing video oversight and intelligence for each operation performed, tracking every step of their execution. By enabling continuous improvement of medical teams and surgeons through detailed case reviews. In this fascinating episode, we delve into the world of cutting-edge surgery in the era of robotics, AI, and automation. Björn opens up about the inside story of this unique healthtech entrepreneurial adventure, revealing the challenges and successes that have made Caresyntax a pillar of modern surgery! Timeline: 00:00:00 - Bjoern’s story as an aspiring surgeon who shifted toward healthcare entrepreneurship 00:08:14 - The idea behind Caresyntax and solving major needs for surgery 00:14:16 - The functioning of Caresyntax’s platform 00:18:07 - Helping surgeons get better at what they do 00:26:45 - Giving transparency to hospitals on their operations and opportunities for improvement 00:31:55 - The role of AI in Caresyntax’s platform 00:34:44 - Helping hospitals fight the burnout crisis 00:39:08 - Setting the right expectations from patients prior to surgery 00:42:39 - What excites Björn for the future of surgery What we also talked about with Björn: Quantum Surgical Intuitive Surgical Radical prostatectomy Total knee arthroplasty Neuralink General Catalyst We cited with Björn some of the past episodes of the series: #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical This episode was made possible with the support of HLTH Europe! As mentioned by Björn during the episode, we recommend reading The Checklist Manifesto: How to Get Things Right by Atul Gawande. To dive further into the applications and use cases around Caresyntax’s platform for surgery, take a look at the Resources section of their website. You can follow Caresyntax’s activities on LinkedIn and X, and get in touch with Björn via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 13 Oct 2024 15:48:00 -0000 full Mathieu Chaffard Modernizing surgery by making it smarter, safer, and more predictive. This is the mission of Björn Von Siemens and his team at Caresyntax. By developing a platform that integrates into hospitals’ infrastructures and leveraging their data flows throughout the planning, execution, and follow-up of surgeries, the company has established itself as a leader in connected surgery. Their impact on health systems worldwide is massive and continues to grow at pace: +3000 equipped operating rooms +30,000 surgical teams served +3 million surgeries assisted each year In a world where healthcare resources are growing scarce and where access to surgery is highly unequal, Caresyntax aims to be one of those enabling a profound change in medicine at scale, for the benefit of patients, healthcare professionals, and hospitals. By helping them optimize the use of operating rooms, staffing, and costs. By providing video oversight and intelligence for each operation performed, tracking every step of their execution. By enabling continuous improvement of medical teams and surgeons through detailed case reviews. In this fascinating episode, we delve into the world of cutting-edge surgery in the era of robotics, AI, and automation. Björn opens up about the inside story of this unique healthtech entrepreneurial adventure, revealing the challenges and successes that have made Caresyntax a pillar of modern surgery! Timeline: 00:00:00 - Bjoern’s story as an aspiring surgeon who shifted toward healthcare entrepreneurship 00:08:14 - The idea behind Caresyntax and solving major needs for surgery 00:14:16 - The functioning of Caresyntax’s platform 00:18:07 - Helping surgeons get better at what they do 00:26:45 - Giving transparency to hospitals on their operations and opportunities for improvement 00:31:55 - The role of AI in Caresyntax’s platform 00:34:44 - Helping hospitals fight the burnout crisis 00:39:08 - Setting the right expectations from patients prior to surgery 00:42:39 - What excites Björn for the future of surgery What we also talked about with Björn: Quantum Surgical Intuitive Surgical Radical prostatectomy Total knee arthroplasty Neuralink General Catalyst We cited with Björn some of the past episodes of the series: #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical This episode was made possible with the support of HLTH Europe! As mentioned by Björn during the episode, we recommend reading The Checklist Manifesto: How to Get Things Right by Atul Gawande. To dive further into the applications and use cases around Caresyntax’s platform for surgery, take a look at the Resources section of their website. You can follow Caresyntax’s activities on LinkedIn and X, and get in touch with Björn via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Modernizing surgery by making it smarter, safer, and more predictive.

This is the mission of Björn Von Siemens and his team at Caresyntax.

By developing a platform that integrates into hospitals’ infrastructures and leveraging their data flows throughout the planning, execution, and follow-up of surgeries, the company has established itself as a leader in connected surgery.

Their impact on health systems worldwide is massive and continues to grow at pace:

  • +3000 equipped operating rooms
  • +30,000 surgical teams served
  • +3 million surgeries assisted each year


In a world where healthcare resources are growing scarce and where access to surgery is highly unequal, Caresyntax aims to be one of those enabling a profound change in medicine at scale, for the benefit of patients, healthcare professionals, and hospitals.

By helping them optimize the use of operating rooms, staffing, and costs.

By providing video oversight and intelligence for each operation performed, tracking every step of their execution.

By enabling continuous improvement of medical teams and surgeons through detailed case reviews.

In this fascinating episode, we delve into the world of cutting-edge surgery in the era of robotics, AI, and automation.

Björn opens up about the inside story of this unique healthtech entrepreneurial adventure, revealing the challenges and successes that have made Caresyntax a pillar of modern surgery!


Timeline:

00:00:00 - Bjoern’s story as an aspiring surgeon who shifted toward healthcare entrepreneurship

00:08:14 - The idea behind Caresyntax and solving major needs for surgery

00:14:16 - The functioning of Caresyntax’s platform

00:18:07 - Helping surgeons get better at what they do

00:26:45 - Giving transparency to hospitals on their operations and opportunities for improvement

00:31:55 - The role of AI in Caresyntax’s platform

00:34:44 - Helping hospitals fight the burnout crisis

00:39:08 - Setting the right expectations from patients prior to surgery

00:42:39 - What excites Björn for the future of surgery


What we also talked about with Björn:


We cited with Björn some of the past episodes of the series:


This episode was made possible with the support of HLTH Europe!

As mentioned by Björn during the episode, we recommend reading The Checklist Manifesto: How to Get Things Right by Atul Gawande.

To dive further into the applications and use cases around Caresyntax’s platform for surgery, take a look at the Resources section of their website.

You can follow Caresyntax’s activities on LinkedIn and X, and get in touch with Björn via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3347 [SNIPPET] - Björn Von Siemens on providing modern tools for surgery To discover the whole episode type "#35 - Making surgery smarter and safer - Björn Von Siemens - Caresyntax" on your preferred streaming platform. Sun, 13 Oct 2024 15:46:00 -0000 full Mathieu Chaffard To discover the whole episode type "#35 - Making surgery smarter and safer - Björn Von Siemens - Caresyntax" on your preferred streaming platform. To discover the whole episode type "#35 - Making surgery smarter and safer - Björn Von Siemens - Caresyntax" on your preferred streaming platform.

]]> 277 #34 - Uniting to bring medical technology forward - Dylan Attard - MedTech World Leaving your surgical training to create a healthcare conference from scratch... ...On an island of 300 km² in the middle of the Mediterranean! This is the crazy bet that Dylan Attard took 5 years ago by founding MedTech World. From its first online conference held in 2020 in the midst of COVID-19 to its early roadshows around the world two years later, the annual Maltese event led by Dylan and his team has now established itself as a must on the global healthtech scene! Far from traditional trade shows sponsored by industry giants, MedTech World aims to be a platform to accelerate healthcare innovation by fostering an intimate connection between entrepreneurs, investors, HCPs, and industry professionals. This year, more than 2000 participants will gather at the Mediterranean Conference Center (a building built as a hospital in the 16th century!), including more than 300 startups, 100 investors, and 200 partners. So how do we plan such an event? How to curate its content to create value for its participants and partners? What does it take to build a strong community centered on medical innovation? And how to differentiate yourself from other global conferences? In this Masterclass on healthcare event management, Dylan unveils the keys to MedTech World's success and many more reasons to join in in Malta in November this year! Timeline: 00:00:00 - Dylan’s background from surgery trainee to founding a global conference 00:06:12 - Mutual benefits of having a medical background and being an entrepreneur 00:09:03 - The idea behind MedTech World 00:16:01 - Attractivity of Malta as a medical technology hub 00:18:20 - Expanding MedTech World’s reach beyond Malta 00:20:51 - Shaping the conference program and curating the highest quality content 00:27:17 - Trends and emerging technologies in MedTech worth following 0029:36 - Dylan’s advice on making a career change from medical professional to entrepreneur What we also talked about with Dylan: Malta Medical Students’ Association Prof. Shafi Ahmed We mentioned with Dylan some of the past episodes of the series: #2 - Treating liver cancer with surgical robotics - Lucien Blondel This episode was made possible with the support of MedTech World! As Dylan mentioned during the episode, you can learn more about the different events that MedTech World hosts throughout the year on their official website. To register for the conference in Malta, click here and use the code MTWMaltaMathieuChaffard150OFF to get 150€ off your attendance ticket! You can follow MedTech World’s activities on LinkedIn, X, and Instagram, and contact Dylan via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, reach out via LinkedIn or email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Mon, 07 Oct 2024 19:37:00 -0000 full Mathieu Chaffard Leaving your surgical training to create a healthcare conference from scratch... ...On an island of 300 km² in the middle of the Mediterranean! This is the crazy bet that Dylan Attard took 5 years ago by founding MedTech World. From its first online conference held in 2020 in the midst of COVID-19 to its early roadshows around the world two years later, the annual Maltese event led by Dylan and his team has now established itself as a must on the global healthtech scene! Far from traditional trade shows sponsored by industry giants, MedTech World aims to be a platform to accelerate healthcare innovation by fostering an intimate connection between entrepreneurs, investors, HCPs, and industry professionals. This year, more than 2000 participants will gather at the Mediterranean Conference Center (a building built as a hospital in the 16th century!), including more than 300 startups, 100 investors, and 200 partners. So how do we plan such an event? How to curate its content to create value for its participants and partners? What does it take to build a strong community centered on medical innovation? And how to differentiate yourself from other global conferences? In this Masterclass on healthcare event management, Dylan unveils the keys to MedTech World's success and many more reasons to join in in Malta in November this year! Timeline: 00:00:00 - Dylan’s background from surgery trainee to founding a global conference 00:06:12 - Mutual benefits of having a medical background and being an entrepreneur 00:09:03 - The idea behind MedTech World 00:16:01 - Attractivity of Malta as a medical technology hub 00:18:20 - Expanding MedTech World’s reach beyond Malta 00:20:51 - Shaping the conference program and curating the highest quality content 00:27:17 - Trends and emerging technologies in MedTech worth following 0029:36 - Dylan’s advice on making a career change from medical professional to entrepreneur What we also talked about with Dylan: Malta Medical Students’ Association Prof. Shafi Ahmed We mentioned with Dylan some of the past episodes of the series: #2 - Treating liver cancer with surgical robotics - Lucien Blondel This episode was made possible with the support of MedTech World! As Dylan mentioned during the episode, you can learn more about the different events that MedTech World hosts throughout the year on their official website. To register for the conference in Malta, click here and use the code MTWMaltaMathieuChaffard150OFF to get 150€ off your attendance ticket! You can follow MedTech World’s activities on LinkedIn, X, and Instagram, and contact Dylan via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, reach out via LinkedIn or email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Leaving your surgical training to create a healthcare conference from scratch...

...On an island of 300 km² in the middle of the Mediterranean!

This is the crazy bet that Dylan Attard took 5 years ago by founding MedTech World.

From its first online conference held in 2020 in the midst of COVID-19 to its early roadshows around the world two years later, the annual Maltese event led by Dylan and his team has now established itself as a must on the global healthtech scene!

Far from traditional trade shows sponsored by industry giants, MedTech World aims to be a platform to accelerate healthcare innovation by fostering an intimate connection between entrepreneurs, investors, HCPs, and industry professionals.

This year, more than 2000 participants will gather at the Mediterranean Conference Center (a building built as a hospital in the 16th century!), including more than 300 startups, 100 investors, and 200 partners.

So how do we plan such an event?

How to curate its content to create value for its participants and partners?

What does it take to build a strong community centered on medical innovation?

And how to differentiate yourself from other global conferences?

In this Masterclass on healthcare event management, Dylan unveils the keys to MedTech World's success and many more reasons to join in in Malta in November this year!


Timeline:

00:00:00 - Dylan’s background from surgery trainee to founding a global conference

00:06:12 - Mutual benefits of having a medical background and being an entrepreneur

00:09:03 - The idea behind MedTech World

00:16:01 - Attractivity of Malta as a medical technology hub

00:18:20 - Expanding MedTech World’s reach beyond Malta

00:20:51 - Shaping the conference program and curating the highest quality content

00:27:17 - Trends and emerging technologies in MedTech worth following

0029:36 - Dylan’s advice on making a career change from medical professional to entrepreneur


What we also talked about with Dylan:


We mentioned with Dylan some of the past episodes of the series:


This episode was made possible with the support of MedTech World!

As Dylan mentioned during the episode, you can learn more about the different events that MedTech World hosts throughout the year on their official website.

To register for the conference in Malta, click here and use the code MTWMaltaMathieuChaffard150OFF to get 150€ off your attendance ticket!

You can follow MedTech World’s activities on LinkedIn, X, and Instagram, and contact Dylan via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, reach out via LinkedIn or email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2481 [SNIPPET] - Dylan Attard on making a successful healthcare conference To discover the whole episode type "#34 - Uniting to bring medical technology forward - Dylan Attard - MedTech World" on your preferred streaming platform. Mon, 07 Oct 2024 19:36:00 -0000 full Mathieu Chaffard To discover the whole episode type "#34 - Uniting to bring medical technology forward - Dylan Attard - MedTech World" on your preferred streaming platform. To discover the whole episode type "#34 - Uniting to bring medical technology forward - Dylan Attard - MedTech World" on your preferred streaming platform.

]]> 265 #33 - Building the next TechBio venture - Mati Gill - AION Labs AI and computational science are revolutionizing the biotechnology sector. From identifying new therapeutic approaches to their production and accelerating the administrative processes for bringing them to market, the entire value chain of this sector is impacted! These recent advancements have given rise to a new field in the industry: TechBio. But what lies behind this futuristic term? And how exactly do these technologies accelerate the development and introduction of new treatments? These two questions are at the heart of this episode featuring Mati Gill from AION Labs. With a background in law and in the pharmaceutical industry, Mati is the CEO of this venture builder focused on this emerging field, at the cutting edge of computer science and biology. A true startup factory for TechBio, formed around partnerships with the world's largest Tech and Biotechnology companies. Unlike conventional innovation platforms such as incubators or startup accelerators, AION Labs enables Founders to accelerate the development of their companies through a holistic range of services and tools: Anchoring the startup’s mission around a clear R&D issue identified by industrial partners Funding new ventures at the pre-seed or seed stage Assisting Founders in identifying and recruiting talent Providing the infrastructure and resources necessary for co-developing new solutions with industrial partners A masterclass on innovation in TechBio and what this industry will change for health and patients soon! Timeline: 00:00:00 - Mati’s background from studying law to entering the TechBio field 00:07:00 - A new way to discover medical treatments and drugs 00:12:42 - The current impact of TechBio on the pharmaceutical industry 00:15:58 - The attitude of regulators toward TechBio and how they adapt to it 00:19:00 - Breaking down fantasies around TechBio and its promises 00:23:54 - AION Lab’s operating model and how to build the next TechBio success 00:34:06 - Relationships and investments between startups and partners from AION Labs 00:41:30 - Advice for TechBio enthusiasts and future entrepreneurs in the field What we also talked about with Mati: Sharon Kredo-Russo Nature’s article on AI’s potential to accelerate drug discovery (from October 2023) FDA EMA DenovAI Biotech Kashif Sadiq PromiseBio Prof. Yifat Merbl We cited with Mati some of the past episodes of the series: #8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche This episode was made possible with the support of HLTH Europe! As Mati mentioned during the episode, you can learn more about the latest in TechBio through Christian Tidona’s work with Biomed X. You can follow AION Labs’ activities on LinkedIn and X, and get in touch with Mati via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 29 Sep 2024 19:09:00 -0000 full Mathieu Chaffard AI and computational science are revolutionizing the biotechnology sector. From identifying new therapeutic approaches to their production and accelerating the administrative processes for bringing them to market, the entire value chain of this sector is impacted! These recent advancements have given rise to a new field in the industry: TechBio. But what lies behind this futuristic term? And how exactly do these technologies accelerate the development and introduction of new treatments? These two questions are at the heart of this episode featuring Mati Gill from AION Labs. With a background in law and in the pharmaceutical industry, Mati is the CEO of this venture builder focused on this emerging field, at the cutting edge of computer science and biology. A true startup factory for TechBio, formed around partnerships with the world's largest Tech and Biotechnology companies. Unlike conventional innovation platforms such as incubators or startup accelerators, AION Labs enables Founders to accelerate the development of their companies through a holistic range of services and tools: Anchoring the startup’s mission around a clear R&D issue identified by industrial partners Funding new ventures at the pre-seed or seed stage Assisting Founders in identifying and recruiting talent Providing the infrastructure and resources necessary for co-developing new solutions with industrial partners A masterclass on innovation in TechBio and what this industry will change for health and patients soon! Timeline: 00:00:00 - Mati’s background from studying law to entering the TechBio field 00:07:00 - A new way to discover medical treatments and drugs 00:12:42 - The current impact of TechBio on the pharmaceutical industry 00:15:58 - The attitude of regulators toward TechBio and how they adapt to it 00:19:00 - Breaking down fantasies around TechBio and its promises 00:23:54 - AION Lab’s operating model and how to build the next TechBio success 00:34:06 - Relationships and investments between startups and partners from AION Labs 00:41:30 - Advice for TechBio enthusiasts and future entrepreneurs in the field What we also talked about with Mati: Sharon Kredo-Russo Nature’s article on AI’s potential to accelerate drug discovery (from October 2023) FDA EMA DenovAI Biotech Kashif Sadiq PromiseBio Prof. Yifat Merbl We cited with Mati some of the past episodes of the series: #8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche This episode was made possible with the support of HLTH Europe! As Mati mentioned during the episode, you can learn more about the latest in TechBio through Christian Tidona’s work with Biomed X. You can follow AION Labs’ activities on LinkedIn and X, and get in touch with Mati via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! AI and computational science are revolutionizing the biotechnology sector.

From identifying new therapeutic approaches to their production and accelerating the administrative processes for bringing them to market, the entire value chain of this sector is impacted!

These recent advancements have given rise to a new field in the industry: TechBio.

But what lies behind this futuristic term?

And how exactly do these technologies accelerate the development and introduction of new treatments?

These two questions are at the heart of this episode featuring Mati Gill from AION Labs.

With a background in law and in the pharmaceutical industry, Mati is the CEO of this venture builder focused on this emerging field, at the cutting edge of computer science and biology.

A true startup factory for TechBio, formed around partnerships with the world's largest Tech and Biotechnology companies.

Unlike conventional innovation platforms such as incubators or startup accelerators, AION Labs enables Founders to accelerate the development of their companies through a holistic range of services and tools:

  • Anchoring the startup’s mission around a clear R&D issue identified by industrial partners
  • Funding new ventures at the pre-seed or seed stage
  • Assisting Founders in identifying and recruiting talent
  • Providing the infrastructure and resources necessary for co-developing new solutions with industrial partners


A masterclass on innovation in TechBio and what this industry will change for health and patients soon!


Timeline:

00:00:00 - Mati’s background from studying law to entering the TechBio field

00:07:00 - A new way to discover medical treatments and drugs

00:12:42 - The current impact of TechBio on the pharmaceutical industry

00:15:58 - The attitude of regulators toward TechBio and how they adapt to it

00:19:00 - Breaking down fantasies around TechBio and its promises

00:23:54 - AION Lab’s operating model and how to build the next TechBio success

00:34:06 - Relationships and investments between startups and partners from AION Labs

00:41:30 - Advice for TechBio enthusiasts and future entrepreneurs in the field


What we also talked about with Mati:


We cited with Mati some of the past episodes of the series:


This episode was made possible with the support of HLTH Europe!

As Mati mentioned during the episode, you can learn more about the latest in TechBio through Christian Tidona’s work with Biomed X.

You can follow AION Labs’ activities on LinkedIn and X, and get in touch with Mati via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3196 no [SNIPPET] - Mati Gill on identifying key challenges in biotechnology To discover the whole episode type "#33 - Building the next TechBio venture - Mati Gill - AION Labs" on your preferred streaming platform. Sun, 29 Sep 2024 19:07:00 -0000 full Mathieu Chaffard To discover the whole episode type "#33 - Building the next TechBio venture - Mati Gill - AION Labs" on your preferred streaming platform. To discover the whole episode type "#33 - Building the next TechBio venture - Mati Gill - AION Labs" on your preferred streaming platform.

]]> 364 no #32 - Accelerating radiology with AI - Amine Korchi - Radiologist Radiology is the field of medicine that has experienced some of the most dramatic technological changes over the past decades. And given the record number of approvals for AI-based and machine-learning tools dedicated to radiology in Europe and the US (far ahead of all other medical specialties combined!), this trend is unlikely to slow down. Such rapid evolution can be attributed to the abundance of imaging data from clinical practice, and it already has a huge impact on the way radiologists work and care for patients. Faster workflows, enhanced diagnostic accuracy, and better informed clinical decisions… As we enter the era of multimodal AI models capable of simultaneously interpreting volumes of data from different formats (such as voice notes, images, videos, texts, etc.), we can only expect this evolution to accelerate even more in the coming months and years. As we seek to understand this transformation, we sit down with Amine Korchi, a Swiss radiologist, entrepreneur, investor, and renowned advocate for technological progress in radiology. In this eye-opening episode, Amine offers us a rich perspective on: the evolution of medical imaging, from static 2D images, through dynamic 3D, to AI the impact of AI on the training of physicians and their specialization current use cases of AI in radiology and their impact on patient care the barriers to its adoption and the fears AI raises among radiologists future developments of AI in radiology and their promises An episode to help us understand one of the major technological revolutions in medicine - and one we're far from seeing the end of! Timeline: 00:00:00 - Amine’s background as a radiologist, entrepreneur, and investor in clinical AI 00:06:10 - How radiology transformed over the past 20 years 00:13:43 - Is ultra-specialization in medicine a good thing? 00:17:39 - Concrete use cases of AI in clinical radiology 00:21:50 - Barriers to AI adoption in radiology 00:27:44 - Future developments of AI in radiology 00:33:17 - The tasks that AI will replace in radiology 00:36:16 - Impact of AI on future radiologists’ training What we also talked about with Amine: Intravenous urography CT Scan Iseult MRI machine Tumor board GPT4-o Cerebriu Smart Reporting Gleamer Owkin Kicky Van Leeuwen Hugh Harvey Microlearning We mentioned with Amine some of the past episodes of the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens #16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius As mentioned by Amine during the episode, you can learn more about the latest in radiology through The Imaging Wire newsletter or on Radiology Business. If you want to get in touch with Amine, you can do so via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 22 Sep 2024 19:59:00 -0000 full Mathieu Chaffard Radiology is the field of medicine that has experienced some of the most dramatic technological changes over the past decades. And given the record number of approvals for AI-based and machine-learning tools dedicated to radiology in Europe and the US (far ahead of all other medical specialties combined!), this trend is unlikely to slow down. Such rapid evolution can be attributed to the abundance of imaging data from clinical practice, and it already has a huge impact on the way radiologists work and care for patients. Faster workflows, enhanced diagnostic accuracy, and better informed clinical decisions… As we enter the era of multimodal AI models capable of simultaneously interpreting volumes of data from different formats (such as voice notes, images, videos, texts, etc.), we can only expect this evolution to accelerate even more in the coming months and years. As we seek to understand this transformation, we sit down with Amine Korchi, a Swiss radiologist, entrepreneur, investor, and renowned advocate for technological progress in radiology. In this eye-opening episode, Amine offers us a rich perspective on: the evolution of medical imaging, from static 2D images, through dynamic 3D, to AI the impact of AI on the training of physicians and their specialization current use cases of AI in radiology and their impact on patient care the barriers to its adoption and the fears AI raises among radiologists future developments of AI in radiology and their promises An episode to help us understand one of the major technological revolutions in medicine - and one we're far from seeing the end of! Timeline: 00:00:00 - Amine’s background as a radiologist, entrepreneur, and investor in clinical AI 00:06:10 - How radiology transformed over the past 20 years 00:13:43 - Is ultra-specialization in medicine a good thing? 00:17:39 - Concrete use cases of AI in clinical radiology 00:21:50 - Barriers to AI adoption in radiology 00:27:44 - Future developments of AI in radiology 00:33:17 - The tasks that AI will replace in radiology 00:36:16 - Impact of AI on future radiologists’ training What we also talked about with Amine: Intravenous urography CT Scan Iseult MRI machine Tumor board GPT4-o Cerebriu Smart Reporting Gleamer Owkin Kicky Van Leeuwen Hugh Harvey Microlearning We mentioned with Amine some of the past episodes of the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens #16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius As mentioned by Amine during the episode, you can learn more about the latest in radiology through The Imaging Wire newsletter or on Radiology Business. If you want to get in touch with Amine, you can do so via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Radiology is the field of medicine that has experienced some of the most dramatic technological changes over the past decades.

And given the record number of approvals for AI-based and machine-learning tools dedicated to radiology in Europe and the US (far ahead of all other medical specialties combined!), this trend is unlikely to slow down.

Such rapid evolution can be attributed to the abundance of imaging data from clinical practice, and it already has a huge impact on the way radiologists work and care for patients.

Faster workflows, enhanced diagnostic accuracy, and better informed clinical decisions…

As we enter the era of multimodal AI models capable of simultaneously interpreting volumes of data from different formats (such as voice notes, images, videos, texts, etc.), we can only expect this evolution to accelerate even more in the coming months and years.

As we seek to understand this transformation, we sit down with Amine Korchi, a Swiss radiologist, entrepreneur, investor, and renowned advocate for technological progress in radiology.

In this eye-opening episode, Amine offers us a rich perspective on:

  • the evolution of medical imaging, from static 2D images, through dynamic 3D, to AI
  • the impact of AI on the training of physicians and their specialization
  • current use cases of AI in radiology and their impact on patient care
  • the barriers to its adoption and the fears AI raises among radiologists
  • future developments of AI in radiology and their promises


An episode to help us understand one of the major technological revolutions in medicine - and one we're far from seeing the end of!


Timeline:

00:00:00 - Amine’s background as a radiologist, entrepreneur, and investor in clinical AI

00:06:10 - How radiology transformed over the past 20 years

00:13:43 - Is ultra-specialization in medicine a good thing?

00:17:39 - Concrete use cases of AI in clinical radiology

00:21:50 - Barriers to AI adoption in radiology

00:27:44 - Future developments of AI in radiology

00:33:17 - The tasks that AI will replace in radiology

00:36:16 - Impact of AI on future radiologists’ training


What we also talked about with Amine:


We mentioned with Amine some of the past episodes of the series:

#1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens

#16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius


As mentioned by Amine during the episode, you can learn more about the latest in radiology through The Imaging Wire newsletter or on Radiology Business.

If you want to get in touch with Amine, you can do so via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3288 [SNIPPET] - Amine Korchi on the power of multimodal AI in medicine To discover the whole episode type "#32 - Accelerating radiology with AI - Amine Korchi - Radiologist" on your streaming platform. Sun, 22 Sep 2024 19:57:00 -0000 full Mathieu Chaffard To discover the whole episode type "#32 - Accelerating radiology with AI - Amine Korchi - Radiologist" on your streaming platform. To discover the whole episode type "#32 - Accelerating radiology with AI - Amine Korchi - Radiologist" on your streaming platform.

]]> 155 #31 - Measuring sleep remotely - Soumya Dash - Sleepiz Sleep is the resting state that nature has chosen for us by default. Long overlooked or even neglected, it is one of the keys to good health, alongside nutrition, physical exercise, and mental and emotional health. Moreover, it is an excellent indicator of our overall health: when our sleep is disturbed, it usually means at least one of these four components is affected. It thus seems essential to be able to measure the quality of our sleep while minimizing the interaction or invasiveness of the measurement method with our body. And that is precisely the promise of Soumya Dash and his company Sleepiz! Based on radar technology, this Swiss startup has developed a compact device to place on a bedside table, capable of remotely clinically measuring sleep and detecting potential disorders such as sleep apnea or insomnia. No electroencephalogram to wear on the head, no pulse oximeter on the finger, nor any wearable around the wrist: everything is measured from the bedside table and without any direct interaction with the subject measured. In this surprising episode, we dive into the fascinating world of sleep, a realm with many secrets still to be uncovered! Soumya shares with us insights into the technology his team has developed, the difference between consumer-grade and medical-grade sleep monitors, and a glimpse into the future of healthcare in this field! Timeline: 00:00:00 - How Soumya came across sleep monitoring and why it matters 00:12:45 - How the Sleepiz device monitors sleep 00:18:20 - Relevant use cases and target indications of sleep disorders 00:22:35 - Differences between consumer-grade vs. medical-grade sleep monitors 00:25:35 - B2C and B2B business models 00:37:43 - Past milestones and challenges ahead What we also talked about with Soumya: ETH Zürich ISO 13485 norm Class IIa medical device 510(k) FDA clearance Chronic Obstructive Pulmonary Disease (COPD) Oura Ring WHOOP IDUN Technologies SmartCardia As mentioned by Soumya during the episode, you can learn more about sleep and the current state of research in the book Why We Sleep: Unlocking the Power of Sleep and Dreams by Matthew Walker. You will find more information about Sleepiz on their website and you can follow their activities on LinkedIn. If you want to get in touch with Soumya, you can do so via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 15 Sep 2024 16:22:00 -0000 full Mathieu Chaffard Sleep is the resting state that nature has chosen for us by default. Long overlooked or even neglected, it is one of the keys to good health, alongside nutrition, physical exercise, and mental and emotional health. Moreover, it is an excellent indicator of our overall health: when our sleep is disturbed, it usually means at least one of these four components is affected. It thus seems essential to be able to measure the quality of our sleep while minimizing the interaction or invasiveness of the measurement method with our body. And that is precisely the promise of Soumya Dash and his company Sleepiz! Based on radar technology, this Swiss startup has developed a compact device to place on a bedside table, capable of remotely clinically measuring sleep and detecting potential disorders such as sleep apnea or insomnia. No electroencephalogram to wear on the head, no pulse oximeter on the finger, nor any wearable around the wrist: everything is measured from the bedside table and without any direct interaction with the subject measured. In this surprising episode, we dive into the fascinating world of sleep, a realm with many secrets still to be uncovered! Soumya shares with us insights into the technology his team has developed, the difference between consumer-grade and medical-grade sleep monitors, and a glimpse into the future of healthcare in this field! Timeline: 00:00:00 - How Soumya came across sleep monitoring and why it matters 00:12:45 - How the Sleepiz device monitors sleep 00:18:20 - Relevant use cases and target indications of sleep disorders 00:22:35 - Differences between consumer-grade vs. medical-grade sleep monitors 00:25:35 - B2C and B2B business models 00:37:43 - Past milestones and challenges ahead What we also talked about with Soumya: ETH Zürich ISO 13485 norm Class IIa medical device 510(k) FDA clearance Chronic Obstructive Pulmonary Disease (COPD) Oura Ring WHOOP IDUN Technologies SmartCardia As mentioned by Soumya during the episode, you can learn more about sleep and the current state of research in the book Why We Sleep: Unlocking the Power of Sleep and Dreams by Matthew Walker. You will find more information about Sleepiz on their website and you can follow their activities on LinkedIn. If you want to get in touch with Soumya, you can do so via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sleep is the resting state that nature has chosen for us by default.

Long overlooked or even neglected, it is one of the keys to good health, alongside nutrition, physical exercise, and mental and emotional health.

Moreover, it is an excellent indicator of our overall health: when our sleep is disturbed, it usually means at least one of these four components is affected.

It thus seems essential to be able to measure the quality of our sleep while minimizing the interaction or invasiveness of the measurement method with our body.

And that is precisely the promise of Soumya Dash and his company Sleepiz!

Based on radar technology, this Swiss startup has developed a compact device to place on a bedside table, capable of remotely clinically measuring sleep and detecting potential disorders such as sleep apnea or insomnia.

No electroencephalogram to wear on the head, no pulse oximeter on the finger, nor any wearable around the wrist: everything is measured from the bedside table and without any direct interaction with the subject measured.

In this surprising episode, we dive into the fascinating world of sleep, a realm with many secrets still to be uncovered!

Soumya shares with us insights into the technology his team has developed, the difference between consumer-grade and medical-grade sleep monitors, and a glimpse into the future of healthcare in this field!


Timeline:

00:00:00 - How Soumya came across sleep monitoring and why it matters

00:12:45 - How the Sleepiz device monitors sleep

00:18:20 - Relevant use cases and target indications of sleep disorders

00:22:35 - Differences between consumer-grade vs. medical-grade sleep monitors

00:25:35 - B2C and B2B business models

00:37:43 - Past milestones and challenges ahead


What we also talked about with Soumya:


As mentioned by Soumya during the episode, you can learn more about sleep and the current state of research in the book Why We Sleep: Unlocking the Power of Sleep and Dreams by Matthew Walker.

You will find more information about Sleepiz on their website and you can follow their activities on LinkedIn.

If you want to get in touch with Soumya, you can do so via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 3291 [SNIPPET] - Soumya Dash on consumer versus medical grade products To discover the whole episode type "#31 - Measuring sleep remotely - Soumya Dash - Sleepiz" on your streaming platform. Sun, 15 Sep 2024 16:21:00 -0000 full Mathieu Chaffard To discover the whole episode type "#31 - Measuring sleep remotely - Soumya Dash - Sleepiz" on your streaming platform. To discover the whole episode type "#31 - Measuring sleep remotely - Soumya Dash - Sleepiz" on your streaming platform.

]]> 171 #30 - Building the Shopify of digital health - Dan Vahdat - Huma Dan Vahdat is an emblematic figure and entrepreneur in healthtech. A visionary we could say, having anticipated the problem of point solutions in the industry, while predicting the essential role smartphones would have in empowering patients to take control of their health. The company he founded after pausing his PhD, Huma, has pioneered the field of digital health and remote patient monitoring, having been one of the first to successfully deliver digital disease management programs across multiple conditions. The first to receive regulatory clearance in Europe (IIb) and the US (II) for its configurable disease management platform. As the firm is nearing the status of “unicorn” in its 13th year and approaching profitability, it’s never been so close to realizing Dan’s vision: augmenting the capacity of health systems at scale while enabling true proactive and predictive care. Huma’s list of successes is immense: more than 3000 hospitals and clinics supported, 27 million patients served, Winner of the 2022 Prix Galien award for digital health, and the list goes on… But the Founder’s ambition does not stop there. In this fascinating episode, Dan explains Huma’s journey toward becoming the “Shopify” of digital health, or in other words, the central infrastructure on which other digital health companies can successfully build disease management programs, more efficiently and at less cost. In the challenging business of digital health, Dan shares his reflections on what enabled Huma to succeed where many other companies failed. He explains the approach they took when it comes to fostering patient engagement, addressing healthcare professionals’ needs, and being relentless about building robust clinical and economic evidence. An inside look into one of the most innovative firms in digital health, and the future of this industry! Timeline: 00:00:00 - Dan’s background from dropping out of his PhD to founding Huma 00:06:16 - Huma’s starting point focusing on rare diseases 00:08:09 - The Huma platform and how it is changing how we deliver care 00:10:56 - Creating the Shopify for digital health 00:17:25 - How Huma is improving running decentralized clinical trials 00:21:53 - The importance of UX and evidence generation 00:24:42 - Making engaging digital health solutions 00:28:14 - What excites Dan about digital health’s future 00:34:02 - Dan’s reflections on his journey from PhD dropout to Huma’s CEO 00:37:40 - Maximizing operational efficiency in a healthtech startup What we also talked about with Dan: Second Opinion Peterson Technology Health Institute Elon Musk by Walter Isaacson 23andme Vertex Pharmaceuticals We cited with Dan some of the past episodes of the series: #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden This episode was made possible with the support of HLTH Europe! As mentioned by Dan during the episode, you can join the waitlist for the Huma Cloud Platform here. You will find on their website more information about their latest news and research. You can follow Huma’s activities on LinkedIn and X, and get in touch with Dan via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 08 Sep 2024 13:50:00 -0000 full Mathieu Chaffard Dan Vahdat is an emblematic figure and entrepreneur in healthtech. A visionary we could say, having anticipated the problem of point solutions in the industry, while predicting the essential role smartphones would have in empowering patients to take control of their health. The company he founded after pausing his PhD, Huma, has pioneered the field of digital health and remote patient monitoring, having been one of the first to successfully deliver digital disease management programs across multiple conditions. The first to receive regulatory clearance in Europe (IIb) and the US (II) for its configurable disease management platform. As the firm is nearing the status of “unicorn” in its 13th year and approaching profitability, it’s never been so close to realizing Dan’s vision: augmenting the capacity of health systems at scale while enabling true proactive and predictive care. Huma’s list of successes is immense: more than 3000 hospitals and clinics supported, 27 million patients served, Winner of the 2022 Prix Galien award for digital health, and the list goes on… But the Founder’s ambition does not stop there. In this fascinating episode, Dan explains Huma’s journey toward becoming the “Shopify” of digital health, or in other words, the central infrastructure on which other digital health companies can successfully build disease management programs, more efficiently and at less cost. In the challenging business of digital health, Dan shares his reflections on what enabled Huma to succeed where many other companies failed. He explains the approach they took when it comes to fostering patient engagement, addressing healthcare professionals’ needs, and being relentless about building robust clinical and economic evidence. An inside look into one of the most innovative firms in digital health, and the future of this industry! Timeline: 00:00:00 - Dan’s background from dropping out of his PhD to founding Huma 00:06:16 - Huma’s starting point focusing on rare diseases 00:08:09 - The Huma platform and how it is changing how we deliver care 00:10:56 - Creating the Shopify for digital health 00:17:25 - How Huma is improving running decentralized clinical trials 00:21:53 - The importance of UX and evidence generation 00:24:42 - Making engaging digital health solutions 00:28:14 - What excites Dan about digital health’s future 00:34:02 - Dan’s reflections on his journey from PhD dropout to Huma’s CEO 00:37:40 - Maximizing operational efficiency in a healthtech startup What we also talked about with Dan: Second Opinion Peterson Technology Health Institute Elon Musk by Walter Isaacson 23andme Vertex Pharmaceuticals We cited with Dan some of the past episodes of the series: #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden This episode was made possible with the support of HLTH Europe! As mentioned by Dan during the episode, you can join the waitlist for the Huma Cloud Platform here. You will find on their website more information about their latest news and research. You can follow Huma’s activities on LinkedIn and X, and get in touch with Dan via LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Dan Vahdat is an emblematic figure and entrepreneur in healthtech.

A visionary we could say, having anticipated the problem of point solutions in the industry, while predicting the essential role smartphones would have in empowering patients to take control of their health.

The company he founded after pausing his PhD, Huma, has pioneered the field of digital health and remote patient monitoring, having been one of the first to successfully deliver digital disease management programs across multiple conditions.

The first to receive regulatory clearance in Europe (IIb) and the US (II) for its configurable disease management platform.

As the firm is nearing the status of “unicorn” in its 13th year and approaching profitability, it’s never been so close to realizing Dan’s vision: augmenting the capacity of health systems at scale while enabling true proactive and predictive care.

Huma’s list of successes is immense: more than 3000 hospitals and clinics supported, 27 million patients served, Winner of the 2022 Prix Galien award for digital health, and the list goes on…

But the Founder’s ambition does not stop there.

In this fascinating episode, Dan explains Huma’s journey toward becoming the “Shopify” of digital health, or in other words, the central infrastructure on which other digital health companies can successfully build disease management programs, more efficiently and at less cost.

In the challenging business of digital health, Dan shares his reflections on what enabled Huma to succeed where many other companies failed.

He explains the approach they took when it comes to fostering patient engagement, addressing healthcare professionals’ needs, and being relentless about building robust clinical and economic evidence.

An inside look into one of the most innovative firms in digital health, and the future of this industry!


Timeline:

00:00:00 - Dan’s background from dropping out of his PhD to founding Huma

00:06:16 - Huma’s starting point focusing on rare diseases

00:08:09 - The Huma platform and how it is changing how we deliver care

00:10:56 - Creating the Shopify for digital health

00:17:25 - How Huma is improving running decentralized clinical trials

00:21:53 - The importance of UX and evidence generation

00:24:42 - Making engaging digital health solutions

00:28:14 - What excites Dan about digital health’s future

00:34:02 - Dan’s reflections on his journey from PhD dropout to Huma’s CEO

00:37:40 - Maximizing operational efficiency in a healthtech startup


What we also talked about with Dan:


We cited with Dan some of the past episodes of the series:


This episode was made possible with the support of HLTH Europe!

As mentioned by Dan during the episode, you can join the waitlist for the Huma Cloud Platform here. You will find on their website more information about their latest news and research.

You can follow Huma’s activities on LinkedIn and X, and get in touch with Dan via LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2923 [SNIPPET] - Dan Vahdat on enabling digital health programs at scale To discover the whole episode type "#30 - Building the Shopify of digital health - Dan Vahdat - Huma" on your streaming platform. Sun, 08 Sep 2024 13:47:00 -0000 full Mathieu Chaffard To discover the whole episode type "#30 - Building the Shopify of digital health - Dan Vahdat - Huma" on your streaming platform. To discover the whole episode type "#30 - Building the Shopify of digital health - Dan Vahdat - Huma" on your streaming platform.

]]> 171 #29 - Fighting atherosclerosis with cavitation - Scott Nelson - FastWave Medical Scott Nelson is a true authority in the Medtech field. A serial entrepreneur, investor, and early podcaster with Medsider, he currently leads FastWave Medical, a startup developing a method to combat atherosclerosis, specifically the rigid plaques formed by significant calcium deposits in blood vessels. The principle behind this technology is cavitation, which involves the formation, growth, and implosive collapse of bubbles in a liquid medium. When sonic pressure waves are transmitted through a balloon catheter filled with liquid, they cause rapid pressure changes in the surrounding fluid. These pressure changes result in the formation of bubbles within the fluid rapidly expanding and collapsing violently. The shock waves created by these bubbles' explosion weaken solid nearby structures while leaving soft tissues intact. The idea is to break down calcium deposits without affecting the blood vessels, which regain flexibility. It thereby reduces the risk of obstruction or increased local blood pressure, and facilitates the placement of a stent or the expansion of the vessel with another balloon catheter. The method, called intravascular lithotripsy (IVL), is already used by interventional cardiologists. Still, much work remains to make it easier to use, more cost-efficient, and ultimately democratize further this practice, whose clinical benefits have already been proven. This is at the core of FastWave Medical’s mission. Given the rapid development of the company (having raised $12 million in just six months after its incorporation in 2021) and its progress in clinical validation stages, there is no doubt that it is poised to disrupt and expand an emerging market where only a few firms operate. In this episode, we talk with Scott about medtech entrepreneurship, being a visionary in a highly regulated industry, and the importance of sharing experience and expertise to progress daily in one’s healthcare career. An episode with one of the leading voices in the medtech scene, offering a glimpse into the future of cardiac surgery! Timeline: 00:00:00 - Scott’s background in Medtech 00:07:34 - FastWave Medical’s mission in cardiac surgery 00:10:35 - Working principle of IVL 00:20:23 - Adoption in clinical practice 00:22:30 - What FastWave Medical does differently than its competitors 00:26:33 - Driving the costs of the surgical intervention down 00:27:44 - Towards additional medical indications for IVL 00:30:58 - Starting Medsider and podcasting before the iPhone What we also talked about with Scott: Stents Balloon catheters Atherectomy Joovv Shockwave Medical CTO Plus Cardiovascular Research Foundation Miguel Montero-Baker Venkatesh Ramaiah As mentioned by Scott during the episode, we recommend looking at the IVL Science page on FastWave Medical’s website as well as The Catalyst Blog curated by Shockwave Medical, to learn more about IVL and its latest progress. If you are yourself in MedTech entrepreneurship, do check out Medsider and the numerous resources and insights it offers, including interviews from other Founders and CEOs, a newsletter, and playbooks. You can also listen to the Medsider Podcast on all streaming platforms! You can contact Scott via email and follow his activities on LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! ⭐️ Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 01 Sep 2024 22:48:00 -0000 full Mathieu Chaffard Scott Nelson is a true authority in the Medtech field. A serial entrepreneur, investor, and early podcaster with Medsider, he currently leads FastWave Medical, a startup developing a method to combat atherosclerosis, specifically the rigid plaques formed by significant calcium deposits in blood vessels. The principle behind this technology is cavitation, which involves the formation, growth, and implosive collapse of bubbles in a liquid medium. When sonic pressure waves are transmitted through a balloon catheter filled with liquid, they cause rapid pressure changes in the surrounding fluid. These pressure changes result in the formation of bubbles within the fluid rapidly expanding and collapsing violently. The shock waves created by these bubbles' explosion weaken solid nearby structures while leaving soft tissues intact. The idea is to break down calcium deposits without affecting the blood vessels, which regain flexibility. It thereby reduces the risk of obstruction or increased local blood pressure, and facilitates the placement of a stent or the expansion of the vessel with another balloon catheter. The method, called intravascular lithotripsy (IVL), is already used by interventional cardiologists. Still, much work remains to make it easier to use, more cost-efficient, and ultimately democratize further this practice, whose clinical benefits have already been proven. This is at the core of FastWave Medical’s mission. Given the rapid development of the company (having raised $12 million in just six months after its incorporation in 2021) and its progress in clinical validation stages, there is no doubt that it is poised to disrupt and expand an emerging market where only a few firms operate. In this episode, we talk with Scott about medtech entrepreneurship, being a visionary in a highly regulated industry, and the importance of sharing experience and expertise to progress daily in one’s healthcare career. An episode with one of the leading voices in the medtech scene, offering a glimpse into the future of cardiac surgery! Timeline: 00:00:00 - Scott’s background in Medtech 00:07:34 - FastWave Medical’s mission in cardiac surgery 00:10:35 - Working principle of IVL 00:20:23 - Adoption in clinical practice 00:22:30 - What FastWave Medical does differently than its competitors 00:26:33 - Driving the costs of the surgical intervention down 00:27:44 - Towards additional medical indications for IVL 00:30:58 - Starting Medsider and podcasting before the iPhone What we also talked about with Scott: Stents Balloon catheters Atherectomy Joovv Shockwave Medical CTO Plus Cardiovascular Research Foundation Miguel Montero-Baker Venkatesh Ramaiah As mentioned by Scott during the episode, we recommend looking at the IVL Science page on FastWave Medical’s website as well as The Catalyst Blog curated by Shockwave Medical, to learn more about IVL and its latest progress. If you are yourself in MedTech entrepreneurship, do check out Medsider and the numerous resources and insights it offers, including interviews from other Founders and CEOs, a newsletter, and playbooks. You can also listen to the Medsider Podcast on all streaming platforms! You can contact Scott via email and follow his activities on LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! ⭐️ Lastly, don’t forget to follow our activities on LinkedIn and our website! Scott Nelson is a true authority in the Medtech field. A serial entrepreneur, investor, and early podcaster with Medsider, he currently leads FastWave Medical, a startup developing a method to combat atherosclerosis, specifically the rigid plaques formed by significant calcium deposits in blood vessels.

The principle behind this technology is cavitation, which involves the formation, growth, and implosive collapse of bubbles in a liquid medium. When sonic pressure waves are transmitted through a balloon catheter filled with liquid, they cause rapid pressure changes in the surrounding fluid. These pressure changes result in the formation of bubbles within the fluid rapidly expanding and collapsing violently. The shock waves created by these bubbles' explosion weaken solid nearby structures while leaving soft tissues intact. The idea is to break down calcium deposits without affecting the blood vessels, which regain flexibility. It thereby reduces the risk of obstruction or increased local blood pressure, and facilitates the placement of a stent or the expansion of the vessel with another balloon catheter.

The method, called intravascular lithotripsy (IVL), is already used by interventional cardiologists. Still, much work remains to make it easier to use, more cost-efficient, and ultimately democratize further this practice, whose clinical benefits have already been proven. This is at the core of FastWave Medical’s mission.

Given the rapid development of the company (having raised $12 million in just six months after its incorporation in 2021) and its progress in clinical validation stages, there is no doubt that it is poised to disrupt and expand an emerging market where only a few firms operate.

In this episode, we talk with Scott about medtech entrepreneurship, being a visionary in a highly regulated industry, and the importance of sharing experience and expertise to progress daily in one’s healthcare career.

An episode with one of the leading voices in the medtech scene, offering a glimpse into the future of cardiac surgery!


Timeline:

00:00:00 - Scott’s background in Medtech

00:07:34 - FastWave Medical’s mission in cardiac surgery

00:10:35 - Working principle of IVL

00:20:23 - Adoption in clinical practice

00:22:30 - What FastWave Medical does differently than its competitors

00:26:33 - Driving the costs of the surgical intervention down

00:27:44 - Towards additional medical indications for IVL

00:30:58 - Starting Medsider and podcasting before the iPhone


What we also talked about with Scott:


As mentioned by Scott during the episode, we recommend looking at the IVL Science page on FastWave Medical’s website as well as The Catalyst Blog curated by Shockwave Medical, to learn more about IVL and its latest progress.

If you are yourself in MedTech entrepreneurship, do check out Medsider and the numerous resources and insights it offers, including interviews from other Founders and CEOs, a newsletter, and playbooks. You can also listen to the Medsider Podcast on all streaming platforms!

You can contact Scott via email and follow his activities on LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! ⭐️

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2823 [SNIPPET] - Scott Nelson on proposing new tools for cardiac surgery To discover the whole episode type "#29 - Fighting atherosclerosis with cavitation - Scott Nelson - FastWave Medical" on your streaming platform. Sun, 01 Sep 2024 22:46:00 -0000 full Mathieu Chaffard To discover the whole episode type "#29 - Fighting atherosclerosis with cavitation - Scott Nelson - FastWave Medical" on your streaming platform. To discover the whole episode type "#29 - Fighting atherosclerosis with cavitation - Scott Nelson - FastWave Medical" on your streaming platform.

]]> 260 #28 - Modeling embryos to understand early life - Jacob Hanna - Weizmann Institute of Science Because of ethical and medical challenges, early human embryo development remains “a black box” to us, as Prof. Jacob Hanna himself puts it. Despite all the progress made in medicine over the past decades, there is still a whole lot to learn about the causes of miscarriages, infertility, or early developmental defects. In 2023, Jacob’s group from the Weizmann Institute of Science published a pivotal paper in Nature that redefines how we study developmental biology, with the potential to accelerate our understanding of early human life. Their achievement? The creation of the first synthetic embryo model closely resembling a day-14 fetus, obtained “ex utero” without gametes and outside a womb. A human embryo model derived from “naive” stem cells in the lab, which can be obtained from “adult” cells that make up our body (like skin cells for instance). A technology that could generate embryo models of ourselves based on a simple cell sample. This work had an unprecedented impact on the scientific community and the general public, being named by TIME Magazine as one of the 100 best inventions of 2023. A breakthrough that raises important ethical, technical, and legal questions. I had the honor of meeting Jacob for this episode of Impulse, with whom we discuss the functioning of this fascinating technology, its potential medical applications in the future, and the key societal questions it raises. A conversation where we dive into the magic of human development, with a stellar scientist and advocate for responsible scientific research! Timeline: 00:00:00 - Jacob’s journey from his medical practice to studying developmental biology 00:06:09 - Why we know so little about early human development 00:08:45 - Jacob’s lab breakthrough in modeling human embryos 00:16:20 - Reprogramming cells to their “naïve” state 00:18:09 - Dealing with your research being put under the spotlight 00:20:02 - The “recipe” to create human embryo models without gametes and outside a womb 00:27:22 - Ethical considerations and how far we can go with this technology 00:35:15 - Potential medical applications for the future 00:38:05 - Jacob’s role as an adviser to the startup Renewal Bio What we also talked about with Jacob: Prof. Shinya Yamanaka (2012 Nobel Prize in Physiology or Medicine with Prof. John Gurdon) Induced pluripotent stem cells (iPSCs) Embryonic stem cells International Society for Stem Cell Research (ISSCR) Taledomide We cited with Jacob some of the past episodes of the series:: #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden As mentioned by Jacob during the episode, we recommend the book “The Master Builder” by Prof. Alfonso Martinez Arias, challenging the traditional thinking where cells (and not DNA) may hold the key to understanding life’s past and present. Feel free to follow the Weizmann Institute of Science on LinkedIn. You can contact Jacob via email and follow his activities on LinkedIn, X, and Facebook! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Tue, 07 May 2024 20:37:00 -0000 Modeling embryos to understand early life - Jacob Hanna - Weizmann Institute of Science full Mathieu Chaffard Because of ethical and medical challenges, early human embryo development remains “a black box” to us, as Prof. Jacob Hanna himself puts it. Despite all the progress made in medicine over the past decades, there is still a whole lot to learn about the causes of miscarriages, infertility, or early developmental defects. In 2023, Jacob’s group from the Weizmann Institute of Science published a pivotal paper in Nature that redefines how we study developmental biology, with the potential to accelerate our understanding of early human life. Their achievement? The creation of the first synthetic embryo model closely resembling a day-14 fetus, obtained “ex utero” without gametes and outside a womb. A human embryo model derived from “naive” stem cells in the lab, which can be obtained from “adult” cells that make up our body (like skin cells for instance). A technology that could generate embryo models of ourselves based on a simple cell sample. This work had an unprecedented impact on the scientific community and the general public, being named by TIME Magazine as one of the 100 best inventions of 2023. A breakthrough that raises important ethical, technical, and legal questions. I had the honor of meeting Jacob for this episode of Impulse, with whom we discuss the functioning of this fascinating technology, its potential medical applications in the future, and the key societal questions it raises. A conversation where we dive into the magic of human development, with a stellar scientist and advocate for responsible scientific research! Timeline: 00:00:00 - Jacob’s journey from his medical practice to studying developmental biology 00:06:09 - Why we know so little about early human development 00:08:45 - Jacob’s lab breakthrough in modeling human embryos 00:16:20 - Reprogramming cells to their “naïve” state 00:18:09 - Dealing with your research being put under the spotlight 00:20:02 - The “recipe” to create human embryo models without gametes and outside a womb 00:27:22 - Ethical considerations and how far we can go with this technology 00:35:15 - Potential medical applications for the future 00:38:05 - Jacob’s role as an adviser to the startup Renewal Bio What we also talked about with Jacob: Prof. Shinya Yamanaka (2012 Nobel Prize in Physiology or Medicine with Prof. John Gurdon) Induced pluripotent stem cells (iPSCs) Embryonic stem cells International Society for Stem Cell Research (ISSCR) Taledomide We cited with Jacob some of the past episodes of the series:: #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden As mentioned by Jacob during the episode, we recommend the book “The Master Builder” by Prof. Alfonso Martinez Arias, challenging the traditional thinking where cells (and not DNA) may hold the key to understanding life’s past and present. Feel free to follow the Weizmann Institute of Science on LinkedIn. You can contact Jacob via email and follow his activities on LinkedIn, X, and Facebook! If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email! And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Because of ethical and medical challenges, early human embryo development remains “a black box” to us, as Prof. Jacob Hanna himself puts it.

Despite all the progress made in medicine over the past decades, there is still a whole lot to learn about the causes of miscarriages, infertility, or early developmental defects.

In 2023, Jacob’s group from the Weizmann Institute of Science published a pivotal paper in Nature that redefines how we study developmental biology, with the potential to accelerate our understanding of early human life.

Their achievement?

The creation of the first synthetic embryo model closely resembling a day-14 fetus, obtained “ex utero” without gametes and outside a womb.

A human embryo model derived from “naive” stem cells in the lab, which can be obtained from “adult” cells that make up our body (like skin cells for instance). A technology that could generate embryo models of ourselves based on a simple cell sample.

This work had an unprecedented impact on the scientific community and the general public, being named by TIME Magazine as one of the 100 best inventions of 2023.

A breakthrough that raises important ethical, technical, and legal questions.

I had the honor of meeting Jacob for this episode of Impulse, with whom we discuss the functioning of this fascinating technology, its potential medical applications in the future, and the key societal questions it raises.

A conversation where we dive into the magic of human development, with a stellar scientist and advocate for responsible scientific research!


Timeline:

00:00:00 - Jacob’s journey from his medical practice to studying developmental biology

00:06:09 - Why we know so little about early human development

00:08:45 - Jacob’s lab breakthrough in modeling human embryos

00:16:20 - Reprogramming cells to their “naïve” state

00:18:09 - Dealing with your research being put under the spotlight

00:20:02 - The “recipe” to create human embryo models without gametes and outside a womb

00:27:22 - Ethical considerations and how far we can go with this technology

00:35:15 - Potential medical applications for the future

00:38:05 - Jacob’s role as an adviser to the startup Renewal Bio


What we also talked about with Jacob:


We cited with Jacob some of the past episodes of the series::


As mentioned by Jacob during the episode, we recommend the book “The Master Builder” by Prof. Alfonso Martinez Arias, challenging the traditional thinking where cells (and not DNA) may hold the key to understanding life’s past and present.

Feel free to follow the Weizmann Institute of Science on LinkedIn.

You can contact Jacob via email and follow his activities on LinkedIn, X, and Facebook!

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email!

And if you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2896 [SNIPPET] - Jacob Hanna on the ethical implications of human embryo models To discover the whole episode type "#28 - Modeling embryos to understand early life - Jacob Hanna - Weizmann Institute of Science" on your streaming platform. Tue, 07 May 2024 20:34:00 -0000 full Mathieu Chaffard To discover the whole episode type "#28 - Modeling embryos to understand early life - Jacob Hanna - Weizmann Institute of Science" on your streaming platform. To discover the whole episode type "#28 - Modeling embryos to understand early life - Jacob Hanna - Weizmann Institute of Science" on your streaming platform.

]]> 253 #27 - Reinventing neuroelectronic therapies - Carolina Aguilar - Inbrain Neuroelectronics We are at a turning point for brain-computer interfaces (BCIs) and neurotechnology. We have all witnessed phenomenal progress in this field recently via images shared by Neuralink, showing paralyzed patients who can communicate with a computer through their own thoughts. Other fascinating applications, such as those being worked on by Gregoire Courtine and Jocelyne Bloch, enable paraplegics to regain an unprecedented degree of walking mobility. These advancements are mind-blowing and illustrate the potential of these technologies to address conditions that have a major impact on quality of life. What if we were to enhance the physical properties of these implants while making them more accessible in terms of costs to health systems? Where could this paradigm shift take us, and what prospects could it open up for treating complex neurological disorders? This is what we explore in this episode with Carolina Aguilar, CEO of Inbrain Neuroelectronics, a company developing a cutting-edge neural platform based on graphene, promising to change the way we decode, modulate, and stimulate neuronal activity. We talk with Carolina about: How Inbrain Neuroelectronics' technology enhances the resolution of BCIs and their therapeutic potential The stakes around BCIs and their promise in treating serious neurological disorders The importance of focusing their development around therapeutic indications vs. aiming for human augmentation The commercialization of these solutions through a value-based care approach and key success factors Empowering women in science and business An outlook on the future of brain therapies that bridges the gap between reality and science fiction! Timeline: 00:00:00 - Explaining Inbrain Neuroelectronics’ neural platform 00:07:32 - The medical need for BCIs and the first indications targeted by Inbrain Neuroelectronics 00:18:46 - Risks around BCIs and ethical considerations for the field to head in the right direction 00:26:17 - Toward value-based commercial models for BCIs 00:29:40 - Transitioning from Medtronic to an early-stage Medtech startup 00:33:29 - Empowering women in science and business What we also talked about with Carolina: Neuralink Elon Musk Sapiens Steering Brain Stimulation Medtronic ONWARD Medical Precision Neuroscience Paradromics Synchron Neurosoft Bioelectronics We cited with Carolina some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore As mentioned by Carolina during the episode, you can access Inbrain Neuroelectronics’ publications here and learn more about their ongoing research and therapy development efforts. You can listen to the Neurotech Pub podcast hosted by Matt Angle here. Feel free to follow Inbrain Neuroelectronics activities on LinkedIn. If you want to contact Carolina, you can reach out to her over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 07 Apr 2024 19:23:00 -0000 Reinventing neuroelectronic therapies - Carolina Aguilar - Inbrain Neuroelectronics full Mathieu Chaffard We are at a turning point for brain-computer interfaces (BCIs) and neurotechnology. We have all witnessed phenomenal progress in this field recently via images shared by Neuralink, showing paralyzed patients who can communicate with a computer through their own thoughts. Other fascinating applications, such as those being worked on by Gregoire Courtine and Jocelyne Bloch, enable paraplegics to regain an unprecedented degree of walking mobility. These advancements are mind-blowing and illustrate the potential of these technologies to address conditions that have a major impact on quality of life. What if we were to enhance the physical properties of these implants while making them more accessible in terms of costs to health systems? Where could this paradigm shift take us, and what prospects could it open up for treating complex neurological disorders? This is what we explore in this episode with Carolina Aguilar, CEO of Inbrain Neuroelectronics, a company developing a cutting-edge neural platform based on graphene, promising to change the way we decode, modulate, and stimulate neuronal activity. We talk with Carolina about: How Inbrain Neuroelectronics' technology enhances the resolution of BCIs and their therapeutic potential The stakes around BCIs and their promise in treating serious neurological disorders The importance of focusing their development around therapeutic indications vs. aiming for human augmentation The commercialization of these solutions through a value-based care approach and key success factors Empowering women in science and business An outlook on the future of brain therapies that bridges the gap between reality and science fiction! Timeline: 00:00:00 - Explaining Inbrain Neuroelectronics’ neural platform 00:07:32 - The medical need for BCIs and the first indications targeted by Inbrain Neuroelectronics 00:18:46 - Risks around BCIs and ethical considerations for the field to head in the right direction 00:26:17 - Toward value-based commercial models for BCIs 00:29:40 - Transitioning from Medtronic to an early-stage Medtech startup 00:33:29 - Empowering women in science and business What we also talked about with Carolina: Neuralink Elon Musk Sapiens Steering Brain Stimulation Medtronic ONWARD Medical Precision Neuroscience Paradromics Synchron Neurosoft Bioelectronics We cited with Carolina some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore As mentioned by Carolina during the episode, you can access Inbrain Neuroelectronics’ publications here and learn more about their ongoing research and therapy development efforts. You can listen to the Neurotech Pub podcast hosted by Matt Angle here. Feel free to follow Inbrain Neuroelectronics activities on LinkedIn. If you want to contact Carolina, you can reach out to her over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! We are at a turning point for brain-computer interfaces (BCIs) and neurotechnology.

We have all witnessed phenomenal progress in this field recently via images shared by Neuralink, showing paralyzed patients who can communicate with a computer through their own thoughts. Other fascinating applications, such as those being worked on by Gregoire Courtine and Jocelyne Bloch, enable paraplegics to regain an unprecedented degree of walking mobility.

These advancements are mind-blowing and illustrate the potential of these technologies to address conditions that have a major impact on quality of life.

What if we were to enhance the physical properties of these implants while making them more accessible in terms of costs to health systems? Where could this paradigm shift take us, and what prospects could it open up for treating complex neurological disorders?

This is what we explore in this episode with Carolina Aguilar, CEO of Inbrain Neuroelectronics, a company developing a cutting-edge neural platform based on graphene, promising to change the way we decode, modulate, and stimulate neuronal activity.

We talk with Carolina about:

  • How Inbrain Neuroelectronics' technology enhances the resolution of BCIs and their therapeutic potential
  • The stakes around BCIs and their promise in treating serious neurological disorders
  • The importance of focusing their development around therapeutic indications vs. aiming for human augmentation
  • The commercialization of these solutions through a value-based care approach and key success factors
  • Empowering women in science and business


An outlook on the future of brain therapies that bridges the gap between reality and science fiction!


Timeline:

00:00:00 - Explaining Inbrain Neuroelectronics’ neural platform

00:07:32 - The medical need for BCIs and the first indications targeted by Inbrain Neuroelectronics

00:18:46 - Risks around BCIs and ethical considerations for the field to head in the right direction

00:26:17 - Toward value-based commercial models for BCIs

00:29:40 - Transitioning from Medtronic to an early-stage Medtech startup

00:33:29 - Empowering women in science and business


What we also talked about with Carolina:


We cited with Carolina some of the past episodes from the series:


As mentioned by Carolina during the episode, you can access Inbrain Neuroelectronics’ publications here and learn more about their ongoing research and therapy development efforts. You can listen to the Neurotech Pub podcast hosted by Matt Angle here.

Feel free to follow Inbrain Neuroelectronics activities on LinkedIn.

If you want to contact Carolina, you can reach out to her over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2712 [SNIPPET] - Carolina Aguilar on the future of neurotechnology To discover the whole episode type "#27 - Reinventing neuroelectronic therapies - Carolina Aguilar - Inbrain Neuroelectronics" on your streaming platform. Sun, 07 Apr 2024 19:19:00 -0000 full Mathieu Chaffard To discover the whole episode type "#27 - Reinventing neuroelectronic therapies - Carolina Aguilar - Inbrain Neuroelectronics" on your streaming platform. To discover the whole episode type "#27 - Reinventing neuroelectronic therapies - Carolina Aguilar - Inbrain Neuroelectronics" on your streaming platform.

]]> 181 #26 - Redefining allergy care - Kenneth Chahine - Nectar Life Sciences Many of us struggle with allergies, usually something we’ve been dealing with our whole life, either continuously or episodically. Be it related to food, pollen, dust, pets, or many others, it’s quite a pain and it can take us away from many things we appreciate in life. And I deliberately include myself in this group. Somehow it was engraved in my brain as a condition one needs to cope with, without much opportunity for improvement. It turns out companies like Nectar Life Sciences are redefining the way we detect and treat allergies from the comfort of our homes. Based on the latest science in this field, and backed by his extensive experience in consumer healthcare, Kenneth Chahine and his team are transforming the experience of allergy care for patients, offering a convenient and personalized approach to it. In this revealing episode, we talk with Kenneth about: The inconvenience of past approaches to allergy detection and treatment How allergy immunotherapy works and can be delivered through a few drops delivered to the tongue How Nectar Life Sciences enables personalized allergy immunotherapy for patients The transformative power of preventing acute allergic shocks Lessons learned from a serial healthcare entrepreneur at the interface of genetics, biochemistry, and intellectual property A conversation with a tireless figure in healthcare entrepreneurship, shedding light on one of the largest chronic conditions globally and how it can be tackled in a modern way! Timeline: 00:00:00 - Kenneth’s background at the interface of genetics, biochemistry, and intellectual property 00:04:14 - The global burden of allergies as a chronic condition 00:05:53 - Origins of allergies 00:07:49 - Immunotherapy or how to train your immune system to be desensitized to allergens 00:09:43 - Detecting which allergens you are sensitive to 00:11:17 - How Nectar Life Sciences approaches allergy treatment 00:22:11 - Kenneth’s mindset toward solving complex healthcare challenges in new ways 00:26:01 - Opportunities beyond allergy care 00:32:16 - Kenneth’s advice to fellow healthcare entrepreneurs What we also talked about with Kenneth: Avigen Ancestry Anaphylaxis Neurimmune University of Utah We cited with Kenneth some of the past episodes from the series: 15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic As mentioned by Kenneth during the episode, you can access Nectar Life Sciences’ Learning Hub here and learn more about Prof. Edwin H. Kim’s research there. Feel free to follow Nectar Life Sciences activities on Instagram, Facebook, and TikTok! If you want to contact Kenneth, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 04 Feb 2024 14:37:00 -0000 full Mathieu Chaffard Many of us struggle with allergies, usually something we’ve been dealing with our whole life, either continuously or episodically. Be it related to food, pollen, dust, pets, or many others, it’s quite a pain and it can take us away from many things we appreciate in life. And I deliberately include myself in this group. Somehow it was engraved in my brain as a condition one needs to cope with, without much opportunity for improvement. It turns out companies like Nectar Life Sciences are redefining the way we detect and treat allergies from the comfort of our homes. Based on the latest science in this field, and backed by his extensive experience in consumer healthcare, Kenneth Chahine and his team are transforming the experience of allergy care for patients, offering a convenient and personalized approach to it. In this revealing episode, we talk with Kenneth about: The inconvenience of past approaches to allergy detection and treatment How allergy immunotherapy works and can be delivered through a few drops delivered to the tongue How Nectar Life Sciences enables personalized allergy immunotherapy for patients The transformative power of preventing acute allergic shocks Lessons learned from a serial healthcare entrepreneur at the interface of genetics, biochemistry, and intellectual property A conversation with a tireless figure in healthcare entrepreneurship, shedding light on one of the largest chronic conditions globally and how it can be tackled in a modern way! Timeline: 00:00:00 - Kenneth’s background at the interface of genetics, biochemistry, and intellectual property 00:04:14 - The global burden of allergies as a chronic condition 00:05:53 - Origins of allergies 00:07:49 - Immunotherapy or how to train your immune system to be desensitized to allergens 00:09:43 - Detecting which allergens you are sensitive to 00:11:17 - How Nectar Life Sciences approaches allergy treatment 00:22:11 - Kenneth’s mindset toward solving complex healthcare challenges in new ways 00:26:01 - Opportunities beyond allergy care 00:32:16 - Kenneth’s advice to fellow healthcare entrepreneurs What we also talked about with Kenneth: Avigen Ancestry Anaphylaxis Neurimmune University of Utah We cited with Kenneth some of the past episodes from the series: 15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic As mentioned by Kenneth during the episode, you can access Nectar Life Sciences’ Learning Hub here and learn more about Prof. Edwin H. Kim’s research there. Feel free to follow Nectar Life Sciences activities on Instagram, Facebook, and TikTok! If you want to contact Kenneth, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Many of us struggle with allergies, usually something we’ve been dealing with our whole life, either continuously or episodically.

Be it related to food, pollen, dust, pets, or many others, it’s quite a pain and it can take us away from many things we appreciate in life. And I deliberately include myself in this group.

Somehow it was engraved in my brain as a condition one needs to cope with, without much opportunity for improvement.

It turns out companies like Nectar Life Sciences are redefining the way we detect and treat allergies from the comfort of our homes.

Based on the latest science in this field, and backed by his extensive experience in consumer healthcare, Kenneth Chahine and his team are transforming the experience of allergy care for patients, offering a convenient and personalized approach to it.

In this revealing episode, we talk with Kenneth about:

  • The inconvenience of past approaches to allergy detection and treatment
  • How allergy immunotherapy works and can be delivered through a few drops delivered to the tongue
  • How Nectar Life Sciences enables personalized allergy immunotherapy for patients
  • The transformative power of preventing acute allergic shocks
  • Lessons learned from a serial healthcare entrepreneur at the interface of genetics, biochemistry, and intellectual property


A conversation with a tireless figure in healthcare entrepreneurship, shedding light on one of the largest chronic conditions globally and how it can be tackled in a modern way!


Timeline:

00:00:00 - Kenneth’s background at the interface of genetics, biochemistry, and intellectual property

00:04:14 - The global burden of allergies as a chronic condition

00:05:53 - Origins of allergies

00:07:49 - Immunotherapy or how to train your immune system to be desensitized to allergens

00:09:43 - Detecting which allergens you are sensitive to

00:11:17 - How Nectar Life Sciences approaches allergy treatment

00:22:11 - Kenneth’s mindset toward solving complex healthcare challenges in new ways

00:26:01 - Opportunities beyond allergy care

00:32:16 - Kenneth’s advice to fellow healthcare entrepreneurs


What we also talked about with Kenneth:


We cited with Kenneth some of the past episodes from the series:


As mentioned by Kenneth during the episode, you can access Nectar Life Sciences’ Learning Hub here and learn more about Prof. Edwin H. Kim’s research there.

Feel free to follow Nectar Life Sciences activities on Instagram, Facebook, and TikTok!

If you want to contact Kenneth, you can reach out to him over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2740 [SNIPPET] - Kenneth Chahine on being dogmatic about improving allergy care To discover the whole episode type "#26 - Redefining allergy care - Kenneth Chahine - Nectar Life Sciences" on your streaming platform. Sun, 04 Feb 2024 14:34:00 -0000 full Mathieu Chaffard To discover the whole episode type "#26 - Redefining allergy care - Kenneth Chahine - Nectar Life Sciences" on your streaming platform. To discover the whole episode type "#26 - Redefining allergy care - Kenneth Chahine - Nectar Life Sciences" on your streaming platform.

]]> 246 #25 - Stopping a bleed in three seconds - Joe Landolina - Cresilon We don’t need to look far in the daily news to understand the stakes and the importance of having efficient solutions to control and stop bleeding. In the times we live in, where the world is crippled by a series of humanitarian catastrophes (some of natural origin, some of human origin), technological wonders from the medical field make me truly hopeful about the future, and about what we can achieve as humans. One of them is the hemostatic gel - a gel that can stop bleeding - that Joe Landolina and his team at Cresilon created. And its astonishing performance is easy to grasp: any bleed can be stopped within three seconds. Compared to traditional methods that require several minutes, it can mean the difference between life and death. There’s so much that impresses in Joe’s journey since the foundation of Cresilon: the fact that he developed the gel formulation himself, that he founded the company at 17 years old in his first year at University, or that Cresilon now represents the largest biotech manufacturing site in New York, and so much more! Beyond these successes, this episode is an ode to biomimicry and the science of biomaterials. Joe reveals everything about the functioning of this revolutionary medical product, its ability to stop bleeding almost instantly, and what it changes in medicine for the treatment of superficial injuries, but especially for the most severe traumatic cases. A surprising encounter with a prodigious entrepreneur, building his path on resilience and adaptability, with the long-term vision to transform bleeding control in humans! Timeline: 00:00:00 - Joe’s background and founding Cresilon in his first year in college 00:06:15 - Cresilon’s mission and the technology at its core 00:08:42 - How the hemostatic gel from Cresilon compares to traditional bleeding control methods 00:10:40 - The explanation behind Cresilon’s hemostatic gel unique performance 00:16:06 - How the gel is applied and removed 00:21:44 - Marketing first the product for veterinary application before moving to human use 00:25:27 - Being the only biotech company with manufacturing capabilities in New York 00:34:15 - Setting up the company to become a large medtech player in the long term What we also talked about with Joe: New York University Columbia University Scar tissue formation Fibrin Extracellular matrix Hurricane Sandy American Veterinary Medical Association Roche Pfizer Cutiss We cited with Joe some of the past episodes from the series: 18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics Feel free to follow Cresilon’s activities on LinkedIn! You will find here the TED Talk that Joe held in 2015, and here the Medsider podcast episode between Joe and Scott Nelson that we mention in this episode of Impulse. If you want to contact Joe, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Sun, 12 Nov 2023 21:22:00 -0000 full Mathieu Chaffard We don’t need to look far in the daily news to understand the stakes and the importance of having efficient solutions to control and stop bleeding. In the times we live in, where the world is crippled by a series of humanitarian catastrophes (some of natural origin, some of human origin), technological wonders from the medical field make me truly hopeful about the future, and about what we can achieve as humans. One of them is the hemostatic gel - a gel that can stop bleeding - that Joe Landolina and his team at Cresilon created. And its astonishing performance is easy to grasp: any bleed can be stopped within three seconds. Compared to traditional methods that require several minutes, it can mean the difference between life and death. There’s so much that impresses in Joe’s journey since the foundation of Cresilon: the fact that he developed the gel formulation himself, that he founded the company at 17 years old in his first year at University, or that Cresilon now represents the largest biotech manufacturing site in New York, and so much more! Beyond these successes, this episode is an ode to biomimicry and the science of biomaterials. Joe reveals everything about the functioning of this revolutionary medical product, its ability to stop bleeding almost instantly, and what it changes in medicine for the treatment of superficial injuries, but especially for the most severe traumatic cases. A surprising encounter with a prodigious entrepreneur, building his path on resilience and adaptability, with the long-term vision to transform bleeding control in humans! Timeline: 00:00:00 - Joe’s background and founding Cresilon in his first year in college 00:06:15 - Cresilon’s mission and the technology at its core 00:08:42 - How the hemostatic gel from Cresilon compares to traditional bleeding control methods 00:10:40 - The explanation behind Cresilon’s hemostatic gel unique performance 00:16:06 - How the gel is applied and removed 00:21:44 - Marketing first the product for veterinary application before moving to human use 00:25:27 - Being the only biotech company with manufacturing capabilities in New York 00:34:15 - Setting up the company to become a large medtech player in the long term What we also talked about with Joe: New York University Columbia University Scar tissue formation Fibrin Extracellular matrix Hurricane Sandy American Veterinary Medical Association Roche Pfizer Cutiss We cited with Joe some of the past episodes from the series: 18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics Feel free to follow Cresilon’s activities on LinkedIn! You will find here the TED Talk that Joe held in 2015, and here the Medsider podcast episode between Joe and Scott Nelson that we mention in this episode of Impulse. If you want to contact Joe, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! We don’t need to look far in the daily news to understand the stakes and the importance of having efficient solutions to control and stop bleeding.

In the times we live in, where the world is crippled by a series of humanitarian catastrophes (some of natural origin, some of human origin), technological wonders from the medical field make me truly hopeful about the future, and about what we can achieve as humans.

One of them is the hemostatic gel - a gel that can stop bleeding - that Joe Landolina and his team at Cresilon created.

And its astonishing performance is easy to grasp: any bleed can be stopped within three seconds.

Compared to traditional methods that require several minutes, it can mean the difference between life and death.

There’s so much that impresses in Joe’s journey since the foundation of Cresilon: the fact that he developed the gel formulation himself, that he founded the company at 17 years old in his first year at University, or that Cresilon now represents the largest biotech manufacturing site in New York, and so much more!

Beyond these successes, this episode is an ode to biomimicry and the science of biomaterials. Joe reveals everything about the functioning of this revolutionary medical product, its ability to stop bleeding almost instantly, and what it changes in medicine for the treatment of superficial injuries, but especially for the most severe traumatic cases.

A surprising encounter with a prodigious entrepreneur, building his path on resilience and adaptability, with the long-term vision to transform bleeding control in humans!


Timeline:

00:00:00 - Joe’s background and founding Cresilon in his first year in college

00:06:15 - Cresilon’s mission and the technology at its core

00:08:42 - How the hemostatic gel from Cresilon compares to traditional bleeding control methods

00:10:40 - The explanation behind Cresilon’s hemostatic gel unique performance

00:16:06 - How the gel is applied and removed

00:21:44 - Marketing first the product for veterinary application before moving to human use

00:25:27 - Being the only biotech company with manufacturing capabilities in New York

00:34:15 - Setting up the company to become a large medtech player in the long term


What we also talked about with Joe:


We cited with Joe some of the past episodes from the series:


Feel free to follow Cresilon’s activities on LinkedIn!

You will find here the TED Talk that Joe held in 2015, and here the Medsider podcast episode between Joe and Scott Nelson that we mention in this episode of Impulse.

If you want to contact Joe, you can reach out to him over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2727 [SNIPPET] - Joe Landolina on the criticality of rapid bleeding control in medicine To discover the whole episode type "#25 - Stopping a bleed in three seconds - Joe Landolina - Cresilon" on your streaming platform. Sun, 12 Nov 2023 21:21:00 -0000 full Mathieu Chaffard To discover the whole episode type "#25 - Stopping a bleed in three seconds - Joe Landolina - Cresilon" on your streaming platform. To discover the whole episode type "#25 - Stopping a bleed in three seconds - Joe Landolina - Cresilon" on your streaming platform.

]]> 221 #24 - Reimagining male contraception - L.R. Fox - NEXT Life Sciences How would the world look like if men had the most efficient and reversible means of birth control? The outstanding work that L.R. Fox and his team at NEXT Life Sciences are leading might bring a very tangible answer to this question. Based on the pioneering work from Prof. Sujoy K. Guha and The Parsemus Foundation, they are developing one of the most promising male birth control methods medicine has ever known, under the name of Plan A. As an American citizen who has grown under the Foster Care program, Fox (as he likes to be called) has witnessed firsthand the dramatic consequences that unplanned pregnancies can have on individuals and their relatives in the long term. According to him, we have gone quite far already in terms of available options for women and men when it comes to birth control methods. But Plan A could be a revolution in the space, as it is completely hormone-free, painless to deliver and revert, and has an efficacy duration that is way beyond current standards. And most importantly, it can redistribute the heavy responsibility of family planning from women to men. In this episode, we talk about the science behind Plan A, where the technology comes from, how far is it from being available worldwide, and what it would change for society as a whole! A fascinating conversation with a visionary founder, deeply led by the purpose of fostering a positive impact in the world, and with a strong social approach to entrepreneurship! Timeline: 00:00:00 - Fox’s background and how he landed in the field of male contraception 00:06:16 - Experiencing firsthand the consequences of unplanned pregnancies 00:09:34 - The mission of NEXT Life Sciences 00:11:50 - The need, the science, and the functioning of Plan A 00:16:02 - How the Plan A procedure works and gets reverted 00:25:02 - Guaranteeing a 10-year efficacy claim 00:26:56 - Launching the first human clinical trials 00:33:55 - Making it accessible to the broadest population 00:38:17 - The philosophy of Fox and NEXT Life Sciences What we also talked about with Fox: Sexually transmissible diseases (STDs) Condoms Vasectomy Reversible inhibition of sperm under guidance (RISUG) Plan B Public benefit corporation We cited with Fox some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore You can learn more about NEXT Life Sciences through their website, and feel free to follow their activities on LinkedIn! As mentioned by Fox during the episode, you can learn more about Plan A on the dedicated website as well as on Instagram, X, Facebook, and TikTok. If you want to contact Fox, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! Wed, 18 Oct 2023 20:41:00 -0000 Reimagining male contraception - L.R. Fox - NEXT Life Sciences full Mathieu Chaffard How would the world look like if men had the most efficient and reversible means of birth control? The outstanding work that L.R. Fox and his team at NEXT Life Sciences are leading might bring a very tangible answer to this question. Based on the pioneering work from Prof. Sujoy K. Guha and The Parsemus Foundation, they are developing one of the most promising male birth control methods medicine has ever known, under the name of Plan A. As an American citizen who has grown under the Foster Care program, Fox (as he likes to be called) has witnessed firsthand the dramatic consequences that unplanned pregnancies can have on individuals and their relatives in the long term. According to him, we have gone quite far already in terms of available options for women and men when it comes to birth control methods. But Plan A could be a revolution in the space, as it is completely hormone-free, painless to deliver and revert, and has an efficacy duration that is way beyond current standards. And most importantly, it can redistribute the heavy responsibility of family planning from women to men. In this episode, we talk about the science behind Plan A, where the technology comes from, how far is it from being available worldwide, and what it would change for society as a whole! A fascinating conversation with a visionary founder, deeply led by the purpose of fostering a positive impact in the world, and with a strong social approach to entrepreneurship! Timeline: 00:00:00 - Fox’s background and how he landed in the field of male contraception 00:06:16 - Experiencing firsthand the consequences of unplanned pregnancies 00:09:34 - The mission of NEXT Life Sciences 00:11:50 - The need, the science, and the functioning of Plan A 00:16:02 - How the Plan A procedure works and gets reverted 00:25:02 - Guaranteeing a 10-year efficacy claim 00:26:56 - Launching the first human clinical trials 00:33:55 - Making it accessible to the broadest population 00:38:17 - The philosophy of Fox and NEXT Life Sciences What we also talked about with Fox: Sexually transmissible diseases (STDs) Condoms Vasectomy Reversible inhibition of sperm under guidance (RISUG) Plan B Public benefit corporation We cited with Fox some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore You can learn more about NEXT Life Sciences through their website, and feel free to follow their activities on LinkedIn! As mentioned by Fox during the episode, you can learn more about Plan A on the dedicated website as well as on Instagram, X, Facebook, and TikTok. If you want to contact Fox, you can reach out to him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 Lastly, don’t forget to follow our activities on LinkedIn and our website! How would the world look like if men had the most efficient and reversible means of birth control?

The outstanding work that L.R. Fox and his team at NEXT Life Sciences are leading might bring a very tangible answer to this question.

Based on the pioneering work from Prof. Sujoy K. Guha and The Parsemus Foundation, they are developing one of the most promising male birth control methods medicine has ever known, under the name of Plan A.

As an American citizen who has grown under the Foster Care program, Fox (as he likes to be called) has witnessed firsthand the dramatic consequences that unplanned pregnancies can have on individuals and their relatives in the long term.

According to him, we have gone quite far already in terms of available options for women and men when it comes to birth control methods. But Plan A could be a revolution in the space, as it is completely hormone-free, painless to deliver and revert, and has an efficacy duration that is way beyond current standards.

And most importantly, it can redistribute the heavy responsibility of family planning from women to men.

In this episode, we talk about the science behind Plan A, where the technology comes from, how far is it from being available worldwide, and what it would change for society as a whole!

A fascinating conversation with a visionary founder, deeply led by the purpose of fostering a positive impact in the world, and with a strong social approach to entrepreneurship!


Timeline:

00:00:00 - Fox’s background and how he landed in the field of male contraception

00:06:16 - Experiencing firsthand the consequences of unplanned pregnancies

00:09:34 - The mission of NEXT Life Sciences

00:11:50 - The need, the science, and the functioning of Plan A

00:16:02 - How the Plan A procedure works and gets reverted

00:25:02 - Guaranteeing a 10-year efficacy claim

00:26:56 - Launching the first human clinical trials

00:33:55 - Making it accessible to the broadest population

00:38:17 - The philosophy of Fox and NEXT Life Sciences


What we also talked about with Fox:


We cited with Fox some of the past episodes from the series:


You can learn more about NEXT Life Sciences through their website, and feel free to follow their activities on LinkedIn!

As mentioned by Fox during the episode, you can learn more about Plan A on the dedicated website as well as on Instagram, X, Facebook, and TikTok.

If you want to contact Fox, you can reach out to him over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

Lastly, don’t forget to follow our activities on LinkedIn and our website!

]]> 2986 [SNIPPET] - L.R. Fox on the next generation of male contraceptives To discover the whole episode type "#24 - Reimagining male contraception - L.R. Fox - NEXT Life Sciences" on your streaming platform. Wed, 18 Oct 2023 20:38:00 -0000 full Mathieu Chaffard To discover the whole episode type "#24 - Reimagining male contraception - L.R. Fox - NEXT Life Sciences" on your streaming platform. To discover the whole episode type "#24 - Reimagining male contraception - L.R. Fox - NEXT Life Sciences" on your streaming platform.

]]> 153 #23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden Wearables are a form of technology that has rapidly become a part of our lives over the past 15 years, with the introduction of devices from Fitbit, Apple, Samsung, and others to the market. Initially informing us about our heart rate and daily step count, they have evolved to incorporate increasingly sophisticated features, allowing us to track our sleep relatively accurately, monitor our overall physical activity, and sometimes even include recognized medical functions (such as the FDA-approved atrial fibrillation detection of the Apple Watch). However, no device of this type allows for real-time quantification of molecules circulating in our blood or other bodily fluids, through optical methods. And that's exactly the challenge that Leo and his team at Spiden have set for themselves: to create the most advanced wearable, capable of continuously and non-invasively measuring multiple biomarkers circulating in our bodies. This could redefine our understanding of our own physiology and change our approach to medicine, by providing insights for the prevention, diagnosis, and monitoring of several conditions, that were previously inaccessible. Since its creation in 2017, Spiden has been operating away from the spotlight, but Leo does us the honor in this exclusive episode to reveal the first secrets behind Spiden’s technology. We discuss its functioning, its initial applications, who the future users will be, and also the incredible team of world-renowned scientists Leo has managed to bring together in the fields of optics, electronic engineering, and machine learning (three fields that were originally completely foreign to him) to achieve his vision. A fascinating conversation about the future of personalized medicine with a bold and successful entrepreneur! Timeline: 00:00:00 - Leo’s background as a serial entrepreneur from fintech to deep tech 00:04:56 - Why Leo found Spiden and works towards improving our health 00:07:14 - The mission of Spiden 00:11:00 - The technology behind Spiden 00:14:47 - The biomarkers that Spiden can track 00:19:02 - Target users of Spiden’s future wearable 00:22:28 - Designing a health-dedicated device 00:24:10 - Attracting world talents in fields you are not initially from 00:34:01 - The importance of in-person interactions in a scientific and multidisciplinary team What we also talked about with Leo: Continuous glucose monitoring (Abbott Freestyle Libre) Bits & Pretzels HealthTech Photoplethysmography (PPG) Biohacking Glucose Goddess Whoop Oura Garmin Huberman Lab induced pluripotent stem cells (iPSCs) We cited with Leo some of the past episodes from the series: #4 - Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia You can learn more about Spiden through their website. Feel free to follow as well their activities on LinkedIn! As mentioned by Leo during the episode, you can learn about the painful history of non-invasive glucose measurement through the book “The Pursuit of Noninvasive Glucose - Hunting the Deceitful Turkey” by John L. Smith. If you want to get in touch with Leo, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and our website! Mon, 04 Sep 2023 08:27:00 -0000 Disrupting the smart wearables industry - Leo Grünstein - Spiden full Mathieu Chaffard Wearables are a form of technology that has rapidly become a part of our lives over the past 15 years, with the introduction of devices from Fitbit, Apple, Samsung, and others to the market. Initially informing us about our heart rate and daily step count, they have evolved to incorporate increasingly sophisticated features, allowing us to track our sleep relatively accurately, monitor our overall physical activity, and sometimes even include recognized medical functions (such as the FDA-approved atrial fibrillation detection of the Apple Watch). However, no device of this type allows for real-time quantification of molecules circulating in our blood or other bodily fluids, through optical methods. And that's exactly the challenge that Leo and his team at Spiden have set for themselves: to create the most advanced wearable, capable of continuously and non-invasively measuring multiple biomarkers circulating in our bodies. This could redefine our understanding of our own physiology and change our approach to medicine, by providing insights for the prevention, diagnosis, and monitoring of several conditions, that were previously inaccessible. Since its creation in 2017, Spiden has been operating away from the spotlight, but Leo does us the honor in this exclusive episode to reveal the first secrets behind Spiden’s technology. We discuss its functioning, its initial applications, who the future users will be, and also the incredible team of world-renowned scientists Leo has managed to bring together in the fields of optics, electronic engineering, and machine learning (three fields that were originally completely foreign to him) to achieve his vision. A fascinating conversation about the future of personalized medicine with a bold and successful entrepreneur! Timeline: 00:00:00 - Leo’s background as a serial entrepreneur from fintech to deep tech 00:04:56 - Why Leo found Spiden and works towards improving our health 00:07:14 - The mission of Spiden 00:11:00 - The technology behind Spiden 00:14:47 - The biomarkers that Spiden can track 00:19:02 - Target users of Spiden’s future wearable 00:22:28 - Designing a health-dedicated device 00:24:10 - Attracting world talents in fields you are not initially from 00:34:01 - The importance of in-person interactions in a scientific and multidisciplinary team What we also talked about with Leo: Continuous glucose monitoring (Abbott Freestyle Libre) Bits & Pretzels HealthTech Photoplethysmography (PPG) Biohacking Glucose Goddess Whoop Oura Garmin Huberman Lab induced pluripotent stem cells (iPSCs) We cited with Leo some of the past episodes from the series: #4 - Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia You can learn more about Spiden through their website. Feel free to follow as well their activities on LinkedIn! As mentioned by Leo during the episode, you can learn about the painful history of non-invasive glucose measurement through the book “The Pursuit of Noninvasive Glucose - Hunting the Deceitful Turkey” by John L. Smith. If you want to get in touch with Leo, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and our website! Wearables are a form of technology that has rapidly become a part of our lives over the past 15 years, with the introduction of devices from Fitbit, Apple, Samsung, and others to the market.

Initially informing us about our heart rate and daily step count, they have evolved to incorporate increasingly sophisticated features, allowing us to track our sleep relatively accurately, monitor our overall physical activity, and sometimes even include recognized medical functions (such as the FDA-approved atrial fibrillation detection of the Apple Watch).

However, no device of this type allows for real-time quantification of molecules circulating in our blood or other bodily fluids, through optical methods.

And that's exactly the challenge that Leo and his team at Spiden have set for themselves: to create the most advanced wearable, capable of continuously and non-invasively measuring multiple biomarkers circulating in our bodies.

This could redefine our understanding of our own physiology and change our approach to medicine, by providing insights for the prevention, diagnosis, and monitoring of several conditions, that were previously inaccessible.

Since its creation in 2017, Spiden has been operating away from the spotlight, but Leo does us the honor in this exclusive episode to reveal the first secrets behind Spiden’s technology.

We discuss its functioning, its initial applications, who the future users will be, and also the incredible team of world-renowned scientists Leo has managed to bring together in the fields of optics, electronic engineering, and machine learning (three fields that were originally completely foreign to him) to achieve his vision.

A fascinating conversation about the future of personalized medicine with a bold and successful entrepreneur!


Timeline:

00:00:00 - Leo’s background as a serial entrepreneur from fintech to deep tech

00:04:56 - Why Leo found Spiden and works towards improving our health

00:07:14 - The mission of Spiden

00:11:00 - The technology behind Spiden

00:14:47 - The biomarkers that Spiden can track

00:19:02 - Target users of Spiden’s future wearable

00:22:28 - Designing a health-dedicated device

00:24:10 - Attracting world talents in fields you are not initially from

00:34:01 - The importance of in-person interactions in a scientific and multidisciplinary team


What we also talked about with Leo:


We cited with Leo some of the past episodes from the series:


You can learn more about Spiden through their website. Feel free to follow as well their activities on LinkedIn!

As mentioned by Leo during the episode, you can learn about the painful history of non-invasive glucose measurement through the book “The Pursuit of Noninvasive Glucose - Hunting the Deceitful Turkey” by John L. Smith.

If you want to get in touch with Leo, feel free to contact him over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

And don’t forget to follow our activities on LinkedIn and our website!

]]> 2948 [SNIPPET] - Leo Grünstein on the future of smart wearables To discover the whole episode type "#23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden" on your streaming platform. Mon, 04 Sep 2023 08:25:00 -0000 full Mathieu Chaffard To discover the whole episode type "#23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden" on your streaming platform. To discover the whole episode type "#23 - Disrupting the smart wearables industry - Leo Grünstein - Spiden" on your streaming platform.

]]> 286 #22 - Harnessing self-driving technology to guide the visually impaired - Maël Fabien - Biped.ai Given the rapid progress made in this field in recent years, autonomous vehicles could soon become part of our daily lives, bringing with them all the consequences and questions they raise in terms of modern mobility. This would benefit people with visual impairments who are unable to drive. However, it wouldn't necessarily assist them in their pedestrian moves, which will always play a significant role in their daily lives. Maël Fabien became aware of the lack of available solutions in this regard during a walk in town. He noticed a visually impaired person video calling a friend, who was guiding her through his voice based on the video she was sharing. As a result, he took inspiration from the latest advances in autonomous vehicles to create a harness capable of continuously analyzing the pedestrian environment, and safely guiding its users in all their movements. From there, Biped was born, a device that promises to improve the life of the 270 million visually impaired people worldwide, by providing them with a much more accurate and secure perception of their environment than traditional solutions. In this surprising episode, you will learn about: The daily life of a visually impaired person and its impact on mobility How Biped was developed in close collaboration with its end users Some key concepts of autonomous mobility and the sensors that constitute it How Biped translates the user's 3D environment into audio cues for guidance The potential applications of Biped beyond ophthalmology An outlook on the future of mobility and what it might change for those with limited vision! Timeline: 00:00:00 - Maël’s interests at the interface of economics and speech processing 00:04:07 - Addressing the need for 270 million visually impaired 00:07:50 - What Biped is about 00:15:32 - How Biped reads and translates the environment of the user 00:22:30 - How users are trained on the system 00:24:14 - The spectrum of visually impaired people that Biped serves 00:30:08 - The underlying business model 00:32:19 - Potential applications beyond ophthalmology 00:34:58 - What users say about it 00:39:09 - Maël’s definition of impact What we talked also talked about with Maël: Idiap Research Institute Mobility training Lidar Bone conduction headphones Jules Gonin Eye Hospital Glaucoma Retinitis Pigmentosa Macular Degeneration Cochlear Implants You can learn more about Biped.ai through their website. Feel free to follow as well their activities on LinkedIn! As mentioned by Maël during the episode, you can find out more about the latest advances in autonomous driving and related AI through Tesla’s yearly AI Day (2022 recording here). He also recommends The Blind Life YouTube channel to understand how it feels to be in the shoes of a visually impaired person. If you want to learn more about Maël and his other endeavors besides Biped.ai, have a look at his blog! If you want to get in touch with Maël, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and through our website! Tue, 15 Aug 2023 13:47:00 -0000 Harnessing self-driving technology to guide the visually impaired - Maël Fabien - Biped.ai full Mathieu Chaffard Given the rapid progress made in this field in recent years, autonomous vehicles could soon become part of our daily lives, bringing with them all the consequences and questions they raise in terms of modern mobility. This would benefit people with visual impairments who are unable to drive. However, it wouldn't necessarily assist them in their pedestrian moves, which will always play a significant role in their daily lives. Maël Fabien became aware of the lack of available solutions in this regard during a walk in town. He noticed a visually impaired person video calling a friend, who was guiding her through his voice based on the video she was sharing. As a result, he took inspiration from the latest advances in autonomous vehicles to create a harness capable of continuously analyzing the pedestrian environment, and safely guiding its users in all their movements. From there, Biped was born, a device that promises to improve the life of the 270 million visually impaired people worldwide, by providing them with a much more accurate and secure perception of their environment than traditional solutions. In this surprising episode, you will learn about: The daily life of a visually impaired person and its impact on mobility How Biped was developed in close collaboration with its end users Some key concepts of autonomous mobility and the sensors that constitute it How Biped translates the user's 3D environment into audio cues for guidance The potential applications of Biped beyond ophthalmology An outlook on the future of mobility and what it might change for those with limited vision! Timeline: 00:00:00 - Maël’s interests at the interface of economics and speech processing 00:04:07 - Addressing the need for 270 million visually impaired 00:07:50 - What Biped is about 00:15:32 - How Biped reads and translates the environment of the user 00:22:30 - How users are trained on the system 00:24:14 - The spectrum of visually impaired people that Biped serves 00:30:08 - The underlying business model 00:32:19 - Potential applications beyond ophthalmology 00:34:58 - What users say about it 00:39:09 - Maël’s definition of impact What we talked also talked about with Maël: Idiap Research Institute Mobility training Lidar Bone conduction headphones Jules Gonin Eye Hospital Glaucoma Retinitis Pigmentosa Macular Degeneration Cochlear Implants You can learn more about Biped.ai through their website. Feel free to follow as well their activities on LinkedIn! As mentioned by Maël during the episode, you can find out more about the latest advances in autonomous driving and related AI through Tesla’s yearly AI Day (2022 recording here). He also recommends The Blind Life YouTube channel to understand how it feels to be in the shoes of a visually impaired person. If you want to learn more about Maël and his other endeavors besides Biped.ai, have a look at his blog! If you want to get in touch with Maël, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and through our website! Given the rapid progress made in this field in recent years, autonomous vehicles could soon become part of our daily lives, bringing with them all the consequences and questions they raise in terms of modern mobility.

This would benefit people with visual impairments who are unable to drive.

However, it wouldn't necessarily assist them in their pedestrian moves, which will always play a significant role in their daily lives.

Maël Fabien became aware of the lack of available solutions in this regard during a walk in town. He noticed a visually impaired person video calling a friend, who was guiding her through his voice based on the video she was sharing.

As a result, he took inspiration from the latest advances in autonomous vehicles to create a harness capable of continuously analyzing the pedestrian environment, and safely guiding its users in all their movements.

From there, Biped was born, a device that promises to improve the life of the 270 million visually impaired people worldwide, by providing them with a much more accurate and secure perception of their environment than traditional solutions.


In this surprising episode, you will learn about:

  • The daily life of a visually impaired person and its impact on mobility
  • How Biped was developed in close collaboration with its end users
  • Some key concepts of autonomous mobility and the sensors that constitute it
  • How Biped translates the user's 3D environment into audio cues for guidance
  • The potential applications of Biped beyond ophthalmology


An outlook on the future of mobility and what it might change for those with limited vision!


Timeline:

00:00:00 - Maël’s interests at the interface of economics and speech processing

00:04:07 - Addressing the need for 270 million visually impaired

00:07:50 - What Biped is about

00:15:32 - How Biped reads and translates the environment of the user

00:22:30 - How users are trained on the system

00:24:14 - The spectrum of visually impaired people that Biped serves

00:30:08 - The underlying business model

00:32:19 - Potential applications beyond ophthalmology

00:34:58 - What users say about it

00:39:09 - Maël’s definition of impact


What we talked also talked about with Maël:


You can learn more about Biped.ai through their website.

Feel free to follow as well their activities on LinkedIn!

As mentioned by Maël during the episode, you can find out more about the latest advances in autonomous driving and related AI through Tesla’s yearly AI Day (2022 recording here). He also recommends The Blind Life YouTube channel to understand how it feels to be in the shoes of a visually impaired person. If you want to learn more about Maël and his other endeavors besides Biped.ai, have a look at his blog!

If you want to get in touch with Maël, feel free to contact him over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

And don’t forget to follow our activities on LinkedIn and through our website!

]]> 2989 [SNIPPET] - Maël Fabien on the notion of impact and building things that matter To discover the whole episode type "#22 - Harnessing self-driving technology to guide the visually impaired - Maël Fabien - Biped.ai" on your streaming platform. Tue, 15 Aug 2023 13:46:00 -0000 full Mathieu Chaffard To discover the whole episode type "#22 - Harnessing self-driving technology to guide the visually impaired - Maël Fabien - Biped.ai" on your streaming platform. To discover the whole episode type "#22 - Harnessing self-driving technology to guide the visually impaired - Maël Fabien - Biped.ai" on your streaming platform.

]]> 242 #21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia Few companies can claim to be a step ahead of tech giants in the wearable race. The Swiss company Aktiia can. They were the first to successfully bring to market a device capable of continuously and accurately measuring blood pressure, officially approved in Europe and soon to be in the US. All in a discreet bracelet that resembles a traditional jewel. It changes the game for how we approach hypertension, the first chronic condition worldwide affecting a staggering 1.4 billion people, and which comes with dire long-term consequences like strokes and heart attacks. The impact such groundbreaking technology can have on the daily lives of those affected is immense, not to mention its benefits for those in charge of their medical care. Say goodbye to the uncomfortable and cumbersome inflatable cuff (the actual “gold standard” to measure blood pressure), not to mention the major step forward in terms of design! Aktiia has defied expectations by merging optical and machine learning expertise over nearly two decades of cutting-edge research, resulting in a significant breakthrough in the world of wearables. In this new episode of the series, we sit with Jay Shah - the leading cardiologist and current Chief Medical Officer at Aktiia - who shares with us the story and functioning behind this stunning piece of technology. You will learn about: Hypertension and the public health crisis it represents The benefits of continuous blood pressure measurement How the Aktiia bracelet works How a small company like Aktiia was able to stand up to the biggest tech companies Preventive medicine and why empowering patients in their self-care matters A fascinating episode exploring the medical potential of wearables in our lives! Timeline: 00:00:00 - Jay’s background as a cardiologist and what led him to Aktiia 00:05:30 - The most common cause of cardiovascular diseases: hypertension 00:10:15 - What Aktiia is about and what it changes for blood pressure monitoring 00:15:50 - How Aktiia’s technology work 00:20:12 - The limits of the pattern-matching approach with wearable data 00:24:00 - Why Aktiia succeeded where big tech companies failed 00:27:45 - Who can get access to Aktiia’s bracelet 00:30:35 - How Aktiia empowers patients to take better control of their condition What we also talked about with Jay: Mattia Bertschi Josep Sola Massachusetts General Hospital Mayo Clinic Blood pressure cuff (sphygmomanometer) Photoplethysmography NextMed Health We cited with Jay some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health You can learn more about Aktiia through their website. Feel free to follow their activities on LinkedIn, Twitter, and Instagram! As mentioned by Jay during the episode, you can find out more about the clinical research in hypertension and all the evidence developed around the bracelet in that regard here. For a very technical deep dive into cuffless blood pressure monitoring, we invite you to consult “The Handbook of Cuffless Blood Pressure Monitoring: A Practical Guide for Clinicians, Researchers, and Engineers” by Josep Sola himself, one of the founders from Aktiia. If you want to get in touch with Jay, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and through our website! Tue, 01 Aug 2023 13:58:00 -0000 Transforming hypertension care with a bracelet - Jay Shah - Aktiia full Mathieu Chaffard Few companies can claim to be a step ahead of tech giants in the wearable race. The Swiss company Aktiia can. They were the first to successfully bring to market a device capable of continuously and accurately measuring blood pressure, officially approved in Europe and soon to be in the US. All in a discreet bracelet that resembles a traditional jewel. It changes the game for how we approach hypertension, the first chronic condition worldwide affecting a staggering 1.4 billion people, and which comes with dire long-term consequences like strokes and heart attacks. The impact such groundbreaking technology can have on the daily lives of those affected is immense, not to mention its benefits for those in charge of their medical care. Say goodbye to the uncomfortable and cumbersome inflatable cuff (the actual “gold standard” to measure blood pressure), not to mention the major step forward in terms of design! Aktiia has defied expectations by merging optical and machine learning expertise over nearly two decades of cutting-edge research, resulting in a significant breakthrough in the world of wearables. In this new episode of the series, we sit with Jay Shah - the leading cardiologist and current Chief Medical Officer at Aktiia - who shares with us the story and functioning behind this stunning piece of technology. You will learn about: Hypertension and the public health crisis it represents The benefits of continuous blood pressure measurement How the Aktiia bracelet works How a small company like Aktiia was able to stand up to the biggest tech companies Preventive medicine and why empowering patients in their self-care matters A fascinating episode exploring the medical potential of wearables in our lives! Timeline: 00:00:00 - Jay’s background as a cardiologist and what led him to Aktiia 00:05:30 - The most common cause of cardiovascular diseases: hypertension 00:10:15 - What Aktiia is about and what it changes for blood pressure monitoring 00:15:50 - How Aktiia’s technology work 00:20:12 - The limits of the pattern-matching approach with wearable data 00:24:00 - Why Aktiia succeeded where big tech companies failed 00:27:45 - Who can get access to Aktiia’s bracelet 00:30:35 - How Aktiia empowers patients to take better control of their condition What we also talked about with Jay: Mattia Bertschi Josep Sola Massachusetts General Hospital Mayo Clinic Blood pressure cuff (sphygmomanometer) Photoplethysmography NextMed Health We cited with Jay some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health You can learn more about Aktiia through their website. Feel free to follow their activities on LinkedIn, Twitter, and Instagram! As mentioned by Jay during the episode, you can find out more about the clinical research in hypertension and all the evidence developed around the bracelet in that regard here. For a very technical deep dive into cuffless blood pressure monitoring, we invite you to consult “The Handbook of Cuffless Blood Pressure Monitoring: A Practical Guide for Clinicians, Researchers, and Engineers” by Josep Sola himself, one of the founders from Aktiia. If you want to get in touch with Jay, feel free to contact him over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏 And don’t forget to follow our activities on LinkedIn and through our website! Few companies can claim to be a step ahead of tech giants in the wearable race.

The Swiss company Aktiia can.

They were the first to successfully bring to market a device capable of continuously and accurately measuring blood pressure, officially approved in Europe and soon to be in the US. All in a discreet bracelet that resembles a traditional jewel.

It changes the game for how we approach hypertension, the first chronic condition worldwide affecting a staggering 1.4 billion people, and which comes with dire long-term consequences like strokes and heart attacks.

The impact such groundbreaking technology can have on the daily lives of those affected is immense, not to mention its benefits for those in charge of their medical care.

Say goodbye to the uncomfortable and cumbersome inflatable cuff (the actual “gold standard” to measure blood pressure), not to mention the major step forward in terms of design!

Aktiia has defied expectations by merging optical and machine learning expertise over nearly two decades of cutting-edge research, resulting in a significant breakthrough in the world of wearables.

In this new episode of the series, we sit with Jay Shah - the leading cardiologist and current Chief Medical Officer at Aktiia - who shares with us the story and functioning behind this stunning piece of technology.

You will learn about:

  • Hypertension and the public health crisis it represents
  • The benefits of continuous blood pressure measurement
  • How the Aktiia bracelet works
  • How a small company like Aktiia was able to stand up to the biggest tech companies
  • Preventive medicine and why empowering patients in their self-care matters


A fascinating episode exploring the medical potential of wearables in our lives!


Timeline:

00:00:00 - Jay’s background as a cardiologist and what led him to Aktiia

00:05:30 - The most common cause of cardiovascular diseases: hypertension

00:10:15 - What Aktiia is about and what it changes for blood pressure monitoring

00:15:50 - How Aktiia’s technology work

00:20:12 - The limits of the pattern-matching approach with wearable data

00:24:00 - Why Aktiia succeeded where big tech companies failed

00:27:45 - Who can get access to Aktiia’s bracelet

00:30:35 - How Aktiia empowers patients to take better control of their condition


What we also talked about with Jay:


We cited with Jay some of the past episodes from the series:


You can learn more about Aktiia through their website.

Feel free to follow their activities on LinkedIn, Twitter, and Instagram!

As mentioned by Jay during the episode, you can find out more about the clinical research in hypertension and all the evidence developed around the bracelet in that regard here. For a very technical deep dive into cuffless blood pressure monitoring, we invite you to consult “The Handbook of Cuffless Blood Pressure Monitoring: A Practical Guide for Clinicians, Researchers, and Engineers” by Josep Sola himself, one of the founders from Aktiia.

If you want to get in touch with Jay, feel free to contact him over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, you can contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! 🙏

And don’t forget to follow our activities on LinkedIn and through our website!

]]> 3100 [SNIPPET] - Jay Shah on how wearables are changing healthcare To discover the whole episode type "#21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia" on your streaming platform. Tue, 01 Aug 2023 13:50:00 -0000 Jay Shah on how wearables are changing healthcare full Mathieu Chaffard To discover the whole episode type "#21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia" on your streaming platform. To discover the whole episode type "#21 - Transforming hypertension care with a bracelet - Jay Shah - Aktiia" on your streaming platform.

]]> 245 #20 - Restoring touch through nerve repair - Karen Zaderej - Axogen Restoring one of our five senses, in this case, touch. The stakes are immense (1 in 1000 people are affected yearly by a peripheral nerve injury!) and the origins are diverse: traumatic accident, cancer, amputation, and many others. And solutions to this problem have long needed to be improved. Karen Zaderej and her team at Axogen have set themselves the goal of changing this situation, by proposing new ways of treating nerves, taking advantage of their regenerative potential. A chemical engineer by training, Karen began her career at Johnson & Johnson in its surgical solutions subsidiary, ETHICON. With 17 years of experience in roles ranging from manufacturing to product development and sales, she decided to leave her corporate career behind. In 2006 she joined a Floridian start-up in its infancy, developing a new type of medical device enabling nerves to regenerate, still at the prototype stage and not yet tested on humans. The outcome? A company that has become a world leader in the development of cutting-edge nerve repair solutions, listed on the stock exchange and now employs over 400 people. In this new episode, we delve into the world of peripheral nerves, the source of our physical and motor sensations, and their formidable regenerative capacities. You will learn about: How our nerves work and current approaches to repairing them Phantom pain, how to explain it, and how to treat it How women today can regain sensation in their breasts following a mastectomy The journey of a remarkable woman entrepreneur who has made addressing nerve damage her life mission Prepare to be nervously amazed as we unravel the secrets of touch restoration! Timeline: 00:00:00 - Karen’s background as a nerve evangelist 00:07:35 - Key evolutions in medical technology that Karen witnessed 00:10:42 - What Karen learned at J&J that shaped the rest of her career 00:15:43 - What attracted Karen to Axogen and the potential of their technology 00:20:40 - Scaling up a medical device company from a very early stage onwards 00:23:15 - How Axogen enables nerve repair 00:27:18 - Bringing an answer to phantom pain 00:30:47 - The main indication areas covered by Axogen 00:38:31 - What the future of nerve repair might look like What we also talked about with Karen: Autograft Allograft Mastectomy Neuroma Da Vinci Surgical Systems We cited with Karen some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical You can learn more about Axogen through their website and their portfolio here. Feel free to follow as well their activities on LinkedIn, Twitter, and Facebook! As mentioned by Karen during the episode, you can find out more about clinical research in peripheral nerve repair through the complete library of published papers curated by the company. Karen also invites you to consult resensation.com and rethinkpain.com to hear about patient stories and find resources in case you face a similar situation. If you want to get in touch with Karen, feel free to contact her over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, feel free to do so contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! Follow also our activities on LinkedIn and through our website! Mon, 26 Jun 2023 20:00:00 -0000 Restoring touch through nerve repair - Karen Zaderej - Axogen full Mathieu Chaffard Restoring one of our five senses, in this case, touch. The stakes are immense (1 in 1000 people are affected yearly by a peripheral nerve injury!) and the origins are diverse: traumatic accident, cancer, amputation, and many others. And solutions to this problem have long needed to be improved. Karen Zaderej and her team at Axogen have set themselves the goal of changing this situation, by proposing new ways of treating nerves, taking advantage of their regenerative potential. A chemical engineer by training, Karen began her career at Johnson & Johnson in its surgical solutions subsidiary, ETHICON. With 17 years of experience in roles ranging from manufacturing to product development and sales, she decided to leave her corporate career behind. In 2006 she joined a Floridian start-up in its infancy, developing a new type of medical device enabling nerves to regenerate, still at the prototype stage and not yet tested on humans. The outcome? A company that has become a world leader in the development of cutting-edge nerve repair solutions, listed on the stock exchange and now employs over 400 people. In this new episode, we delve into the world of peripheral nerves, the source of our physical and motor sensations, and their formidable regenerative capacities. You will learn about: How our nerves work and current approaches to repairing them Phantom pain, how to explain it, and how to treat it How women today can regain sensation in their breasts following a mastectomy The journey of a remarkable woman entrepreneur who has made addressing nerve damage her life mission Prepare to be nervously amazed as we unravel the secrets of touch restoration! Timeline: 00:00:00 - Karen’s background as a nerve evangelist 00:07:35 - Key evolutions in medical technology that Karen witnessed 00:10:42 - What Karen learned at J&J that shaped the rest of her career 00:15:43 - What attracted Karen to Axogen and the potential of their technology 00:20:40 - Scaling up a medical device company from a very early stage onwards 00:23:15 - How Axogen enables nerve repair 00:27:18 - Bringing an answer to phantom pain 00:30:47 - The main indication areas covered by Axogen 00:38:31 - What the future of nerve repair might look like What we also talked about with Karen: Autograft Allograft Mastectomy Neuroma Da Vinci Surgical Systems We cited with Karen some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical You can learn more about Axogen through their website and their portfolio here. Feel free to follow as well their activities on LinkedIn, Twitter, and Facebook! As mentioned by Karen during the episode, you can find out more about clinical research in peripheral nerve repair through the complete library of published papers curated by the company. Karen also invites you to consult resensation.com and rethinkpain.com to hear about patient stories and find resources in case you face a similar situation. If you want to get in touch with Karen, feel free to contact her over LinkedIn. If you want to give me feedback on the episode or suggest potential guests, feel free to do so contact me over LinkedIn or via email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms! Follow also our activities on LinkedIn and through our website! Restoring one of our five senses, in this case, touch.

The stakes are immense (1 in 1000 people are affected yearly by a peripheral nerve injury!) and the origins are diverse: traumatic accident, cancer, amputation, and many others.

And solutions to this problem have long needed to be improved.

Karen Zaderej and her team at Axogen have set themselves the goal of changing this situation, by proposing new ways of treating nerves, taking advantage of their regenerative potential.

A chemical engineer by training, Karen began her career at Johnson & Johnson in its surgical solutions subsidiary, ETHICON.

With 17 years of experience in roles ranging from manufacturing to product development and sales, she decided to leave her corporate career behind.

In 2006 she joined a Floridian start-up in its infancy, developing a new type of medical device enabling nerves to regenerate, still at the prototype stage and not yet tested on humans.

The outcome?

A company that has become a world leader in the development of cutting-edge nerve repair solutions, listed on the stock exchange and now employs over 400 people.

In this new episode, we delve into the world of peripheral nerves, the source of our physical and motor sensations, and their formidable regenerative capacities.


You will learn about:

  • How our nerves work and current approaches to repairing them
  • Phantom pain, how to explain it, and how to treat it
  • How women today can regain sensation in their breasts following a mastectomy
  • The journey of a remarkable woman entrepreneur who has made addressing nerve damage her life mission


Prepare to be nervously amazed as we unravel the secrets of touch restoration!


Timeline:

00:00:00 - Karen’s background as a nerve evangelist

00:07:35 - Key evolutions in medical technology that Karen witnessed

00:10:42 - What Karen learned at J&J that shaped the rest of her career

00:15:43 - What attracted Karen to Axogen and the potential of their technology

00:20:40 - Scaling up a medical device company from a very early stage onwards

00:23:15 - How Axogen enables nerve repair

00:27:18 - Bringing an answer to phantom pain

00:30:47 - The main indication areas covered by Axogen

00:38:31 - What the future of nerve repair might look like


What we also talked about with Karen:


We cited with Karen some of the past episodes from the series:


You can learn more about Axogen through their website and their portfolio here.

Feel free to follow as well their activities on LinkedIn, Twitter, and Facebook!

As mentioned by Karen during the episode, you can find out more about clinical research in peripheral nerve repair through the complete library of published papers curated by the company.

Karen also invites you to consult resensation.com and rethinkpain.com to hear about patient stories and find resources in case you face a similar situation.

If you want to get in touch with Karen, feel free to contact her over LinkedIn.

If you want to give me feedback on the episode or suggest potential guests, feel free to do so contact me over LinkedIn or via email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast, and leave a 5-star review on streaming platforms!

Follow also our activities on LinkedIn and through our website!

]]> 3145 [SNIPPET] - Karen Zaderej on the resensation technique for women having gone through mastectomy To discover the whole episode type "#20 - Restoring touch through nerve repair - Karen Zaderej - Axogen" on your streaming platform. Sun, 25 Jun 2023 20:00:00 -0000 full Mathieu Chaffard To discover the whole episode type "#20 - Restoring touch through nerve repair - Karen Zaderej - Axogen" on your streaming platform. To discover the whole episode type "#20 - Restoring touch through nerve repair - Karen Zaderej - Axogen" on your streaming platform.

]]> 243 #19 - Saving lives through cybersecurity - Richard Staynings - Cylera We all know that medical data is sensitive personal information, which we would not like to have falling into the wrong hands. Along with the progress of digitalisation in healthcare, the number of cyberattacks towards this particular sector has dramatically increased over the past years. The ultimate risk? Slowed or even paralysed hospitals, with lives lost as a consequence. Since all of this happens in the background, it’s hard to grasp the severity of the situation, and the majority of us are not equipped with the expertise to understand how those events actually unfold. With decades of experience as a healthcare Chief Information Security Officer and current Chief Security Strategist at Cylera, Richard Staynings has seen firsthand the devastating consequences of such attacks on patients, providers, and organizations. But he's also a firm believer that with the right strategies, tools, and mindset, we can win the war against cyber threats in healthcare. In this episode, we dive headfirst into the high-stakes world of healthcare cybersecurity with one of the industry's most respected voices. You will learn about: The risks cyberattacks carry for health systems The most common types of cyberattacks in this sector The entities behind those threats What health systems can do to ensure their safety A conversation packed with eye-opening perspectives and actionable advice for anyone working in healthcare or concerned about its future! Timeline: 00:00:00 - introduction on Richard’s background and the mission of Cylera 00:03:26 - why cybersecurity matters in healthcare 00:07:58 - the example of WannaCry in the UK 00:10:46 - the main sources of threat for healthcare systems 00:29:46 - the approach Cylera takes to safeguard its clients What we also talked about with Richard: General Keith Alexander Malware Ransomware Denial-of-service attack Zero-day exploits The Interview The CIA Triad As mentioned in the episode, you can learn more about Cylera through their website and their approach here. You can also follow their activities on LinkedIn or Twitter! For further information about cybersecurity in healthcare, we’d recommend the Blog section from Cylera and the website curated by Richard himself: cyberthoughts.org. If you want to get in touch with Richard, feel free to contact him per email at richard.staynings@cylera.com, on LinkedIn or Twitter. In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn and Instagram! Wed, 26 Apr 2023 07:23:00 -0000 Saving lives through cybersecurity - Richard Staynings - Cylera full Mathieu Chaffard We all know that medical data is sensitive personal information, which we would not like to have falling into the wrong hands. Along with the progress of digitalisation in healthcare, the number of cyberattacks towards this particular sector has dramatically increased over the past years. The ultimate risk? Slowed or even paralysed hospitals, with lives lost as a consequence. Since all of this happens in the background, it’s hard to grasp the severity of the situation, and the majority of us are not equipped with the expertise to understand how those events actually unfold. With decades of experience as a healthcare Chief Information Security Officer and current Chief Security Strategist at Cylera, Richard Staynings has seen firsthand the devastating consequences of such attacks on patients, providers, and organizations. But he's also a firm believer that with the right strategies, tools, and mindset, we can win the war against cyber threats in healthcare. In this episode, we dive headfirst into the high-stakes world of healthcare cybersecurity with one of the industry's most respected voices. You will learn about: The risks cyberattacks carry for health systems The most common types of cyberattacks in this sector The entities behind those threats What health systems can do to ensure their safety A conversation packed with eye-opening perspectives and actionable advice for anyone working in healthcare or concerned about its future! Timeline: 00:00:00 - introduction on Richard’s background and the mission of Cylera 00:03:26 - why cybersecurity matters in healthcare 00:07:58 - the example of WannaCry in the UK 00:10:46 - the main sources of threat for healthcare systems 00:29:46 - the approach Cylera takes to safeguard its clients What we also talked about with Richard: General Keith Alexander Malware Ransomware Denial-of-service attack Zero-day exploits The Interview The CIA Triad As mentioned in the episode, you can learn more about Cylera through their website and their approach here. You can also follow their activities on LinkedIn or Twitter! For further information about cybersecurity in healthcare, we’d recommend the Blog section from Cylera and the website curated by Richard himself: cyberthoughts.org. If you want to get in touch with Richard, feel free to contact him per email at richard.staynings@cylera.com, on LinkedIn or Twitter. In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com! If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn and Instagram! We all know that medical data is sensitive personal information, which we would not like to have falling into the wrong hands.

Along with the progress of digitalisation in healthcare, the number of cyberattacks towards this particular sector has dramatically increased over the past years.

The ultimate risk?

Slowed or even paralysed hospitals, with lives lost as a consequence.

Since all of this happens in the background, it’s hard to grasp the severity of the situation, and the majority of us are not equipped with the expertise to understand how those events actually unfold.

With decades of experience as a healthcare Chief Information Security Officer and current Chief Security Strategist at Cylera, Richard Staynings has seen firsthand the devastating consequences of such attacks on patients, providers, and organizations. But he's also a firm believer that with the right strategies, tools, and mindset, we can win the war against cyber threats in healthcare.

In this episode, we dive headfirst into the high-stakes world of healthcare cybersecurity with one of the industry's most respected voices.


You will learn about:

  • The risks cyberattacks carry for health systems
  • The most common types of cyberattacks in this sector
  • The entities behind those threats
  • What health systems can do to ensure their safety

A conversation packed with eye-opening perspectives and actionable advice for anyone working in healthcare or concerned about its future!


Timeline:

00:00:00 - introduction on Richard’s background and the mission of Cylera

00:03:26 - why cybersecurity matters in healthcare

00:07:58 - the example of WannaCry in the UK

00:10:46 - the main sources of threat for healthcare systems

00:29:46 - the approach Cylera takes to safeguard its clients


What we also talked about with Richard:


As mentioned in the episode, you can learn more about Cylera through their website and their approach here.

You can also follow their activities on LinkedIn or Twitter!

For further information about cybersecurity in healthcare, we’d recommend the Blog section from Cylera and the website curated by Richard himself: cyberthoughts.org.

If you want to get in touch with Richard, feel free to contact him per email at richard.staynings@cylera.com, on LinkedIn or Twitter.


In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com!

If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms!

We also invite you to follow our activities through our website, LinkedIn and Instagram!

]]> 3354 [SNIPPET] - Richard Staynings on the consequences of cyberattacks in healthcare To discover the whole episode type "#19 - Saving lives through cybersecurity - Richard Staynings - Cylera" on your streaming platform. Wed, 26 Apr 2023 07:19:00 -0000 full Mathieu Chaffard To discover the whole episode type "#19 - Saving lives through cybersecurity - Richard Staynings - Cylera" on your streaming platform. To discover the whole episode type "#19 - Saving lives through cybersecurity - Richard Staynings - Cylera" on your streaming platform.

]]> 229 #18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics Most of our genome does not code for any protein, which led us to believe that 98% of our genetic material was useless. But what was initially termed as the “dark side of the genome” (which Star Wars fans will certainly appreciate!) turns out to play a crucial role in modulating our biology. It is in fact the software translating environmental factors (e.g. air quality, lifestyle, stress, etc.) into biological mechanisms, which can either lead to the proper functioning of our body or to certain illnesses. The stakes and the potential around its use to develop new treatments are therefore immense! And this is exactly what HAYA Therapeutics has been focusing on over the past few years: leveraging the science behind the “dark genome” to develop revolutionary treatments for chronic diseases, starting with heart failure. The promise compared to traditional approaches? More effective and targeted effects, focusing on one type of tissue only Lower therapy development costs due to shorter development processes So what stands behind this mysterious concept exactly? What is the science behind it? And how can this drive the development of new therapies to address some of the most widespread conditions across the globe? In this new episode of Impulse, learn all about this fascinating field in the words of Samir Ounzain - CEO from HAYA Therapeutics - on a mission to radically change the way we approach drug discovery and development. Passionate and didactic, he unveils the secrets of the “dark genome”, the influence of our surrounding environment on our genetics, and how we could leverage our understanding of this field to treat chronic diseases in a new way! Timeline: 00:00:00 - Samir’s background and how he got passionate about genetics 00:08:30 - What the “dark genome” is actually about 00:11:38 - How our understanding of the “dark genome” sparked the idea of what will become HAYA Therapeutics 00:25:30 - How HAYA Therapeutics aims to address heart failure 00:32:47 - Longevity and other applications on the long run 00:36:42 - How such new treatment would be delivered What we also talked about with Samir: Jurassic Park Wisper long noncoding RNA RNA interference & Anti-Sense Oligonucleotides Renin-angiotensin system We cited with Samir some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens As mentioned in the episode, you can learn more about HAYA Therapeutics through their website and their approach here. You can also follow their activities on LinkedIn or Twitter! For further information about the dark side of the genome and the science behind it, we’d recommend you to check out the book from John Mattick and Paulo Amaral entitled “RNA the Epicenter of Genetic Information”, as well as the interview of Manolis Kelis on Lex Fridman Podcast. A recent article by the BBC featuring Samir also details out what the dark genome is about and goes quite deep into the topic, worth checking out as well! If you want to get in touch with Samir, feel free to contact him per email at samir@hayatx.com, on LinkedIn or Twitter. In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn and Instagram pages! Fri, 14 Apr 2023 10:14:00 -0000 The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics full Mathieu Chaffard Most of our genome does not code for any protein, which led us to believe that 98% of our genetic material was useless. But what was initially termed as the “dark side of the genome” (which Star Wars fans will certainly appreciate!) turns out to play a crucial role in modulating our biology. It is in fact the software translating environmental factors (e.g. air quality, lifestyle, stress, etc.) into biological mechanisms, which can either lead to the proper functioning of our body or to certain illnesses. The stakes and the potential around its use to develop new treatments are therefore immense! And this is exactly what HAYA Therapeutics has been focusing on over the past few years: leveraging the science behind the “dark genome” to develop revolutionary treatments for chronic diseases, starting with heart failure. The promise compared to traditional approaches? More effective and targeted effects, focusing on one type of tissue only Lower therapy development costs due to shorter development processes So what stands behind this mysterious concept exactly? What is the science behind it? And how can this drive the development of new therapies to address some of the most widespread conditions across the globe? In this new episode of Impulse, learn all about this fascinating field in the words of Samir Ounzain - CEO from HAYA Therapeutics - on a mission to radically change the way we approach drug discovery and development. Passionate and didactic, he unveils the secrets of the “dark genome”, the influence of our surrounding environment on our genetics, and how we could leverage our understanding of this field to treat chronic diseases in a new way! Timeline: 00:00:00 - Samir’s background and how he got passionate about genetics 00:08:30 - What the “dark genome” is actually about 00:11:38 - How our understanding of the “dark genome” sparked the idea of what will become HAYA Therapeutics 00:25:30 - How HAYA Therapeutics aims to address heart failure 00:32:47 - Longevity and other applications on the long run 00:36:42 - How such new treatment would be delivered What we also talked about with Samir: Jurassic Park Wisper long noncoding RNA RNA interference & Anti-Sense Oligonucleotides Renin-angiotensin system We cited with Samir some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens As mentioned in the episode, you can learn more about HAYA Therapeutics through their website and their approach here. You can also follow their activities on LinkedIn or Twitter! For further information about the dark side of the genome and the science behind it, we’d recommend you to check out the book from John Mattick and Paulo Amaral entitled “RNA the Epicenter of Genetic Information”, as well as the interview of Manolis Kelis on Lex Fridman Podcast. A recent article by the BBC featuring Samir also details out what the dark genome is about and goes quite deep into the topic, worth checking out as well! If you want to get in touch with Samir, feel free to contact him per email at samir@hayatx.com, on LinkedIn or Twitter. In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn and Instagram pages! Most of our genome does not code for any protein, which led us to believe that 98% of our genetic material was useless.

But what was initially termed as the “dark side of the genome” (which Star Wars fans will certainly appreciate!) turns out to play a crucial role in modulating our biology.

It is in fact the software translating environmental factors (e.g. air quality, lifestyle, stress, etc.) into biological mechanisms, which can either lead to the proper functioning of our body or to certain illnesses.

The stakes and the potential around its use to develop new treatments are therefore immense!

And this is exactly what HAYA Therapeutics has been focusing on over the past few years: leveraging the science behind the “dark genome” to develop revolutionary treatments for chronic diseases, starting with heart failure.

The promise compared to traditional approaches?

  • More effective and targeted effects, focusing on one type of tissue only
  • Lower therapy development costs due to shorter development processes

So what stands behind this mysterious concept exactly? What is the science behind it? And how can this drive the development of new therapies to address some of the most widespread conditions across the globe?

In this new episode of Impulse, learn all about this fascinating field in the words of Samir Ounzain - CEO from HAYA Therapeutics - on a mission to radically change the way we approach drug discovery and development.

Passionate and didactic, he unveils the secrets of the “dark genome”, the influence of our surrounding environment on our genetics, and how we could leverage our understanding of this field to treat chronic diseases in a new way!


Timeline:

00:00:00 - Samir’s background and how he got passionate about genetics

00:08:30 - What the “dark genome” is actually about

00:11:38 - How our understanding of the “dark genome” sparked the idea of what will become HAYA Therapeutics

00:25:30 - How HAYA Therapeutics aims to address heart failure

00:32:47 - Longevity and other applications on the long run

00:36:42 - How such new treatment would be delivered


What we also talked about with Samir:


We cited with Samir some of the past episodes from the series:


As mentioned in the episode, you can learn more about HAYA Therapeutics through their website and their approach here.

You can also follow their activities on LinkedIn or Twitter!

For further information about the dark side of the genome and the science behind it, we’d recommend you to check out the book from John Mattick and Paulo Amaral entitled “RNA the Epicenter of Genetic Information”, as well as the interview of Manolis Kelis on Lex Fridman Podcast. A recent article by the BBC featuring Samir also details out what the dark genome is about and goes quite deep into the topic, worth checking out as well!

If you want to get in touch with Samir, feel free to contact him per email at samir@hayatx.com, on LinkedIn or Twitter.


In case you want to give me feedback on the episode or the podcast in general, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com.

If you liked the episode, please share it, subscribe to the podcast and leave a 5-star review on streaming platforms!

We also invite you to follow our activities through our website, LinkedIn and Instagram pages!

]]> 3214 [SNIPPET] - Samir Ounzain on the dark genome and its importance in human biology To discover the whole episode type "#18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics" on your streaming platform. Fri, 14 Apr 2023 10:12:00 -0000 full Mathieu Chaffard To discover the whole episode type "#18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics" on your streaming platform. To discover the whole episode type "#18 - The dark genome as the next revolution in drug discovery - Samir Ounzain - HAYA Therapeutics" on your streaming platform.

]]> 233 #17 - Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health How can we support each and every one of us in identifying and pursuing our goals towards a healthier life, in a world where access to care seems to be continuously shrinking? The solution may lie in health coaching and making it accessible across the globe. Having witnessed his wife successfully battling breast cancer and becoming a certified health coach, Eugene Borukhovich joined her entrepreneurial adventure at YourCoach.Health in 2020 to co-found the first and only operating system for behavior change powered by an army of helath and wellness coaches. As a recognized and beloved leader in the healthcare space, Eugene relies on his incredibly diverse experience in the space - as an intra- and entrepreneur, executive, venture builder, advisor and even podcaster - to drive the operations of the platform. Three years down the line, it regroups more than 3000 certified health coaches, impacting a number of lives higher by several orders of magnitude, on a daily basis. There is still a long way to go to reach the projected 9 billion people on earth by 2030, but their determination is unquestionable: join the journey and learn all about health coaching in this new episode, the science behind it, and what it can do for you! Timeline: 00:00:00 - Eugene’s background in healthcare and most particularly digital health 00:07:35 - What triggered Eugene’s move towards entrepreneurship and health coaching 00:11:19 - What health coaching is about 00:20:41 - Moving from a Global corporate role to being your own boss 00:24:54 - Eugene’s take on making collaborations between startups and corporates in healthcare successful 00:29:23 - What led Eugene to go into podcasting and start the DTx Podcast and Shot of Digital Health Therapy What we also talked about with Eugene: Meetup Scott Heiferman Matthew Holt Indu Subaiya Health 2.0 Conference Lark Health Twill Marina Borukhovich Bayer G4A Hard Pill To Swallow Dan Kendall Jim Joyce As mentioned in the episode, you can learn more about YourCoach.Health through their website and their app available on the App Store or Google Play Store. You can also follow their activities on LinkedIn, Instagram, Twitter and Facebook! For further information about health coaching and the science behind it, we’d recommend you to check out the podcast produced by the YourCoach.Health team, as well as The National Board for Health and Wellness Coaching. If you want to get in touch with Eugene, feel free to contact him per email at eugene@yourcoachhealth.com, or on LinkedIn, Twitter and Instagram. In case you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. If you liked the episode, share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn, Twitter and Instagram pages. Tue, 21 Feb 2023 21:42:00 -0000 Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health full Mathieu Chaffard How can we support each and every one of us in identifying and pursuing our goals towards a healthier life, in a world where access to care seems to be continuously shrinking? The solution may lie in health coaching and making it accessible across the globe. Having witnessed his wife successfully battling breast cancer and becoming a certified health coach, Eugene Borukhovich joined her entrepreneurial adventure at YourCoach.Health in 2020 to co-found the first and only operating system for behavior change powered by an army of helath and wellness coaches. As a recognized and beloved leader in the healthcare space, Eugene relies on his incredibly diverse experience in the space - as an intra- and entrepreneur, executive, venture builder, advisor and even podcaster - to drive the operations of the platform. Three years down the line, it regroups more than 3000 certified health coaches, impacting a number of lives higher by several orders of magnitude, on a daily basis. There is still a long way to go to reach the projected 9 billion people on earth by 2030, but their determination is unquestionable: join the journey and learn all about health coaching in this new episode, the science behind it, and what it can do for you! Timeline: 00:00:00 - Eugene’s background in healthcare and most particularly digital health 00:07:35 - What triggered Eugene’s move towards entrepreneurship and health coaching 00:11:19 - What health coaching is about 00:20:41 - Moving from a Global corporate role to being your own boss 00:24:54 - Eugene’s take on making collaborations between startups and corporates in healthcare successful 00:29:23 - What led Eugene to go into podcasting and start the DTx Podcast and Shot of Digital Health Therapy What we also talked about with Eugene: Meetup Scott Heiferman Matthew Holt Indu Subaiya Health 2.0 Conference Lark Health Twill Marina Borukhovich Bayer G4A Hard Pill To Swallow Dan Kendall Jim Joyce As mentioned in the episode, you can learn more about YourCoach.Health through their website and their app available on the App Store or Google Play Store. You can also follow their activities on LinkedIn, Instagram, Twitter and Facebook! For further information about health coaching and the science behind it, we’d recommend you to check out the podcast produced by the YourCoach.Health team, as well as The National Board for Health and Wellness Coaching. If you want to get in touch with Eugene, feel free to contact him per email at eugene@yourcoachhealth.com, or on LinkedIn, Twitter and Instagram. In case you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. If you liked the episode, share it, subscribe to the podcast and leave a 5-star review on streaming platforms! We also invite you to follow our activities through our website, LinkedIn, Twitter and Instagram pages. How can we support each and every one of us in identifying and pursuing our goals towards a healthier life, in a world where access to care seems to be continuously shrinking?

The solution may lie in health coaching and making it accessible across the globe.

Having witnessed his wife successfully battling breast cancer and becoming a certified health coach, Eugene Borukhovich joined her entrepreneurial adventure at YourCoach.Health in 2020 to co-found the first and only operating system for behavior change powered by an army of helath and wellness coaches.

As a recognized and beloved leader in the healthcare space, Eugene relies on his incredibly diverse experience in the space - as an intra- and entrepreneur, executive, venture builder, advisor and even podcaster - to drive the operations of the platform.

Three years down the line, it regroups more than 3000 certified health coaches, impacting a number of lives higher by several orders of magnitude, on a daily basis.

There is still a long way to go to reach the projected 9 billion people on earth by 2030, but their determination is unquestionable: join the journey and learn all about health coaching in this new episode, the science behind it, and what it can do for you!


Timeline:

00:00:00 - Eugene’s background in healthcare and most particularly digital health

00:07:35 - What triggered Eugene’s move towards entrepreneurship and health coaching

00:11:19 - What health coaching is about

00:20:41 - Moving from a Global corporate role to being your own boss

00:24:54 - Eugene’s take on making collaborations between startups and corporates in healthcare successful

00:29:23 - What led Eugene to go into podcasting and start the DTx Podcast and Shot of Digital Health Therapy


What we also talked about with Eugene:


As mentioned in the episode, you can learn more about YourCoach.Health through their website and their app available on the App Store or Google Play Store.

You can also follow their activities on LinkedIn, Instagram, Twitter and Facebook!

For further information about health coaching and the science behind it, we’d recommend you to check out the podcast produced by the YourCoach.Health team, as well as The National Board for Health and Wellness Coaching.

If you want to get in touch with Eugene, feel free to contact him per email at eugene@yourcoachhealth.com, or on LinkedIn, Twitter and Instagram.

In case you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com.

If you liked the episode, share it, subscribe to the podcast and leave a 5-star review on streaming platforms!

We also invite you to follow our activities through our website, LinkedIn, Twitter and Instagram pages.

]]> 2588 [SNIPPET] - Eugene Borukhovich on health coaching and the importance of human-to-human interactions To discover the whole episode type "#17 - Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health" on your streaming platform. Tue, 21 Feb 2023 21:41:00 -0000 full Mathieu Chaffard To discover the whole episode type "#17 - Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health" on your streaming platform. To discover the whole episode type "#17 - Coaching as the key to a better health - Eugene Borukhovich - YourCoach.Health" on your streaming platform.

]]> 235 #16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius Starting a career in the Israeli army, becoming a lawyer, and finally transforming the field of medical imaging. In a very schematic way, this is what might define Ohad Arazi’s path, who is now spearheading the field of handheld ultrasound as the CEO of Clarius. His curiosity for medical imaging - coupled with a very product-oriented mindset and an unrelenting desire to understand the problems that healthcare faces - leads him to integrate different structures, including the Fortune 500 giant McKesson, the Canadian telecommunication company Telus, and the Israeli startup Zebra Medical Vision, where he quickly occupies leadership roles with great responsibility. At Clarius (this “true gem” as he calls it in his own words) he draws on his expertise in the field of medical imaging to embed artificial intelligence into the most compact high quality ultrasound imaging platform on the market, developed by its brilliant founder Laurent Pelissier. The goal? Allowing any healthcare professional to perform an ultrasound scan, with a system as intuitive, qualitative, and compact as an iPhone. Perhaps those will even find their place in patient’s homes at some point! In light of the current boom in digital health and the radical developments in AI, Ohad shares his perspective on the role that these technologies will have on certain medical specialities and notably radiology, where he believes that they will rather augment them without replacing them. He also explains why he thinks that most technological capabilities in digital health are outstripping the value they can create, and reflects on his career path where his transitions from huge corporates to human-sized startups shaped his evolution and leadership. A surprising dive into the future of medical imaging, that we invite you to discover in this new episode! Timeline: 00:00:00 - Ohad’s background, from the military in Israel to healthcare in Canada 00:10:46 - What the medical imaging landscape looked like in the early 2000s 00:14:51 - Ohad’s take on the current boom in digital health 00:19:36 - Clarius’ mission in transforming high-end ultrasound for healthcare professionals 00:33:11 - How AI is embedded into the products from Clarius 00:35:09 - Dealing with hypergrowth as a medical imaging startup 00:39:48 - Ohad’s reflections on his career path and the story of the Disney brothers What we also talked about with Ohad: OpenAI Turtle Health US2.ai PACS DICOM EHR James Hare Carolyn Lam We cited with Ohad some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health As mentioned in the episode, you can learn more about Clarius through their website and follow their activities on LinkedIn, Twitter, Facebook, Instagram and YouTube! If you want to get in touch with Ohad, feel free to contact him per email at ohad.arazi@clarius.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Thu, 09 Feb 2023 07:10:00 -0000 Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius full Mathieu Chaffard Starting a career in the Israeli army, becoming a lawyer, and finally transforming the field of medical imaging. In a very schematic way, this is what might define Ohad Arazi’s path, who is now spearheading the field of handheld ultrasound as the CEO of Clarius. His curiosity for medical imaging - coupled with a very product-oriented mindset and an unrelenting desire to understand the problems that healthcare faces - leads him to integrate different structures, including the Fortune 500 giant McKesson, the Canadian telecommunication company Telus, and the Israeli startup Zebra Medical Vision, where he quickly occupies leadership roles with great responsibility. At Clarius (this “true gem” as he calls it in his own words) he draws on his expertise in the field of medical imaging to embed artificial intelligence into the most compact high quality ultrasound imaging platform on the market, developed by its brilliant founder Laurent Pelissier. The goal? Allowing any healthcare professional to perform an ultrasound scan, with a system as intuitive, qualitative, and compact as an iPhone. Perhaps those will even find their place in patient’s homes at some point! In light of the current boom in digital health and the radical developments in AI, Ohad shares his perspective on the role that these technologies will have on certain medical specialities and notably radiology, where he believes that they will rather augment them without replacing them. He also explains why he thinks that most technological capabilities in digital health are outstripping the value they can create, and reflects on his career path where his transitions from huge corporates to human-sized startups shaped his evolution and leadership. A surprising dive into the future of medical imaging, that we invite you to discover in this new episode! Timeline: 00:00:00 - Ohad’s background, from the military in Israel to healthcare in Canada 00:10:46 - What the medical imaging landscape looked like in the early 2000s 00:14:51 - Ohad’s take on the current boom in digital health 00:19:36 - Clarius’ mission in transforming high-end ultrasound for healthcare professionals 00:33:11 - How AI is embedded into the products from Clarius 00:35:09 - Dealing with hypergrowth as a medical imaging startup 00:39:48 - Ohad’s reflections on his career path and the story of the Disney brothers What we also talked about with Ohad: OpenAI Turtle Health US2.ai PACS DICOM EHR James Hare Carolyn Lam We cited with Ohad some of the past episodes from the series: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health As mentioned in the episode, you can learn more about Clarius through their website and follow their activities on LinkedIn, Twitter, Facebook, Instagram and YouTube! If you want to get in touch with Ohad, feel free to contact him per email at ohad.arazi@clarius.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Starting a career in the Israeli army, becoming a lawyer, and finally transforming the field of medical imaging.

In a very schematic way, this is what might define Ohad Arazi’s path, who is now spearheading the field of handheld ultrasound as the CEO of Clarius.

His curiosity for medical imaging - coupled with a very product-oriented mindset and an unrelenting desire to understand the problems that healthcare faces - leads him to integrate different structures, including the Fortune 500 giant McKesson, the Canadian telecommunication company Telus, and the Israeli startup Zebra Medical Vision, where he quickly occupies leadership roles with great responsibility.

At Clarius (this “true gem” as he calls it in his own words) he draws on his expertise in the field of medical imaging to embed artificial intelligence into the most compact high quality ultrasound imaging platform on the market, developed by its brilliant founder Laurent Pelissier.

The goal? Allowing any healthcare professional to perform an ultrasound scan, with a system as intuitive, qualitative, and compact as an iPhone. Perhaps those will even find their place in patient’s homes at some point!

In light of the current boom in digital health and the radical developments in AI, Ohad shares his perspective on the role that these technologies will have on certain medical specialities and notably radiology, where he believes that they will rather augment them without replacing them. He also explains why he thinks that most technological capabilities in digital health are outstripping the value they can create, and reflects on his career path where his transitions from huge corporates to human-sized startups shaped his evolution and leadership.

A surprising dive into the future of medical imaging, that we invite you to discover in this new episode!


Timeline:

00:00:00 - Ohad’s background, from the military in Israel to healthcare in Canada

00:10:46 - What the medical imaging landscape looked like in the early 2000s

00:14:51 - Ohad’s take on the current boom in digital health

00:19:36 - Clarius’ mission in transforming high-end ultrasound for healthcare professionals

00:33:11 - How AI is embedded into the products from Clarius

00:35:09 - Dealing with hypergrowth as a medical imaging startup

00:39:48 - Ohad’s reflections on his career path and the story of the Disney brothers


What we also talked about with Ohad:


We cited with Ohad some of the past episodes from the series:


As mentioned in the episode, you can learn more about Clarius through their website and follow their activities on LinkedIn, Twitter, Facebook, Instagram and YouTube!

If you want to get in touch with Ohad, feel free to contact him per email at ohad.arazi@clarius.com or through LinkedIn.

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com.

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

]]> 3020 [SNIPPET] - Ohad Arazi on the importance of understanding the problem you are trying to solve To discover the whole episode type "#16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius" on your streaming platform. Thu, 09 Feb 2023 07:09:00 -0000 full Mathieu Chaffard To discover the whole episode type "#16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius" on your streaming platform. To discover the whole episode type "#16 - Making ultrasound portable to transform medical imaging - Ohad Arazi - Clarius" on your streaming platform.

]]> 158 #15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic Nicolas Durand is the CEO of Abionic, a Swiss-based startup which developed and commercialises the abioSCOPE®, a unique diagnostic platform characterised by its compact size and ability to deliver high quality results in a fraction of time. Passionate about high tech and wishing to become an entrepreneur from a very early age (he created his first company with a friend at school when he was 14 years old) he turned his PhD work into a venture, which today represents one of the most successful medtech startups in the country! We discuss with Nicolas the nanotechnology behind Abionic, the types of tests it can run, the targeted diseases, the efforts it takes to demonstrate the clinical efficacy of a new diagnostic device, but also the energy required to convince all the actors involved in the care pathway, from regulators, doctors, to patients. He also shares openly about his vision regarding the potential emergence of home diagnostic systems in the future, as well as his perspective on the impact that the Theranos scandal had on the diagnostics industry, and in particular on startups operating in this field. A conversation under the sign of resilience and excellence that we invite you to discover in this new episode! Timeline: 00:00:00 - Nicolas’ background and his original interest in high technology and entrepreneurship 00:04:07 - Creating your first company at 14 years old 00:06:54 - What Abionic is about and how its core diagnostic technology works 00:21:45 - Miniaturizing diagnostic tests beyond immunoassays 00:25:07 - The clinical settings where the abioSCOPE® is placed 00:27:25 - Towards the use of diagnostic systems at home 00:32:15 - The impact of the Theranos scandal on medtech startups What we also talked about with Nicolas: Philippe Renaud Robopoly PSP Sepsis IVDR Elizabeth Holmes Red Bull Air Race We cited with Nicolas some of the past episodes from the series: #4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune #5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health #13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas As mentioned in the episode, you can learn more about Abionic through their website and follow their activities on LinkedIn, Twitter and Facebook! Based on Nicolas’ suggestion, we invite you to read Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou to learn more about Elizabeth Holmes and the scandal around Theranos which literally shook the whole medtech industry in the past years! If you want to get in touch with Nicolas, feel free to contact him per email at nicolas.durand@abionic.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Wed, 18 Jan 2023 19:43:00 -0000 Propelling diagnostics through miniaturization - Nicolas Durand - Abionic full Mathieu Chaffard Nicolas Durand is the CEO of Abionic, a Swiss-based startup which developed and commercialises the abioSCOPE®, a unique diagnostic platform characterised by its compact size and ability to deliver high quality results in a fraction of time. Passionate about high tech and wishing to become an entrepreneur from a very early age (he created his first company with a friend at school when he was 14 years old) he turned his PhD work into a venture, which today represents one of the most successful medtech startups in the country! We discuss with Nicolas the nanotechnology behind Abionic, the types of tests it can run, the targeted diseases, the efforts it takes to demonstrate the clinical efficacy of a new diagnostic device, but also the energy required to convince all the actors involved in the care pathway, from regulators, doctors, to patients. He also shares openly about his vision regarding the potential emergence of home diagnostic systems in the future, as well as his perspective on the impact that the Theranos scandal had on the diagnostics industry, and in particular on startups operating in this field. A conversation under the sign of resilience and excellence that we invite you to discover in this new episode! Timeline: 00:00:00 - Nicolas’ background and his original interest in high technology and entrepreneurship 00:04:07 - Creating your first company at 14 years old 00:06:54 - What Abionic is about and how its core diagnostic technology works 00:21:45 - Miniaturizing diagnostic tests beyond immunoassays 00:25:07 - The clinical settings where the abioSCOPE® is placed 00:27:25 - Towards the use of diagnostic systems at home 00:32:15 - The impact of the Theranos scandal on medtech startups What we also talked about with Nicolas: Philippe Renaud Robopoly PSP Sepsis IVDR Elizabeth Holmes Red Bull Air Race We cited with Nicolas some of the past episodes from the series: #4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune #5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health #13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas As mentioned in the episode, you can learn more about Abionic through their website and follow their activities on LinkedIn, Twitter and Facebook! Based on Nicolas’ suggestion, we invite you to read Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou to learn more about Elizabeth Holmes and the scandal around Theranos which literally shook the whole medtech industry in the past years! If you want to get in touch with Nicolas, feel free to contact him per email at nicolas.durand@abionic.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Nicolas Durand is the CEO of Abionic, a Swiss-based startup which developed and commercialises the abioSCOPE®, a unique diagnostic platform characterised by its compact size and ability to deliver high quality results in a fraction of time.

Passionate about high tech and wishing to become an entrepreneur from a very early age (he created his first company with a friend at school when he was 14 years old) he turned his PhD work into a venture, which today represents one of the most successful medtech startups in the country!

We discuss with Nicolas the nanotechnology behind Abionic, the types of tests it can run, the targeted diseases, the efforts it takes to demonstrate the clinical efficacy of a new diagnostic device, but also the energy required to convince all the actors involved in the care pathway, from regulators, doctors, to patients.

He also shares openly about his vision regarding the potential emergence of home diagnostic systems in the future, as well as his perspective on the impact that the Theranos scandal had on the diagnostics industry, and in particular on startups operating in this field.

A conversation under the sign of resilience and excellence that we invite you to discover in this new episode!


Timeline:

00:00:00 - Nicolas’ background and his original interest in high technology and entrepreneurship

00:04:07 - Creating your first company at 14 years old

00:06:54 - What Abionic is about and how its core diagnostic technology works

00:21:45 - Miniaturizing diagnostic tests beyond immunoassays

00:25:07 - The clinical settings where the abioSCOPE® is placed

00:27:25 - Towards the use of diagnostic systems at home

00:32:15 - The impact of the Theranos scandal on medtech startups


What we also talked about with Nicolas:


We cited with Nicolas some of the past episodes from the series:


As mentioned in the episode, you can learn more about Abionic through their website and follow their activities on LinkedIn, Twitter and Facebook!

Based on Nicolas’ suggestion, we invite you to read Bad Blood: Secrets and Lies in a Silicon Valley Startup by John Carreyrou to learn more about Elizabeth Holmes and the scandal around Theranos which literally shook the whole medtech industry in the past years!

If you want to get in touch with Nicolas, feel free to contact him per email at nicolas.durand@abionic.com or through LinkedIn.

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com.

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

]]> 2650 [SNIPPET] - Nicolas Durand on Theranos and how it could have been a success To discover the whole episode type "#15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic" on your streaming platform. Wed, 18 Jan 2023 11:36:00 -0000 full Mathieu Chaffard To discover the whole episode type "#15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic" on your streaming platform. To discover the whole episode type "#15 - Propelling diagnostics through miniaturization - Nicolas Durand - Abionic" on your streaming platform.

]]> 216 #14 - Preserving our health with smart clothes - Vincent Martinez - Nanoleq Will the next revolution in personalized health be led by connected clothes? This is the bet that Vincent Martinez and his team at Nanoleq are making, and they are putting all their efforts into turning their vision into reality! Originally, their idea was to target the cable industry with a proprietary technology enabling to create stretchable cables, with superior physical and electrical properties. The targeted companies being too slow in their adoption of the proposed approach, Vincent and his team decide to tackle the field of connected clothing, by proposing a set of components and tools enabling any clothing manufacturer to turn their garments into smart ones, able to measure multiple vital parameters but also to electrically stimulate certain regions of the body. Building upon their expertise in this space, they developed the first breathing smart garment with live biofeedback - Oxa - around which they designed a whole personalized program for everyone to reconnect to their body through breathing, the only vital sign we can consciously control. We talked with Vincent about the emergence of connected clothes and what role they will play in the preservation of our health, how stretchable electronics work, and how Nanoleq managed to develop a full breathing experience combining cutting-edge sensors with gamification, backed by the most renown ambassadors in the field. Timeline: 00:00:00 - Vincent’s background at the interface of materials science and biomedical engineering 00:02:57 - Launching a company to address the premature breakage of electronic cables 00:07:45 - What lies behind the term « stretchable electronics » 00:09:55 - Shifting the focus towards smart textiles 00:19:48 - The vision of Nanoleq around connected health 00:24:05 - Starting a new product line focused on breathing optimization: Oxa Life 00:35:00 - Federating a community of breathing specialists 00:37:46 - Making the most personalised and digitally engaging breathing optimization program 00:44:14 - Towards everyday wear of smart clothes What we also talked about with Vincent: ETH Pioneer Fellowships Luca Hirt Grégoire Courtine Start Summit Venture Kick Venture Electrical Muscle Stimulation (EMS) Wim Hof Sleep apnea Dan Brulé Headspace Petit Bambou Andrew Huberman We cited with Vincent some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio As mentioned in the episode, you can learn more about Nanoleq and the field of stretchable electronics through their website. The Kickstarter campaign for Oxa runs until Sunday December 18 and you can contribute to it at this page! For more information about Oxa, check out the official product page: www.oxalife.com. Based on Vincent’s suggestions, check out the book Breath from James Nestor or this episode of Huberman Lab if you want to know more about the science behind breathing and the exercises that we discussed in this episode. You can also learn more about the Buteyko method here. If you want to get in touch with Vincent, feel free to contact him per email at martinez@nanoleq.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Wed, 14 Dec 2022 14:59:00 -0000 Preserving our health with smart clothes - Vincent Martinez - Nanoleq full Mathieu Chaffard Will the next revolution in personalized health be led by connected clothes? This is the bet that Vincent Martinez and his team at Nanoleq are making, and they are putting all their efforts into turning their vision into reality! Originally, their idea was to target the cable industry with a proprietary technology enabling to create stretchable cables, with superior physical and electrical properties. The targeted companies being too slow in their adoption of the proposed approach, Vincent and his team decide to tackle the field of connected clothing, by proposing a set of components and tools enabling any clothing manufacturer to turn their garments into smart ones, able to measure multiple vital parameters but also to electrically stimulate certain regions of the body. Building upon their expertise in this space, they developed the first breathing smart garment with live biofeedback - Oxa - around which they designed a whole personalized program for everyone to reconnect to their body through breathing, the only vital sign we can consciously control. We talked with Vincent about the emergence of connected clothes and what role they will play in the preservation of our health, how stretchable electronics work, and how Nanoleq managed to develop a full breathing experience combining cutting-edge sensors with gamification, backed by the most renown ambassadors in the field. Timeline: 00:00:00 - Vincent’s background at the interface of materials science and biomedical engineering 00:02:57 - Launching a company to address the premature breakage of electronic cables 00:07:45 - What lies behind the term « stretchable electronics » 00:09:55 - Shifting the focus towards smart textiles 00:19:48 - The vision of Nanoleq around connected health 00:24:05 - Starting a new product line focused on breathing optimization: Oxa Life 00:35:00 - Federating a community of breathing specialists 00:37:46 - Making the most personalised and digitally engaging breathing optimization program 00:44:14 - Towards everyday wear of smart clothes What we also talked about with Vincent: ETH Pioneer Fellowships Luca Hirt Grégoire Courtine Start Summit Venture Kick Venture Electrical Muscle Stimulation (EMS) Wim Hof Sleep apnea Dan Brulé Headspace Petit Bambou Andrew Huberman We cited with Vincent some of the past episodes from the series: #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio As mentioned in the episode, you can learn more about Nanoleq and the field of stretchable electronics through their website. The Kickstarter campaign for Oxa runs until Sunday December 18 and you can contribute to it at this page! For more information about Oxa, check out the official product page: www.oxalife.com. Based on Vincent’s suggestions, check out the book Breath from James Nestor or this episode of Huberman Lab if you want to know more about the science behind breathing and the exercises that we discussed in this episode. You can also learn more about the Buteyko method here. If you want to get in touch with Vincent, feel free to contact him per email at martinez@nanoleq.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Will the next revolution in personalized health be led by connected clothes?

This is the bet that Vincent Martinez and his team at Nanoleq are making, and they are putting all their efforts into turning their vision into reality!

Originally, their idea was to target the cable industry with a proprietary technology enabling to create stretchable cables, with superior physical and electrical properties.

The targeted companies being too slow in their adoption of the proposed approach, Vincent and his team decide to tackle the field of connected clothing, by proposing a set of components and tools enabling any clothing manufacturer to turn their garments into smart ones, able to measure multiple vital parameters but also to electrically stimulate certain regions of the body.

Building upon their expertise in this space, they developed the first breathing smart garment with live biofeedback - Oxa - around which they designed a whole personalized program for everyone to reconnect to their body through breathing, the only vital sign we can consciously control.

We talked with Vincent about the emergence of connected clothes and what role they will play in the preservation of our health, how stretchable electronics work, and how Nanoleq managed to develop a full breathing experience combining cutting-edge sensors with gamification, backed by the most renown ambassadors in the field.


Timeline:

00:00:00 - Vincent’s background at the interface of materials science and biomedical engineering

00:02:57 - Launching a company to address the premature breakage of electronic cables

00:07:45 - What lies behind the term « stretchable electronics »

00:09:55 - Shifting the focus towards smart textiles

00:19:48 - The vision of Nanoleq around connected health

00:24:05 - Starting a new product line focused on breathing optimization: Oxa Life

00:35:00 - Federating a community of breathing specialists

00:37:46 - Making the most personalised and digitally engaging breathing optimization program

00:44:14 - Towards everyday wear of smart clothes


What we also talked about with Vincent:


We cited with Vincent some of the past episodes from the series:


As mentioned in the episode, you can learn more about Nanoleq and the field of stretchable electronics through their website.

The Kickstarter campaign for Oxa runs until Sunday December 18 and you can contribute to it at this page! For more information about Oxa, check out the official product page: www.oxalife.com.

Based on Vincent’s suggestions, check out the book Breath from James Nestor or this episode of Huberman Lab if you want to know more about the science behind breathing and the exercises that we discussed in this episode. You can also learn more about the Buteyko method here.

If you want to get in touch with Vincent, feel free to contact him per email at martinez@nanoleq.com or through LinkedIn.

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com.

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

]]> 3372 [SNIPPET] - Vincent Martinez on the rise of smart textiles and their relevance in personalized health To discover the whole episode type "#14 - Preserving our health with smart clothes - Vincent Martinez - Nanoleq" on your streaming platform. Wed, 14 Dec 2022 14:57:00 -0000 full Mathieu Chaffard To discover the whole episode type "#14 - Preserving our health with smart clothes - Vincent Martinez - Nanoleq" on your streaming platform. To discover the whole episode type "#14 - Preserving our health with smart clothes - Vincent Martinez - Nanoleq" on your streaming platform.

]]> 239 #13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas Developing a new drug is a tough and strenuous endeavour, requiring investments that go beyond $1 billion and sometimes up to 15 years of time. On top of that, only 1 out of 10 drug candidates successfully passes clinical trial testing and regulatory approval. The Dutch company Mimetas, specialized in the use of organ-on-a-chip technology, aims to address exactly this challenge by accelerating this laborious process and making it more predictable. Their expertise actually lies in the development of in-vitro human tissue models (including diseases) which recapitulate the cellular complexity but also the biochemical and mechanical cues that make up the real tissues from our body. Such models can then be used as a powerful experimental platform for drug discovery, since they reflect our actual biology so well. Bas Triestch is one of the three founders from Mimetas (alongside Jos Joore and Paul Vulto) who saw in the early 2010s the potential to leverage organ-on-a-chip methods at scale for the benefit of drug discovery, leading them to become the most innovative Dutch company in 2022! In this episode, Bas takes us behind the scenes of the fascinating science that they are driving at Mimetas, the impact that they are having on the R&D efforts from some of the biggest players in the biotech industry, but also the shift that they have operated as a company, starting as a “hardware” provider and gradually becoming a specialized scientific service firm. Timeline: 00:00:00 - Bas’ background and the origins of Mimetas centered around new drug discovery approaches 00:05:31 - What organ-on-a-chip technology means and how it serves the development of new human tissue and disease models 00:09:05 - The OrganoPlate® as the key platform providing scalability and reproducibility for the study of such models 00:15:40 - Merging organoids and organ-on-a-chip technologies in a unique platform, the OrganoPlate® Graft 00:24:03 - Moving from better understanding diseases, through medication guidance, and up to personalized medicine 00:28:47 - Mimetas’ mission in accelerating the development of new treatments and finding the right drugs for the right patients 00:34:50 - Dealing with a substantial amount of experimental data 00:39:24 - Shifting Mimetas’ business model from selling hardware components to offering specialized scientific services in the field of drug discovery What we also talked about with Bas: Leiden University Hans Clevers Roche Galapagos Trans-Epithelial Electrical Resistance (TEER) Wnt signaling pathway We cited with Bas some of the past episodes from the series: #5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore #8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche As mentioned in the episode, you can learn more about Mimetas and the field of organ-on-a-chip engineering through their website. Based on Bas’ recommendation, we also invite you to check out this review to get a deeper understanding of the field and where it stands at the moment. If you want to get in touch with Bas, feel free to contact him per email at s.trietsch@mimetas.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Mon, 28 Nov 2022 20:36:00 -0000 Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas full Mathieu Chaffard Developing a new drug is a tough and strenuous endeavour, requiring investments that go beyond $1 billion and sometimes up to 15 years of time. On top of that, only 1 out of 10 drug candidates successfully passes clinical trial testing and regulatory approval. The Dutch company Mimetas, specialized in the use of organ-on-a-chip technology, aims to address exactly this challenge by accelerating this laborious process and making it more predictable. Their expertise actually lies in the development of in-vitro human tissue models (including diseases) which recapitulate the cellular complexity but also the biochemical and mechanical cues that make up the real tissues from our body. Such models can then be used as a powerful experimental platform for drug discovery, since they reflect our actual biology so well. Bas Triestch is one of the three founders from Mimetas (alongside Jos Joore and Paul Vulto) who saw in the early 2010s the potential to leverage organ-on-a-chip methods at scale for the benefit of drug discovery, leading them to become the most innovative Dutch company in 2022! In this episode, Bas takes us behind the scenes of the fascinating science that they are driving at Mimetas, the impact that they are having on the R&D efforts from some of the biggest players in the biotech industry, but also the shift that they have operated as a company, starting as a “hardware” provider and gradually becoming a specialized scientific service firm. Timeline: 00:00:00 - Bas’ background and the origins of Mimetas centered around new drug discovery approaches 00:05:31 - What organ-on-a-chip technology means and how it serves the development of new human tissue and disease models 00:09:05 - The OrganoPlate® as the key platform providing scalability and reproducibility for the study of such models 00:15:40 - Merging organoids and organ-on-a-chip technologies in a unique platform, the OrganoPlate® Graft 00:24:03 - Moving from better understanding diseases, through medication guidance, and up to personalized medicine 00:28:47 - Mimetas’ mission in accelerating the development of new treatments and finding the right drugs for the right patients 00:34:50 - Dealing with a substantial amount of experimental data 00:39:24 - Shifting Mimetas’ business model from selling hardware components to offering specialized scientific services in the field of drug discovery What we also talked about with Bas: Leiden University Hans Clevers Roche Galapagos Trans-Epithelial Electrical Resistance (TEER) Wnt signaling pathway We cited with Bas some of the past episodes from the series: #5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore #8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche As mentioned in the episode, you can learn more about Mimetas and the field of organ-on-a-chip engineering through their website. Based on Bas’ recommendation, we also invite you to check out this review to get a deeper understanding of the field and where it stands at the moment. If you want to get in touch with Bas, feel free to contact him per email at s.trietsch@mimetas.com or through LinkedIn. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram! Developing a new drug is a tough and strenuous endeavour, requiring investments that go beyond $1 billion and sometimes up to 15 years of time.

On top of that, only 1 out of 10 drug candidates successfully passes clinical trial testing and regulatory approval.

The Dutch company Mimetas, specialized in the use of organ-on-a-chip technology, aims to address exactly this challenge by accelerating this laborious process and making it more predictable.

Their expertise actually lies in the development of in-vitro human tissue models (including diseases) which recapitulate the cellular complexity but also the biochemical and mechanical cues that make up the real tissues from our body. Such models can then be used as a powerful experimental platform for drug discovery, since they reflect our actual biology so well.

Bas Triestch is one of the three founders from Mimetas (alongside Jos Joore and Paul Vulto) who saw in the early 2010s the potential to leverage organ-on-a-chip methods at scale for the benefit of drug discovery, leading them to become the most innovative Dutch company in 2022!

In this episode, Bas takes us behind the scenes of the fascinating science that they are driving at Mimetas, the impact that they are having on the R&D efforts from some of the biggest players in the biotech industry, but also the shift that they have operated as a company, starting as a “hardware” provider and gradually becoming a specialized scientific service firm.


Timeline:

00:00:00 - Bas’ background and the origins of Mimetas centered around new drug discovery approaches

00:05:31 - What organ-on-a-chip technology means and how it serves the development of new human tissue and disease models

00:09:05 - The OrganoPlate® as the key platform providing scalability and reproducibility for the study of such models

00:15:40 - Merging organoids and organ-on-a-chip technologies in a unique platform, the OrganoPlate® Graft

00:24:03 - Moving from better understanding diseases, through medication guidance, and up to personalized medicine

00:28:47 - Mimetas’ mission in accelerating the development of new treatments and finding the right drugs for the right patients

00:34:50 - Dealing with a substantial amount of experimental data

00:39:24 - Shifting Mimetas’ business model from selling hardware components to offering specialized scientific services in the field of drug discovery


What we also talked about with Bas:


We cited with Bas some of the past episodes from the series:


As mentioned in the episode, you can learn more about Mimetas and the field of organ-on-a-chip engineering through their website.

Based on Bas’ recommendation, we also invite you to check out this review to get a deeper understanding of the field and where it stands at the moment.

If you want to get in touch with Bas, feel free to contact him per email at s.trietsch@mimetas.com or through LinkedIn.

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or per email at mathieu@impulsepodcast.com.

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

Finally, you can follow our activities through our website, over LinkedIn, Twitter or on Instagram!

]]> 3240 [SNIPPET] - Bas Trietsch on the radical benefits of using organ-on-a-chip models early in drug discovery To discover the whole episode type “#13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas" on your streaming platform. Mon, 28 Nov 2022 20:33:00 -0000 full Mathieu Chaffard To discover the whole episode type “#13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas" on your streaming platform. To discover the whole episode type “#13 - Catalyzing drug discovery using organ-on-a-chip models - Bas Trietsch - Mimetas" on your streaming platform.

]]> 195 #12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health Daniel Kraft is a surprising and admirable figure in the digital health landscape. Originally trained as a physician in internal medicine and pediatrics, he then distinguished himself by his research work focusing on regenerative medicine, while at the same time initiating several entrepreneurial projects in the medtech space. RegenMed Systems is one of them, a company that he founded and which led him to create a new type of medical device to facilitate bone marrow harvest procedures. IntelliMedicine is another one, where he aims to create a system enabling patients to 3D print their own medication at home, avoiding the intake of multiple pills on a daily basis. Aside from his own entrepreneurial endeavours, he advises several Fortune-50 and digital health-related startups, and is on the board of Healthy.io. As one of the most renowned ambassadors of digital health, he is driven by the conviction that innovation in this space can only result from the synergies of disciplines and technologies that may initially be totally distant from the medical sphere. Through his activities at the Singularity University or through the program Exponential Medicine that he initiated, he brings together brilliant minds from a broad range of specialties who come together to explore convergent and rapidly developing technologies, to develop relevant applications in healthcare. Often called upon to speak to the future of health, medicine and technology, he has already given multiple TED and TEDMED Talks, and delivered keynotes to a wide array of organizations on those subjects. We talked with Daniel about his early days in the healthcare world, why he decided to study medicine and orient himself on this path, his perspective on the importance of collaboration and boldness when it comes to creating new digital health solutions, what the future looks like from his lens, but also how he manages to stay on top of things while keeping a healthy lifestyle! Timeline: 00:00:00 - Daniel’s background moving from medicine, research, and entrepreneurship in digital health 00:03:56 - What drove Daniel to start a career in healthcare 00:05:54 - How converging new digital technologies can benefit medical progress 00:09:00 - The shift in adoption within the medical community towards digital health 00:10:49 - The types of medical data available these days to advance our understanding and management of diseases 00:14:30 - Establishing a general database to reference all things digital health - Digital.Health 00:20:16 - Zooming in on RegenMed Systems and IntelliMedicine 00:26:25 - A look at Daniel’s potential future projects in healthcare 00:31:54 - Daniel’s tips and secrets on his (almost) endless source of energy and drive What we also talked about with Daniel: Bits & Pretzels HealthTech Xolair Stanford Byers Center for Biodesign NASA IBM Watson CRISPR/Cas9 Continuum Health Ventures Digitale Gesundheitsanwendungen (DiGA) You can learn more about Daniel’s activities through his website (we recommend you to subscribe to his weekly newsletter), and you can follow him on LinkedIn and Twitter. For a deep-dive into digital health solutions, we recommend you to consult Digital.Health, the database that Daniel and his team put together and which regroups most of the solutions already available out there. In case you want to experience the thrill of digital health and share your ideas with some of the brightest minds in the field, check out NextMed.Health, the conference in San Diego curated by Daniel and his team from March 13 to 16 next year. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com And if you liked the episode, don’t hesitate to share it, subscribe to the podcast, leave a positive review on streaming platforms and follow our activities on LinkedIn, Instagram, Twitter as well as on our website! Tue, 01 Nov 2022 09:52:00 -0000 Unleashing the power of digital health - Daniel Kraft - Digital.Health full Mathieu Chaffard Daniel Kraft is a surprising and admirable figure in the digital health landscape. Originally trained as a physician in internal medicine and pediatrics, he then distinguished himself by his research work focusing on regenerative medicine, while at the same time initiating several entrepreneurial projects in the medtech space. RegenMed Systems is one of them, a company that he founded and which led him to create a new type of medical device to facilitate bone marrow harvest procedures. IntelliMedicine is another one, where he aims to create a system enabling patients to 3D print their own medication at home, avoiding the intake of multiple pills on a daily basis. Aside from his own entrepreneurial endeavours, he advises several Fortune-50 and digital health-related startups, and is on the board of Healthy.io. As one of the most renowned ambassadors of digital health, he is driven by the conviction that innovation in this space can only result from the synergies of disciplines and technologies that may initially be totally distant from the medical sphere. Through his activities at the Singularity University or through the program Exponential Medicine that he initiated, he brings together brilliant minds from a broad range of specialties who come together to explore convergent and rapidly developing technologies, to develop relevant applications in healthcare. Often called upon to speak to the future of health, medicine and technology, he has already given multiple TED and TEDMED Talks, and delivered keynotes to a wide array of organizations on those subjects. We talked with Daniel about his early days in the healthcare world, why he decided to study medicine and orient himself on this path, his perspective on the importance of collaboration and boldness when it comes to creating new digital health solutions, what the future looks like from his lens, but also how he manages to stay on top of things while keeping a healthy lifestyle! Timeline: 00:00:00 - Daniel’s background moving from medicine, research, and entrepreneurship in digital health 00:03:56 - What drove Daniel to start a career in healthcare 00:05:54 - How converging new digital technologies can benefit medical progress 00:09:00 - The shift in adoption within the medical community towards digital health 00:10:49 - The types of medical data available these days to advance our understanding and management of diseases 00:14:30 - Establishing a general database to reference all things digital health - Digital.Health 00:20:16 - Zooming in on RegenMed Systems and IntelliMedicine 00:26:25 - A look at Daniel’s potential future projects in healthcare 00:31:54 - Daniel’s tips and secrets on his (almost) endless source of energy and drive What we also talked about with Daniel: Bits & Pretzels HealthTech Xolair Stanford Byers Center for Biodesign NASA IBM Watson CRISPR/Cas9 Continuum Health Ventures Digitale Gesundheitsanwendungen (DiGA) You can learn more about Daniel’s activities through his website (we recommend you to subscribe to his weekly newsletter), and you can follow him on LinkedIn and Twitter. For a deep-dive into digital health solutions, we recommend you to consult Digital.Health, the database that Daniel and his team put together and which regroups most of the solutions already available out there. In case you want to experience the thrill of digital health and share your ideas with some of the brightest minds in the field, check out NextMed.Health, the conference in San Diego curated by Daniel and his team from March 13 to 16 next year. If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com And if you liked the episode, don’t hesitate to share it, subscribe to the podcast, leave a positive review on streaming platforms and follow our activities on LinkedIn, Instagram, Twitter as well as on our website! Daniel Kraft is a surprising and admirable figure in the digital health landscape.

Originally trained as a physician in internal medicine and pediatrics, he then distinguished himself by his research work focusing on regenerative medicine, while at the same time initiating several entrepreneurial projects in the medtech space. RegenMed Systems is one of them, a company that he founded and which led him to create a new type of medical device to facilitate bone marrow harvest procedures. IntelliMedicine is another one, where he aims to create a system enabling patients to 3D print their own medication at home, avoiding the intake of multiple pills on a daily basis. Aside from his own entrepreneurial endeavours, he advises several Fortune-50 and digital health-related startups, and is on the board of Healthy.io.

As one of the most renowned ambassadors of digital health, he is driven by the conviction that innovation in this space can only result from the synergies of disciplines and technologies that may initially be totally distant from the medical sphere. Through his activities at the Singularity University or through the program Exponential Medicine that he initiated, he brings together brilliant minds from a broad range of specialties who come together to explore convergent and rapidly developing technologies, to develop relevant applications in healthcare.

Often called upon to speak to the future of health, medicine and technology, he has already given multiple TED and TEDMED Talks, and delivered keynotes to a wide array of organizations on those subjects.

We talked with Daniel about his early days in the healthcare world, why he decided to study medicine and orient himself on this path, his perspective on the importance of collaboration and boldness when it comes to creating new digital health solutions, what the future looks like from his lens, but also how he manages to stay on top of things while keeping a healthy lifestyle!


Timeline:

00:00:00 - Daniel’s background moving from medicine, research, and entrepreneurship in digital health

00:03:56 - What drove Daniel to start a career in healthcare

00:05:54 - How converging new digital technologies can benefit medical progress

00:09:00 - The shift in adoption within the medical community towards digital health

00:10:49 - The types of medical data available these days to advance our understanding and management of diseases

00:14:30 - Establishing a general database to reference all things digital health - Digital.Health

00:20:16 - Zooming in on RegenMed Systems and IntelliMedicine

00:26:25 - A look at Daniel’s potential future projects in healthcare

00:31:54 - Daniel’s tips and secrets on his (almost) endless source of energy and drive


What we also talked about with Daniel:


You can learn more about Daniel’s activities through his website (we recommend you to subscribe to his weekly newsletter), and you can follow him on LinkedIn and Twitter.

For a deep-dive into digital health solutions, we recommend you to consult Digital.Health, the database that Daniel and his team put together and which regroups most of the solutions already available out there.

In case you want to experience the thrill of digital health and share your ideas with some of the brightest minds in the field, check out NextMed.Health, the conference in San Diego curated by Daniel and his team from March 13 to 16 next year.

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast, leave a positive review on streaming platforms and follow our activities on LinkedIn, Instagram, Twitter as well as on our website!

]]> 2856 [SNIPPET] - Daniel Kraft on 3D printing your own pills at home To discover the whole episode type “#12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health" on your streaming platform. Tue, 01 Nov 2022 09:34:00 -0000 full Mathieu Chaffard To discover the whole episode type “#12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health" on your streaming platform. To discover the whole episode type “#12 - Unleashing the power of digital health - Daniel Kraft - Digital.Health" on your streaming platform.

]]> 137 #11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio Miniaturizing the lab to allow for the continuous analysis of proteins and hormones circulating in our body through a wearable. This is the aim of Xsensio - a Swiss startup developing the Lab-on-Skin(c) platform - which will enable in the future to continuously track compounds present in the interstitial fluid, right underneath our skin. It is in essence a similar concept as the established continuous glucose measurement devices (which are nowadays moving from pure medical applications to consumer-oriented wellness programs), the difference being the type of biomarkers that the Lab-on-Skin(c) platform will enable to monitor - proteins and hormones on-body, continuously and in real-time - opening applications ranging from cardiology to oncology, in the hospital setting or at home. Esmeralda Megally (CEO of the company) shares with us her vision around personalized medicine and which role the Lab-on-Skin(c) platform will play in this regard. With passion, she explains us the concepts behind the functioning of this surprising technology, what it takes to bring it to the market, and reveals the potential synergies that it may have in the future with the current wearables that are already part of our daily living. Timeline: 00:00:00 - Esmeralda’s background and how it led to the creation of Xsensio 00:09:14 - The unmet need that Xsensio is addressing with its Lab-on-Skin(c) platform 00:13:51 - The applications where the Lab-on-Skin(c) platform will play a role 00:17:28 - The functioning of the Lab-on-Skin(c) platform and its components 00:22:50 - What lies ahead of Xsensio before making its first product commercialized 00:28:09 - Combining the Lab-on-Skin(c) platform with traditional wearables data 00:29:57 - Defining a medical product development roadmap in an emerging field and how to deal with accompanying uncertainty What we also talked about with Esmeralda: Fitbit Apple Watch Bill & Melinda Gates Foundation Lab for Youth Mental Health NANOLAB Veri Supersapiens C-reactive protein Troponin T Mayo Clinic Rea Diagnostics We cited with Esmeralda some of the past episodes from the series: #4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune If you want to know more about Xsensio, we invite you to consult their website and follow their activities on LinkedIn or Twitter. As mentioned by Esmeralda in the episode, have a read at this paper from Nature Biotechnology if you want to know more about the field of biosensing. You can get in touch with Esmeralda through LinkedIn or by email: esmeralda.megally@xsensio.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Wed, 19 Oct 2022 09:27:00 -0000 Turning the lab into a wearable platform - Esmeralda Megally - Xsensio full Mathieu Chaffard Miniaturizing the lab to allow for the continuous analysis of proteins and hormones circulating in our body through a wearable. This is the aim of Xsensio - a Swiss startup developing the Lab-on-Skin(c) platform - which will enable in the future to continuously track compounds present in the interstitial fluid, right underneath our skin. It is in essence a similar concept as the established continuous glucose measurement devices (which are nowadays moving from pure medical applications to consumer-oriented wellness programs), the difference being the type of biomarkers that the Lab-on-Skin(c) platform will enable to monitor - proteins and hormones on-body, continuously and in real-time - opening applications ranging from cardiology to oncology, in the hospital setting or at home. Esmeralda Megally (CEO of the company) shares with us her vision around personalized medicine and which role the Lab-on-Skin(c) platform will play in this regard. With passion, she explains us the concepts behind the functioning of this surprising technology, what it takes to bring it to the market, and reveals the potential synergies that it may have in the future with the current wearables that are already part of our daily living. Timeline: 00:00:00 - Esmeralda’s background and how it led to the creation of Xsensio 00:09:14 - The unmet need that Xsensio is addressing with its Lab-on-Skin(c) platform 00:13:51 - The applications where the Lab-on-Skin(c) platform will play a role 00:17:28 - The functioning of the Lab-on-Skin(c) platform and its components 00:22:50 - What lies ahead of Xsensio before making its first product commercialized 00:28:09 - Combining the Lab-on-Skin(c) platform with traditional wearables data 00:29:57 - Defining a medical product development roadmap in an emerging field and how to deal with accompanying uncertainty What we also talked about with Esmeralda: Fitbit Apple Watch Bill & Melinda Gates Foundation Lab for Youth Mental Health NANOLAB Veri Supersapiens C-reactive protein Troponin T Mayo Clinic Rea Diagnostics We cited with Esmeralda some of the past episodes from the series: #4 - Fighting sepsis with nanoengineered beads to filter the blood - Lukas Langenegger - Hemotune If you want to know more about Xsensio, we invite you to consult their website and follow their activities on LinkedIn or Twitter. As mentioned by Esmeralda in the episode, have a read at this paper from Nature Biotechnology if you want to know more about the field of biosensing. You can get in touch with Esmeralda through LinkedIn or by email: esmeralda.megally@xsensio.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Miniaturizing the lab to allow for the continuous analysis of proteins and hormones circulating in our body through a wearable.

This is the aim of Xsensio - a Swiss startup developing the Lab-on-Skin(c) platform - which will enable in the future to continuously track compounds present in the interstitial fluid, right underneath our skin.

It is in essence a similar concept as the established continuous glucose measurement devices (which are nowadays moving from pure medical applications to consumer-oriented wellness programs), the difference being the type of biomarkers that the Lab-on-Skin(c) platform will enable to monitor - proteins and hormones on-body, continuously and in real-time - opening applications ranging from cardiology to oncology, in the hospital setting or at home.

Esmeralda Megally (CEO of the company) shares with us her vision around personalized medicine and which role the Lab-on-Skin(c) platform will play in this regard. With passion, she explains us the concepts behind the functioning of this surprising technology, what it takes to bring it to the market, and reveals the potential synergies that it may have in the future with the current wearables that are already part of our daily living.


Timeline:

00:00:00 - Esmeralda’s background and how it led to the creation of Xsensio

00:09:14 - The unmet need that Xsensio is addressing with its Lab-on-Skin(c) platform

00:13:51 - The applications where the Lab-on-Skin(c) platform will play a role

00:17:28 - The functioning of the Lab-on-Skin(c) platform and its components

00:22:50 - What lies ahead of Xsensio before making its first product commercialized

00:28:09 - Combining the Lab-on-Skin(c) platform with traditional wearables data

00:29:57 - Defining a medical product development roadmap in an emerging field and how to deal with accompanying uncertainty


What we also talked about with Esmeralda:


We cited with Esmeralda some of the past episodes from the series:


If you want to know more about Xsensio, we invite you to consult their website and follow their activities on LinkedIn or Twitter.

As mentioned by Esmeralda in the episode, have a read at this paper from Nature Biotechnology if you want to know more about the field of biosensing.

You can get in touch with Esmeralda through LinkedIn or by email: esmeralda.megally@xsensio.com

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

You can follow our activities through our website, over LinkedIn, or on Instagram!

]]> 2504 [SNIPPET] - Esmeralda Megally on the emergence of wearable biosensors To discover the whole episode type “#11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio" on your streaming platform. Wed, 19 Oct 2022 09:24:00 -0000 full Mathieu Chaffard To discover the whole episode type “#11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio" on your streaming platform. To discover the whole episode type “#11 - Turning the lab into a wearable platform - Esmeralda Megally - Xsensio" on your streaming platform.

]]> 220 #10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation Most of us have already heard about blockchain technology, as well as many things about cryptocurrencies and how they are transforming traditional approaches in the field of finance. But what about its relevance to healthcare and the potential applications it may have in this space? Eberhard Scheuer is the President of the dHealth Foundation, a not-for-profit organization from Switzerland providing the infrastructure and tools to major stakeholders in healthcare to leverage blockchain technology. He takes us through the basic concepts around blockchain and guides us through the benefits and the applications it may have in this field, when it comes for instance to empowering patients in managing their own health and the data that accompanies it, creating transparency across the pharmaceutical supply chain, or even preserving the authenticity of medical test results! A fascinating exchange and good entry point for newcomers in the field of blockchain and web3 applied to healthcare! Timeline: 00:00:00 - Eberhard’s background and his entry point in web3 concepts applied to healthcare 00:06:29 - What blockchain is about 00:11:12 - Applications of blockchain technology to healthcare and its benefits 00:21:51 - The example of Estonia with blockchain-enabled electronic health records and the efforts of big tech companies in that regard 00:25:58 - The reason behind the dHealth Foundation and monetizing health data 00:38:30 - The services provided by the dHealth Foundation to its partners 00:46:44 - Misleading ideas around blockchain applications in healthcare What we also talked about with Eberhard Bitcoin Ethereum The Swiss Tropical and Public Health Institute Roche Digital twin Alex Cahana If you want to know more about the dHealth Foundation, we invite you to consult their website and follow their activities on LinkedIn, Medium and Twitter. As mentioned by Eberhard in the episode, if you want to know more about the field of blockchain and the latest trends in that regard, have a look at Blockchain Revolution, Bloomberg Crypto, CoinDesk and Cointelegraph. You can get in touch with Eberhard through LinkedIn or by email: es@dhealth.foundation If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Sun, 02 Oct 2022 18:35:00 -0000 Applying blockchain technology to the healthcare sector - Eberhard Scheuer - dHealth Foundation full Mathieu Chaffard Most of us have already heard about blockchain technology, as well as many things about cryptocurrencies and how they are transforming traditional approaches in the field of finance. But what about its relevance to healthcare and the potential applications it may have in this space? Eberhard Scheuer is the President of the dHealth Foundation, a not-for-profit organization from Switzerland providing the infrastructure and tools to major stakeholders in healthcare to leverage blockchain technology. He takes us through the basic concepts around blockchain and guides us through the benefits and the applications it may have in this field, when it comes for instance to empowering patients in managing their own health and the data that accompanies it, creating transparency across the pharmaceutical supply chain, or even preserving the authenticity of medical test results! A fascinating exchange and good entry point for newcomers in the field of blockchain and web3 applied to healthcare! Timeline: 00:00:00 - Eberhard’s background and his entry point in web3 concepts applied to healthcare 00:06:29 - What blockchain is about 00:11:12 - Applications of blockchain technology to healthcare and its benefits 00:21:51 - The example of Estonia with blockchain-enabled electronic health records and the efforts of big tech companies in that regard 00:25:58 - The reason behind the dHealth Foundation and monetizing health data 00:38:30 - The services provided by the dHealth Foundation to its partners 00:46:44 - Misleading ideas around blockchain applications in healthcare What we also talked about with Eberhard Bitcoin Ethereum The Swiss Tropical and Public Health Institute Roche Digital twin Alex Cahana If you want to know more about the dHealth Foundation, we invite you to consult their website and follow their activities on LinkedIn, Medium and Twitter. As mentioned by Eberhard in the episode, if you want to know more about the field of blockchain and the latest trends in that regard, have a look at Blockchain Revolution, Bloomberg Crypto, CoinDesk and Cointelegraph. You can get in touch with Eberhard through LinkedIn or by email: es@dhealth.foundation If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Most of us have already heard about blockchain technology, as well as many things about cryptocurrencies and how they are transforming traditional approaches in the field of finance.

But what about its relevance to healthcare and the potential applications it may have in this space?

Eberhard Scheuer is the President of the dHealth Foundation, a not-for-profit organization from Switzerland providing the infrastructure and tools to major stakeholders in healthcare to leverage blockchain technology.

He takes us through the basic concepts around blockchain and guides us through the benefits and the applications it may have in this field, when it comes for instance to empowering patients in managing their own health and the data that accompanies it, creating transparency across the pharmaceutical supply chain, or even preserving the authenticity of medical test results!

A fascinating exchange and good entry point for newcomers in the field of blockchain and web3 applied to healthcare!


Timeline:

00:00:00 - Eberhard’s background and his entry point in web3 concepts applied to healthcare

00:06:29 - What blockchain is about

00:11:12 - Applications of blockchain technology to healthcare and its benefits

00:21:51 - The example of Estonia with blockchain-enabled electronic health records and the efforts of big tech companies in that regard

00:25:58 - The reason behind the dHealth Foundation and monetizing health data

00:38:30 - The services provided by the dHealth Foundation to its partners

00:46:44 - Misleading ideas around blockchain applications in healthcare


What we also talked about with Eberhard


If you want to know more about the dHealth Foundation, we invite you to consult their website and follow their activities on LinkedIn, Medium and Twitter.

As mentioned by Eberhard in the episode, if you want to know more about the field of blockchain and the latest trends in that regard, have a look at Blockchain Revolution, Bloomberg Crypto, CoinDesk and Cointelegraph.

You can get in touch with Eberhard through LinkedIn or by email: es@dhealth.foundation

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com.

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

You can follow our activities through our website, over LinkedIn, or on Instagram!

]]> 3406 [SNIPPET] - Eberhard Scheuer on the benefits of tokenizing health data To discover the whole episode type “#10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation" on your streaming platform. Sun, 02 Oct 2022 18:33:00 -0000 full Mathieu Chaffard To discover the whole episode type “#10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation" on your streaming platform. To discover the whole episode type “#10 - Applying blockchain technology to healthcare - Eberhard Scheuer - dHealth Foundation" on your streaming platform.

]]> 137 #9 - Creating the Gran Turismo of surgery - Raimundo Sierra - VirtaMed Raimundo Sierra is the Founder and CEO from VirtaMed, a Swiss company specialized in surgical simulation systems, covering interventions in orthopaedics, gynecology, laparoscopy and urology, providing true-to-life training for aspiring surgeons and established ones, as part of their continuing education. At the edge of robotics and gaming, Raimundo takes us through the origins of this extremely ambitious project, explaining how the first systems from VirtaMed were developed, and how they currently fit in the diverse surgical curricula provided by established institutions in Europe, China and the US. Beyond the volume of training that such platforms can offer and the positive repercussions in terms of operative results, they also provide equitable access to surgical training, a point that is particularly close to Raimundo's heart given his personal experience. Timeline: 00:00:00 - Raimundo’s background and what led him to the world of surgical simulation systems 00:07:33 - The origins of VirtaMed and what differentiates its solutions from medical devices 00:11:24 - How surgical simulation systems are integrated to medical curricula 00:16:16 - The components of VirtaMed surgical simulation systems 00:20:38 - VirtaMed’s global footprint and driving adoption of its products 00:24:58 - The potential of emerging technologies like machine learning in the field of surgical simulation 00:27:11 - How VirtaMed works with surgeons 00:34:47 - VirtaMed’s business model What we also talked about with Raimundo: Stefan Tuchschmid AANA AGA Charité - Universitätsmedizin Berlin B. Braun Melsungen AG Bruno Schmied Dieter Hahnloser Melanie Aregger Avelo We cited with Raimundo some of the past episodes from the series: #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical #7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - Mindmaze If you want to know more about VirtaMed, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Raimundo in the episode, you can learn more about the field of surgical simulations and the latest trends in that regard through the following sources: Society for Simulation in Healthcare The PROFICIENCY project You can get in touch with Raimundo by email: raimundo.sierra@virtamed.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Thu, 15 Sep 2022 19:24:00 -0000 Creating the Gran Turismo of surgery - Raimundo Sierra - VirtaMed full Mathieu Chaffard Raimundo Sierra is the Founder and CEO from VirtaMed, a Swiss company specialized in surgical simulation systems, covering interventions in orthopaedics, gynecology, laparoscopy and urology, providing true-to-life training for aspiring surgeons and established ones, as part of their continuing education. At the edge of robotics and gaming, Raimundo takes us through the origins of this extremely ambitious project, explaining how the first systems from VirtaMed were developed, and how they currently fit in the diverse surgical curricula provided by established institutions in Europe, China and the US. Beyond the volume of training that such platforms can offer and the positive repercussions in terms of operative results, they also provide equitable access to surgical training, a point that is particularly close to Raimundo's heart given his personal experience. Timeline: 00:00:00 - Raimundo’s background and what led him to the world of surgical simulation systems 00:07:33 - The origins of VirtaMed and what differentiates its solutions from medical devices 00:11:24 - How surgical simulation systems are integrated to medical curricula 00:16:16 - The components of VirtaMed surgical simulation systems 00:20:38 - VirtaMed’s global footprint and driving adoption of its products 00:24:58 - The potential of emerging technologies like machine learning in the field of surgical simulation 00:27:11 - How VirtaMed works with surgeons 00:34:47 - VirtaMed’s business model What we also talked about with Raimundo: Stefan Tuchschmid AANA AGA Charité - Universitätsmedizin Berlin B. Braun Melsungen AG Bruno Schmied Dieter Hahnloser Melanie Aregger Avelo We cited with Raimundo some of the past episodes from the series: #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical #7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - Mindmaze If you want to know more about VirtaMed, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Raimundo in the episode, you can learn more about the field of surgical simulations and the latest trends in that regard through the following sources: Society for Simulation in Healthcare The PROFICIENCY project You can get in touch with Raimundo by email: raimundo.sierra@virtamed.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Raimundo Sierra is the Founder and CEO from VirtaMed, a Swiss company specialized in surgical simulation systems, covering interventions in orthopaedics, gynecology, laparoscopy and urology, providing true-to-life training for aspiring surgeons and established ones, as part of their continuing education.

At the edge of robotics and gaming, Raimundo takes us through the origins of this extremely ambitious project, explaining how the first systems from VirtaMed were developed, and how they currently fit in the diverse surgical curricula provided by established institutions in Europe, China and the US.

Beyond the volume of training that such platforms can offer and the positive repercussions in terms of operative results, they also provide equitable access to surgical training, a point that is particularly close to Raimundo's heart given his personal experience.


Timeline:

00:00:00 - Raimundo’s background and what led him to the world of surgical simulation systems

00:07:33 - The origins of VirtaMed and what differentiates its solutions from medical devices

00:11:24 - How surgical simulation systems are integrated to medical curricula

00:16:16 - The components of VirtaMed surgical simulation systems

00:20:38 - VirtaMed’s global footprint and driving adoption of its products

00:24:58 - The potential of emerging technologies like machine learning in the field of surgical simulation

00:27:11 - How VirtaMed works with surgeons

00:34:47 - VirtaMed’s business model


What we also talked about with Raimundo:


We cited with Raimundo some of the past episodes from the series:


If you want to know more about VirtaMed, we invite you to consult their website and follow their activities on LinkedIn.

As mentioned by Raimundo in the episode, you can learn more about the field of surgical simulations and the latest trends in that regard through the following sources:


You can get in touch with Raimundo by email: raimundo.sierra@virtamed.com

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com.

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

You can follow our activities through our website, over LinkedIn, or on Instagram!

]]> 2840 [SNIPPET] - Raimundo Sierra on creating the most realistic surgical simulation system To discover the whole episode type “#9 - Creating the Gran Turismo of surgery - Raimundo Sierra - VirtaMed" on your streaming platform. Thu, 15 Sep 2022 19:22:00 -0000 full Mathieu Chaffard To discover the whole episode type “#9 - Creating the Gran Turismo of surgery - Raimundo Sierra - VirtaMed" on your streaming platform. To discover the whole episode type “#9 - Creating the Gran Turismo of surgery - Raimundo Sierra - VirtaMed" on your streaming platform.

]]> 129 #8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. Nikolce is leading the Organoid Engineering Group at the Roche Institute for Translational Bioengineering. Organoids are miniaturised versions of the organs and tissues that make up our bodies, sharing phenotypic and genetic aspects of them. They carry a lot of hope in terms of applications in healthcare, from the replacement of animal testing involved in the assessment of drug safety and efficacy, to personalized medicine where they can be leveraged to inform the treatment most suitable to a particular patient, or in terms of potential transplants to address certain diseases. We exchanged with Nikolce on the what, the how and the why behind this fascinating field of bioengineering, which tremendously developed over the past years. He takes us through the current status of the technology and the clinical applications it has already demonstrated, and shares his view on how the field will evolve in the future. Timeline: 00:00:00 - Mandate and ambition of the Roche Institute for Translational Bioengineering 00:06:18 - What organoids are and from which tissues they are derived 00:09:53 - Reprogramming cells’ fates from tissues and deriving induced pluripotent stem cells 00:11:05 - Growing organoids in vitro and related challenges 00:13:50 - Applications leveraged at the ITB and the types of tissues at stake 00:15:55 - Refining the biology and turning the theoretical promises around organoids into practice 00:20:38 - Towards the use of organoids as human grafts or replacing animal testing 00:22:37 - Organ-on-a-chip technologies and how they complement organoids 00:26:17 - Synergies with bioprinting technologies and the challenges that come along with building tissue replicas 00:28:03 - Looking back at the main advancements since the first organoids came out and their ability to recapitulate features proper to a patient 00:33:56 - The ethical framework around the use of organoids 00:37:38 - Moving from Academia to the Industry as a scientist What we also talked about with Nikolce: Matthias Lütolf Hans Clevers Mina Bissell Celeste M. Nelson Nathalie Brandenberg Silke Hoehnel Sun Bioscience Cellink Embryonic stem cells HeLa cells If you want to learn more about the Roche Institute for Translational Bioengineering, we encourage you to consult their website. As mentioned by Nikolce during the episode, the Harvard Stem Cell Institute and Stem Cell Technologies are two information sources worth checking out in case you want to take a deep-dive into what organoids are, and go further into the topics we discussed with him. If you want to reach out to Nikolce, you can contact him over LinkedIn. If you liked the episode, please share it, rate it and leave a 5 star review on Apple Podcasts! You can find more about the podcast through its dedicated website or follow our activities on LinkedIn and Instagram. If you want to give me feedback on this episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com. Tue, 30 Aug 2022 16:57:00 -0000 Using organoids to transform drug discovery - Nikolce Gjorevski - Roche full Mathieu Chaffard Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. Nikolce is leading the Organoid Engineering Group at the Roche Institute for Translational Bioengineering. Organoids are miniaturised versions of the organs and tissues that make up our bodies, sharing phenotypic and genetic aspects of them. They carry a lot of hope in terms of applications in healthcare, from the replacement of animal testing involved in the assessment of drug safety and efficacy, to personalized medicine where they can be leveraged to inform the treatment most suitable to a particular patient, or in terms of potential transplants to address certain diseases. We exchanged with Nikolce on the what, the how and the why behind this fascinating field of bioengineering, which tremendously developed over the past years. He takes us through the current status of the technology and the clinical applications it has already demonstrated, and shares his view on how the field will evolve in the future. Timeline: 00:00:00 - Mandate and ambition of the Roche Institute for Translational Bioengineering 00:06:18 - What organoids are and from which tissues they are derived 00:09:53 - Reprogramming cells’ fates from tissues and deriving induced pluripotent stem cells 00:11:05 - Growing organoids in vitro and related challenges 00:13:50 - Applications leveraged at the ITB and the types of tissues at stake 00:15:55 - Refining the biology and turning the theoretical promises around organoids into practice 00:20:38 - Towards the use of organoids as human grafts or replacing animal testing 00:22:37 - Organ-on-a-chip technologies and how they complement organoids 00:26:17 - Synergies with bioprinting technologies and the challenges that come along with building tissue replicas 00:28:03 - Looking back at the main advancements since the first organoids came out and their ability to recapitulate features proper to a patient 00:33:56 - The ethical framework around the use of organoids 00:37:38 - Moving from Academia to the Industry as a scientist What we also talked about with Nikolce: Matthias Lütolf Hans Clevers Mina Bissell Celeste M. Nelson Nathalie Brandenberg Silke Hoehnel Sun Bioscience Cellink Embryonic stem cells HeLa cells If you want to learn more about the Roche Institute for Translational Bioengineering, we encourage you to consult their website. As mentioned by Nikolce during the episode, the Harvard Stem Cell Institute and Stem Cell Technologies are two information sources worth checking out in case you want to take a deep-dive into what organoids are, and go further into the topics we discussed with him. If you want to reach out to Nikolce, you can contact him over LinkedIn. If you liked the episode, please share it, rate it and leave a 5 star review on Apple Podcasts! You can find more about the podcast through its dedicated website or follow our activities on LinkedIn and Instagram. If you want to give me feedback on this episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com. Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer.


Nikolce is leading the Organoid Engineering Group at the Roche Institute for Translational Bioengineering.

Organoids are miniaturised versions of the organs and tissues that make up our bodies, sharing phenotypic and genetic aspects of them.

They carry a lot of hope in terms of applications in healthcare, from the replacement of animal testing involved in the assessment of drug safety and efficacy, to personalized medicine where they can be leveraged to inform the treatment most suitable to a particular patient, or in terms of potential transplants to address certain diseases.

We exchanged with Nikolce on the what, the how and the why behind this fascinating field of bioengineering, which tremendously developed over the past years.

He takes us through the current status of the technology and the clinical applications it has already demonstrated, and shares his view on how the field will evolve in the future.


Timeline:

00:00:00 - Mandate and ambition of the Roche Institute for Translational Bioengineering

00:06:18 - What organoids are and from which tissues they are derived

00:09:53 - Reprogramming cells’ fates from tissues and deriving induced pluripotent stem cells

00:11:05 - Growing organoids in vitro and related challenges

00:13:50 - Applications leveraged at the ITB and the types of tissues at stake

00:15:55 - Refining the biology and turning the theoretical promises around organoids into practice

00:20:38 - Towards the use of organoids as human grafts or replacing animal testing

00:22:37 - Organ-on-a-chip technologies and how they complement organoids

00:26:17 - Synergies with bioprinting technologies and the challenges that come along with building tissue replicas

00:28:03 - Looking back at the main advancements since the first organoids came out and their ability to recapitulate features proper to a patient

00:33:56 - The ethical framework around the use of organoids

00:37:38 - Moving from Academia to the Industry as a scientist


What we also talked about with Nikolce:


If you want to learn more about the Roche Institute for Translational Bioengineering, we encourage you to consult their website.

As mentioned by Nikolce during the episode, the Harvard Stem Cell Institute and Stem Cell Technologies are two information sources worth checking out in case you want to take a deep-dive into what organoids are, and go further into the topics we discussed with him.

If you want to reach out to Nikolce, you can contact him over LinkedIn.

If you liked the episode, please share it, rate it and leave a 5 star review on Apple Podcasts!

You can find more about the podcast through its dedicated website or follow our activities on LinkedIn and Instagram.

If you want to give me feedback on this episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com.

]]> 3005 [SNIPPET] - Nikolce Gjorevski on transforming personalized medicine with organoids Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. To discover the whole episode type “#8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche” on your streaming platform. Tue, 30 Aug 2022 16:54:00 -0000 full Mathieu Chaffard Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer. To discover the whole episode type “#8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche” on your streaming platform. Disclaimer: Nikolce and I both work for Roche, nevertheless all opinions expressed in this episode are our own and do not necessarily represent the position of our employer.


To discover the whole episode type “#8 - Using organoids to transform drug discovery - Nikolce Gjorevski - Roche” on your streaming platform.

]]> 122 #7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze Naveed Ejaz is VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) at MindMaze, the very first unicorn from Switzerland, pioneering the fascinating field of digital neurotherapeutics. Underneath these fluffy terms lies the concept of “software-as-a-medicine”, where pieces of code come together to drive a behavioural intervention, enabling patients suffering from neurological diseases to improve their condition. In the area of neurology where pharmaceutical and medical device solutions have been limited, this field opens up promising perspectives in terms of extended care delivery, stronger engagement from patients towards their treatment plans, and facilitated care coordination. We talked with Naveed about how video games could be leveraged to create an engaging therapy for the benefits of patients suffering from neurological diseases, the challenges that companies involved in the field of digital therapeutics face, MindMaze’s vision to build an integrated platform delivering cutting-edge rehabilitation programs for patients, and why all of that is not purely about technology but rather engaging the patients as much as all healthcare professionals surrounding them. We also get a sneak peek at the activities led within MindMaze Labs, the R&D division of the company partnering with institutions like Formula One to understand better how the brain works under extreme situations! Timeline: 00:00:00 - Naveed’s background and what drove him towards neuroscience and neurorehabilitation 00:13:03 - What digital neurotherapeutics are and what “software-as-a-medicine” entails 00:20:30 - Conceptual acceptability towards digital neurotherapeutics in healthcare 00:23:38 - The benefits of gamification in neurorehabilitation therapies 00:29:44 - How the rehabilitation therapies from MindMaze are designed 00:42:57 - The key characteristics of a therapeutic video game that keeps patients engaged 00:47:15 - Rehabilitating fine dextrous motion versus gross movement 00:52:04 - Naveed’s role as VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) 00:55:03 - Initiatives led by MindMaze Labs R&D center and partnering with Formula One What we also talked about with Naveed: BrainGate John Krakauer Johns Hopkins University MindMaze Labs Formula One If you want to know more about MindMaze, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Naveed in the episode, if you want to know more about the field of digital neurotherapeutics and the latest trends in that regard, have a look at Rock Health (and subscribe to their newsletter) and MobiHealthNews. You can get in touch with Naveed through LinkedIn or by email: naveed.ejaz@mindmaze.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Mon, 01 Aug 2022 14:20:00 -0000 Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze full Mathieu Chaffard Naveed Ejaz is VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) at MindMaze, the very first unicorn from Switzerland, pioneering the fascinating field of digital neurotherapeutics. Underneath these fluffy terms lies the concept of “software-as-a-medicine”, where pieces of code come together to drive a behavioural intervention, enabling patients suffering from neurological diseases to improve their condition. In the area of neurology where pharmaceutical and medical device solutions have been limited, this field opens up promising perspectives in terms of extended care delivery, stronger engagement from patients towards their treatment plans, and facilitated care coordination. We talked with Naveed about how video games could be leveraged to create an engaging therapy for the benefits of patients suffering from neurological diseases, the challenges that companies involved in the field of digital therapeutics face, MindMaze’s vision to build an integrated platform delivering cutting-edge rehabilitation programs for patients, and why all of that is not purely about technology but rather engaging the patients as much as all healthcare professionals surrounding them. We also get a sneak peek at the activities led within MindMaze Labs, the R&D division of the company partnering with institutions like Formula One to understand better how the brain works under extreme situations! Timeline: 00:00:00 - Naveed’s background and what drove him towards neuroscience and neurorehabilitation 00:13:03 - What digital neurotherapeutics are and what “software-as-a-medicine” entails 00:20:30 - Conceptual acceptability towards digital neurotherapeutics in healthcare 00:23:38 - The benefits of gamification in neurorehabilitation therapies 00:29:44 - How the rehabilitation therapies from MindMaze are designed 00:42:57 - The key characteristics of a therapeutic video game that keeps patients engaged 00:47:15 - Rehabilitating fine dextrous motion versus gross movement 00:52:04 - Naveed’s role as VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) 00:55:03 - Initiatives led by MindMaze Labs R&D center and partnering with Formula One What we also talked about with Naveed: BrainGate John Krakauer Johns Hopkins University MindMaze Labs Formula One If you want to know more about MindMaze, we invite you to consult their website and follow their activities on LinkedIn. As mentioned by Naveed in the episode, if you want to know more about the field of digital neurotherapeutics and the latest trends in that regard, have a look at Rock Health (and subscribe to their newsletter) and MobiHealthNews. You can get in touch with Naveed through LinkedIn or by email: naveed.ejaz@mindmaze.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! You can follow our activities through our website, over LinkedIn, or on Instagram! Naveed Ejaz is VP Product Strategy and Clinical Development (formerly Director of Digital Therapies) at MindMaze, the very first unicorn from Switzerland, pioneering the fascinating field of digital neurotherapeutics.

Underneath these fluffy terms lies the concept of “software-as-a-medicine”, where pieces of code come together to drive a behavioural intervention, enabling patients suffering from neurological diseases to improve their condition.

In the area of neurology where pharmaceutical and medical device solutions have been limited, this field opens up promising perspectives in terms of extended care delivery, stronger engagement from patients towards their treatment plans, and facilitated care coordination.

We talked with Naveed about how video games could be leveraged to create an engaging therapy for the benefits of patients suffering from neurological diseases, the challenges that companies involved in the field of digital therapeutics face, MindMaze’s vision to build an integrated platform delivering cutting-edge rehabilitation programs for patients, and why all of that is not purely about technology but rather engaging the patients as much as all healthcare professionals surrounding them.

We also get a sneak peek at the activities led within MindMaze Labs, the R&D division of the company partnering with institutions like Formula One to understand better how the brain works under extreme situations!


Timeline:

00:00:00 - Naveed’s background and what drove him towards neuroscience and neurorehabilitation

00:13:03 - What digital neurotherapeutics are and what “software-as-a-medicine” entails

00:20:30 - Conceptual acceptability towards digital neurotherapeutics in healthcare

00:23:38 - The benefits of gamification in neurorehabilitation therapies

00:29:44 - How the rehabilitation therapies from MindMaze are designed

00:42:57 - The key characteristics of a therapeutic video game that keeps patients engaged

00:47:15 - Rehabilitating fine dextrous motion versus gross movement

00:52:04 - Naveed’s role as VP Product Strategy and Clinical Development (formerly Director of Digital Therapies)

00:55:03 - Initiatives led by MindMaze Labs R&D center and partnering with Formula One


What we also talked about with Naveed:


If you want to know more about MindMaze, we invite you to consult their website and follow their activities on LinkedIn.

As mentioned by Naveed in the episode, if you want to know more about the field of digital neurotherapeutics and the latest trends in that regard, have a look at Rock Health (and subscribe to their newsletter) and MobiHealthNews.

You can get in touch with Naveed through LinkedIn or by email: naveed.ejaz@mindmaze.ch


If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: mathieu@impulsepodcast.com.

And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

You can follow our activities through our website, over LinkedIn, or on Instagram!

]]> 4126 [SNIPPET] - Naveed Ejaz on the concept of software-as-a-medicine To discover the whole episode type "#7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze" on your streaming platform. Mon, 01 Aug 2022 14:03:00 -0000 full Mathieu Chaffard To discover the whole episode type "#7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze" on your streaming platform. To discover the whole episode type "#7 - Redefining motor rehabilitation with digital neurotherapeutics - Naveed Ejaz - MindMaze" on your streaming platform.

]]> 158 #6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore Bringing back mobility to those who lost it. This is the challenge that Jocelyne Bloch, neurosurgeon at the CHUV, together with the neuroscientist Grégoire Courtine from EPFL and their teams at .NeuroRestore and Onward set out to address. A decade after demonstrating that the technology developed by Prof. Courtine’s lab was able to bring back lower limb mobility to paraplegic rats, it has now been applied to humans in a research context through their joint work with phenomenal outcomes: most paraplegic patients implanted with the stimulation system they have developed were able to retrieve significant mobility of their lower limbs, enabling them to stand, walk and even climb stairs! Based on an electrode array coupled to a pulse generator (both fully implantable) remotely controlled, the system delivers selective stimulation of the spinal cord at the locations where the lower limb muscles are activated, in a sequence that replicates the mobility patterns that abled people demonstrate. Images of patients having experienced this technology, moving out of their wheelchair to stand and walk, have been seen throughout the world, and the hope that it brings for those concerned is immense, considering also the other applications that it could open for the rehabilitation of the upper limbs or for blood pressure regulation. In the latest episode from Impulse, we had the chance to sit down with Jocelyne and exchange with her on the infancy of this therapy, where she takes us through its working principle, the challenges that come along with bringing such a technology from the lab to the market, as well as on the life-changing benefits it may hold for patients in the future. With great humility, she also talks about how she manages to combine her clinical practice as a functional neurosurgeon, to leading a research group composed of over 80 collaborators, all of that while raising two children and with a husband at home! Timeline: 00:00:00 - Jocelyne’s background and what led her to functional neurosurgery 00:08:18 - Approach taken to enable paraplegic rats to walk again and moving towards human applications 00:14:55 - The first human implantation 00:17:20 - Towards autonomous mobility renewal 00:18:25 - The STIMO study focusing on mobility and upcoming trials 00:21:03 - Managing expectations of patients 00:23:20 - Making a viable therapy with a reasonable rehabilitation training phase 00:26:17 - Leveraging potential synergies with exoskeletons 00:27:23 - Current technological constraints 00:28:34 - Origins and purpose of .NeuroRestore, and the close collaboration with Onward 00:33:03 - Towards upper limbs and hands rehabilitation therapies 00:34:10 - Retrieving sensory feedback thanks to the current therapy 00:35:23 - Adding brain-computer interaction layers to the current therapy 00:37:56 - Staying on top of things when working as a neurosurgeon, leading a clinical research center, and managing a family life 00:39:41 - Evolving as a woman in the field of neurosurgery What we also talked about with Jocelyne: Grégoire Courtine Patrick Aebischer Jean-Guy Villemure Bogdan Draganski Baroreflex Neuroprosthetics Neuroplasticity EEG ECoG CHUV UNIL EPFL Medtronic Elon Musk We cited with Jocelyne some of the past episodes from the series: #3 – Augmenting the lives of paraplegics with exoskeletons – Tristan Vouga – Twiice #5 – Transforming diagnostics through spatial biology – Déborah Heintze – Lunaphore If you want to know more about .NeuroRestore, we invite you to consult their website. We also invite you to follow their activities on LinkedIn. If you are interested in learning more about the startup Onward, we invite you to check out their website as well as their LinkedIn page. You can contact Jocelyne by email: jocelyne.bloch@chuv.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com. Tue, 05 Jul 2022 19:52:00 -0000 Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore full Mathieu Chaffard Bringing back mobility to those who lost it. This is the challenge that Jocelyne Bloch, neurosurgeon at the CHUV, together with the neuroscientist Grégoire Courtine from EPFL and their teams at .NeuroRestore and Onward set out to address. A decade after demonstrating that the technology developed by Prof. Courtine’s lab was able to bring back lower limb mobility to paraplegic rats, it has now been applied to humans in a research context through their joint work with phenomenal outcomes: most paraplegic patients implanted with the stimulation system they have developed were able to retrieve significant mobility of their lower limbs, enabling them to stand, walk and even climb stairs! Based on an electrode array coupled to a pulse generator (both fully implantable) remotely controlled, the system delivers selective stimulation of the spinal cord at the locations where the lower limb muscles are activated, in a sequence that replicates the mobility patterns that abled people demonstrate. Images of patients having experienced this technology, moving out of their wheelchair to stand and walk, have been seen throughout the world, and the hope that it brings for those concerned is immense, considering also the other applications that it could open for the rehabilitation of the upper limbs or for blood pressure regulation. In the latest episode from Impulse, we had the chance to sit down with Jocelyne and exchange with her on the infancy of this therapy, where she takes us through its working principle, the challenges that come along with bringing such a technology from the lab to the market, as well as on the life-changing benefits it may hold for patients in the future. With great humility, she also talks about how she manages to combine her clinical practice as a functional neurosurgeon, to leading a research group composed of over 80 collaborators, all of that while raising two children and with a husband at home! Timeline: 00:00:00 - Jocelyne’s background and what led her to functional neurosurgery 00:08:18 - Approach taken to enable paraplegic rats to walk again and moving towards human applications 00:14:55 - The first human implantation 00:17:20 - Towards autonomous mobility renewal 00:18:25 - The STIMO study focusing on mobility and upcoming trials 00:21:03 - Managing expectations of patients 00:23:20 - Making a viable therapy with a reasonable rehabilitation training phase 00:26:17 - Leveraging potential synergies with exoskeletons 00:27:23 - Current technological constraints 00:28:34 - Origins and purpose of .NeuroRestore, and the close collaboration with Onward 00:33:03 - Towards upper limbs and hands rehabilitation therapies 00:34:10 - Retrieving sensory feedback thanks to the current therapy 00:35:23 - Adding brain-computer interaction layers to the current therapy 00:37:56 - Staying on top of things when working as a neurosurgeon, leading a clinical research center, and managing a family life 00:39:41 - Evolving as a woman in the field of neurosurgery What we also talked about with Jocelyne: Grégoire Courtine Patrick Aebischer Jean-Guy Villemure Bogdan Draganski Baroreflex Neuroprosthetics Neuroplasticity EEG ECoG CHUV UNIL EPFL Medtronic Elon Musk We cited with Jocelyne some of the past episodes from the series: #3 – Augmenting the lives of paraplegics with exoskeletons – Tristan Vouga – Twiice #5 – Transforming diagnostics through spatial biology – Déborah Heintze – Lunaphore If you want to know more about .NeuroRestore, we invite you to consult their website. We also invite you to follow their activities on LinkedIn. If you are interested in learning more about the startup Onward, we invite you to check out their website as well as their LinkedIn page. You can contact Jocelyne by email: jocelyne.bloch@chuv.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com. Bringing back mobility to those who lost it.

This is the challenge that Jocelyne Bloch, neurosurgeon at the CHUV, together with the neuroscientist Grégoire Courtine from EPFL and their teams at .NeuroRestore and Onward set out to address.

A decade after demonstrating that the technology developed by Prof. Courtine’s lab was able to bring back lower limb mobility to paraplegic rats, it has now been applied to humans in a research context through their joint work with phenomenal outcomes: most paraplegic patients implanted with the stimulation system they have developed were able to retrieve significant mobility of their lower limbs, enabling them to stand, walk and even climb stairs!

Based on an electrode array coupled to a pulse generator (both fully implantable) remotely controlled, the system delivers selective stimulation of the spinal cord at the locations where the lower limb muscles are activated, in a sequence that replicates the mobility patterns that abled people demonstrate.

Images of patients having experienced this technology, moving out of their wheelchair to stand and walk, have been seen throughout the world, and the hope that it brings for those concerned is immense, considering also the other applications that it could open for the rehabilitation of the upper limbs or for blood pressure regulation.

In the latest episode from Impulse, we had the chance to sit down with Jocelyne and exchange with her on the infancy of this therapy, where she takes us through its working principle, the challenges that come along with bringing such a technology from the lab to the market, as well as on the life-changing benefits it may hold for patients in the future.

With great humility, she also talks about how she manages to combine her clinical practice as a functional neurosurgeon, to leading a research group composed of over 80 collaborators, all of that while raising two children and with a husband at home!


Timeline:

00:00:00 - Jocelyne’s background and what led her to functional neurosurgery

00:08:18 - Approach taken to enable paraplegic rats to walk again and moving towards human applications

00:14:55 - The first human implantation

00:17:20 - Towards autonomous mobility renewal

00:18:25 - The STIMO study focusing on mobility and upcoming trials

00:21:03 - Managing expectations of patients

00:23:20 - Making a viable therapy with a reasonable rehabilitation training phase

00:26:17 - Leveraging potential synergies with exoskeletons

00:27:23 - Current technological constraints

00:28:34 - Origins and purpose of .NeuroRestore, and the close collaboration with Onward

00:33:03 - Towards upper limbs and hands rehabilitation therapies

00:34:10 - Retrieving sensory feedback thanks to the current therapy

00:35:23 - Adding brain-computer interaction layers to the current therapy

00:37:56 - Staying on top of things when working as a neurosurgeon, leading a clinical research center, and managing a family life

00:39:41 - Evolving as a woman in the field of neurosurgery


What we also talked about with Jocelyne:


We cited with Jocelyne some of the past episodes from the series:


If you want to know more about .NeuroRestore, we invite you to consult their website. We also invite you to follow their activities on LinkedIn.

If you are interested in learning more about the startup Onward, we invite you to check out their website as well as their LinkedIn page.

You can contact Jocelyne by email: jocelyne.bloch@chuv.ch

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com.

]]> 2717 [SNIPPET] - Jocelyne Bloch on decoding brain signals to enable mind-controlled stimulation of the spinal cord To discover the whole episode type “#6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore” on your streaming platform. Tue, 05 Jul 2022 18:43:00 -0000 full Mathieu Chaffard To discover the whole episode type “#6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore” on your streaming platform. To discover the whole episode type “#6 - Bringing back walking to paraplegics - Jocelyne Bloch - .NeuroRestore” on your streaming platform.

]]> 199 #5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore Transforming our understanding of how our immune system works and how certain pathologies like cancer unfold: that is the mission to which Lunaphore has committed since 2014. Through a cutting-edge platform capable of accelerating complex staining and imaging procedures, the Swiss startup is pioneering what is now named “spatial biology”, recognized by the journal Nature as Method of the Year 2020. Applicable to many disease areas, the field carries great hopes in bringing to light new insights that will accelerate drug discovery and drive the development of personalized therapies in the long run. Its power resides in the possibility to analyze multiple biomarkers in parallel, while preserving the spatial properties of the tissue studied. Alongside Ata Tuna Ciftlik and Diego Dupouy, Déborah Heintze is one of the three co-founders of Lunaphore. She joined the adventure soon after the completion of her curriculum in biomedical engineering, the same day that an offer was made to her by a large company for a position that would have been synonymous with stability and comfort from the outset. The gamble paid off, as she now leads as Chief Marketing Officer the product and marketing efforts of the startup, which has been recognized many times as one of the most innovative and promising emerging companies in the Swiss ecosystem. She takes us through the origins of the project, explaining how the opportunity to co-found the startup arose, how the technology they developed functions, and how spatial biology will revolutionize the way we understand immunology and the promises it holds in the fight against many diseases. Timeline: 00:00:00 - Déborah’s background and evolution within Lunaphore since its creation 00:04:48 - How Lunaphore emerged from a PhD thesis 00:06:49 - How the opportunity to co-found a startup emerged 00:10:22 - What the technology from Lunaphore is about 00:12:27 - Paving the way for spatial biology for diagnostic purposes 00:16:48 - The promise that spatial biology holds in our understanding of pathologies like cancer and how Lunaphore is supporting it 00:20:04 - The features and functioning of LabSat® and COMET™ 00:22:50 - Dealing with the analysis of large pathology data volumes 00:25:24 - Transitioning from research applications to clinical ones 00:27:50 - Deploying LabSat® and COMET™ in labs while making sure the onboarding remains flawless for users 00:29:29 - The time and efforts required to build these platforms from scratch up to their market launch 00:33:37 - Moving towards new applications and disease areas 00:35:08 - How the technology from Lunaphore is transforming the staining and imaging workflows in labs 00:38:39 - Evolving as a woman in the medical technology entrepreneurial sphere What we also talked about with Déborah : EPFL Technology Transfer Office Harvard-MIT Health Sciences and Technology CHUV Spatial biology Immunostaining Microfluidics Cytometry Omics DistalMotion Sophia Genetics We cited with Déborah some of the past episodes from “Impulse - Meeting Healthcare Pioneers”: #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical If you want to know more about Lunaphore, we invite you to consult their website. As mentioned in the episode, we strongly recommend you to check out their blog which aims to democratize spatial biology and all of its aspects in a simple yet informative manner. We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website). You can contact Déborah through LinkedIn or by email: deborah.heintze@lunaphore.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Tue, 31 May 2022 22:20:00 -0000 Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore full Mathieu Chaffard Transforming our understanding of how our immune system works and how certain pathologies like cancer unfold: that is the mission to which Lunaphore has committed since 2014. Through a cutting-edge platform capable of accelerating complex staining and imaging procedures, the Swiss startup is pioneering what is now named “spatial biology”, recognized by the journal Nature as Method of the Year 2020. Applicable to many disease areas, the field carries great hopes in bringing to light new insights that will accelerate drug discovery and drive the development of personalized therapies in the long run. Its power resides in the possibility to analyze multiple biomarkers in parallel, while preserving the spatial properties of the tissue studied. Alongside Ata Tuna Ciftlik and Diego Dupouy, Déborah Heintze is one of the three co-founders of Lunaphore. She joined the adventure soon after the completion of her curriculum in biomedical engineering, the same day that an offer was made to her by a large company for a position that would have been synonymous with stability and comfort from the outset. The gamble paid off, as she now leads as Chief Marketing Officer the product and marketing efforts of the startup, which has been recognized many times as one of the most innovative and promising emerging companies in the Swiss ecosystem. She takes us through the origins of the project, explaining how the opportunity to co-found the startup arose, how the technology they developed functions, and how spatial biology will revolutionize the way we understand immunology and the promises it holds in the fight against many diseases. Timeline: 00:00:00 - Déborah’s background and evolution within Lunaphore since its creation 00:04:48 - How Lunaphore emerged from a PhD thesis 00:06:49 - How the opportunity to co-found a startup emerged 00:10:22 - What the technology from Lunaphore is about 00:12:27 - Paving the way for spatial biology for diagnostic purposes 00:16:48 - The promise that spatial biology holds in our understanding of pathologies like cancer and how Lunaphore is supporting it 00:20:04 - The features and functioning of LabSat® and COMET™ 00:22:50 - Dealing with the analysis of large pathology data volumes 00:25:24 - Transitioning from research applications to clinical ones 00:27:50 - Deploying LabSat® and COMET™ in labs while making sure the onboarding remains flawless for users 00:29:29 - The time and efforts required to build these platforms from scratch up to their market launch 00:33:37 - Moving towards new applications and disease areas 00:35:08 - How the technology from Lunaphore is transforming the staining and imaging workflows in labs 00:38:39 - Evolving as a woman in the medical technology entrepreneurial sphere What we also talked about with Déborah : EPFL Technology Transfer Office Harvard-MIT Health Sciences and Technology CHUV Spatial biology Immunostaining Microfluidics Cytometry Omics DistalMotion Sophia Genetics We cited with Déborah some of the past episodes from “Impulse - Meeting Healthcare Pioneers”: #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical If you want to know more about Lunaphore, we invite you to consult their website. As mentioned in the episode, we strongly recommend you to check out their blog which aims to democratize spatial biology and all of its aspects in a simple yet informative manner. We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website). You can contact Déborah through LinkedIn or by email: deborah.heintze@lunaphore.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com. And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms! Transforming our understanding of how our immune system works and how certain pathologies like cancer unfold: that is the mission to which Lunaphore has committed since 2014.

Through a cutting-edge platform capable of accelerating complex staining and imaging procedures, the Swiss startup is pioneering what is now named “spatial biology”, recognized by the journal Nature as Method of the Year 2020.

Applicable to many disease areas, the field carries great hopes in bringing to light new insights that will accelerate drug discovery and drive the development of personalized therapies in the long run. Its power resides in the possibility to analyze multiple biomarkers in parallel, while preserving the spatial properties of the tissue studied.

Alongside Ata Tuna Ciftlik and Diego Dupouy, Déborah Heintze is one of the three co-founders of Lunaphore. She joined the adventure soon after the completion of her curriculum in biomedical engineering, the same day that an offer was made to her by a large company for a position that would have been synonymous with stability and comfort from the outset. The gamble paid off, as she now leads as Chief Marketing Officer the product and marketing efforts of the startup, which has been recognized many times as one of the most innovative and promising emerging companies in the Swiss ecosystem.

She takes us through the origins of the project, explaining how the opportunity to co-found the startup arose, how the technology they developed functions, and how spatial biology will revolutionize the way we understand immunology and the promises it holds in the fight against many diseases.


Timeline:

00:00:00 - Déborah’s background and evolution within Lunaphore since its creation

00:04:48 - How Lunaphore emerged from a PhD thesis

00:06:49 - How the opportunity to co-found a startup emerged

00:10:22 - What the technology from Lunaphore is about

00:12:27 - Paving the way for spatial biology for diagnostic purposes

00:16:48 - The promise that spatial biology holds in our understanding of pathologies like cancer and how Lunaphore is supporting it

00:20:04 - The features and functioning of LabSat® and COMET™

00:22:50 - Dealing with the analysis of large pathology data volumes

00:25:24 - Transitioning from research applications to clinical ones

00:27:50 - Deploying LabSat® and COMET™ in labs while making sure the onboarding remains flawless for users

00:29:29 - The time and efforts required to build these platforms from scratch up to their market launch

00:33:37 - Moving towards new applications and disease areas

00:35:08 - How the technology from Lunaphore is transforming the staining and imaging workflows in labs

00:38:39 - Evolving as a woman in the medical technology entrepreneurial sphere


What we also talked about with Déborah :


We cited with Déborah some of the past episodes from “Impulse - Meeting Healthcare Pioneers”:


If you want to know more about Lunaphore, we invite you to consult their website.

As mentioned in the episode, we strongly recommend you to check out their blog which aims to democratize spatial biology and all of its aspects in a simple yet informative manner.

We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website).


You can contact Déborah through LinkedIn or by email: deborah.heintze@lunaphore.com


If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com.


And if you liked the episode, don’t hesitate to share it, subscribe to the podcast and leave a positive review on streaming platforms!

]]> 3079 no [SNIPPET] - Déborah Heintze on spatial biology and its potential applications in diagnostics To discover the whole episode type "#5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore" on your streaming platform. Tue, 31 May 2022 22:17:00 -0000 full Mathieu Chaffard To discover the whole episode type "#5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore" on your streaming platform. To discover the whole episode type "#5 - Transforming diagnostics through spatial biology - Déborah Heintze - Lunaphore" on your streaming platform.

]]> 256 no #4 - Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune One consequence of the covid-19 crisis we are still going through is sepsis, a lethal misguided reaction of the immune system following an infection, currently responsible for 11 million deaths yearly on a global scale. Together with his team, Lukas Langenegger is addressing this life-threatening condition using a unique technology leveraging magnetic microscopic beads that enable the filtration of blood and the removal of toxic compounds circulating through the body during such a medical episode. The so-called Hemosystem is akin to a dialysis machine where the traditional membrane filter is replaced by a solution containing these beads. Offering a very large surface area, they are used to selectively trap key toxic compounds known to contribute to sepsis: their removal enables in fact to reestablish the immune balance of the patient, leading to drastically improved outcomes. This disruptive technology has been rewarded and praised multiple times in the Swiss medtech sphere and the media. Lukas himself has already been featured in the German issue of Forbes, as a recognition for the pioneering work and contribution that he and his team are bringing in the fight against this terrible condition. We exchanged with Lukas on his professional path, which started in the world of banking before moving towards chemical engineering and the start of a PhD, which he interrupted after a few months to embrace the entrepreneurial route. He guides us with passion through the genesis of Hemotune, the functioning of the system they have created and the surprising development perspectives that such a platform could allow, from the treatment of cancer up to the extension of our longevity! Timeline: 00:00:00 - Introduction to Lukas’ background and the origins of Hemotune 00:02:12 - Transitioning from banking to chemical engineering 00:04:59 - Quitting a PhD to become an entrepreneur 00:07:34 - Bringing multiple specialties together to found Hemotune 00:08:58 - Finding support from the Swiss ecosystem to kick start your own firm 00:09:49 - Hemotune’s technology and its first indication: sepsis 00:11:17 - Understanding the mechanisms of sepsis and the lack of current recovery treatment 00:14:20 - Timing of the intervention for patients using the Hemosystem 00:15:01 - Current standard of care and keeping patients suffering from sepsis alive 00:16:22 - Reestablishing the immune balance thanks to the Hemosystem 00:18:10 - Towards magnetic microscopic beads tailored to each patient 00:19:56 - The Hemosystem workflow and blood filtering cycles 00:20:57 - Engineering the magnetic microscopic beads 00:22:30 - Preventing toxicity from the beads towards the blood 00:26:00 - The development roadmap of the Hemosystem and its foreseen availability 00:30:18 - Moving towards other indications (e.g. cancer, autoimmune diseases, longevity) 00:32:02 - Establishing a new treatment modality at the interface of a drug and a medical device 00:33:15 - Addressing the burden of antimicrobial resistance What we also talked about with Lukas : Carlos Andrea Mora Corinne Hofer Precision Medicine ETHZ MIT Functional Materials Laboratory from Prof. Wendelin Stark HLA-DR Kurz Gesagt Immune: A Journey into the Mysterious System That Keeps You Alive Leo Grünstein Spiden If you want to know more about Hemotune, we invite you to consult their website: https://www.hemotune.ch/ We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website). You can contact Lukas through LinkedIn or by email: lukas.langenegger@hemotune.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com Sun, 01 May 2022 20:56:00 -0000 Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune full 4 Mathieu Chaffard One consequence of the covid-19 crisis we are still going through is sepsis, a lethal misguided reaction of the immune system following an infection, currently responsible for 11 million deaths yearly on a global scale. Together with his team, Lukas Langenegger is addressing this life-threatening condition using a unique technology leveraging magnetic microscopic beads that enable the filtration of blood and the removal of toxic compounds circulating through the body during such a medical episode. The so-called Hemosystem is akin to a dialysis machine where the traditional membrane filter is replaced by a solution containing these beads. Offering a very large surface area, they are used to selectively trap key toxic compounds known to contribute to sepsis: their removal enables in fact to reestablish the immune balance of the patient, leading to drastically improved outcomes. This disruptive technology has been rewarded and praised multiple times in the Swiss medtech sphere and the media. Lukas himself has already been featured in the German issue of Forbes, as a recognition for the pioneering work and contribution that he and his team are bringing in the fight against this terrible condition. We exchanged with Lukas on his professional path, which started in the world of banking before moving towards chemical engineering and the start of a PhD, which he interrupted after a few months to embrace the entrepreneurial route. He guides us with passion through the genesis of Hemotune, the functioning of the system they have created and the surprising development perspectives that such a platform could allow, from the treatment of cancer up to the extension of our longevity! Timeline: 00:00:00 - Introduction to Lukas’ background and the origins of Hemotune 00:02:12 - Transitioning from banking to chemical engineering 00:04:59 - Quitting a PhD to become an entrepreneur 00:07:34 - Bringing multiple specialties together to found Hemotune 00:08:58 - Finding support from the Swiss ecosystem to kick start your own firm 00:09:49 - Hemotune’s technology and its first indication: sepsis 00:11:17 - Understanding the mechanisms of sepsis and the lack of current recovery treatment 00:14:20 - Timing of the intervention for patients using the Hemosystem 00:15:01 - Current standard of care and keeping patients suffering from sepsis alive 00:16:22 - Reestablishing the immune balance thanks to the Hemosystem 00:18:10 - Towards magnetic microscopic beads tailored to each patient 00:19:56 - The Hemosystem workflow and blood filtering cycles 00:20:57 - Engineering the magnetic microscopic beads 00:22:30 - Preventing toxicity from the beads towards the blood 00:26:00 - The development roadmap of the Hemosystem and its foreseen availability 00:30:18 - Moving towards other indications (e.g. cancer, autoimmune diseases, longevity) 00:32:02 - Establishing a new treatment modality at the interface of a drug and a medical device 00:33:15 - Addressing the burden of antimicrobial resistance What we also talked about with Lukas : Carlos Andrea Mora Corinne Hofer Precision Medicine ETHZ MIT Functional Materials Laboratory from Prof. Wendelin Stark HLA-DR Kurz Gesagt Immune: A Journey into the Mysterious System That Keeps You Alive Leo Grünstein Spiden If you want to know more about Hemotune, we invite you to consult their website: https://www.hemotune.ch/ We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website). You can contact Lukas through LinkedIn or by email: lukas.langenegger@hemotune.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com One consequence of the covid-19 crisis we are still going through is sepsis, a lethal misguided reaction of the immune system following an infection, currently responsible for 11 million deaths yearly on a global scale.

Together with his team, Lukas Langenegger is addressing this life-threatening condition using a unique technology leveraging magnetic microscopic beads that enable the filtration of blood and the removal of toxic compounds circulating through the body during such a medical episode.

The so-called Hemosystem is akin to a dialysis machine where the traditional membrane filter is replaced by a solution containing these beads. Offering a very large surface area, they are used to selectively trap key toxic compounds known to contribute to sepsis: their removal enables in fact to reestablish the immune balance of the patient, leading to drastically improved outcomes.

This disruptive technology has been rewarded and praised multiple times in the Swiss medtech sphere and the media. Lukas himself has already been featured in the German issue of Forbes, as a recognition for the pioneering work and contribution that he and his team are bringing in the fight against this terrible condition.

We exchanged with Lukas on his professional path, which started in the world of banking before moving towards chemical engineering and the start of a PhD, which he interrupted after a few months to embrace the entrepreneurial route.

He guides us with passion through the genesis of Hemotune, the functioning of the system they have created and the surprising development perspectives that such a platform could allow, from the treatment of cancer up to the extension of our longevity!


Timeline:

00:00:00 - Introduction to Lukas’ background and the origins of Hemotune

00:02:12 - Transitioning from banking to chemical engineering

00:04:59 - Quitting a PhD to become an entrepreneur

00:07:34 - Bringing multiple specialties together to found Hemotune

00:08:58 - Finding support from the Swiss ecosystem to kick start your own firm

00:09:49 - Hemotune’s technology and its first indication: sepsis

00:11:17 - Understanding the mechanisms of sepsis and the lack of current recovery treatment

00:14:20 - Timing of the intervention for patients using the Hemosystem

00:15:01 - Current standard of care and keeping patients suffering from sepsis alive

00:16:22 - Reestablishing the immune balance thanks to the Hemosystem

00:18:10 - Towards magnetic microscopic beads tailored to each patient

00:19:56 - The Hemosystem workflow and blood filtering cycles

00:20:57 - Engineering the magnetic microscopic beads

00:22:30 - Preventing toxicity from the beads towards the blood

00:26:00 - The development roadmap of the Hemosystem and its foreseen availability

00:30:18 - Moving towards other indications (e.g. cancer, autoimmune diseases, longevity)

00:32:02 - Establishing a new treatment modality at the interface of a drug and a medical device

00:33:15 - Addressing the burden of antimicrobial resistance


What we also talked about with Lukas :


If you want to know more about Hemotune, we invite you to consult their website: https://www.hemotune.ch/

We also invite you to follow their activities on LinkedIn or through their newsletter (subscription link available through the company website).

You can contact Lukas through LinkedIn or by email: lukas.langenegger@hemotune.ch

If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com

]]> 2582 no [SNIPPET] - Lukas Langenegger on blood filtration and its applications for the extension of our longevity To discover the whole episode type "#4 - Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune" on your streaming platform. Thu, 28 Apr 2022 13:46:00 -0000 full Mathieu Chaffard To discover the whole episode type "#4 - Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune" on your streaming platform. To discover the whole episode type "#4 - Filtering the blood with nanoengineered beads - Lukas Langenegger - Hemotune" on your streaming platform.

]]> 236 #3 - Augmenting the lives of paraplegics with exoskeletons - Tristan Vouga - TWIICE Wearables bringing back the ability to walk for paraplegics: this is the world in which Tristan Vouga is evolving. Passionate by the field of robotics and willing to have an impact on society, he turned his PhD thesis into the Swiss startup TWIICE. The company is developing a modular exoskeleton, bringing back the ability for its users to stand, walk, climb stairs and even go on a ski tour! Beyond the technological achievement and the numerous awards it has won in international contests, their platform has the potential to transform the lives of many paraplegics as well as amputees. We talked with Tristan about his transition from PhD student to entrepreneur, about their exoskeleton capabilities, the feelings of “ownership, embodiement and agency” that are key to a seamless human-machine interaction, and about how innovation can be derived from science-fiction! Timeline: 00:00:00 - Tristan’s introduction and background in wearable robotics 00:03:22 - Moving to the US to explore brain-controlled exoskeletons 00:08:10 - Description of the exoskeleton TWIICE, how it operates and supports paraplegics 00:10:52 - The importance of embodiment, ownership and agency in human-machine interactions 00:12:42 - Leveraging brain signals to control wearable exoskeletons 00:14:03 - Generating haptic feedback to enhance the feelings of ownership, embodiment and agency 00:15:57 - Developing an exoskeleton for ski touring 00:18:38 - Exploring new use cases for amputees 00:21:01 - Innovative commercial models to distribute the cost of ownership among patients 00:22:59 - A clinical trial to demonstrate the efficacy and safety of TWIICE in a community setting 00:24:29 - Seamless human-machine interaction as a key differentiator 00:26:16 - Moving towards an exoskeleton not requiring crutches 00:30:20 - The Cybathlon and competing against other exoskeletons 00:35:02 - Dealing with the frustration of access hurdles for patients 00:36:11 - Coping with the demand from patients while driving R&D efforts 00:38:17 - Transitioning from PhD student to entrepreneur 00:40:18 - Drawing inspiration from science-fiction What we also talked about with Tristan: EPFL ETHZ Duke University ReHassist The Nicolelis Lab Neuralink The triad: embodiment-ownership-agency Boston Dynamics The Cybathlon The Global Innovation Challenge Blade Runner Testmate Health We cited with Tristan some of the past episodes from the podcast: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens If you want to know more about Twiice, we invite you to consult their website: https://twiice.ch/ You can contact Tristan through LinkedIn or by email: tristan.vouga@twiice.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com Wed, 30 Mar 2022 21:20:00 -0000 Augmenting the lives of paraplegics with exoskeletons - Tristan Vouga - TWIICE full 3 Mathieu Chaffard Wearables bringing back the ability to walk for paraplegics: this is the world in which Tristan Vouga is evolving. Passionate by the field of robotics and willing to have an impact on society, he turned his PhD thesis into the Swiss startup TWIICE. The company is developing a modular exoskeleton, bringing back the ability for its users to stand, walk, climb stairs and even go on a ski tour! Beyond the technological achievement and the numerous awards it has won in international contests, their platform has the potential to transform the lives of many paraplegics as well as amputees. We talked with Tristan about his transition from PhD student to entrepreneur, about their exoskeleton capabilities, the feelings of “ownership, embodiement and agency” that are key to a seamless human-machine interaction, and about how innovation can be derived from science-fiction! Timeline: 00:00:00 - Tristan’s introduction and background in wearable robotics 00:03:22 - Moving to the US to explore brain-controlled exoskeletons 00:08:10 - Description of the exoskeleton TWIICE, how it operates and supports paraplegics 00:10:52 - The importance of embodiment, ownership and agency in human-machine interactions 00:12:42 - Leveraging brain signals to control wearable exoskeletons 00:14:03 - Generating haptic feedback to enhance the feelings of ownership, embodiment and agency 00:15:57 - Developing an exoskeleton for ski touring 00:18:38 - Exploring new use cases for amputees 00:21:01 - Innovative commercial models to distribute the cost of ownership among patients 00:22:59 - A clinical trial to demonstrate the efficacy and safety of TWIICE in a community setting 00:24:29 - Seamless human-machine interaction as a key differentiator 00:26:16 - Moving towards an exoskeleton not requiring crutches 00:30:20 - The Cybathlon and competing against other exoskeletons 00:35:02 - Dealing with the frustration of access hurdles for patients 00:36:11 - Coping with the demand from patients while driving R&D efforts 00:38:17 - Transitioning from PhD student to entrepreneur 00:40:18 - Drawing inspiration from science-fiction What we also talked about with Tristan: EPFL ETHZ Duke University ReHassist The Nicolelis Lab Neuralink The triad: embodiment-ownership-agency Boston Dynamics The Cybathlon The Global Innovation Challenge Blade Runner Testmate Health We cited with Tristan some of the past episodes from the podcast: #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens If you want to know more about Twiice, we invite you to consult their website: https://twiice.ch/ You can contact Tristan through LinkedIn or by email: tristan.vouga@twiice.ch If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com Wearables bringing back the ability to walk for paraplegics: this is the world in which Tristan Vouga is evolving.

Passionate by the field of robotics and willing to have an impact on society, he turned his PhD thesis into the Swiss startup TWIICE.

The company is developing a modular exoskeleton, bringing back the ability for its users to stand, walk, climb stairs and even go on a ski tour!

Beyond the technological achievement and the numerous awards it has won in international contests, their platform has the potential to transform the lives of many paraplegics as well as amputees.

We talked with Tristan about his transition from PhD student to entrepreneur, about their exoskeleton capabilities, the feelings of “ownership, embodiement and agency” that are key to a seamless human-machine interaction, and about how innovation can be derived from science-fiction!


Timeline:

00:00:00 - Tristan’s introduction and background in wearable robotics

00:03:22 - Moving to the US to explore brain-controlled exoskeletons

00:08:10 - Description of the exoskeleton TWIICE, how it operates and supports paraplegics

00:10:52 - The importance of embodiment, ownership and agency in human-machine interactions

00:12:42 - Leveraging brain signals to control wearable exoskeletons

00:14:03 - Generating haptic feedback to enhance the feelings of ownership, embodiment and agency

00:15:57 - Developing an exoskeleton for ski touring

00:18:38 - Exploring new use cases for amputees

00:21:01 - Innovative commercial models to distribute the cost of ownership among patients

00:22:59 - A clinical trial to demonstrate the efficacy and safety of TWIICE in a community setting

00:24:29 - Seamless human-machine interaction as a key differentiator

00:26:16 - Moving towards an exoskeleton not requiring crutches

00:30:20 - The Cybathlon and competing against other exoskeletons

00:35:02 - Dealing with the frustration of access hurdles for patients

00:36:11 - Coping with the demand from patients while driving R&D efforts

00:38:17 - Transitioning from PhD student to entrepreneur

00:40:18 - Drawing inspiration from science-fiction


What we also talked about with Tristan:


We cited with Tristan some of the past episodes from the podcast:


If you want to know more about Twiice, we invite you to consult their website: https://twiice.ch/


You can contact Tristan through LinkedIn or by email: tristan.vouga@twiice.ch


If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com

]]> 2896 no [SNIPPET] - Tristan Vouga on developing an exoskeleton for ski touring To discover the whole episode type "#3 - Augmenting the lives of paraplegics with exoskeletons - Tristan Vouga - TWIICE" on your streaming platform. Mon, 28 Mar 2022 15:24:00 -0000 full Mathieu Chaffard To discover the whole episode type "#3 - Augmenting the lives of paraplegics with exoskeletons - Tristan Vouga - TWIICE" on your streaming platform. To discover the whole episode type "#3 - Augmenting the lives of paraplegics with exoskeletons - Tristan Vouga - TWIICE" on your streaming platform.

]]> 151 #2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical Lucien Blondel is one of the leading figures in the field of surgical robotics, having already led the development of several platforms supporting orthopaedic, spinal and brain surgeries. Together with Quantum Surgical, which he co-founded alongside Bertin Nahum, Fernand Badano and Sophie Roca, they are addressing liver cancer through a new robotic platform supporting ablation procedures. Under the name of “Epione” (the goddess of care in the Greek mythology), it represents a breakthrough in this field, not only supporting surgeons in the execution of the ablation procedure, but also in the planning phase up to the validation of the surgical act. Through a combination of cutting-edge image processing technology, computer vision and haptics, Epione is on its way to revolutionize interventional oncology and improve access to liver cancer ablation, for patients and for surgeons. We exchanged with Lucien on his background, what brought him to surgical robotics, the specificities of this field, his role in leading the technical development of Epione, and its underlying promise in the cure of liver cancer. Timeline: 00:00:00 - Lucien’s introduction and background in surgical robotics 00:04:51 - How he got into this field and what drove his interest to it 00:07:43 - The uprising of surgical robotics and key developments over the past years 00:14:16 - Identifying the right disease area and type of intervention 00:20:02 - The type of cancer targeted by Epione and the surgical act it complements 00:22:49 - Enabling percutaneous ablation beyond interventional radiologists 00:25:02 - Applications of Epione beyond liver cancer 00:27:20 - Epione’s components and workflow 00:32:51 - Synchronizing the patient’s breathing to the robotic arm positioning 00:35:43 - Synergies between Epione and other platforms previously developed by Lucien and his team 00:38:22 - Moving towards fully autonomous surgical interventions 00:41:20 - The meaning behind “Epione” 00:43:11 - Suggested resources to dig deeper into surgical robotics 00:45:34 - The “Why” What we also talked about with Lucien: ROSA Epione Mako Robotic-Arm Assisted Surgery Versius Surgical Robotic System Da Vinci Surgical Systems ExcelsiusGPS Gustave Roussy Institute Mayo Clinic The International Journal of Medical Robotics and Computer Assisted Surgery If you want to know more about Quantum Surgical, we invite you to consult their website: https://www.quantumsurgical.com/ You can contact Lucien through LinkedIn or by email: l.blondel@quantumsurgical.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com Mon, 28 Feb 2022 21:28:00 -0000 Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical full 2 Mathieu Chaffard Lucien Blondel is one of the leading figures in the field of surgical robotics, having already led the development of several platforms supporting orthopaedic, spinal and brain surgeries. Together with Quantum Surgical, which he co-founded alongside Bertin Nahum, Fernand Badano and Sophie Roca, they are addressing liver cancer through a new robotic platform supporting ablation procedures. Under the name of “Epione” (the goddess of care in the Greek mythology), it represents a breakthrough in this field, not only supporting surgeons in the execution of the ablation procedure, but also in the planning phase up to the validation of the surgical act. Through a combination of cutting-edge image processing technology, computer vision and haptics, Epione is on its way to revolutionize interventional oncology and improve access to liver cancer ablation, for patients and for surgeons. We exchanged with Lucien on his background, what brought him to surgical robotics, the specificities of this field, his role in leading the technical development of Epione, and its underlying promise in the cure of liver cancer. Timeline: 00:00:00 - Lucien’s introduction and background in surgical robotics 00:04:51 - How he got into this field and what drove his interest to it 00:07:43 - The uprising of surgical robotics and key developments over the past years 00:14:16 - Identifying the right disease area and type of intervention 00:20:02 - The type of cancer targeted by Epione and the surgical act it complements 00:22:49 - Enabling percutaneous ablation beyond interventional radiologists 00:25:02 - Applications of Epione beyond liver cancer 00:27:20 - Epione’s components and workflow 00:32:51 - Synchronizing the patient’s breathing to the robotic arm positioning 00:35:43 - Synergies between Epione and other platforms previously developed by Lucien and his team 00:38:22 - Moving towards fully autonomous surgical interventions 00:41:20 - The meaning behind “Epione” 00:43:11 - Suggested resources to dig deeper into surgical robotics 00:45:34 - The “Why” What we also talked about with Lucien: ROSA Epione Mako Robotic-Arm Assisted Surgery Versius Surgical Robotic System Da Vinci Surgical Systems ExcelsiusGPS Gustave Roussy Institute Mayo Clinic The International Journal of Medical Robotics and Computer Assisted Surgery If you want to know more about Quantum Surgical, we invite you to consult their website: https://www.quantumsurgical.com/ You can contact Lucien through LinkedIn or by email: l.blondel@quantumsurgical.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com Lucien Blondel is one of the leading figures in the field of surgical robotics, having already led the development of several platforms supporting orthopaedic, spinal and brain surgeries.

Together with Quantum Surgical, which he co-founded alongside Bertin Nahum, Fernand Badano and Sophie Roca, they are addressing liver cancer through a new robotic platform supporting ablation procedures.

Under the name of “Epione” (the goddess of care in the Greek mythology), it represents a breakthrough in this field, not only supporting surgeons in the execution of the ablation procedure, but also in the planning phase up to the validation of the surgical act.

Through a combination of cutting-edge image processing technology, computer vision and haptics, Epione is on its way to revolutionize interventional oncology and improve access to liver cancer ablation, for patients and for surgeons.

We exchanged with Lucien on his background, what brought him to surgical robotics, the specificities of this field, his role in leading the technical development of Epione, and its underlying promise in the cure of liver cancer.


Timeline:

00:00:00 - Lucien’s introduction and background in surgical robotics

00:04:51 - How he got into this field and what drove his interest to it

00:07:43 - The uprising of surgical robotics and key developments over the past years

00:14:16 - Identifying the right disease area and type of intervention

00:20:02 - The type of cancer targeted by Epione and the surgical act it complements

00:22:49 - Enabling percutaneous ablation beyond interventional radiologists

00:25:02 - Applications of Epione beyond liver cancer

00:27:20 - Epione’s components and workflow

00:32:51 - Synchronizing the patient’s breathing to the robotic arm positioning

00:35:43 - Synergies between Epione and other platforms previously developed by Lucien and his team

00:38:22 - Moving towards fully autonomous surgical interventions

00:41:20 - The meaning behind “Epione”

00:43:11 - Suggested resources to dig deeper into surgical robotics

00:45:34 - The “Why”


What we also talked about with Lucien:


If you want to know more about Quantum Surgical, we invite you to consult their website: https://www.quantumsurgical.com/


You can contact Lucien through LinkedIn or by email: l.blondel@quantumsurgical.com


If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com

]]> 3099 no [SNIPPET] - Lucien Blondel on surgical robotics and maximizing their potential in a clinical setting To discover the whole episode type "#2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical" on your streaming platform. Sat, 26 Feb 2022 16:26:00 -0000 full Mathieu Chaffard To discover the whole episode type "#2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical" on your streaming platform. To discover the whole episode type "#2 - Treating liver cancer with surgical robotics - Lucien Blondel - Quantum Surgical" on your streaming platform.

]]> 174 #1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens Cardiovascular diseases represent the leading cause of deaths worldwide. Despite the permanent progress in the treatment of such conditions, targeted prevention approaches remain a key solution to address this issue. This is the challenge that Imageens, a Paris-based startup led by Ted Baldwin, is tackling through the application of artificial intelligence to medical imaging, with the aim to quantify your arterial age. This specific biomarker unvails unique opportunities to anticipate heart conditions for people at moderate risk, with the promise to inform better clinical care decisions. We exchanged with Ted on the burden that cardiovascular diseases represent on a global level, the power of AI applied to medical imaging to discover early indicators of these pathologies, and how these insights can drive better personalized prevention programs to stay away from them. Timeline: 00:01:50 - The origins of Imageens 00:06:23 - The unmet need that Imageens is addressing 00:08:53 - Existing cardiac risk scores and the arterial age concept 00:13:10 - Technical approach to quantify the arterial age using MRI and AI 00:15:41 - Relationship between biological and arterial ages 00:20:32 - The MESA trial led by Johns Hopkins University and its link to the discovery of cardiac risk scores 00:23:26 - Imageens softwares Artfun+ and LABEL, their functioning and role in predictive imaging biomarkers discovery 00:30:21 - Moving beyond MRI to other imaging modalities 00:31:35 - Target patient population and access to Imageens technology 00:33:43 - Acceptance by physicians and the medical community 00:36:48 - Patient journey description 00:38:00 - Moving towards predictive analysis of the optimal cardiac prevention program What we also talked with Ted about: Assistance Publique - Hôpitaux de Paris (AP-HP) MESA trial Framingham risk score Cardiac CT calcium score Ascending aortic distensibility Ted’s TEDx presentation Ganymed Robotics Zoï Altos Labs Qualitiso If you want to know more about Imageens, we invite you to consult their website: https://www.imageens.com/ You can contact Ted through LinkedIn or by email: tbaldwin@imageens.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com Wed, 02 Feb 2022 10:49:00 -0000 Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens full 1 Mathieu Chaffard Cardiovascular diseases represent the leading cause of deaths worldwide. Despite the permanent progress in the treatment of such conditions, targeted prevention approaches remain a key solution to address this issue. This is the challenge that Imageens, a Paris-based startup led by Ted Baldwin, is tackling through the application of artificial intelligence to medical imaging, with the aim to quantify your arterial age. This specific biomarker unvails unique opportunities to anticipate heart conditions for people at moderate risk, with the promise to inform better clinical care decisions. We exchanged with Ted on the burden that cardiovascular diseases represent on a global level, the power of AI applied to medical imaging to discover early indicators of these pathologies, and how these insights can drive better personalized prevention programs to stay away from them. Timeline: 00:01:50 - The origins of Imageens 00:06:23 - The unmet need that Imageens is addressing 00:08:53 - Existing cardiac risk scores and the arterial age concept 00:13:10 - Technical approach to quantify the arterial age using MRI and AI 00:15:41 - Relationship between biological and arterial ages 00:20:32 - The MESA trial led by Johns Hopkins University and its link to the discovery of cardiac risk scores 00:23:26 - Imageens softwares Artfun+ and LABEL, their functioning and role in predictive imaging biomarkers discovery 00:30:21 - Moving beyond MRI to other imaging modalities 00:31:35 - Target patient population and access to Imageens technology 00:33:43 - Acceptance by physicians and the medical community 00:36:48 - Patient journey description 00:38:00 - Moving towards predictive analysis of the optimal cardiac prevention program What we also talked with Ted about: Assistance Publique - Hôpitaux de Paris (AP-HP) MESA trial Framingham risk score Cardiac CT calcium score Ascending aortic distensibility Ted’s TEDx presentation Ganymed Robotics Zoï Altos Labs Qualitiso If you want to know more about Imageens, we invite you to consult their website: https://www.imageens.com/ You can contact Ted through LinkedIn or by email: tbaldwin@imageens.com If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com Cardiovascular diseases represent the leading cause of deaths worldwide. Despite the permanent progress in the treatment of such conditions, targeted prevention approaches remain a key solution to address this issue.

This is the challenge that Imageens, a Paris-based startup led by Ted Baldwin, is tackling through the application of artificial intelligence to medical imaging, with the aim to quantify your arterial age. This specific biomarker unvails unique opportunities to anticipate heart conditions for people at moderate risk, with the promise to inform better clinical care decisions.

We exchanged with Ted on the burden that cardiovascular diseases represent on a global level, the power of AI applied to medical imaging to discover early indicators of these pathologies, and how these insights can drive better personalized prevention programs to stay away from them.


Timeline:

00:01:50 - The origins of Imageens

00:06:23 - The unmet need that Imageens is addressing

00:08:53 - Existing cardiac risk scores and the arterial age concept

00:13:10 - Technical approach to quantify the arterial age using MRI and AI

00:15:41 - Relationship between biological and arterial ages

00:20:32 - The MESA trial led by Johns Hopkins University and its link to the discovery of cardiac risk scores

00:23:26 - Imageens softwares Artfun+ and LABEL, their functioning and role in predictive imaging biomarkers discovery

00:30:21 - Moving beyond MRI to other imaging modalities

00:31:35 - Target patient population and access to Imageens technology

00:33:43 - Acceptance by physicians and the medical community

00:36:48 - Patient journey description

00:38:00 - Moving towards predictive analysis of the optimal cardiac prevention program


What we also talked with Ted about:


If you want to know more about Imageens, we invite you to consult their website: https://www.imageens.com/


You can contact Ted through LinkedIn or by email: tbaldwin@imageens.com


If you want to give me feedback on the episode, ask questions or suggest potential guests, feel free to do so through LinkedIn or by email: m.chaffard05@gmail.com

]]> 2904 no [SNIPPET] - Ted Baldwin on the importance of prognostic cardiac biomarkers and prevention To discover the whole episode type "#1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens" on your streaming platform. Tue, 01 Feb 2022 18:07:00 -0000 full Mathieu Chaffard To discover the whole episode type "#1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens" on your streaming platform. To discover the whole episode type "#1 - Measuring your arterial age to prevent heart diseases - Ted Baldwin - Imageens" on your streaming platform.

]]> 197 [TRAILER] - Impulse - Meeting Healthcare Pioneers Welcome to Impulse, the podcast where you will meet the people shaping the current medical advancements, through in-depth conversations about their field of expertise, and the journey that took them where they are now. Its aim is to democratize ongoing advances in medical technology, and introduce listeners to some of its key actors. Mon, 31 Jan 2022 20:57:00 -0000 [TRAILER] - Impulse - Meeting Healthcare Pioneers full Mathieu Chaffard Welcome to Impulse, the podcast where you will meet the people shaping the current medical advancements, through in-depth conversations about their field of expertise, and the journey that took them where they are now. Its aim is to democratize ongoing advances in medical technology, and introduce listeners to some of its key actors. Welcome to Impulse, the podcast where you will meet the people shaping the current medical advancements, through in-depth conversations about their field of expertise, and the journey that took them where they are now. Its aim is to democratize ongoing advances in medical technology, and introduce listeners to some of its key actors.

]]> 121